

CPDD 86th Annual Scientific Meeting Program Book

Hotel Information

Fairmont The Queen Elizabeth
900 Rene Levesque Blvd West
Montreal, QC
+1 514 861 3511

Ideally located in downtown Montreal, luxurious Fairmont The Queen Elizabeth is the best place to start your exploration of our vibrant city. With legendary Sainte-Catherine Street a block away, we're a short walk from retail, culinary and cultural highlights including The Montreal Museum of Fine Arts and the Notre-Dame Basilica of Montreal.

REGISTRATION INFORMATION

Please visit the CPDD Registration desk to pick up your name badge and other meeting materials. Registration is located at the Fairmont The Queen Elizabeth, in the 2nd Floor Foyer. Registration will be open during the following hours:

Saturday, June 15	11:00 am-7:00 pm
Sunday, June 16	7:00 am-6:00 pm
Monday, June 17	7:00 am-6:00 pm
Tuesday, June 18	7:00 am-6:00 pm
Wednesday, June 19	7:00 am-3:00 pm

CONFERENCE WIFI

Complimentary internet is available for CPDD attendees throughout the meeting spaces.

Network Name: **Fairmont_Meeting**
Password: **cpdd24**

Table of Contents

General Information	4
2023-2024 Board of Directors	5
2024 Program Committee	6
Agenda	
Saturday, June 15	7
Sunday, June 16	8
Monday, June 17	9
Tuesday, June 18	10
Wednesday, June 19	12
Plenary Sessions	13
Abstracts	17
Posters	68
2023-2024 Donors	139
2025 Save the Date	Back Cover

General Information

QUESTIONS?

If you have questions during the conference, we encourage you to:

1) Stop by the registration desk, located in the 2nd Floor Foyer.

2) Email info@cpdd.org with additional questions or concerns, or call (615) 432-0099.

3) Visit the Speaker Ready Room, located in Rue Crescent, 2nd Floor, for assistance with presentation or presenter questions.

FOLLOW US ON SOCIAL!

@CPDDMEMBERS **@CPDDORG** **@CPDD**

And don't forget to use #CPDD24 if you post about the Meeting.

CPDD DISCLAIMER STATEMENT

Information obtained via CPDD channels, including webinars, conferences, websites, etc., is intended only for research and information purposes. CPDD cannot be held liable for the information consumed and information presented may not reflect the opinions of CPDD or its members. The content and information shared should be used at the discretion of the consumer.

Funding for this conference was made possible (in part)
by 5 R13 DA 013182-15
from the National Institute on Drug Abuse.

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations, imply endorsement by the U.S. Government.

Board of Directors

EXECUTIVE COMMITTEE

Deborah Hasin, PhD
President

Kelly Dunn, MBA, PhD
President-Elect

Amy Janes, PhD
Past-President

William Stoops, PhD
Treasurer

Sandra Comer, PhD
Public Policy Officer

BOARD MEMBERS

Sudie Back, PhD
Qiana Brown, LCSW, MPH, MSW, PhD
Francesca Filbey, PhD
Kevin Freeman, PhD
Diann Gaalema, PhD
Albert Garcia-Romeu, MA, PhD
Cassandra Gipson-Reichardt, PhD
Angela Heads, PhD
Joshua Lile, PhD
Silvia Martins, MD
Sterling McPherson, PhD
Angela Moreland, PhD
Marco Pravetoni, PhD
James Rowlett, PhD
Michael Taffe, PhD
Charles Gorodetzky, MD, PhD

2024 Program Committee

CHAIR

Kevin Freeman, PhD

MEMBERS

Marc Auriacombe, MD
Cecilia Bergeria, PhD
Mance E. Buttram, PhD
Abenaa A. Jones, PhD
Heather L. Kimmel, PhD
Catalina Lopez-Quintero, MD, PhD
Sterling Marshall McPherson, PhD
Kevin Murname, PhD
Carol A. Paronis, PhD
Dustin J. Stairs, PhD
Denise C. Vidot, PhD
Healther Burrell Ward, MD
Rhiannon Chou Wiley, MA
J. Michael Wilkerson, PhD

AGENDA

8:30 AM	4:30 PM	ISGIDAR Annual Meeting (Registration Required)	Square Dorchester, 2nd Floor
8:30 AM	4:45 PM	NIDA International Forum (Registration Required)	Place du Canada, 2nd Floor
11:00 AM	7:00 PM	Registration	2nd Floor Foyer
12:00 PM	5:00 PM	Speaker Ready Room	Rue Crescent, 2nd Floor
12:00 PM	1:30 PM	Sex, Gender, and Cannabis: Methodological Approaches and New Findings	Av. Duluth, 2nd Floor
12:00 PM	1:30 PM	Trailblazing Innovations and Lessons Learned in Substance Use Disorder Treatment: An International Perspective	Av. Laurier, 2nd Floor
12:00 PM	1:30 PM	30th Annual Contingency Management Working Group	Av. Van Horne, 2nd Floor
12:00 PM	1:30 PM	Practical Aspects of Working with Vulnerable Populations and Practicing Community Engaged Research	Av. Viger, 2nd Floor
12:00 PM	1:30 PM	Setting the Stage: How Current and Future Academic Leaders Foster Team Addiction Science	Rue Saint-Denis-Notre-Dame, 2nd Floor
12:00 PM	1:30 PM	Publishing in Addiction Science: A Workshop from the International Society of Addiction Journal Editors	Rue Sainte Catherine-Saint Paul, 2nd Floor
1:30 PM	2:00 PM	Networking Break	2nd Floor Foyer
2:00 PM	3:30 PM	Planning for Success: Shared Decision-Making and the Outpatient Transition from Fentanyl to Buprenorphine	Av. Duluth, 2nd Floor
2:00 PM	3:30 PM	Navigating a Career in Addiction Science: A Workshop Presented by the Early Career Member Committee	Av. Laurier, 2nd Floor
2:00 PM	3:30 PM	Utilizing Innovative Approaches to Enhance the Full Potential of Substance Use Data to Benefit Minoritized Populations	Av. Van Horne, 2nd Floor
2:00 PM	3:30 PM	Stigmatizing Language: The Science Behind our Language, Tools We Can Use to Impact Change, and Real-World Experiences	Av. Viger, 2nd Floor
2:00 PM	3:30 PM	Skill-Building Workshop: What is Design-Thinking and how can it Improve Your SUD Research?	Rue Saint-Denis-Notre-Dame, 2nd Floor
2:00 PM	3:30 PM	On the Cutting Edge - Advancing the Methods to Evaluate Abuse and Dependence-Potential in Preclinical and Clinical Studies	Rue Sainte Catherine-Saint Paul, 2nd Floor
3:45 PM	5:15 PM	NIDA Grant Workshop	Av. Viger, 2nd Floor
4:00 PM	6:30 PM	NIDA NDEWS Summit	Av. Duluth, 2nd Floor
5:00 PM	6:00 PM	Closed Abstinence-Based Recovery Meeting (NA/AA)	Diese, 3rd Floor
5:30 PM	7:00 PM	NIDA International Forum Poster Session	Centre-Ville, Lobby Level
6:00 PM	7:00 PM	CPDD Committee Chairs Meeting (Invitation Only)	Rue Sherbrooke, 2nd Floor
7:00 PM	8:30 PM	CPDD Opening Reception	Place du Canada, 2nd Floor

SUNDAY, JUNE 16

7:00 AM	6:00 PM	Registration	2nd Floor Foyer
8:00 AM	5:00 PM	Speaker Ready Room	Rue Crescent, 2nd Floor
8:00 AM	10:00 AM	Opening Session: President's Remarks, Awards, NIDA Update	Place du Canada, 2nd Floor
10:00 AM	10:30 AM	Networking Break	2nd Floor Foyer
10:30 AM	12:00 PM	Computational Addiction Psychiatry: Theory- and Data-Driven Approaches to Tackle Complex Phenotypes in SUD	Av. Duluth, 2nd Floor
10:30 AM	12:00 PM	Invited Symposium: The Use of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for the Treatment of SUD in Rats and Humans	Av. Van Horne, 2nd Floor
10:30 AM	12:00 PM	The Healing Communities Study: Disrupting the Status Quo to Address Opioid Overdose Deaths	Av. Viger, 2nd Floor
10:30 AM	12:00 PM	The Growing Older Adult Population and Substance Use: Multimorbidity, Healthcare Utilization, and Harm Reduction Considerations	Place du Canada, 2nd Floor
10:30 AM	12:00 PM	Acute Stimulant Toxicity: This is not Opioid Overdose	Rue Sainte Catherine-Saint Paul, 2nd Floor
10:30 AM	12:00 PM	Invited Symposium: Translationally Evaluating Causes and Consequences of Xylazine Adulteration in the Opioid Supply	Square Dorchester, 2nd Floor
12:15 PM	1:45 PM	NIDA 50th Anniversary Presentation - Session 1	Place du Canada, 2nd Floor
12:30 PM	2:00 PM	DAD/DADR Editors Meeting	Square Victoria, 2nd Floor
2:00 PM	3:00 PM	Neuroinflammatory Signaling in Substance Use Disorders? Recent Evidence from Molecular Imaging Studies	Av. Van Horne, 2nd Floor
2:00 PM	3:00 PM	Oral Session: From Lab Rats to Smokestacks: Preclinical Insights into Nicotine Addiction	Rue Sainte Catherine-Saint Paul, 2nd Floor
2:00 PM	3:00 PM	Oral Session: Amygdala Activity and SUDs - Deep in the Feels	Av. Duluth, 2nd Floor
2:00 PM	3:00 PM	Oral Session: Advancing Drug Use Prevention Across the Continuum	Place du Canada, 2nd Floor
2:00 PM	3:00 PM	Oral Session: Ouch!!! Pass the Cannabis	Square Dorchester, 2nd Floor
2:00 PM	3:00 PM	Oral Session: Intersecting Perspectives on Suicidality and Substance Use	Av. Viger, 2nd Floor
3:00 PM	3:30 PM	Networking Break	2nd Floor Foyer
3:00 PM	3:30 PM	ECMC Mentor/Mentee Mixer	Square Victoria, 2nd Floor
3:30 PM	4:45 PM	CPDD Public Policy Committee Forum	Av. Viger, 2nd Floor
3:30 PM	4:45 PM	Media Forum	Place du Canada, 2nd Floor
3:30 PM	4:45 PM	Late-Breaking Oral Session #1	Av. Duluth, 2nd Floor
4:30 PM	5:30 PM	ECMC-NIDA PO Networking	Parc Mont-Royal C, 2nd floor
5:00 PM	6:00 PM	Closed Abstinence-Based Recovery Meeting (NA/AA)	Rue Notre-Dame, 2nd Floor
5:30 PM	7:00 PM	Poster Session 1	Centre-Ville, Lobby Level
7:00 PM	8:00 PM	LGBTQIA+ Networking Reception	Square Victoria, 2nd Floor
7:00 PM	8:00 PM	Pre- and Post-Doctoral Mixer with T-32 Directors	Parc Mont-Royal C, 2nd floor
7:00 PM	8:00 PM	Addiction Pharmacy Practice Meeting	Av. Van Horne, 2nd Floor

MONDAY, JUNE 17

7:00 AM	6:00 PM	Registration	2nd Floor Foyer
8:00 AM	5:00 PM	Speaker Ready Room	Rue Crescent, 2nd Floor
8:00 AM	9:00 AM	Advancing Data Science Ethics in Drug Addiction Epidemiology, Services, and Prevention Research	Place du Canada, 2nd Floor
8:00 AM	9:00 AM	Oral Session: Discussing Opioid Withdrawal in Montreal	Av. Duluth, 2nd Floor
8:00 AM	9:00 AM	Oral Session: Tails from the Lab	Rue Sainte Catherine-Saint Paul, 2nd Floor
8:00 AM	9:00 AM	Oral Session: Leafing Through Cannabis Predictions	Square Dorchester, 2nd Floor
8:00 AM	9:00 AM	Oral Session: Investigating and Tackling the HIV/AIDS and Drug Use Syndemic	Av. Van Horne, 2nd Floor
8:00 AM	9:00 AM	Oral Session: Science and Regulation	Av. Viger, 2nd Floor
9:15 AM	10:15 AM	Fischman Lecture	Place du Canada, 2nd Floor
10:15 AM	10:45 AM	Networking Break	
10:45 AM	12:15 PM	Substance Use Disorders and Associated Medical Consequences	Av. Duluth, 2nd Floor
10:45 AM	12:15 PM	Two-Eyed Seeing for Opioid Use Disorder Treatment and Recovery	Av. Van Horne, 2nd Floor
10:45 AM	12:15 PM	Amplifying Voices of Perinatal Persons with SUDs	Av. Viger, 2nd Floor
10:45 AM	12:15 PM	Invited Symposium: Craving a Novel Treatment Endpoint	Place du Canada, 2nd Floor
10:45 AM	12:15 PM	Drug-Drug Interactions Relevant to Substance Abuse and Toxicity	Rue Sainte Catherine-Saint Paul, 2nd Floor
10:45 AM	12:15 PM	Recent Steps Toward Individualization of Transcranial Magnetic Stimulation for Substance Use Disorders	Square Dorchester, 2nd Floor
12:00 PM	2:00 PM	NIDA K12 Networking Lunch	Square Victoria, 2nd Floor
12:30 PM	2:00 PM	NIDA 50th Anniversary Presentation - Session 2	Place du Canada, 2nd Floor
2:00 PM	5:00 PM	Working with NIDA Drug Supply	Rue Notre-Dame, 2nd Floor
2:15 PM	3:45 PM	Best Practices for Working with IACUC and Other Regulatory Groups	Place du Canada, 2nd Floor
2:15 PM	3:45 PM	CPDD Human Research Committee Forum	Place du Canada, 2nd Floor
2:15 PM	3:30 PM	Late-Breaking Oral Session #2	Av. Duluth, 2nd Floor
2:15 PM	3:45 PM	Bridging the Gap: Practical and Ethical Considerations on the Utility of AI in SUDs	Av. Van Horne, 2nd Floor
3:30 PM	4:00 PM	Networking Break	2nd Floor Foyer
4:00 PM	5:00 PM	NIAAA Update	Place du Canada, 2nd Floor
5:15 PM	6:15 PM	Is Heroin Dependence A "Chronic Long-Term Condition"?	Square Dorchester, 2nd Floor
5:15 PM	6:15 PM	Oral Session: Booze on the Brain	Rue Sainte Catherine-Saint Paul, 2nd Floor
5:15 PM	6:15 PM	Oral Session: Drug Use Involvement	Av. Viger, 2nd Floor
5:15 PM	6:15 PM	Oral Session: More Than a Soda Fountain	Av. Duluth, 2nd Floor
5:15 PM	6:15 PM	Oral Session: Budding Insights	Place du Canada, 2nd Floor
5:15 PM	6:15 PM	Oral Session: Primm Singleton	Av. Van Horne, 2nd Floor
6:15 PM	7:45 PM	Poster Session 2	Centre-Ville, Lobby Level
7:30 PM	8:30 PM	Primm Singleton Reception (Invitation Only)	Parc Mont-Royal C, 2nd floor
7:30 PM	8:30 PM	Closed Abstinence-Based Recovery Meeting (NA/AA)	Rue Notre-Dame, 2nd Floor
7:30 PM	8:30 PM	James L. Sorensen Distinguished Treatment and Service Mentor Award Reception (Invitation Only)	Square Victoria, 2nd Floor
7:30 PM	8:30 PM	Pre- and Post-Doctoral Mixer with R-25 Directors	Rue Saint-Denis, 2nd Floor
8:00 PM	9:00 PM	President's Reception (Invitation Only)	Perluette Lounge, 3rd Floor

TUESDAY, JUNE 18

7:00 AM	6:00 PM	Registration	2nd Floor Foyer
8:00 AM	5:00 PM	Speaker Ready Room	Rue Crescent, 2nd Floor
8:00 AM	9:00 AM	Critical Components to Developing and Delivering Substance Use Interventions for American Indian/Alaska Native People	Av. Van Horne, 2nd Floor
8:00 AM	9:00 AM	Oral Session: All (ok, some) Will be Revealed: Imaging in Addiction Research	Square Dorchester, 2nd Floor
8:00 AM	9:00 AM	Oral Session: Preclinical Studies of Drug Withdrawal	Rue Sainte Catherine-Saint Paul, 2nd Floor
8:00 AM	9:00 AM	Oral Session: Licit and Illicit Use of Psychedelics	Av. Viger, 2nd Floor
8:00 AM	9:00 AM	Oral Session: Breaking Down Barriers	Place du Canada, 2nd Floor
8:00 AM	9:00 AM	Oral Session: Breathing Matters	Av. Duluth, 2nd Floor
9:15 AM	10:15 AM	Stirring the Pot: Recent Findings on Perinatal Cannabis Exposure	Av. Viger, 2nd Floor
9:15 AM	10:15 AM	Oral Session: Circuits and Substrates: Molecular Neuroscience of Addiction	Av. Van Horne, 2nd Floor
9:15 AM	10:15 AM	Oral Session: Poutine the Treatment Where it Counts: Buprenorphine Induction Methods	Place du Canada, 2nd Floor
9:15 AM	10:15 AM	Oral Session: Impact of Recent Trauma on Drug Use	Av. Duluth, 2nd Floor
9:15 AM	10:15 AM	Oral Session: Risky Business: Impulsivity in SUDs	Square Dorchester, 2nd Floor
9:15 AM	10:15 AM	Oral Session: Stretching the Helix: Translational Genetics	Rue Sainte Catherine-Saint Paul, 2nd Floor
10:15 AM	10:45 AM	Networking Break	2nd Floor Foyer
10:45 AM	12:15 PM	Cue Reactivity as a Paradigm to Assess and Intervene in Addiction Across Species	Av. Duluth, 2nd Floor
10:45 AM	12:15 PM	Loneliness as an Important Risk Factor and Treatment Target for Opioid Use Disorder: Evidence From High-Risk Populations	Av. Van Horne, 2nd Floor
10:45 AM	12:15 PM	An Inwomen's Gender Symposium on Intersectional Responses to Opioids and Other Substance Use: Innovative treatment, Social determinants, and Voices from the Ground	Av. Viger, 2nd Floor
10:45 AM	12:15 PM	Invited Symposium: Safer Supply and the Opioid Crisis in Canada	Place du Canada, 2nd Floor
10:45 AM	12:15 PM	Brain Mechanisms Underlying Addiction: Applying New Methods to Answer New Questions	Rue Sainte Catherine-Saint Paul, 2nd Floor
10:45 AM	12:15 PM	Endocannabinoid Function and Adverse Effects of In-Utero Cannabinoid Exposure in the Developing Brain	Square Dorchester, 2nd Floor
12:00 PM	1:00 PM	Early Career Investigator Travel Awards Luncheon (Invitation Only)	Rue Saint-Denis-Notre-Dame, 2nd Floor
12:00 PM	2:15 PM	Lunch on Your Own	
12:00 PM	1:00 PM	CPDD Program Committee (Invitation Only)	Rue Mansfield, 2nd Floor
1:00 PM	2:00 PM	Eddy Lecture	Place du Canada, 2nd Floor
2:15 PM	3:15 PM	Injecting Drug Use and Blood-Borne Virus Disease in Prison Settings: Prevalence, Treatment Coverage, and Long-term Health and Social Outcomes	Av. Duluth, 2nd Floor
2:15 PM	3:15 PM	Oral Session: Nurturing Futures: Supporting and Treating Pregnant Individuals With Substance Use Disorder	Av. Van Horne, 2nd Floor
2:15 PM	3:15 PM	Oral Session: Beyond X and Y: Sex Differences in Addiction	Square Dorchester, 2nd Floor
2:15 PM	3:15 PM	Oral Session: Chasing the High: Exploring the Neurobiology of Cocaine Use Disorder	Rue Sainte Catherine-Saint Paul, 2nd Floor
2:15 PM	3:15 PM	Oral Session: The Power of Prediction: Machine Learning Applications in SUD Research	Place du Canada, 2nd Floor

2:15 PM	3:15 PM	Oral Session: Delving into Disparities: Examining the Drug Use Continuum Among Vulnerable Populations and Racial/Ethnic Minoritized Communities	Av. Viger, 2nd Floor
2:30 PM	4:00 PM	Addiction Science & Clinical Practice Editorial Board Meeting (Invitation Only)	Rue Notre-Dame, 2nd Floor
3:15 PM	3:45 PM	Networking Break	2nd Floor Foyer
3:45 PM	4:45 PM	Utilizing Glutamatergic Mechanisms to Treat Stimulant and Nicotine Use Disorders: Focus on the Beta lactam, Clavulanic Acid	Rue Sainte Catherine-Saint Paul, 2nd Floor
3:45 PM	4:45 PM	Oral Session: The Thrill is Gone: Chemical Disruption of Drug Seeking and Taking	Square Dorchester, 2nd Floor
3:45 PM	4:45 PM	Oral Session: Built to Last? Long-Acting Formulations Use Disorders	Av. Viger, 2nd Floor
3:45 PM	4:45 PM	Oral Session: Exploring the Parent-Child Dyad: Reciprocal Influences and Their Impact on Drug Use and Other Related Outcomes	Av. Duluth, 2nd Floor
3:45 PM	4:45 PM	Oral Session: Smoke Signals: Decoding the Brain's Response to Nicotine Cues	Av. Van Horne, 2nd Floor
3:45 PM	4:45 PM	Forum: Substance Use Disorders Treatment Development Research Supported by NIDA's Division of Therapeutics and Medical Consequences	Place du Canada, 2nd Floor
4:45 PM	5:30 PM	CPDD Business Meeting	Av. Van Horne, 2nd Floor
5:30 PM	7:00 PM	Poster Session 3	Centre-Ville, Lobby Level
6:15 PM	7:15 PM	Closed Abstinence-Based Recovery Meeting (NA/AA)	Rue Saint-Denis, 2nd Floor
7:00 PM	9:00 PM	Closing Reception	Place du Canada, 2nd Floor

WEDNESDAY, JUNE 19

7:00 AM	3:00 PM	Registration	2nd Floor Foyer
8:00 AM	4:00 PM	Speaker Ready Room	Rue Crescent, 2nd Floor
8:00 AM	9:30 AM	Computational Neuroscience and Cannabis: Preclinical, Behavioral and Clinical Insights	Av. Duluth, 2nd Floor
8:00 AM	9:30 AM	Innovations in Digital Interventions for Substance Use	Av. Van Horne, 2nd Floor
8:00 AM	9:30 AM	Advances in the Understanding of PTSD-Substance Use Disorder Comorbidity	Av. Viger, 2nd Floor
8:00 AM	9:30 AM	NIDA Research Center of Excellence Grants: How These Collaborative Centers Contribute to the Understanding and Treatment of SUDs	Place du Canada, 2nd Floor
8:00 AM	9:30 AM	Conditioned Drug Craving and Relapse: New Insights from Rats and Humans	Rue Sainte Catherine-Saint Paul, 2nd Floor
8:00 AM	9:30 AM	Roland Symposium	Square Dorchester, 2nd Floor
8:30 AM	10:00 AM	Brunch with Champions (Invitation Only)	Rue Saint-Denis-Notre-Dame, 2nd Floor
9:45 AM	11:15 AM	Harnessing the Orexin System Across the Translational Science Spectrum to Advance Treatments for Addiction	Av. Duluth, 2nd Floor
9:45 AM	11:15 AM	Using Data Analytics to Guide Community Responses to the Opioid Crisis	Av. Viger, 2nd Floor
9:45 AM	11:15 AM	Invited Symposium: Sentinel Networks for Early Surveillance and Warning of Substance Use Trends in North America	Place du Canada, 2nd Floor
9:45 AM	11:15 AM	Sex Differences Underlying the Effects of Pain on Opioid Use	Rue Sainte Catherine-Saint Paul, 2nd Floor
9:45 AM	11:15 AM	Let's Be Blunt: Neurocognitive Impacts of Cannabinoids are Complicated	Square Dorchester, 2nd Floor
9:45 AM	11:15 AM	Workshop: Epidemiology and Public Health Research Methods	Av. Van Horne, 2nd Floor
11:30 AM	12:30 PM	Oral Session: In Utero Insights	Av. Van Horne, 2nd Floor
11:30 AM	12:30 PM	Oral Session: Smoke-Free Solutions	Square Dorchester, 2nd Floor
11:30 AM	12:30 PM	Oral Session: Bio-Beacons	Av. Duluth, 2nd Floor
11:30 AM	12:30 PM	Oral Session: New Fentanyl Countermeasures	Av. Viger, 2nd Floor
11:30 AM	12:30 PM	Oral Session: The Pressure's On: Cardiovascular Outcomes in SUDs	Rue Sainte Catherine-Saint Paul, 2nd Floor
11:30 AM	12:30 PM	Forum: Drug Checking	Place du Canada, 2nd Floor
12:45 PM	2:15 PM	Presidential Symposium	Place du Canada, 2nd Floor
2:15 PM	3:45 PM	Poster Session 4	Centre-Ville, Lobby Level
3:45 PM	4:45 PM	Oral Session: The Fast Lane Forward	Av. Van Horne, 2nd Floor
3:45 PM	4:45 PM	Oral Session: Dope Dendrites	Av. Viger, 2nd Floor
3:45 PM	4:45 PM	Oral Session: Drug Choice: Pathology in Decision Making	Rue Sainte Catherine-Saint Paul, 2nd Floor
3:45 PM	4:45 PM	Oral Session: Unveiling the Framework: Structural-Level Factors and Their Impact on Substance Use	Place du Canada, 2nd Floor
3:45 PM	4:45 PM	Oral Session: I Thought of it First!	Av. Duluth, 2nd Floor
3:45 PM	4:45 PM	Oral Session: From Horse to Human	Square Dorchester, 2nd Floor
5:00 PM	5:45 PM	Closing Session and Raffle	Av. Van Horne, 2nd Floor

PLENARY SESSIONS

SUNDAY, JUNE 16, 2024

8:00 A.M. - 10:00 A.M.

OPENING SESSION: PRESIDENT'S REMARKS, AWARDS, NIDA UPDATE
Place du Canada, 2nd Floor

NIDA UPDATE
Nora Volkow, National Institute on Drug Abuse

12:15 P.M.-1:45 P.M.

NIDA 50TH ANNIVERSARY PRESENTATION - SESSION 1
Place du Canada, 2nd Floor

ADVANCES IN NEUROBIOLOGY OF ADDICTION
Speaker: **Yan Dong,** ***University of Pittsburgh***
Speaker: **Elizabeth Sowell,** ***University of Southern California***
Speaker: **Marc von Zastrow,** ***University of California, San Francisco***
Speaker: **Hedi Kober,** ***Yale University***

Moderator: **Nora Volkow,** ***National Institute on Drug Abuse***

MONDAY, JUNE 17, 2024

9:15 A.M. - 10:15 A.M.

FISCHMAN LECTURE: TRANSLATIONAL RESEARCH ON STRATEGIES TO ADDRESS THE OPIOID CRISIS
Place du Canada, 2nd Floor

Sandra Comer*, Columbia University and NYSPI*

12:30 P.M.-2:00 P.M.

NIDA 50TH ANNIVERSARY PRESENTATION - SESSION 2
Place du Canada, 2nd Floor

ADVANCES IN PREVENTION AND TREATMENT OF ADDICTION
Speaker: **Gail D'Onofrio,** ***Yale University***
Speaker: **Debra Furr-Holden,** ***New York University***
Speaker: **Hansel Tookes,** ***University of Miami***
Speaker: **Bradley Stein,** ***RAND Corporation***

Moderator: **Nora Volkow,** ***National Institute on Drug Abuse***

PLENARY SESSIONS

4:00 P.M. - 5:00 P.M.

NIAAA UPDATE
Place du Canada, 2nd Floor

Chair: **Patricia Powell*, NIAAA***

Alcohol misuse and related harms are increasing for women. Research suggests that women might be more motivated than men to consume alcohol to relieve emotional discomfort rather than for alcohol's rewarding properties. Societal messages to women reinforce the idea that alcohol facilitates the successful management of multiple roles, enhancing friendships and relieving the stress of motherhood and the workplace. However, emerging evidence highlights the increased vulnerability for women to alcohol-related harms, from blackouts to liver disease. Increased alcohol misuse and susceptibility to alcohol-related pathology are reflected in larger increases in alcohol-related ED visits, hospitalizations, and death for women than men over past 20 years. Opportunities exist to tailor prevention, identification, and treatment of alcohol misuse for women and girls and to change the messages they receive about alcohol from healthcare providers and from society at large.

TUESDAY, JUNE 18, 2024

1:00 P.M. - 2:00 P.M.

NATHAN B. EDDY MEMORIAL LECTURE
Place du Canada, 2nd Floor

Eric Strain*, Johns Hopkins University School of Medicine*

This lecture will provide an overview of Dr. Strain's career, addressing general lessons he has learned over the years as well as reviewing at a high level some of his research findings.

WEDNESDAY, JUNE 19, 2024

12:45 P.M. - 2:15 P.M.

PRESIDENTIAL SYMPOSIUM
Place du Canada, 2nd Floor

Chair: **Deborah Hasin*, Columbia University***

Dr. Deborah Hasin is Professor of Clinical Epidemiology at Columbia University in the College of Physicians and Surgeons, Department of Psychiatry, with a joint appointment in the Mailman School of Public Health, Department of Epidemiology. Her research focuses on drug and alcohol disorders and psychiatric comorbidity. She received her Ph.D. in epidemiology from Columbia

University in 1986. Dr. Hasin directs the Substance Dependence Research Group in the Department of Translational Epidemiology, and the NIDA-funded Substance Abuse Epidemiology Training Program (SAETP) at Columbia University. Dr. Hasin's current research focuses on policy and other large-scale social influences on time trends in cannabis use and cannabis-related harms, and on concepts and measures of addiction and recovery/remission across psychoactive substances. Her studies on drugs and alcohol have been continuously funded by NIDA and NIAAA since 1990. Dr. Hasin is on the Board of Directors of the College on Problems of Drug Dependence, is a member of the steering committee of the Alcohol Clinical Trials Initiative (ACTIVE), and is the text editor for the substance use disorder sections of DSM-5-TR. In the past, she has been President of the American Psychopathological Association and has served as a member of many other national advising and consultative groups. Dr. Hasin has over 450 publications, including papers on time trends and state-level influences on cannabis use, cannabis use disorder, binge drinking and alcohol use disorders and in DSM-5 definitions of substance use disorders in general population and clinical samples. Dr. Hasin's diagnostic research interview, the PRISM, is in use in numerous studies of the relationship of substance and psychiatric disorders in the U.S. and internationally.

Cannabis: Research Needed
Speaker: **Wilson Compton*, National Institute on Drug Abuse, National Institutes of Health***

While cannabis use has been generally steady or declining in recent years among early teens, young adults and older persons have increased their use of cannabis. Of note are increasing rates of frequent (i.e. daily) use of cannabis. Reductions in perceptions of harm and relaxed laws have been implicated in the increases for adults, but the reasons for the lack of increases among youth are less clear. Related to the diagnosis of cannabis use disorder (CUD), evidence of changes have been mixed, but data from the National Survey on Drug Use and Health (NSDUH) from 2022 document markedly higher rates of DSM-5 CUD compared to DSM-IV. Most of the increases are in DSM-5 mild CUD suggesting that DSM-5 may be more sensitive to less severe conditions than the earlier DSM-IV approach. Cannabis use has been associated in population studies with increasing rates of psychotic disorders (e.g. schizophrenia), but the reasons for these associations are not clear. Variations in cannabis products that are consumed (e.g. cannabinoid and formulation variations) adds to the complexity. Ongoing research supported by NIDA and other components of NIH includes exploration of these epidemiological finding as well as studies to develop more effective treatments of CUD, use of cannabis/cannabinoids for various health conditions, and a major set of studies on the role of cannabis (and other substances) in adolescent development. All of these studies are needed to help inform states and local areas that are enacting new laws and policies related to cannabis (i.e. medical and recreational cannabis laws) and additional, creative studies are warranted.

Positive Subjective and Analgesic Effects of Cannabis: Implications for CUD and Therapeutic Use
Speaker: **Margaret Haney*, Columbia University Irving Medical Center***

Biobanks and the Value of GWAS in the Study of Cannabis Use Disorders
Speaker: **Daniel Levey*, Yale University School of Medicine***

As recreational use of cannabis is being decriminalized in many places and medical use widely sanctioned, there are growing concerns about increases in cannabis use disorder (CanUD),

which is associated with numerous medical comorbidities. Here we performed a genome-wide association study of CanUD in the Million Veteran Program (MVP), followed by meta-analysis in 1,054,365 individuals (ncases = 64,314) from four broad ancestries designated by the reference panel used for assignment (European n = 886,025, African n = 123,208, admixed American n = 38,289 and East Asian n = 6,843). Population-specific methods were applied to calculate single nucleotide polymorphism-based heritability within each ancestry. Statistically significant single nucleotide polymorphism-based heritability for CanUD was observed in all but the smallest population (East Asian). We discovered genome-wide significant loci unique to each ancestry: 22 in European, 2 each in African and East Asian, and 1 in admixed American ancestries. A genetically informed causal relationship analysis indicated a possible effect of genetic liability for CanUD on lung cancer risk, suggesting potential unanticipated future medical and psychiatric public health consequences that require further study to disentangle from other known risk factors such as cigarette smoking.

ABSTRACTS

SATURDAY, JUNE 15, 2024

12:00 P.M. - 1:30 P.M.

30TH ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP
Av. Van Horne, 2nd Floor

Chair: Matthew Novak*, University of Maryland, Baltimore County*
Co-Chair: Diann Gaalema*, University of Texas Medical Branch*

The Contingency Management (CM) Working Group, held annually during the CPDD convention, is an opportunity for the discussion and dissemination of current research regarding the use of CM interventions to promote behavior change and reduce drug use. CM is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide range of drugs and across many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). At the 30th annual meeting of the CM Working Group, junior and senior researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research, with an emphasis on developing or improving research strategies by seeking audience input and providing opportunities for junior and senior researchers to interact. As the goal for this working group has always been to provide an informal outlet for discussion of CM data, names of presenters are not included with this submission. Rather, participants and topics will be chosen during the Spring of 2024 to capture the most current data in contingency management research for presentation at our annual working group.

12:00 P.M. - 1:30 P.M.

TRAILBLAZING INNOVATIONS AND LESSONS LEARNED IN SUBSTANCE USE DISORDER TREATMENT: AN INTERNATIONAL PERSPECTIVE
Av. Laurier, 2nd Floor

Chair: Laura Brandt*, City College of New York*
Co-Chair: Dace Svikis*, Virginia Commonwealth University*

While substance use disorders present a global public health challenge, their intricacies vary significantly across regions. Numerous countries have pioneered innovative approaches to address substance use issues, tailored to their unique regional challenges. Hosted by CPDD's International Committee, this workshop will showcase concise panel presentations on trailblazing strategies from our speakers' respective countries while also sharing insights gained from overcoming unique challenges, including financial constraints: Kathryn Biernacki will shed light on Australia's pioneering approach to establishing safe injection sites as a harm reduction measure. Thiago Fidalgo will delve into Brazil's distinctive opioid regulation, effectively averting an opioid crisis despite other systemic challenges. Silvia Cruz will provide a comprehensive analysis of the intricate dynamics surrounding substance contamination and the health risks associated with this practice.

ABSTRACTS

Lalchhanhima Ralte will draw from experiences during his Humphrey scholarship in the US and the subsequent Fulbright Specialist grant, which supported culturally-tailored motivational interviewing training in India, with a unique emphasis on relapse prevention.

The workshop also encourages dynamic, interactive discussions, warmly inviting attendees to share their diverse experiences and regional innovations. Join us to explore how international collaborations and shared insights can propel advances in the treatment of substance use disorders and how context-specific solutions can shape global strategies. Together, we aspire to bridge the gap between cultural and professional perspectives, fostering collaboration to the benefit of those affected by substance use disorders worldwide.

Pharmacologically Active Adulterants: Challenges for Prevention and Treatment
Speaker: **Silvia Cruz*, Department of Pharmacobiology, Cinvestav***

Issues and Challenges in Leading a Nationwide Research Project on Youths who Misuse Substances in Malaysia
Speaker: **Suzaily Wahab*, Universiti Kebangsaan Malaysia Medical Centre***

Opioid Prescription and Sales in Brazil: Have we Learned Something From the American Experience?
Speaker: **Thiago Fidalgo*, Universidade Federal de Sao Paulo***

Shedding Light on Australia's Approach to Safe Injecting Sites
Speaker: **Kathryn Biernacki*, National Institute of Drug Abuse/NIH/DHHS***

Motivational Interviewing for Substance Use Disorders, From Virginia to Mizoram: A NIDA Fulbright Humphrey Scholar's Perspective
Speaker: **Lalchhanhima Ralte*, Presbyterian Hospital***

12:00 P.M. - 1:30 P.M.

PUBLISHING IN ADDICTION SCIENCE: A WORKSHOP FROM THE INTERNATIONAL SOCIETY OF ADDICTION JOURNAL EDITORS
Rue Sainte Catherine-Saint Paul, 2nd Floor

Chair: **William Stoops*, University of Kentucky***
Co-Chair: **Casy Calver*, Boston Medical Center***

Among scholars of addiction-related investigation, there are gaps in knowledge regarding how the publication of addiction scholarship occurs. Scholars often lack an understanding of the scopes of journals, their metrics, and how to navigate a manuscript's journey from origination through final publication. This knowledge gap is particularly pronounced among scholars from low- and middle-income countries. In this workshop, Editors from the International Society of Addiction Journal Editors (ISAJE), through didactic and panel discussions, will engage with early-career and other researchers to demystify issues relevant to publishing addiction science. At the end of the workshop, attendees will be more comfortable in approaching journals (and their editors) and be more effective in navigating the journey of a paper to eventual publication. Topics to be covered will include: 1) journal metrics and choosing the

right journal; 2) strategies for revising and resubmitting papers; 3) authorship and conflict of interest; 4) addressing paper rejections and next steps and 5) maximizing impact after publication. ISAJE Editors will provide didactic and case-based examples of "best practices" in each of these topics. The workshop will consist of a moderator, who will inquire to the ISAJE Editors regarding each topic. Ample time will be allowed for questions and comments from the audience.

Journal Metrics and Choosing the Right Journal
Speaker: **Adam Gordon*, University of Utah SoM and VASLCHCS***

Strategies for Revising and Resubmitting Papers
Speaker: **Emily Williams*, University of Washington***

Addressing Paper Rejections and Next Steps
Speaker: **Caravella McCuistian*, School of Medicine, University of California San Francisco***

Maximizing Impact After Publication
Speaker: **Anees Bahji*, University of Calgary***

12:00 P.M. - 1:30 P.M.

PRACTICAL ASPECTS OF WORKING WITH VULNERABLE POPULATIONS AND PRACTICING COMMUNITY ENGAGED RESEARCH
Av. Viger, 2nd Floor

Chair: **Rachel Luba*, New York State Psychiatric Institute***

In 2023, the Human Research Committee presented a forum focused on incorporating the perspectives of individuals with lived experience of substance use into research practice. The forum was very well attended and there was great interest in this topic. Building on enthusiasm and continued interest in community-engaged research and work with vulnerable populations, this workshop will focus on providing attendees with practical insights for designing, implementing, and disseminating research on substance use with vulnerable populations, and conducting community-engaged research. Presenters with expertise on these topics will provide insights on 1) building inclusive research teams, navigating the hierarchies and bureaucracies of academia to include and compensate community shareholders and ensuring publication and dissemination of findings that is reflective of and accessible to community shareholders 2) intentionally designing research that accommodates and protect vulnerable populations, and building trust in communities that may not have reason to trust researchers 3) Building community partnerships that are sustainable and 3) Navigating practical considerations for working with vulnerable populations (IRB approval, developing consent forms and participant-facing materials that are accessible).
Attendees will gain practical skills while having opportunities to ask questions and engage in discussion with presenters. Interest in developing a toolkit/platform for ongoing conversations and on this topic will be discussed as a potential goal for the Human Research Committee.

Strategies for Engaging Communities With Intentionality and Cultural Humility
Speaker: **Alexandria Bauer*, Rutgers University***

ABSTRACTS

Perinatal Substance Misuse Research: How to Work Within the Context of Mandatory Reporting Laws
Speaker: **Alicia Allen*, University of Arizona***

Building Community Trust and Capacity to Improve Data-Driven Overdose Response Efforts
Speaker: **Kasey Claborn*, The University of Texas at Austin***

Community Engaged Research: Ins and Outs of Entering and Exiting Communities, Respectfully
Speaker: **Chyrell Bellamy*, Yale University***

12:00 P.M. - 1:30 P.M.

SEX, GENDER, AND CANNABIS: METHODOLOGICAL APPROACHES AND NEW FINDINGS
Av. Duluth, 2nd Floor

Chair: **Justin Matheson*, Centre for Addiction and Mental Health***

Sex and gender both have significant impacts on the use and effects of psychoactive substances, including cannabis. Sex refers to biological attributes and functions of bodies, whereas gender refers to the socially and culturally constructed aspects of self-perception and social organization that shape identity, expression, roles, norms, behaviors, and relations. In part due to policy mandates requiring reporting of sex (and sometimes gender) in biomedical research, and in part due to a growing recognition of the role of sex and gender in influencing human health, there have been significant increases in the inclusion of sex- and gender-based analyses in substance use studies. However, there remain challenges in collecting, analyzing, and interpreting sex- and gender-related data, as there is often confusion about key concepts, accurate terminology, and appropriate research designs. The proposed workshop has two primary aims: (1) to present an overview of best practices in conceptualizing sex and gender, choosing accurate and inclusive language, and selecting appropriate research designs and statistical tests for sex- and gender-related research questions, and (2) to present empirical data characterizing sex and gender differences in the effects of cannabis. We hope this workshop will provide guidance for researchers looking to account for and appropriately assess the integration of sex and/or gender into their substance use research. We bring together experts at different career stages who have all contributed to our understanding of how sex and gender impact cannabis use and related harms.

Conceptualizing Sex and Gender in Cannabis Research
Speaker: **Justin Matheson*, Centre for Addiction and Mental Health***

Methodological Approaches to Examining the Impact of the Menstrual Cycle on Acute Responses to Cannabinoids
Speaker: **Elisa Pabon*, University of California, Los Angeles***

Sex Differences in the Pharmacokinetic and Pharmacodynamic Effects of Cannabis: Pooled Findings From Human Laboratory Studies
Speaker: **Tory Spindle*, Johns Hopkins University School of Medicine***

Gender Differences in the Effects of Chronic Cannabis Use on Cognition and Cortisol
Speaker: **Carrie Cuttler*, Washington State University***

ABSTRACTS

12:00 P.M. - 1:30 P.M.

SETTING THE STAGE: HOW CURRENT AND FUTURE ACADEMIC LEADERS FOSTER TEAM ADDICTION SCIENCE
Rue Saint-Denis-Notre-Dame, 2nd Floor

Chair: **Adam Leventhal***, Keck School of Medicine, University of Southern California*
Co-Chair: **Katie Witkiewitz***, University of New Mexico*

Evidence indicates that team science approaches accelerate knowledge discovery, solutions to public health problems, and investigators' enjoyment of the research process. Team science is defined as a cross-disciplinary approach to maximize the effectiveness of multi-investigator research, with the ultimate goal of tackling big research questions by bringing together experts with diverse backgrounds and experiences. Team science requires trust, shared vision, self-awareness, leadership, mentoring, flexibility, communication, recognition and shared success, navigating conflict, and leveraging systems to transcend organizational barriers. This workshop will bring together five directors of interdisciplinary addiction research centers across the US who each have each expertise in supporting early career investigators, developing new programs and initiatives to grow interdisciplinary collaboration that incorporate team science principles. Each presenter will discuss successful examples of team addiction science and how a center's programs and resources can bolster such initiatives. Q and A and discussion involving the audience will address challenges and opportunities, with an eye toward the future of team addiction science. The target audience for this workshop includes: (a) early career investigators considering whether centers that foster team addiction science fit their career goals; (b) mid-career and senior investigators who aim to start a new center or enhance an existing center at their institution that will leverage team addiction science approaches; and (c) funding agencies and institutional administrators that aim to enhance capacity to support team addiction science.

Setting the Stage: How Current and Future Academic Leaders Foster Team Science
Speaker: **Christopher Kahler***, Center for Alcohol and Addiction Studies*

Creating Multidisciplinary Teams in Pain and Addiction
Speaker: **Karen Cropsey***, University of Alabama at Birmingham*

Creating a University-Wide Initiative to Address Addiction: The Rutgers Addiction Research Center
Speaker: **Danielle Dick***, Rutgers University*

Discussant: **Wilson Compton***, National Institute on Drug Abuse, National Institutes of Health*

2:00 P.M. - 3:30 P.M.

STIGMATIZING LANGUAGE: THE SCIENCE BEHIND OUR LANGUAGE, TOOLS WE CAN USE TO IMPACT CHANGE, AND REAL-WORLD EXPERIENCES
Av. Viger, 2nd Floor

Chair: **Teresa Franklin***, University of Pennsylvania*
Co-Chair: **Steve Shoptaw***, University of California Los Angeles*

ABSTRACTS

If you question the prevailing push to reduce and/or eliminate the use of stigmatizing language or if you are unsure of its meaning, or if you would like to learn strategies to combat stigmatizing language in your own work, this workshop will offer information, clarification, and open discussion. 'Stigmatizing language' refers to words or labels that evoke negative attitudes or beliefs (i.e., stereotypes) about certain individuals. The consequences of the use of stigmatizing language are not a mystery. One such consequence is discrimination, the action of excluding groups or individuals based on widely believed implicit and explicit generalizations. This workshop will showcase some of the scientific evidence showing that our language, whether it be written as in our publications or verbal as in our presentations, has tangible impacts – in terms of policy, funding, treatment engagement, quality of care and treatment outcome, among others. For example, according to the U.S. Department of Health and Human Services' Substance Abuse and Mental Health Services Administration, of those individuals who perceive a need for substance use treatment, 39% cite stigma-related reasons as a barrier to accessing care. This workshop will also present currently available tools and new developments that can be used within the substance use research field to combat the use of stigmatizing language. Lastly, the workshop will end with a discussion - led by a scientist with lived experience about how the use of stigmatizing language has affected us personally and what 'action items' we can implement to enact change.

Addressing Addiction Stigma: The Science on Language and Terminology
Speaker: **John Kelly*, Harvard Medical School***

Stigmatizing Language in Addiction Research
Speaker: **Micah Hartwell*, Oklahoma State University Center for Health Sciences***

Discussant: **Martha Tillson*, University of Kentucky***

2:00 P.M. - 3:30 P.M.

PLANNING FOR SUCCESS: SHARED DECISION-MAKING AND THE OUTPATIENT TRANSITION FROM FENTANYL TO BUPRENORPHINE
Av. Duluth, 2nd Floor

Chair: **Stephen Martin*, UMASS Medical School***
Co-Chair: **Jade Waits*, Boulder Care***

The increasing dominance of fentanyl in the American drug supply has made successful transition to buprenorphine more difficult than previous transitions from heroin or prescription opioids. Past approaches to initiating buprenorphine have involved instructing a patient on the time needed to abstain after their last full agonist use (depending on the opioid they are using) and timing the start of buprenorphine with the onset of mild to moderate withdrawal symptoms. This approach was generally successful during the wave of OUD due to prescription opioids and heroin. Illicitly manufactured fentanyl's (IMF) lipophilicity, large volume of distribution, and residual stores have proved particularly challenging in combination with buprenorphine.
In the outpatient setting, patients can experience a spectrum of negative outcomes as they attempt transition from IMF to buprenorphine. The most severe of these difficulties is buprenorphine-precipitated opioid withdrawal (BPOW). Patients may also experience ongoing

withdrawal symptoms and cravings even after buprenorphine is titrated to the FDA-advised maximum dose of 24 mg per day. Additional negative symptoms—while short of BPOW—can also cause harm to patients, both at the time and because buprenorphine's risks can seem to outweigh its life-saving, but seemingly unattainable, benefits. For these reasons, clinicians should have detailed conversations about this transition and the choices patients have in selecting an approach. However, current literature and guidelines do not yet have practical examples of the informed shared decision-making now required in the outpatient setting. Attendees will have the opportunity to role play with developed shared decision-making tools in teaching cases.

Planning for Success: Shared Decision-Making and the Outpatient Transition From Fentanyl to Buprenorphine
Speaker: **Casey Richards*, Boulder Care***

Planning for Success: Shared Decision-Making and the Outpatient Transition From Fentanyl to Buprenorphine
Speaker: **Ilana Hull*, University of Pittsburgh***

Planning for Success: Shared Decision-Making and the Outpatient Transition From Fentanyl to Buprenorphine
Speaker: **Elizabeth Ryan*, Boulder Care***

Planning for Success: Shared Decision-Making and the Outpatient Transition from Fentanyl to Buprenorphine
Speaker: **Beth Williams*, Oregon Health and Sciences University***

Discussant: **Adam Randall*, Boulder Care***

2:00 P.M. - 3:30 P.M.

NAVIGATING A CAREER IN ADDICTION SCIENCE: A WORKSHOP PRESENTED BY THE EARLY CAREER MEMBER COMMITTEE
Av. Laurier, 2nd Floor

Chair: **Danielle Davis*, Yale University School of Medicine***
Co-Chair: **Denise Vidot*, University of Miami School of Medicine***

Summary Abstract Addiction science careers are diverse ranging widely across academia, industry, and government. However, knowledge of these careers and how to navigate them can be limited among junior investigators and trainees. The gap in knowledge can be a function of limited access to resources, mentorship, and/or institutional knowledge. Opportunities may exist for emerging addiction scientists that are well suited for their skillsets or expertise, but are otherwise inaccessible due simply to lack of knowledge on how to pursue certain career opportunities. The purpose of this workshop is to provide early career scientists at CPDD the opportunity to hear from a diverse group of addiction scientists from a range of professions spanning academia, industry, and government agencies. Speakers will present information on their career sector, the skill set and expertise needed to succeed in their area, the costs and benefits of their work, and any "insider information" on how to successful navigate their space

in the field. Additionally, speakers will describe experiences that prepared them for their careers, describe their day-to-day work, and discuss available growth opportunities. Speakers in this workshop range from basic scientists to clinicians and are in the private sector, government agencies, research-focused and teaching-focused academic institutions. CPDD is successful, in part, because of dedicated scientists with careers in academia, industry, and government who collaborate to advance the understanding of addiction science. This workshop will provide critical insights for early career attendees, facilitate unique networking opportunities, and will ultimately enrich the future membership of CPDD.

Addiction Science Research at a Primarily Undergraduate Institution: Balancing the Classroom and Laboratory
Speaker: **Ryan Lacy*, Franklin and Marshall College***

Navigating a Career in Addiction Science
Speaker: **Denis Antoine*, Johns Hopkins University School of Medicine***

Practical Applications of Addiction Science in Industry
Speaker: **Ryan Lanier*, Pinney Associates***

Regulatory Science Careers at FDA for Assessing Abuse Potential and Drug Dependence
Speaker: **Dominic Chiapperino*, US Food and Drug Administration***

Navigating Non-Academic Careers in Addiction Science
Speaker: **Alexandra Duncan*, The Pew Charitable Trusts***

2:00 P.M. - 3:30 P.M.

SKILL-BUILDING WORKSHOP: WHAT IS DESIGN-THINKING AND HOW CAN IT IMPROVE YOUR SUD RESEARCH?
Rue Saint-Denis-Notre-Dame, 2nd Floor

Chair: **Kelly Dunn*, Johns Hopkins University School of Medicine***
Co-Chair: **Supriya Munshaw*, Johns Hopkins University Carey Business School***

This workshop will introduce the established business framework "Design Thinking" and explain how design thinking can be applied to produce novel and innovative preclinical and clinical research hypotheses and methods. Design thinking is a end-user centered business technique that identifies unmet needs from the perspective of a patient and then proposes and tests potential solutions in a rapid and iterative fashion. This workshop proposes that the design thinking framework can be applied to the field of substance use disorder to develop person-centered research and to also facilitate back translation to preclinical designs. By the end of the workshop, attendees will have built skills in design thinking they can use to advance their research. The workshop will begin with a presentation by Kelly Dunn from Johns Hopkins University (JHU) School of Medicine who will introduce the concept of Design Thinking and how it can be mapped onto preclinical and human (patient-centered) research. Next the session will introduce an unmet need/challenge in the SUD field that will be used as an example to interactively demonstrate how the 5 stages of design thinking can be applied to inform, refine, and reconceptualize hypothesis development. Supriya Munshaw from the JHU Carey Business

ABSTRACTS

School and Kelly Dunn will introduce each design-thinking phase and interactively work with attendees to apply design thinking strategies to the problem.

What is Design Thinking and how can it Apply to Preclinical and Human Research Designs?
Speaker: **Kelly Dunn*, Johns Hopkins University School of Medicine***

Introduction to Design Thinking
Speaker: **Supriya Munshaw*, Johns Hopkins University Carey Business School***

2:00 P.M. - 3:30 P.M.

ON THE CUTTING EDGE - ADVANCING THE METHODS TO EVALUATE ABUSE AND DEPENDENCE-POTENTIAL IN PRECLINICAL AND CLINICAL STUDIES
Rue Sainte Catherine-Saint Paul, 2nd Floor

Chair: **Beatriz Rocha*, Fortrea***
Co-Chair: **Dominic Chiapperino*, US Food and Drug Administration***

The pre-marketing evaluation of abuse and dependence potential of CNS-active drugs is integral to safety assessment and drug scheduling in the US, as per the Controlled Substances Act. Development of classes of drugs with unique pharmacological attributes (i.e., psychedelics) and cases of discordant findings between behavioral animal studies and human abuse potential studies and real-world data, as seen with dual orexin receptor antagonists and some anticonvulsant drugs, give rise to the need to re-examine current methodological approaches (inclusion of additional measures in HAP studies and abuse-related AE collection) and explore new approaches. One new approach may be the application of behavioral economic models, such as demand curve assessment, in both nonclinical and clinical evaluations of abuse potential. Pragmatic evaluation of physical dependence in phase 3 trials, including the validity of specific withdrawal scales in the patient population, also requires re-evaluation. Preclinical study methods continue to be under debate with respect to choices of procedures and methods (e.g., fixed vs progressive ratio schedules in self-administration). These topics were recently discussed at a public meeting organized by the Cross-Company Abuse Liability Council with support and representation from FDA Controlled Substance Staff. This workshop will focus on key points raised during the meeting that warrant further discussion amongst the scientific community. The workshop will include brief presentations followed by discussions on each of these topics.

Evaluating Abuse and Dependence Potential in the Clinical Setting – Challenges and Potential Solutions
Speaker: **Beatrice Setnik*, Altasciences***

Applying Behavioral Economics to the Abuse Potential Assessment
Speaker: **Thomas Hudzik*, ALA BioPharma Consulting***

Best Practices in Preclinical Evaluations of Abuse and Dependence
Speaker: **Chad Reissig*, FDA Center for Drug Evaluation and Research***

2:00 P.M. - 3:30 P.M.

ABSTRACTS

UTILIZING INNOVATIVE APPROACHES TO ENHANCE THE FULL POTENTIAL OF SUBSTANCE USE DATA TO BENEFIT MINORITIZED POPULATIONS
Av. Van Horne, 2nd Floor

Chair: **A. Kathleen Burlew*, University of Cincinnati***

Traditional research methods and treatments are not always sufficient for advancing the science of substance use treatment among racial/ethnic minoritized minorities (REMs). The aim of this workshop is to share several innovative approaches for understanding and addressing substance use among REMs. Members of the Minority Interest Group of NIDA's Clinical Trials Network (CTN) will present the following alternative approaches: Dr. Kathy Burlew will describe an Integrative Data Analysis (IDA) conducted within NIDA's CTN to assess the relative efficacy of nine treatments for reducing cocaine use among Black people. Dr. Angela Haeny will share work on the use of personalized imagery laboratory procedures to assess the impact of stress on craving among Black adults with substance use disorder. Dr. Niranjan Karnik's presentation is on the use of electronic health records systems to screen for clinical trials recruitment and the ways that automated data flows can promote recruitment of minoritized participants. Dr. Scott will present findings from CTN-0088 on the development and implementation of a collaborative, community-based MOUD treatment program in a faith-based community organization in a minoritized community in Washington, DC, experiencing high rates of opioid overdose and with low rates of MOUD treatment engagement. Following the presentations, Dr. Lesia Ruglass, who collaborated on two CTN (IDA) projects that examined treatment for Blacks and others who use substances, will serve as the Discussant. She will also encourage audience discussion on alternative approaches.

The Impact of Psychosocial Treatments for Black People who use Cocaine Using Integrative Data Analysis of Data From the Clinical Trials Network
Speaker: **A. Kathleen Burlew*, University of Cincinnati***

Utilizing Personalized Imagery Stress Procedures to Inform the Impact of Racial Stress on Craving among Black Adults
Speaker: **Angela Haeny*, Yale University School of Medicine***

Using Active EHR Screening to Promote Minoritized Population Recruitment for Clinical Trials
Speaker: **Niranjan Karnik*, University of Illinois Chicago***

"Healing in Place" Better Together: A Community-Based Approach to Integrating MOUD in an African American Population
Speaker: **Denise Scott*, Howard University College of Medicine***

Discussant: **Caravella McCuistian*, School of Medicine, University of California San Francisco***

2:00 P.M. - 3:30 P.M.

NAVIGATING A CAREER IN ADDICTION SCIENCE: A WORKSHOP PRESENTED BY THE EARLY CAREER MEMBER COMMITTEE
Av. Laurier, 2nd Floor

Chair: **Danielle Davis*, Yale University School of Medicine***

ABSTRACTS

Co-Chair: **Denise Vidot***, University of Miami School of Medicine*

Addiction science careers are diverse ranging widely across academia, industry, and government. However, knowledge of these careers and how to navigate them can be limited among junior investigators and trainees. The gap in knowledge can be a function of limited access to resources, mentorship, and/or institutional knowledge. Opportunities may exist for emerging addiction scientists that are well suited for their skillsets or expertise but are otherwise inaccessible due simply to lack of knowledge on how to pursue certain career opportunities. The purpose of this workshop is to provide early career scientists at CPDD the opportunity to hear from a diverse group of addiction scientists from a range of professions spanning academia, industry, and government agencies. Speakers will present information on their career sector, the skill set and expertise needed to succeed in their area, the costs and benefits of their work, and any "insider information" on how to successfully navigate their space in the field. Additionally, speakers will describe experiences that prepared them for their careers, describe their day-to-day work, and discuss available growth opportunities. Speakers in this workshop range from basic scientists to clinicians and are in the private sector, government agencies, research-focused and teaching-focused academic institutions. CPDD is successful, in part, because of dedicated scientists with careers in academia, industry, and government who collaborate to advance the understanding of addiction science. This workshop will provide critical insights for early career attendees, facilitate unique networking opportunities, and will ultimately enrich the future membership of CPDD.

Addiction Science Research at a Primarily Undergraduate Institution: Balancing the Classroom and Laboratory
Speaker: **Ryan Lacy***, Franklin and Marshall College*

Navigating a Career in Addiction Science
Speaker: **Denis Antoine***, Johns Hopkins University School of Medicine*

Practical Applications of Addiction Science in Industry
Speaker: **Ryan Lanier***, Pinney Associates*

Regulatory Science Careers at FDA for Assessing Abuse Potential and Drug Dependence
Speaker: **Dominic Chiapperino***, US Food and Drug Administration*

Navigating Non-Academic Careers in Addiction Science
Speaker: **Alexandra Duncan***, The Pew Charitable Trusts*

3:45 P.M. - 5:15 P.M.

NIDA GRANT WORKSHOP: WHAT YOU DIDN'T LEARN (ABOUT GRANTS) IN GRAD SCHOOL
Av. Viger, 2nd Floor

Chair: **Lindsey Friend, National Institution on Drug Abuse**

The NIDA/CPDD Early Career Workshop revolves around uncovering aspects of fellowship (F) and Career Development (K) grants. Moderated by Yohansa Fernandez from the Office of Research Training, Diversity, and Health Disparities at NIDA, the agenda includes sessions on

grant mechanisms and opportunities led by Aria Crump, insights into F and K Review Overview by Sudhirkumar (Sudhir) Yanpallewar, and perspectives from early career researcher Elise Stevens of the University of Massachusetts. The session concludes with a moderated Q&A. Graduate students, postdoctoral fellows, and early career researchers are welcome to attend.

SUNDAY, JUNE 16, 2024

10:30 A.M. - 12:00 P.M.

THE USE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RAS) FOR THE TREATMENT OF SUBSTANCE USE DISORDER IN RATS AND HUMANS
Av. Van Horne, 2nd Floor

Chair: **Patricia Grigson*, Penn State University College of Medicine***
Co-Chair: **Scott Bunce*, Penn State University College of Medicine and Penn State Medical Center***

According to the CDC, over 111,355 people lost their lives to drug overdose from May 2022 to April 2023 in the United States alone. Clearly, new treatments are needed. Here, we will examine the mechanism(s) of action, safety, and possible effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of substance use disorder (SUD) in animal models and in humans. Speaker 1 will report on the safety and efficacy of the GLP-1RA, liraglutide, for the treatment of opioid use disorder (OUD) in rodent models. Data gleaned from light sheet microscopy will describe cFos expression patterns associated with cue-induced fentanyl seeking and reversal following treatment with the GLP-1RA. Speaker 2 will describe data addressing the safety and efficacy of liraglutide in patients in residential treatment for OUD. The effect of the GLP-1RA on opioid craving will be addressed using ecological momentary assessment. Speaker 3 will report on a Phase II Random Clinical Trial (RCT) testing the effect of the GLP-1RA, semaglutide, on craving and use in participants with a SUD. Finally, Speaker 4 will discuss repurposing a GLP-1RA for the treatment of nicotine use disorder and for the mitigation of post-cessation weight gain. While further research is required, GLP-1RAs, already approved for the treatment of type two diabetes and obesity, appear promising as a novel intervention for the treatment of SUD in humans.

The Glucagon-Like Peptide-1 Receptor Agonist, liraglutide, Reduces Heroin and Fentanyl Seeking in Rats
Speaker: **Patricia Grigson*, Penn State University College of Medicine***

Evidence for the Effectiveness of the Glucagon-Like Peptide-1 Receptor Agonist, liraglutide, to Reduce Craving in Humans in Residential Treatment for Opioid Use Disorder
Speaker: **Scott Bunce*, Penn State University College of Medicine and Penn State Medical Center***

Phase II Evaluation of Semaglutide in Non-Treatment-Seeking Participants With Substance Use Disorder
Speaker: **Christian Hendershot*, University of North Carolina at Chapel Hill***

Repurposing GLP-1 Receptor Agonists for the Treatment of Tobacco Dependence and Mitigation of Post-Cessation Weight Gain
Speaker: **Luba Yammine*, The University of Texas Health Science Center at Houston***

ABSTRACTS

10:30 A.M. - 12:00 P.M.

THE HEALING COMMUNITIES STUDY: DISRUPTING THE STATUS QUO TO ADDRESS OPIOID OVERDOSE DEATHS
Av. Viger, 2nd Floor

Chair: **Sharon Walsh*, University of Kentucky***
Co-Chair: **Jeffrey Samet*, Boston University Chobanian and Avedisian School of Medicine***

The HEALing Communities Study is a multi-site, randomized, parallel-group, cluster wait-list controlled trial of communities in Ohio, Kentucky, New York and Massachusetts (n=67) assessing the efficacy of the Communities that Heal intervention (CTH) to decrease opioid overdose deaths. The CTH consists has: 1) a community coalition engagement strategy that guides the intervention; 2) the evidence-based practices (EBPs) for deployment, and 3) health communication campaigns to increase EBP demand and reduce stigma. Community coalitions selected interventions for investment of study resources to address community needs. Many innovative efforts were attempted to disrupt the status quo of overdose deaths that impacted these urban and rural communities. This symposium will share the major outcomes of this trial reporting primary and secondary outcomes, including opioid overdose deaths, distribution of naloxone into communities, and uptake of and retention on medications for opioid use disorder.

HEALing: An Innovative Public Health Response to the Opioid Epidemic
Speaker: **Nabila El-Bassel*, Columbia University***

Impact on Opioid Overdose Deaths: The Healing Communities Study Randomized Controlled Trial
Speaker: **Jeffrey Samet*, Boston University Chobanian and Avedisian School of Medicine***

Increasing Overdose Education and Naloxone Distribution at a Community Level: Strategies and Outcomes
Speaker: **Sharon Walsh*, University of Kentucky***

Increasing Exposure to Medication for Opioid Use Disorder at a Community Level: Strategies and Outcomes
Speaker: **T. John Winhusen*, University of Cincinnati***

Moderator: **Redonna Chandler*, National Institutes of Health, National Institute on Drug Abuse***

10:30 A.M. - 12:00 P.M.

COMPUTATIONAL ADDICTION PSYCHIATRY: THEORY- AND DATA-DRIVEN APPROACHES TO TACKLE COMPLEX PHENOTYPES IN SUBSTANCE USE DISORDER
Av. Duluth, 2nd Floor

Chair: **Sergej Grunevski*, UBHC, Brain Health Institute, Rutgers University***
Co-Chair: **Robert Kohler*, Yale University School of Medicine***

ABSTRACTS

Substance use disorders implicate constant and complex interactions between our neurobiology and our environment. Combining this with a high variability in the expression of individual clinical features is what makes substance use disorders challenging psychiatric conditions to understand, predict, and treat. By leveraging theory- and data-driven models of decision making and neural function, we can probe the mechanisms underlying clinical manifestation and isolate latent signatures capable of identifying at-risk individuals. The first two presentations focus on theory-driven approaches that model belief updating and reinforcement learning relevant to substance use disorders. Emmanuel Alvarez will combine Bayesian modeling and fMRI to describe how neural signatures of optimistic bias inform real-world decisions to use substances in treatment-seeking patients. Dr. Maëlle Gueguen will present on how emotional affect biases explore vs. exploit behaviors that in turn influence clinical trajectories in populations with substance use disorders (opioid and methamphetamine). The final two presentations demonstrate the strength of data-driven methods to model craving and developmental risk factors. Sergej Grunevski will integrate ecological momentary assessment to investigate the timescale of urges and economic value for food and drugs with a neurocomputational model of craving that can decode self-reported urges from neural data in treatment-engaged individuals. Dr. Robert Kohler will discuss how multivariate pattern learning approaches can be used to identify latent dimensions of reward, impulsivity, and behavior, particularly during development, that relate to future substance use risk. Together, findings from this symposium highlight the powerful utility of computational modeling in probing complexity that undergirds substance use disorder.

Combining Neuroimaging and Real-World Sampling to Study Beliefs About Drug Use Risk
Speaker: **Emmanuel Alvarez***, Rutgers Robert Wood Johnson Medical School*

Investigating Decision-Making Biases During Negative Affective States Provides Insight Into Clinical Trajectories in Substance Use Disorders
Speaker: **Maëlle Gueguen***, Laureate Institute for Brain Research*

Longitudinal and Neurocomputational Modeling of Craving for Food and Drugs
Speaker: **Sergej Grunevski***, UBHC, Brain Health Institute, Rutgers University*

Identification of a Composite Latent Dimension of Reward Across Clinical, Behavioral and Neurobiological Domains Among Adolescents
Speaker: **Robert Kohler***, Yale University School of Medicine*

10:30 A.M. - 12:00 P.M.

ACUTE STIMULANT TOXICITY: THIS IS NOT OPIOID OVERDOSE
Rue Sainte Catherine-Saint Paul, 2nd Floor

Chair: **Phillip Coffin***, San Francisco Department of Public Health*
Co-Chair: **Alana Vivolo-Kantor***, Centers for Disease Control and Prevention*

Stimulants are often referred to as the "fourth wave" of the overdose crisis. However, stimulant toxicity is markedly different from opioid toxicity. While opioids cause acute respiratory depression, toxicity due to stimulants is largely cardiovascular and neuropsychiatric, and more likely associated with longterm, cumulative exposure. Vanishingly few studies have directly addressed stimulant toxicity, such that there are no established measures for non-fatal

toxicity, a poor understanding of fatal toxicity, and no interventions designed to address toxicity besides efforts cease stimulant use. In this symposium, we will report on the results of four studies funded by the Centers for Disease Control and Prevention under RFA-CE-21-002 to address acute stimulant toxicity and develop interventions. Dr Wagner will report on the prevalence and symptoms of methamphetamine toxicity among 400 people using methamphetamine in New Mexico and Nevada, including demographics, social determinants, and use behaviors. Dr Delcher will discuss results from natural language processing of medical records of decedents from acute stimulant toxicity in Kentucky. Dr Coffin will discuss the results of a large psychological autopsy study of acute stimulant toxicity decedents in San Francisco, including insights into the medical and social characteristics of these deaths and potential novel interventions. Dr Al-Tayyib will present preliminary findings from a randomized trial of care navigation and contingency management to link patients from acute care to treatment for methamphetamine use disorder in Colorado. Dr Vivolo-Kantor, Associate Director for Science of the Division for Overdose Prevention in the CDC's National Center for Injury Prevention and Control, will moderate.

Behavioral and Substance Use Correlates of Experiencing Acute Methamphetamine Toxicity
Speaker: **Karla Wagner*, University of Nevada School of Public Health***

"Unveiling Insights: Deciphering Acute Stimulant Toxicity through Natural Language Processing in Clinical Notes from Kentucky"
Speaker: **Chris Delcher*, University of Kentucky***

Stimulant Toxicity and Potential Interventions: Insights from Psychological Autopsies
Speaker: **Phillip Coffin*, San Francisco Department of Public Health***

Beat Meth: Beginning Early and Assertive Treatment for Methamphetamine Use
Speaker: **Alia Al-Tayyib*, Denver Health and Hospital Authority***

10:30 A.M. - 12:00 P.M.

THE GROWING OLDER ADULT POPULATION AND SUBSTANCE USE: MULTIMORBIDITY, HEALTHCARE UTILIZATION, AND HARM REDUCTION CONSIDERATIONS
Place du Canada, 2nd Floor

Chair: **Bethea Kleykamp*, University of Maryland School of Medicine***
Co-Chair: **Margaret Fahey*, Medical University of South Carolina***

A growing body of research suggests that other types of substance use are on the rise for older adults, including alcohol, cocaine, opioid, and cannabis use. There are signs that a growing number of older adults are seeking substance use treatment, but only about one-quarter of addiction treatment programs have specialty services for older adults. Further, older adults (65+) are the only age group in the United States that has not seen a reduction in smoking prevalence in over 20 years. These trends are alarming in the context of the exponential growth of the older adult population and highlight the need for pragmatic and timely approaches to addressing this population's substance use, including harm reduction.
This symposium aims to educate the audience on trends in substance use among older adults and includes four presentations addressing 1) considerations for research, treatment, and policy efforts focused on aging adults and substance use, 2) sociodemographic characteristics

and healthcare utilization rates associated with using tobacco in a nationally representative sample of adults 50+ , 3) screening and discussions with healthcare providers about alcohol, tobacco, and drug use as a way to facilitate care engagement and harm reduction; and 4) descriptive epidemiology for poisoning-related deaths among older adults in the United States, including how deaths have grown substantially in the period 2018 to 2021. Given this symposium's broad focus, we expect it will interest clinical researchers, healthcare providers, and health policy organizations interested in learning about trends in substance use among older adults.

How Can We Better Support Older Adults With Co-Occurring Substance use? Methodological, Clinical, and Policy Considerations
Speaker: **Bethea Kleykamp*, University of Maryland School of Medicine***

Individual-Level Sociodemographics & Healthcare Utilization Associated With Tobacco Use Within a Nationally Representative U.S. Sample of Adults 50+ Years
Speaker: **Margaret Fahey*, Medical University of South Carolina***

Older Adults Discussing Alcohol, Tobacco, and Drug Use With Providers in 2021: Identifying Opportunities for Care Engagement
Speaker: **Pia Mauro*, Columbia University***

Increases in Poisoning-Related Mortality Among Older Adults in the United States, 2018-2021
Speaker: **Sarah Cercone Heavey*, School of Public Health and Health Professions, State University of New York at Buffalo***

10:30 A.M. - 12:00 P.M.

TRANSLATIONALLY EVALUATING CAUSES AND CONSEQUENCES OF XYLAZINE ADULTERATION IN THE OPIOID SUPPLY
Square Dorchester, 2nd Floor

Chair: **Cassandra Gipson*, University of Kentucky***
Co-Chair: **Justin Strickland*, Johns Hopkins University School of Medicine***

This session will provide translational evidence of the causes and consequences of xylazine adulteration of the opioid drug supply, including epidemiology, laboratory-based clinical data, and preclinical rat models. First, Dr. Thakrar will present on the clinical manifestations of xylazine adulteration focusing on overdoses involving xylazine, a possible xylazine withdrawal syndrome, and wounds associated with xylazine use. He will summarize existing published literature and will present novel findings from a retrospective cohort of hospitalized patients with confirmed xylazine exposure. Dr. Ellis will then present epidemiological data on xylazine trends, perceptions, comorbid conditions, and sociodemographic correlates among a longitudinal national sample of individuals entering treatment for opioid use disorder. Dr. Strickland will next discuss treatment outcomes data related to xylazine and other opioid supply adulterants derived from two data sources – a national treatment outcomes cohort and human laboratory studies conducted locally. These data emphasize how exposure to emerging adulterants in the drug supply can carry significant risk for poorer treatment outcomes including worsened biopsychological symptoms at substance use treatment entry, altered

withdrawal expression, and overdose risk after discharge. Finally, Dr. Gipson will present novel preclinical rat findings characterizing sex-specific impacts of intravenous xylazine on fentanyl demand and withdrawal and will provide a direct comparison to Lucemyra (lofexidine), an FDA-approved adrenergic 2a agonist for opioid withdrawal treatment. Together, this session will provide a translational overview of the current state of the field with regard to xylazine adulteration of the opioid drug supply.

Clinical Manifestations of Xylazine Exposure Among Hospitalized Patients
Speaker: **Ashish Thakrar*, Perelman School of Medicine University of Pennsylvania***

Xylazine Use, Perception, and Correlates Among a National Sample of Individuals with Opioid Use Disorder
Speaker: **Matthew Ellis*, Washington University in St. Louis***

Clinical Trajectories and Outcomes Associated With Xylazine Exposure in Substance Use Treatment
Speaker: **Justin Strickland*, Johns Hopkins University School of Medicine***

Patterns of Fentanyl Use and Withdrawal When Xylazine is Used as an Adulterant: Leveraging Preclinical Addiction Neuroscience to Address a Pressing Public Health Crisis
Speaker: **Cassandra Gipson*, University of Kentucky***

2:00 P.M. - 3:00 P.M.

NEUROINFLAMMATORY SIGNALING IN SUBSTANCE USE DISORDERS? RECENT EVIDENCE FROM MOLECULAR IMAGING STUDIES
Av. Van Horne, 2nd Floor

Chair: **Eric Woodcock*, Wayne State University***
Co-Chair: **Jacob Dubroff*, Hospital of the University of Pennsylvania***

Substance use disorders (SUDs) are known to modulate peripheral immune function. Individuals with SUDs recover more slowly from illness, infection, and surgery than non-substance-using individuals. However, relatively little is known about the brain's immune system (or neuroimmune system) among individuals with SUDs. Microglia and astrocytes anchor the neuroimmune system and exert immunomodulatory influence via cytokine/chemokine secretion, production of reactive oxygen species, and/or glial proliferation and morphological transformation. Acute neuroimmune responses are adaptive and restore homeostasis. However, unresolved or chronic neuroimmune signaling can become pathological, resulting in synapse loss, cell death, and impaired cognition. In SUDs, postmortem analyses show upregulated glial markers indicative of neuroinflammation in the brains of deceased substance-using individuals. However, to date, studies investigating in vivo neuroimmune phenotypes among living patients with SUDs have been limited. Initial Positron Emission Tomography (PET) imaging studies applied radiotracers that bound to the mitochondrial protein, 18kDa translocator protein (TSPO). The 'first wave' of PET TSPO imaging studies yielded mixed findings, perhaps due to complexities with quantification, lack of glial cell specificity, or limited statistical power. Here, we present novel findings from the 'second wave' of PET imaging studies using 'next generation' neuroimmune radiotracers,

including [18F]NOS and [11C]AMT, among individuals with SUDs. Finally, we show findings from a large, multi-site analysis of TSPO data among tobacco smokers. Neuroimmune signaling has been shown to modulate drug craving, subjective positive drug response, and drug seeking; thus, representing a novel and promising target for medication development for SUDs.

Using [18F]NOS PET Imaging to Examine Neuroinflammation in Vapers and Dual Users
Speaker: **Reagan Wetherill*, University of Pennsylvania***

Kynurenine Pathway Dysfunction in Opioid Use Disorder: Evidence From [11C]AMT PET Imaging
Speaker: **Eric Woodcock*, Wayne State University***

Imaging the Neuroimmune System in Tobacco Smokers: Findings From a Multi-Site [11C]PBR28 Analysis
Speaker: **Corinde Wiers*, University of Pennsylvania***

3:30 P.M. - 4:45 P.M.

COMMUNICATING WITH MEDIA ABOUT SUBSTANCE USE: LESSONS LEARNED AND BEST PRACTICES FROM REPORTING ON ADDICTION
Place du Canada, 2nd Floor

Chair: **Rachel Gicquelais*, University of Wisconsin – Madison***

Background: Researchers are often approached by journalists to synthesize research findings for news articles, radio, and other media. Unfortunately, many researchers lack formal training to interact with the media and most journalists lack formal training about substance use. Collectively, this can leave researchers feeling unprepared to interact with the media in a way that avoids perpetuating substance use stigma, misinformation about substance use disorders, or other harmful narratives. This forum will share lessons learned by researchers with varying levels of experience interacting with media and use these to provide attendees with specific recommendations for science communication.
The Media Forum will be open to all CPDD attendees including graduate-level and early career attendees for whom this forum could serve as a valuable career development experience. The 60-minute forum will consist of 20-minute segments. The first segment includes Ms. Marra, Co-director of Reporting on Addiction, moderating a discussion with two researchers (Dr. Rachel Gicquelais and Dr. Jodi Gilman) sharing their experiences interacting with the media. That is followed by a 20-minute training session on how to prepare for media interviews and the vital role of scientists working with the media. We will conclude with a 20-min Q and A with the audience.

Media Experience Q&A: My First Live Radio Interview
Speaker: **Rachel Gicquelais*, University of Wisconsin, Madison***

Media Experience Q&A: What Happens When Your Paper is Picked up by the Media
Speaker: **Jodi Gilman*, Massachusetts General Hospital-Psychiatry***

Harnessing Your Expertise: How to Improve Your Interactions With the Press
Speaker: **Ashton Marra*, Reporting on Addiction***

ABSTRACTS

3:30 P.M. - 4:45 P.M.

CPDD Public Policy Committee Forum: Data, Policies, and Experiences From Around the World on Overdose Prevention Centers (aka Drug Consumption Rooms, Supervised Consumption Sites)
Av. Viger, 2nd Floor

Chair: **Sandra Comer***, Columbia University and NYSPI*
Co-Chair: **Sergej Grunevski***, UBHC, Brain Health Institute, Rutgers University*

Summary Abstract The relatively recent and rapid increase in drug overdose deaths has been met with a variety of responses to reduce drug-related harms across harm reduction, treatment, and prevention services. One such harm reduction strategy is overdose prevention centers (OPCs), where people consume substances near trained staff who can intervene during overdose incidents and provide a caring, non-stigmatizing environment. Decades of research on OPCs has shown reductions in transmission of blood-borne diseases (e.g., HIV and hepatitis), prevention of overdose-related deaths, and increased enrollment in addiction treatment programs. However, many academics, policy makers, and community members remain skeptical and concerned about safety and effectiveness, necessitating continued dialogue about this controversial harm reduction strategy.
This Policy Forum will provide an overview and scientific evaluation of OPCs across four different countries. Dr. Perrine Roux will present results from three studies conducted after the opening of the first OPCs in France and will discuss effectiveness, cost-effectiveness, and use of scientific data in guiding public policy. Dr. Bennett Allen will present an overview of OPCs in the United States, including their legal status, current epidemiological evidence, and the ongoing evaluation of active sites in the U.S. Dr. Gillian Kolla will examine the rapid scale-up of OPCs in Canada and discuss evidence on their effectiveness, development of policy and programmatic changes, and challenges to and emerging contestation of OPC efforts. Dr. Nicholas Lintzeris will discuss research on the establishment, effectiveness, and policy challenges of OPCs in Australia. Dr. Rafael Torruella will serve as the discussant.

Canadian Perspectives on Supervised Consumption Sites
Speaker: **Gillian Kolla***, Faculty of Medicine, Memorial University of Newfoundland*

Building the US Evidence base: Evaluation of the New York City Overdose Prevention Centers
Speaker: **Bennett Allen***, NYU School of Medicine*

The Trials, Successes and Pitfalls of Medically Supervised Injecting Services in Australia
Speaker: **Nicholas Lintzeris***, South Eastern Sydney Local Health District*

Research on Drug Consumption Rooms in France: From Evaluation to Advocacy
Speaker: **Perrine Roux***, French Institute of Health and Medical Research*

Discussant: **Rafael Torruella***, Intercambios Puerto Rico*

ABSTRACTS

MONDAY, JUNE 17, 2024

8:00 A.M. - 9:00 A.M.

ADVANCING DATA SCIENCE ETHICS IN DRUG ADDICTION EPIDEMIOLOGY, SERVICES, AND PREVENTION RESEARCH
Place du Canada, 2nd Floor

Chair: Janet Kuramoto-Crawford*, DHHS/National Institute on Drug Abuse*
Co-Chair: Karli Hochstatter*, Friends Research Institute*

This symposium brings together three investigators to discuss challenges and opportunities in applying data science ethics in the real-world problem of drug addiction. Drug addiction research generates highly sensitive data such as HIV risk behaviors and illicit drug use, which pose particular risk due to the stigmatization of drug misuse and potential other harms if data were to be used inappropriately. Advancing ethical data science and ethical artificial intelligence (AI) can help detect and mitigate bias within data sets and models, ensure respect of privacy, confidentiality, and ownership of data, and further our understanding and prevention of the societal and unintended consequences from data science applied research. Data science projects also leverage linked data, which necessitates additional ethical considerations of record linkage.
The investigators will highlight the following: 1) ethical complexities of utilizing machine learning models, particularly in formulating impartial definitions of opioid overdose within modern datasets, emphasizing their relevance to advanced data science applications in epidemiology, services, and prevention research; 2) assessing bias and debiasing strategies by incorporating AI in OUD modeling and ChatBot applications, and 3) how leveraging integrated technology to deliver universal question-based substance use screening across healthcare settings and extracting substance use documentation in unstructured fields can eliminate existing bias and ensure all young people have the opportunity to receive prevention and harm reduction interventions to prevent substance use disorder. The chairs will conclude the session with a moderated discussion of current gaps and opportunities in future applications of data science ethics in drug addiction research.

Redefining Opioid Surveillance: Integrating AI and Ethical Frameworks in RADOR-KY's Overdose Definitions
Speaker: Peter Rock*, University of Kentucky*

Bias Assessment and Debiasing Strategies Incorporating Artificial Intelligence in OUD Modeling and Chatbot Applications
Speaker: Andrew Taylor, *Yale School of Medicine*

Detecting and Preventing Substance Use in Pediatric Healthcare Settings
Speaker: Sarah Beal*, Cincinnati Children's Hospital*

ABSTRACTS

10:45 A.M. - 12:15 P.M.

CRAVING A NOVEL TREATMENT ENDPOINT: THE ROLE OF DRUG CRAVING IN THE TREATMENT OF SUBSTANCE USE DISORDERS
Place du Canada, 2nd Floor

Chair: **Ivan Montoya*, DHHS/National Institute on Drug Abuse***
Co-Chair: **Cecilia Bergeria*, Johns Hopkins University School of Medicine***

Summary Abstract Drug craving is the strong and sometimes overwhelming desire to use a drug. Cravings can be elicited by physiological, psychological, and environmental cues and can be associated with poor treatment outcomes (e.g., treatment attrition, non-medical drug use). In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), craving is recognized as a diagnostic criterion for Substance Use Disorders (SUD), but there is very little consensus on how craving should be measured, monitored, nor treated in clinical care. While multiple pharmacological and non-pharmacological interventions have been investigated for the treatment of drug craving, the impact of this research is limited because the FDA does not recognize or accept drug craving as an endpoint for regulatory approval of treatments. In fact, FDA staff members have publicly discouraged the evaluation of drug craving as a primary outcome of clinical trials of treatments for SUD. The purpose of this symposium is to (1) review the advances in the development of the construct of craving and the instruments to evaluate it, (2) to review the results of studies evaluating changes in craving during SUD treatment and its relation to other salutary outcomes, and (3) to learn about the FDA's stand and guidance to advance the evaluation of drug craving to be accepted as a treatment outcome for SUD therapeutics development.

Abstinence and Reduced Use in Stimulant Use Disorders Trials: Association With Craving and Other Outcomes
Speaker: **Masoumeh Amin-Esmaeili*, Johns Hopkins Bloomberg School of Public Health***

The Role of the FDA in Establishing Craving as a Substance Use Disorder Endpoint
Speaker: **Marc Auriacombe*, Charles Perrens Hospital and CHU Bordeaux***

Validation of an Opioid Craving Scale in an Industry Clinical Trial
Speaker: **Anne Le Moigne*, Indivior***

Utilizing the FDA Drug Development Tool Qualification Program to Establish Opioid Craving as a Treatment Endpoint
Speaker: **Cecilia Bergeria*, Johns Hopkins University School of Medicine***

Moderator: **Ivan Montoya*, DHHS/National Institute on Drug Abuse***

Moderator: **Marta Sokolowska*, FDA***

ABSTRACTS

10:45 A.M. - 12:15 P.M.

RECENT STEPS TOWARD INDIVIDUALIZATION OF TRANSCRANIAL MAGNETIC STIMULATION FOR SUBSTANCE USE DISORDERS
Square Dorchester, 2nd Floor

Chair: **Vaughn Steele***, Yale University School of Medicine*
Co-Chair: **Tony George***, University of Toronto*

Substance use disorders (SUDs) are characterized by dysregulated cognitive functions such as drug cue reactivity (e.g., craving), reward processing, and executive control. Decades of translational research give us a deep understanding of these circuits and several therapeutic targets for neuromodulation with repetitive transcranial magnetic stimulation (rTMS). Recent studies continue to suggest the promise of rTMS and opens to the door to methodological advances in individualization to enhance rTMS effects. In the symposium, we will present studies focused on modulating dysregulated circuits in co-occurring clinical disorders, cannabis use disorder (CUD), and opioid use disorder (OUD) with effects measured with neuroimaging and event-related potentials (ERPs). Dr. Ward will present data that identifies a schizophrenia-specific circuit of nicotine dependence, validates this network with a pharmacologic intervention, and then uses an individualized, network-targeted rTMS intervention to modulate nicotine craving in schizophrenia. Dr. Sahlem will report behavioral and functional neuroimaging effects observed in a completed Phase-2 clinical trial designed for translational development of rTMS as a treatment for CUD. He will also outline ongoing work using functional targeting to increase efficacy. Dr. Biernacki will present ERP results supporting a dopamine-mediated reward signature, the reward-positivity, as an rTMS therapeutic target in participants with OUD. Finally, Dr. Steele will present neuroimaging effects of rTMS in participants with OUD suggesting effects are universal for executive control but enhanced with individualization in cue reactivity. Together, these presentations outline recent applications of rTMS in SUDs and highlight substantial steps toward clinical interventions across populations, applications, and cognitive functions.

A Disease-Informed, Network-Targeted Neuromodulation Intervention Affects Craving in Individuals With Schizophrenia and Nicotine Dependence
Speaker: **Heather Ward***, Vanderbilt University Medical Center*

The Translational Development of Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder
Speaker: **Gregory Sahlem***, Stanford University*

Toward Normalization of Reward Processing in People With Opioid Use Disorder Using Excitatory Transcranial Magnetic Stimulation
Speaker: **Kathryn Biernacki***, National Institute of Drug Abuse/NIH/DHHS*

Not All Transcranial Magnetic Stimulation Individualization Efforts are Equal in a Methadone-Maintained Opioid Use Disorder Sample
Speaker: **Vaughn Steele***, Yale University School of Medicine*

ABSTRACTS

10:45 A.M. - 12:15 P.M.

TWO-EYED SEEING FOR OPIOID USE DISORDER TREATMENT AND RECOVERY WITH AMERICAN INDIAN AND ALASKA NATIVE COMMUNITIES
Av. Van Horne, 2nd Floor

Chair: **Carmen Rosa*, National Institute of Drug Abuse, National Institutes of Health***
Co-Chair: **Aimee Campbell*, New York State Psychiatric Institute Division on Substance Use Disorders***

Despite significant strengths, the overdose crisis has disproportionally impacted American Indian/Alaska Native (AI/AN) people and exacerbated by the COVID-19 pandemic. Health disparities, including overdose, are linked to structural factors (e.g., economics, healthcare access). Research is needed to develop interventions in the context of these factors and to promote wellness. The aim of this symposium is to highlight ongoing research conducted in partnership with AI/AN-serving healthcare organizations and describe best practices in the development and use of innovative, culturally responsive, and strength based approaches to increase health equity.
The first speaker will review qualitative findings from a study that is leveraging cultural strengths to increase acceptability and uptake of Medications for Opioid Use Disorder (MUD). Critical elements for assessment and cultural integration using a community-based participatory approach will be highlighted. The second speaker will highlight the impact of the COVID-19 pandemic on delivery and sustainment of telemedicine, medications, and the need to provide a menu of treatment and social service options to meet the needs of AI/AN communities. The third speaker will discuss the development and testing of a novel, moderated, private Facebook group intervention to support AI/AN women in opioid use disorder recovery. The intervention was developed through feedback from key partners and beta tested and refined with AI/AN women in recovery. The fourth speaker will summarize efforts within the Great Plains region to identify AI/AN addiction treatment and research agendas among diverse Tribal communities and to explore feasibility of telehealth platforms to promote access to MOUD.

Perspectives of Opioid Use Disorder Treatment in American Indian and Alaska Native Communities: A Qualitative Study
Speaker: **Kelley Jansen*, Southcentral Foundation***

The Impact of Policy and Regulatory Changes in the Access and Delivery of Medications for Opioid Use Disorder During COVID-19 Among American Indian and Alaska Native Communities
Speaker: **Kait Hirchak*, Washington State University***

Developing a Facebook Group Intervention to Support Opioid Recovery Among American Indian Women: The Wiidookaage'win Study
Speaker: **Christi Patten*, Mayo Clinic***

The Great Plains Initiative: Culturally Safe Space in Recovery Research
Speaker: **Allison Kelliher*, Johns Hopkins Bloomberg School of Public Health***

ABSTRACTS

10:45 A.M. - 12:15 P.M.

SUBSTANCE USE DISORDERS AND ASSOCIATED MEDICAL CONSEQUENCES: IMPLICATIONS FOR PREVENTION AND TREATMENT
Av. Duluth, 2nd Floor

Chair: **Jia Bei Wang*, NIDA, NIH***
Co-Chair: **Guifang Lao*, NIH***

Substance Use Disorders (SUDs) pose a significant challenge to global health. SUDs rarely occur in isolation: Many individuals who use drugs have other health conditions, such as HIV, hepatitis C virus, chronic pain, cardiovascular disease, and cancer. One of NIDA's cross-cutting priorities is understanding interactions between substance use and co-occurring health conditions. This is critical to developing prevention and treatment strategies, ultimately improving the health of individuals with SUDs.
This symposium aims to gather researchers and health professionals to learn and discuss cutting-edge research on the medical consequences of SUDs and the implications for prevention and treatment. This symposium seeks to disseminate research findings, foster interdisciplinary collaborations, and promote evidence-based intervention and treatment strategies. The topic includes:

1. **Frequent Cannabis Use, Risk-Reward Processing, and Neural Response Mechanisms among Young Black Sexual Minority Men Vulnerable to HIV Infection (Dr. Sarah Keedy)**
2. **Effects of HIV, Cocaine, and Prolonged ART Use on Subclinical Cardiovascular Disease (Dr. Shenghan Lai)**
3. **Managing Complex Skin Wounds Associated with Xylazine Use (Dr. Lisa Rae)**
4. **Pulmonary arterial hypertension, methamphetamine, and HIV (Dr. Steve Shoptaw)**

By shedding light on the medical consequences of SUDs, this symposium brings together researchers and practitioners to collaboratively explore innovative solutions to the challenges in preventing and treating SUDs and associated medical consequences and provide a platform for young scientists to explore career paths and network. Participants and panelists will discuss how to tackle these pressing issues and their implications for delivering prevention and care for SUDs and associated medical consequences.

Preliminary Results for the Study on Frequent Cannabis Use, Risk-Reward Processing, and Neural Response Mechanisms Among Young Black Sexual Minority Men Vulnerable to HIV Infection
Speaker: **Sarah Keedy*, University of Chicago***

Pulmonary Arterial Hypertension, Methamphetamine and HIV
Speaker: **Steve Shoptaw*, University of California Los Angeles***

Substance Use Disorders and Associated Medical Consequences: Implications for Prevention and Treatment
Speaker: **Shenghan Lai*, University of Maryland School of Medicine***

Substance Use Disorders and Associated Medical Consequences: Implications for Prevention and Treatment
Speaker: **Lisa Rae*, Temple University***

ABSTRACTS

Moderator: Justin Knox*, Columbia University*

10:45 A.M. - 12:15 P.M.

DRUG-DRUG INTERACTIONS RELEVANT TO SUBSTANCE ABUSE AND TOXICITY
Rue Sainte Catherine-Saint Paul, 2nd Floor

Chair: William Fantegrossi*, University of Arkansas for Medical Sciences*
Co-Chair: Jeffery Moran*, PinPoint Testing, LLC*

Polysubstance use (PSU) is the use of two or more abused substances, either simultaneously or concurrently. Simultaneous use of two drugs can boost abuse-related effects, as in the intentional co-administration of heroin and cocaine producing enhanced reinforcing effects when compared to the delivery of either drug alone. Alternatively, use of a single abused substance can produce different effects in the presence of prescribed therapeutics, including anxiolytics and antidepressants. Finally, there is an increasing prevalence of adulterated drug supplies, the most notable of which is the current threat of fentanyl and xylazine mixtures, which leads to unintentional PSU, and increased toxicity. Recent research has largely focused on pharmacodynamic interactions in PSU, but there remains a lack of mechanistic research on topics relevant to PSU, and significant and clinically relevant pharmacokinetic interactions are under-studied. This symposium will explore consequences of drug-drug interactions across several pharmacological classes, including opioids, cannabinoids, psychostimulants, and nicotine. Speakers will discuss preclinical data from their laboratories, focusing on how the presence of one drug may alter the absorption, distribution, metabolism and excretion of another drug, and how these altered pharmacokinetic factors may drive exacerbated abuse liability and toxicity of the combinations. Presenters from industry and academia will discuss the challenges of studying PSU in terms of analytical procedures, experimental design, and data interpretation. Consequences of PSU ranging from abuse-related effects to cardiovascular effects to drug disposition will be presented, and a moderated discussion session will explore clinical relevance and offer next steps to advance the field.

High-Throughput Quantitation of Fentanyl-Like Opioids Alone and in Combination With Other Drugs
Speaker: Marina Avram*, PinPoint Testing, LLC*

Assessing the Impact of Beta-Nicotyrine on the Metabolism, Drug Discrimination and Abuse Liability of Nicotine, and Its Implications for ENDS Regulation
Speaker: John Smethells*, Hennepin Healthcare Research Institute*

Drug-Drug Interactions With a Single Drug: Effects of Racemic and Non-Racemic Mixtures of MDMA Versus its Component Enantiomers
Speaker: Harpreet Kaur*, PharmAla Biotech*

Interactions Between the Abuse-Related and Toxic Effects of Opioids and Stimulants in Rats
Speaker: Gregory Collins*, University of Texas Health Science Center at San Antonio*

Moderator: Michael Baumann*, NIDA, Intramural Research Program*

ABSTRACTS

10:45 A.M. - 12:15 P.M.

AMPLIFYING VOICES OF PERINATAL PERSONS WITH SUBSTANCE USE DISORDERS
Av. Viger, 2nd Floor

Chair: **Sara Witcraft***, Medical University of South Carolina*
Co-Chair: **Constance Guille***, Medical University of South Carolina*

Perinatal substance use disorders (PSUDs), including drug overdose, are a leading cause of pregnancy-related deaths in the United States (CDC, 2022), and account for significant obstetric (e.g., placental abruption) and neonatal (e.g., preterm birth) morbidity (Logue et al., 2022). Current systems are not structured to provide individuals with PSUDs with the recovery and parenting support they need (Martin and Parlier-Ahmad, 2021). Instead, individuals with PSUDs are marginalized and stigmatized by the healthcare, child welfare, and criminal justice systems, creating barriers to receiving needed services and supports and resulting in in untreated illness or punitive action such as loss of child custody. This symposium seeks to amplify voices of people with lived experiences of PSUDs by presenting primarily qualitative data and discussing patient-centered approaches to improve access to, and equity and quality of substance use services for birthing people. The first talk will present qualitative data on internal (e.g., stress) and external (e.g., stigma) factors that influence pregnant and postpartum people's use of buprenorphine and methadone. The second talk will describe a community-based participatory research approach in the creation of a digital tool to improve parenting and recovery outcomes among mothers in early recovery. Next, data from qualitative interviews will highlight how technology may facilitate increased comfort with disclosure of prenatal substance use and treatment seeking behaviors among Black perinatal people with PSUDs. The final talk will present preliminary data from an ongoing project that cross-trains peer support specialists as doulas to support pregnant people with PSUDs.

The Role of Doulas in Supporting Pregnant and Postpartum People With Substance Use Disorders
Speaker: **Courtney King***, Medical University of South Carolina*

Listening to Women and Pregnant and Postpartum People: Qualitative Research to Inform Opioid Use Disorder Treatment for Pregnant and Postpartum People
Speaker: **Angela Moreland***, Medical University of South Carolina*

Pregnant and Postpartum Peoples' Experience With Using Buprenorphine and Methadone for Perinatal Opioid Use Disorder
Speaker: **Sara Witcraft***, Medical University of South Carolina*

Customizing a Digital Support Intervention for Mothering Women With Substance Use Disorders
Speaker: **Phyllis Raynor***, University of South Carolina*

Moderator: **Constance Guille***, Medical University of South Carolina*

ABSTRACTS

2:15 P.M. - 3:45 P.M.

BRIDGING THE GAP: PRACTICAL AND ETHICAL CONSIDERATIONS ON THE UTILITY OF ARTIFICIAL INTELLIGENCE IN SUBSTANCE USE DISORDERS
Av. Van Horne, 2nd Floor

Chair: Suky Martinez*, Johns Hopkins University School of Medicine*
Co-Chair: Jermaine Jones*, Columbia University Irving Medical Center*

In recent years, Artificial Intelligence (AI) has gained prominence across various scientific domains due to its potential to revolutionize healthcare, especially in the diagnosis, treatment, and understanding of substance use disorders (SUDs). This session will examine the multifaceted dimensions of implementing AI into the field of SUDs and related psychopathologies, prioritizing discussions on ethics and utility. The objective is to rigorously assess the ethical repercussions and practical benefits and challenges of assimilating AI into SUD research and clinical settings, forging a dialogue among esteemed scholars and professionals with varied expertise. During the session, an AI researcher will provide insights into the prevailing trends of AI incorporation in SUD research, spotlighting some current applications. A machine learning engineer, data scientist, and industry expert will shed light on AI's practical roles in both the private and public sectors, underscoring its transformative potential for research. Philosophers will explore the ethical considerations posed by AI in SUD contexts, discussing some of the moral dilemmas inherent in AI-facilitated decision-making and its possible implications for preserving patient autonomy and privacy. A clinician/AI researcher will then explore AI's clinical ramifications in SUDs, focusing on individualized treatment plans and patient monitoring. The session will culminate in an interactive segment and enriching dialogue between the panelists and attendees. This symposium aspires to present an opportunity for a nuanced discussion of AI, ethics, and SUDs with the aim of fostering collaborations and debate.

Bridging the Gap: Practical and Ethical Considerations on the Utility of Artificial Intelligence in Substance Use Disorders
Speaker: Gabriel Odom*, Florida International University*

Bridging the Gap: Practical and Ethical Considerations on the Utility of Artificial Intelligence in Substance Use Disorders
Speaker: Laura Brandt*, City College of New York*

Bridging the Gap: Practical and Ethical Considerations on the Utility of Artificial Intelligence in Substance Use Disorders
Speaker: Ethan Wade, *Booz Allen Hamilton*

Bridging the Gap: Practical and Ethical Considerations on the Utility of Artificial Intelligence in Substance Use Disorders
Speaker: Dominic Sisti*, University of Pennsylvania Perelman School of Medicine*

Bridging the Gap: Practical and Ethical Considerations on the Utility of Artificial Intelligence in Substance Use Disorders
Speaker: Clinton Castro*, University of Wisconsin-Madison*

ABSTRACTS

2:15 P.M. - 3:45 P.M.

CPDD ANIMAL RESEARCH COMMITTEE FORUM: BEST PRACTICES FOR WORKING WITH IACUC AND OTHER REGULATORY GROUPS
Place du Canada, 2nd Floor

Chair: Katherine Serafine*, The University of Texas at El Paso*
Co-Chair: Lindsey Galbo-Thomma*, University of Texas Health Science Center at San Antonio*

This session will feature CPDD members who conduct animal research, as well as members of the Animals in Research Committee who have served on their local Institutional Animal Care and Use Committees (IACUC). The forum will begin with a discussion highlighting challenges members have navigated in communicating with their IACUC about animal research methods used for investigating drugs. Additionally, participants will discuss helpful strategies for interacting with regulatory groups, which sometimes include members of the public/non-scientists. Attendees will leave the session with specific examples of challenges animal researchers might encounter with regulatory groups, and a blueprint for clear and effective communications with such groups. This session is also geared toward providing new or future principal investigators with insight into what to expect with regard to working with institutional regulatory committee members and will provide guidance and recommendations for effective communication to foster successful relationships to reduce the potential for conflict, confusion and experimental delays.

Effective Communication: Fostering Successful Relationships to Reduce the Potential for Conflict, Confusion, and Experimental Delays
Speaker: Paul Czoty*, Wake Forest University School of Medicine*

Navigating Challenges in Communicating
Speaker: Katherine Serafine*, The University of Texas at El Paso*

Helpful Strategies for Interacting With Regulatory Groups
Speaker: Lindsey Galbo-Thomma*, University of Texas Health Science Center at San Antonio*

2:15 P.M. - 3:45 P.M.

CPDD HUMAN RESEARCH COMMITTEE FORUM: NAVIGATING THE LEGISLATIVE AND ETHICAL COMPLEXITIES OF CANNABINOIDS AND PSYCHEDELICS
Place du Canada, 2nd Floor

Chair: Justin Strickland*, Johns Hopkins University School of Medicine*
Co-Chair: Joao De Aquino*, Yale University School of Medicine*

Summary Abstract The emergence of cannabinoids and psychedelics as potential therapeutic agents in modern medicine has garnered significant attention from both the medical community and the general public. Historically linked with countercultural movements and often relegated to non-medical use, these substances have begun to shed their controversial reputations, as recent scientific investigations reveal their potential therapeutic benefits. From alleviating symptoms in various substance use disorders to offering potential breakthroughs in psychiatric care, the clinical implications of cannabinoids and psychedelics are vast and

intriguing. Recognizing the heightened interest among CPDD attendees and the broader medical community, the CPDD Human Research Committee proposes this forum to facilitate discussions about cannabinoids and psychedelics in the landscape of substance use disorder treatment, including regulatory and ethical considerations. It is imperative to address the evolving regulatory landscape surrounding cannabinoids and psychedelics, since these drugs are becoming accessible in the U.S. and beyond through patchwork legislative reforms. Presenters from academic, industry, and regulatory bodies will provide insights on how changes in legislation and policy — both at the state and federal levels — are bound to affect research, clinical applications, and patient access. Additionally, the forum will probe the ethical dilemmas posed by the research, prescription, and use of these substances. We will delve into topics such as setting guidelines for drugs obtained outside traditional medical suppliers, licensing requirements for drug administration in clinical research, potential drug contraindications, and unique ethical considerations for individuals with substance use disorders, particularly for those from racialized/minoritized groups.

Working With Psychedelics in Clinical and Research Settings: Challenges and Opportunities for the Field
Speaker: **Albert Garcia-Romeu*, Johns Hopkins University School of Medicine***

Conundrums of Research With Schedule 1 Substances: NIDA's Priorities and What we can and Cannot do to Help
Speaker: **Susan Weiss*, National Institute on Drug Abuse, National Institutes of Health***

Can I Do That? Regulatory and Ethical Challenges to Conducting Cannabinoid-Based Clinical Research
Speaker: **Staci Gruber*, McLean Hospital, Harvard Medical School***

Cannabinoid Regulatory Science: The Derivation and Recommendation of an Acceptable Daily Intake Value and Upper Intake Limits for CBD
Speaker: **Marcel O. Bonn-Miller*, Charlotte's Web***

No Pain, No Gain: Surmounting the Challenges of Conducting Research With THC, Psilocybin, DMT and Other Schedule 1 Drugs
Speaker: **Deepak D'Souza*, Yale University School of Medicine***

Discussant: **Rachel Luba*, New York State Psychiatric Institute***

5:15 P.M. - 6:15 P.M.

IS HEROIN DEPENDENCE A "CHRONIC LONG-TERM CONDITION"?
Square Dorchester, 2nd Floor

Chair: **Kathleen Brady*, Medical University of South Carolina***
Co-Chair: **Maree Teesson*, The University of Sydney***

Heroin dependence is often described as a recurrent, 'chronic, long-term condition', associated with high rates of mortality and a greater burden of disease than any other illicit drug. But is this type of progression inevitable?

ABSTRACTS

Longitudinal cohort studies of heroin dependence are key to investigating patterns and predictors of remission, mortality, psychopathology and long-term treatment outcome. Although much cross-sectional research exists, the comparably few prospective longitudinal cohort studies provide a unique opportunity to understand the persistence of heroin use and other disorders over time. Long-term patterns and trajectories of heroin use have critical implications for treatment response, clinical practice and policy. This symposium examines long-term patterns of heroin and other opioid use, overdose, and the relationship between cannabis and heroin use using data from an Australian longitudinal cohort study (ATOS), and implications for US clinical practice and policy.

The 18-20-year follow-up of ATOS was completed in 2022, on 615 treatment and non-treatment seeking people with heroin dependence originally recruited in 2001. Over 79% of the surviving cohort was reinterviewed, and we accounted for 95% (including deceased, refusals, incarcerated).

Christina Marel will present patterns of heroin and other opioid use over 20-years, focusing on heroin use trajectories, PTSD and depression, and how these affect patterns of use and abstinence. Maree Teesson will examine patterns and predictors of overdose. Jack Wilson will present the longitudinal relationship between cannabis and heroin, including implications of cannabis for treating heroin dependence. The discussant, Kathleen Brady, will provide international comparisons and overall implications.

20 Year Patterns of Heroin and Other Opioid Use
Speaker: **Christina Marel*, The University of Sydney***

Patterns and Predictors of Overdose over 20 Years
Speaker: **Maree Teesson*, The University of Sydney***

Friend or Foe? the Long-Term Relationship Between Cannabis and Heroin Use
Speaker: **Jack Wilson*, The University of Sydney***

TUESDAY, JUNE 18, 2024

8:00 A.M. - 9:00 A.M.

CRITICAL COMPONENTS TO DEVELOPING AND DELIVERING SUBSTANCE USE INTERVENTIONS FOR AMERICAN INDIAN/ALASKA NATIVE PEOPLE
Av. Van Horne, 2nd Floor

Chair: **Daniel Dickerson*, UCLA Integrated Substance Abuse Programs (ISAP)***
Co-Chair: **Kamilla Venner*, University of New Mexico***

Evidence-based intervention for American Indian/Alaska Native (AI/AN) people with substance use disorders is limited. Similarly, there is a shortage of substance use interventions that are developed and conducted by AI/AN researcher. This presentation provides perspectives from three Alaska Native researchers who are leaders in the field of AI/AN addiction research and study the impact of culture in interventions.

ABSTRACTS

Dr. Venner will cover NIDA funded implementation science efforts to partner with three AI/AN serving behavioral health programs to culturally center screening and brief intervention for opioid use disorder and chronic pain. Dr. Venner will discuss the community engaged approach and use of external facilitators to aid programs, as they developed goals to culturally center their services to leverage cultural strengths to improve well-being.
Dr. Crouch will discuss strategies to culturally adapt CBT4CBT, a self-guided web-based program to treat substance use disorders. Strategies addressing inequities in the context of historical trauma and the inherent strengths of AI/AN people will be discussed to develop the most salient and responsive program. Her research examines cultural participation as an important step in culturally adapting and destigmatizing SUD treatment for AI/AN people.
Dr. Dickerson will describe strategies to develop, analyze, and implement Traditions and Connections for Urban Native Americans (TACUNA), a virtually-delivered opioid prevention intervention program for urban AI/AN emerging adults across the U.S. (co-PIs: Elizabeth D'Amico/Daniel Dickerson). He will demonstrate steps taken in a recently conducted study to maximize the potential reach of TACUNA to a nationwide sample of urban AI/AN emerging adults.

Addressing Implementation Strategies for a New Opioid Prevention Intervention for Urban American Indian/Alaska Native Emerging Adults
Speaker: **Daniel Dickerson*, UCLA Integrated Substance Abuse Programs (ISAP)***

Culturally Centering Screening and Brief Intervention for Opioid Use Disorder and Chronic Pain With American Indian/Alaska Native People
Speaker: **Kamilla Venner*, University of New Mexico***

Culturally Adapting Computer-Based Training for Cognitive Behavioral Therapy for Alcohol Use Disorder Among the American Indian and Alaska Native Population in Alaska
Speaker: **Maria Crouch*, Yale University School of Medicine***

9:15 A.M. - 10:15 A.M.

STIRRING THE POT: RECENT FINDINGS ON PERINATAL CANNABIS EXPOSURE
Av. Viger, 2nd Floor

Chair: **Dace Svikis*, Virginia Commonwealth University***
Co-Chair: **Anna Wiese*, Virginia Commonwealth University***

A growing number of states are legalizing cannabis for medical and/or recreational purposes, thus increasing access to cannabis. Subsequently, rates of perinatal cannabis use have been on the rise, despite potential links between in utero cannabis exposure and negative birth, neonatal, and offspring outcomes. Given these increased rates of perinatal cannabis use and its possible associations with adverse effects, as well as the continued liberalization of cannabis regulations and the evolving landscape of cannabis guidelines, perinatal cannabis use is a timely issue that must be investigated from a variety of perspectives. In this mini symposium, we will use various lenses to examine the current research on cannabis use during the perinatal period, exploring the biological, public health, and clinical considerations of such use. Dr. Carl Wolf will present findings on the identification and presence of cannabinoids in breastmilk and the potential implications. Dr. Qiana Brown will discuss health and social equity considerations

regarding cannabis use both during pregnancy and postpartum. Dr. Judy Chang will describe the experiences, challenges, and suggestions for addressing prenatal cannabis use an in obstetrical care setting. The discussion will highlight different perspectives on perinatal cannabis exposure in the context of rapidly evolving cannabis regulations and guidelines.

Potentially Blemished Nature's Superfood: Cannabinoids in Breast Milk and Participant Self-Reports of Recent Use
Speaker: **Carl Wolf*, VCU Health***

Promoting Maternal and Child Health and Social Equity in the Context of Prenatal and Postpartum Cannabis Use
Speaker: **Qiana Brown*, Rutgers University***

Addressing Prenatal Cannabis Use in Obstetrical Care Visits
Speaker: **Judy Chang*, University of Pittsburgh***

10:45 A.M. - 12:15 P.M.

SAFER SUPPLY AND THE OPIOID CRISIS IN CANADA
Place du Canada, 2nd Floor

Chair: **David Marsh*, Northern Ontario School of Medicine***
Co-Chair: **Mohammad Karamouzian*, St. Michael's Hospital***

In Canada, as in the United States, opioid-related toxicity deaths have grown exponentially over the past decade, due in large part to the appearance of unregulated fentanyl in the street drug supply. This has happened despite widely available Opioid Agonist Treatment (OAT; in particular, in the provinces of Ontario and British Columbia, home to over 80% of OAT patients in Canada). To address the public health crisis characterized by opioid-related toxicity deaths becoming the leading cause of death for men aged 25-45, innovative approaches to engaging those with opioid use disorder (OUD) who have not substantially benefitted from the existing treatment system are evolving. This symposium will review the evidence for the effectiveness of supervised injectable OAT (siOAT) with diacetylmorphine and hydromorphone and describe the evolution of siOAT as a component of a comprehensive treatment and harm reduction continuum. We will also explore approaches that build on the siOAT evidence to offer safer supply interventions to reduce the risk of harm such as risks and benefits of the provision of hydromorphone formulations as safer supply to assist patients in avoiding the use of unregulated fentanyl will be discussed. Stimulant use (methamphetamine in particular) is rising in Canada and is associated with substantial morbidity and mortality. Accumulating evidence supports the safety and effectiveness of treatment of stimulant use disorder with prescribed psychostimulants. Off-label prescribing of psychostimulants to patients with stimulant use disorder will be reviewed, including how it has been implemented on a small scale in certain jurisdictions in Canada.

Evidence for Safety and Effectiveness of Supervised Injectable Opioid Agonist Treatment in Canada
Speaker: **David Marsh*, Northern Ontario School of Medicine***

Challenges and Facilitators of Implementing Safer Supply Programs in Canada
Speaker: **Mohammad Karamouzian*, St. Michael's Hospital***

ABSTRACTS

Current Evidence and Models of Safer Supply in Canada
Speaker: **Gillian Kolla*, Faculty of Medicine, Memorial University of Newfoundland***

Treatment of Stimulant Use Disorder With Prescribed Psychostimulants
Speaker: **Scott MacDonald*, Providence Health Care - Crosstown Clinic***

10:45 A.M. - 12:15 P.M.

CUE REACTIVITY AS A PARADIGM TO ASSESS AND INTERVENE IN ADDICTION ACROSS SPECIES
Av. Duluth, 2nd Floor

Chair: **Stephen Kohut*, McLean Hospital | Harvard Medical School***
Co-Chair: **Kathryn Cunningham*, John Sealy School of Medicine University of Texas Medical Branch***

Drug cue reactivity and craving play a critical role in developing, maintaining, and achieving abstinence from substance use disorders. While important advancements have been made in our understanding of the neurobiological mechanisms underlying cue reactivity in populations with a substance use disorder, a number of significant knowledge gaps remain. This symposium comprises four presentations ranging from pre-clinical approaches to exploring mechanisms of cue-reactivity using animal models including task-based fMRI in nonhuman primates (Stephen J. Kohut) and identifying target-phenotype relationships engaging PFC circuitry and evaluating candidate therapeutics in rodents (Kathryn A. Cunningham), to employing cue-reactivity as a part of a cognitive behavioral intervention for addiction recovery using a novel framework titled "Cue-induced Retrieval and Reconsolidation with Episodic Foresight'' (Parnian Rafei). This symposium will also include a presentation of ongoing studies aimed at developing a multimodal neuroimaging platform centered around fMRI drug cue-reactivity paradigms for a modern drug discovery approach for a difficult to study clinical population, individuals with comorbid bipolar and substance use disorders (James J. Prisciandaro).

Cue Reactivity in Animal Models as a Cross Species Biomarker
Speaker: **Stephen Kohut*, McLean Hospital Harvard Medical School***

Cue Reactivity as the Centerpiece of a Multimodal Neuroimaging Approach to Evaluating Target Engagement of Experimental Medications for Individuals With Co-Occurring Severe Mental Illness and Substance Use Disorder
Speaker: **James Prisciandaro*, Medical University of South Carolina***

Cue Reactivity as a Phenotype: Mining Treatment Interventions in Rodent Models
Speaker: **Kathryn Cunningham*, John Sealy School of Medicine University of Texas Medical Branch***

Cue Reactivity as a Part of an Intervention in Humans
Speaker: **Parnian Rafei*, Trinity College Dublin***

ABSTRACTS

10:45 A.M. - 12:15 P.M.

ENDOCANNABINOID FUNCTION AND ADVERSE EFFECTS OF IN-UTERO CANNABINOID EXPOSURE IN THE DEVELOPING BRAIN
Square Dorchester, 2nd Floor

Chair: Da-Yu Wu*, National Institute on Drug Abuse, National Institutes of Health*
Co-Chair: Jane Acri*, National Institute of Drug Abuse, National Institutes of Health*

Emerging evidence suggest that endocannabinoids are involved in many neural developmental processes, from neurogenesis and differentiation, axonal elongation and pathfinding, to synaptic modulation and neural circuit formation. Meanwhile, the dramatic increase of cannabis use during pregnancy likely results in in-utero exposure of cannabinoids to the fetal brain, with potential negative impacts to fetal and childhood brain and cognitive development. This symposium will present some of the most current discoveries on the activities and function of endocannabinoid system in brain development, and the adverse effects of cannabis and cannabinoids exposure to the developing brain. Torri Mets will report data generated in clinical studies on cannabis exposure during pregnancy and while breastfeeding. Her studies show that cannabis metabolites cross the placenta and are detectable in breastmilk, with consequential damages to placenta, fetus and newborn. Nagina Mangal of Graybiel Lab will present discoveries on the role of endocannabinoid system in the early development of striatonigral circuits. She will demonstrate that constitutive knockout of CB1R causes developmental disorders during establishment of striatonigral innervation of dopamine-containing neurons of the substantial nigra pars compact (SNpc) and the arrangement of the dopamine neurons. Hui-Chen Lu will present how in animal model studies the formation of proper columnar organization is disrupted by external cannabinoid exposure, resulting in lasting changes in cortical column organization and disrupted brain function. Finally, Margaret McCarthy will describe her discoveries on how the timing of in-utero THC exposure impacts a range of brain disorders through the dysregulation of microglia and the complement immune system.

Cannabis Use During Pregnancy and While Breastfeeding
Speaker: Torri Metz*, University of Utah Health*

Effects of Cannabinoid CB1 Receptors on Development of Dopamine Neurons and Their Striatal Innervation
Speaker: Nagina Mangal*, MIT*

Roles of 2AG-CB1R in Cortical Column Formation and the Lasting Impacts of Perinatal Cannabis Exposure
Speaker: Hui-Chen Lu*, Indiana University Bloomington*

Prenatal Cannabis Exposure Effects Depend on the Timing and the Endpoint
Speaker: Jonathan VanRyzin*, University of North Carolina, Chapel Hill*

10:45 A.M. - 12:15 P.M.

LONELINESS AS AN IMPORTANT RISK FACTOR AND TREATMENT TARGET FOR OPIOID USE DISORDER: EVIDENCE FROM HIGH-RISK POPULATIONS
Av. Van Horne, 2nd Floor

ABSTRACTS

Chair: Lisham Ashrafioun*, VA Center of Excellence for Suicide Prevention*
Co-Chair: Alicia Allen*, University of Arizona*

There is mounting evidence that loneliness is a salient risk factor for a wide-range of adverse physical and mental health outcomes. Despite research showing that individuals with opioid use disorder (OUD) report high rates of loneliness and isolation, relatively little is known about the role of loneliness in the prevention, treatment, and recovery from OUD. This symposium will present and discuss novel findings on loneliness as a risk factor and key intervention target for individuals with OUD. We emphasize the importance of loneliness and opportunities for treatment among high-risk populations and during salient transition/inflection points (i.e., pregnancy, postpartum, reintegration following incarceration). Specifically, in the first session Dr. Alicia Allen will present patterns and differences in loneliness during the perinatal period in people with and without OUD. Next, building on this work, Dr. Linnea Linde-Krieger will present findings on loneliness as a barrier to mother-infant bonding for individuals with OUD during the critical early postpartum period. Turning to intervention effects, in the third session Dr. Kirsten Langdon will present qualitative data on perceived barriers and facilitators to deploying a mobile peer recovery support app among individuals with a history of engaging in medication for opioid use disorder during a period of incarceration. Last, Dr. Lisham Ashrafioun will discuss findings from a recently completed randomized clinical trial of telehealth-delivered cognitive-behavioral therapy compared to health education among individuals with OUD reporting elevated loneliness. To conclude this session, Dr. Julia Zur will facilitate a discussion on these findings and future directions of this work.

Loneliness During and After Pregnancy: Does it Vary Between Those With and Without Opioid Use Disorder?
Speaker: Alicia Allen*, University of Arizona*

Loneliness and the Mother-Infant Bond: Findings From Mothers With OUD and Their Infants During the Transitional "Fourth Trimester"
Speaker: Linnea Linde-Krieger*, University of Arizona College of Medicine*

Evaluating the Feasibility and Acceptability of Deploying a Mobile Peer Recovery Support App to Address Loneliness Among Individuals With Criminal Justice-Involvement
Speaker: Kirsten Langdon*, Rhode Island Hospital/Alpert Medical School of Brown University*

Addressing Loneliness to Impact Opioid Use Trajectories
Speaker: Lisham Ashrafioun*, VA Center of Excellence for Suicide Prevention*

Moderator: Julia Zur*, DHHS/NIH/NIDA*

10:45 A.M. - 12:15 P.M.

AN INWOMEN'S GENDER SYMPOSIUM ON INTERSECTIONAL RESPONSES TO OPIOIDS AND OTHER SUBSTANCE USE: INNOVATIVE TREATMENT, SOCIAL DETERMINANTS, AND VOICES FROM THE GROUND
Av. Viger, 2nd Floor

Chair: Wendee Wechsberg*, RTI International*

Co-Chair: **Felicia Browne***, RTI International*

Since 2007, the International Women's and Children's Group (InWomen's) has applied a gender lens to address all aspects of the consequences of substance use. This symposium reflects our continued commitment to research that promotes and centers key populations. Opioid- and alcohol-related deaths among women have been on a steep rise compared to men, worsened by the nascent contamination of the drug supply with synthetic opioids like fentanyl. HIV disproportionately affects minoritized women, which has perpetuated health inequities, and further challenged women's access to and retention in substance use disorder treatment. Pregnant and breastfeeding people and their infants lack evidence-based support and interventions to reduce their alcohol use leaving permanent adverse outcomes across generations. There is an urgent need to understand gendered experiences and intersectional interventions that are gender responsive. The first presentation will share preliminary findings from a multisite randomized clinical trial of telehealth for integrated PrEP and medications for opioid use disorder as compared to enhanced standard of care for women involved in the criminal legal system. The second presentation is a small study trial in South Africa utilizing contingency management to reinforce alcohol abstinence during pregnancy and lactation. The third presentation presents US qualitative data that explores the impact of gender on drug use and service experiences from the voices of marginalized women who used opioids. The last presentation will share data from a cluster randomized trial in 24 communities ending HIV among couples who use alcohol and drugs in South Africa and peer-led de-stigmatizing plays in neighborhoods.

Integrating HIV Prevention Into Treatment for Opioid Use Disorder for Women
Speaker: **Jaimie Meyer***, Yale University School of Medicine*

Feasibility and Preliminary Effects of an Incentive-Based Intervention to Reduce Maternal Alcohol Use During Pregnancy and Lactation (MaRISA study)
Speaker: **Yukiko Washio***, RTI International*

The Impact of Gender on Fentanyl and Substance Use Treatment Experiences
Speaker: **Miriam Harris***, Boston University*

Assessing Gender Differences and Contextual Challenges to HIV Prevention Among Couples who Misuse Substances in South Africa
Speaker: **Felicia Browne***, RTI International*

Moderator: **Wendee Wechsberg***, RTI International*

10:45 A.M. - 12:15 P.M.

BRAIN MECHANISMS UNDERLYING ADDICTION: APPLYING NEW METHODS TO ANSWER NEW QUESTIONS
Rue Sainte Catherine-Saint Paul, 2nd Floor

Chair: **Joy Schmitz***, University of Texas Health Science Center*
Co-Chair: **Consuelo Walss-Bass***, The University of Texas Health Science Center at Houston*

ABSTRACTS

Advances in technical innovations for understanding brain mechanisms of addiction have been monumental. New approaches have made it possible to identify and manipulate molecular and cellular pathways of addiction, and associated brain sites – affording opportunities to answer questions that were inconceivable a few decades ago. Speakers will present examples of how new technologies are being used to answer new questions. First, what is the role of extracellular vesicles in the pathophysiology of drug addiction? Chioma Okeoma will describe novel methods to isolate extracellular vesicles from postmortem brain and identify proteomic and lipidomic signatures, with data showing enrichment of inflammatory pathways in patients with substance use disorder. Second, can single-cell genomic technologies provide new insights into the regulatory mechanisms of addiction? Janitza Montalvo-Ortiz will describe single-cell multiomics approaches to identify cell-specific mechanisms of transcriptional regulation in opioid use disorder. Third, can transcranial magnetic stimulation be used to understand nicotine-related brain circuit abnormalities in schizophrenia? L. Elliot Hong will present data on brain circuitry associated nicotine addiction in patients with schizophrenia and how TMS may modulate such circuitry and associated smoking behaviors. Fourth, can novel animal models of behavior advance our understanding of the mechanisms of addiction? Dr. Noelle Anastasio will present the use of a novel rodent model of impulsivity to understand concepts in corticoaccumbens circuit dysfunction underlying the impulsivity endophenotype to elucidate vulnerability factors for addiction. Consuelo Walss-Bass, Discussant, will integrate the findings and discuss advances that can be gained from studies of the mechanisms underlying substance use disorders.

Isolation and Characterization of Brain Extracellular Vesicles in Substance Use Disorders
Speaker: **Chioma Okeoma*, New York Medical College***

Deciphering and Mining a Cocaine Use Disorder Vulnerability Biosignature
Speaker: **Noelle Anastasio*, John Sealy School of Medicine University of Texas Medical Branch***

TMS to Identify Nicotine Addiction-Related Circuitry in Patients With Severe Mental Illness
Speaker: **Elliot Hong*, UTHealth Houston***

2:15 P.M. - 3:15 P.M.

INJECTING DRUG USE AND BLOOD-BORNE VIRUS DISEASE IN PRISON SETTINGS: PREVALENCE, TREATMENT COVERAGE, AND LONG-TERM HEALTH AND SOCIAL OUTCOMES
Av. Duluth, 2nd Floor

Chair: **Thomas Santo*, National Drug and Alcohol Research Centre, UNSW Sydney***
Co-Chair: **Louisa Degenhardt*, National Drug and Alcohol Research Centre***

This mini symposium comprises three studies illuminating the challenges of injecting drug use, opioid use disorder (OUD), and associated harms within incarcerated populations.
Studies 1 and 2 extend our Lancet series, which reviewed injecting drug use, related harms, and treatment coverage in the community, to focus on prison settings. As part of a global collaboration with the World Health Organisation and the United Nations Office of Drugs and Crime, we expand the scope of our project to prison environments. In Study 1, we estimate the prevalence of injecting drug use in prisons, along with associated health risks (e.g., HIV, hepatitis C (HCV), and related behaviors). We systematically review these harms within

correctional facilities, providing region and country-specific prevalence estimates and identifying factors associated with variance. Building upon the findings from Study 1, Study 2 reviews the provision of treatment and harm reduction services for injecting drug use and associated harms in prisons. We conduct a systematic review in collaboration with global partners, examining interventions like Opioid Agonist Treatment (OAT), needle and syringe programs, HIV/HCV testing, and treatment. Study 3: Drawing from a large data linkage study in New South Wales, Australia, we present findings from the Prison Outcomes Study (POST). Including over 200,000 individuals incarcerated since 2000, this study delves into the impact of opioid dependence, HCV, and related treatments on health, social, and recidivism outcomes during and after release from prison. Together, these studies provide timely insights into evidence-based policies and region-specific harm reduction strategies for incarcerated populations worldwide.

Epidemiology of Injecting Drug Use, HIV, Hepatitis C, and Injecting-Related Harms Among Incarcerated Populations: A Systematic Review
Speaker: **Louisa Degenhardt*, National Drug and Alcohol Research Centre***

Assessing Global and Country-Specific Coverage of Interventions for Injecting Drug Use and Related Harms in Prison Settings: A systematic review and meta-analysis
Speaker: **Thomas Santo*, National Drug and Alcohol Research Centre, UNSW Sydney***

The Prison Outcomes Study (POST): Health, Social, and Recidivism Outcomes Among People who Have Been Incarcerated in NSW
Speaker: **Nicola Jones*, National Drug and Alcohol Research Centre***

3:45 P.M. - 4:45 P.M.

UTILIZING GLUTAMATERGIC MECHANISMS TO TREAT STIMULANT AND NICOTINE USE DISORDERS: FOCUS ON THE BETA LACTAM, CLAVULANIC ACID
Rue Sainte Catherine-Saint Paul, 2nd Floor

Chair: **Mary Morrison*, Lewis Katz School of Medicine at Temple University***
Co-Chair: **Aimee McRae-Clark*, Medical University of South Carolina***

Preclinical evidence shows that clavulanic acid (CLAV) reduces the reinforcing efficacy of cocaine using a progressive-ratio schedule of reinforcement but does not affect acquisition of cocaine self-administration or retention of learning. CLAV efficacy may extend to methamphetamine (METH). At the cellular level, our evidence suggests that CLAV engages two glutamate biomarkers of psychostimulant addiction. In METH-sensitized mice, glutaminase (a neuronal enzyme that converts glutamine into glutamate) mRNA levels are altered in the nucleus accumbens. One injection of CLAV also reduces activity and protein levels of glutamate carboxypeptidase II (GCPII). CLAV is also known to upregulate glutamate transporter (GLT-1). These mechanisms are involved in restoring the balance in corticostriatal glutamate which is believed to be critical to the therapeutic effects of CLAV for addictive disorders, and will be discussed by Dr. Rawls. There is currently a dearth of mechanistic work in humans on the effects of β-lactams and no reports on CLAV for treating nicotine dependence. The Froeliger team has conducted a pilot placebo control randomized controlled trial examining safety, tolerability and neurocognitive changes following the administration of a 3-day course of CLAV to nicotine dependent adults who smoke. Preliminary findings from this

study will be discussed. In small studies of people with cocaine use disorder, the Morrison team will present evidence from a neuroimaging pilot demonstrating support for CLAV as an efficacious cocaine craving reduction therapeutic. Findings from resting state functional resonance imaging supports strengthening of executive function with 10 days of CLAV treatment.

Clavulanic Acid (CLAV) for Methamphetamine and Cocaine Use disorders: New Evidence from Preclinical Studies
Speaker: **Scott Rawls*, Temple University***

Effects of Clavulanic Acid in Nicotine Dependent Adults
Speaker: **Brett Froeliger*, University of Missouri***

Decreasing Cocaine Craving with Clavulanic Acid Associated Glutamatergic Modulation in People with Cocaine Use disorder: Neuroimaging Evidence
Speaker: **Mary Morrison*, Lewis Katz School of Medicine at Temple University***

3:45 P.M. - 4:45 P.M.

SUBSTANCE USE DISORDERS TREATMENT DEVELOPMENT RESEARCH SUPPORTED BY NIDA'S DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES
Place du Canada, 2nd Floor

Chair: **Evan Herrmann*, NIDA***
Co-Chair: **Ivan Montoya*, DHHS/National Institute on Drug Abuse***

In 1990, U.S. Congress mandated a NIDA medications development program in response to surging cocaine use and lack of pharmaceutical industry investment in substance use disorder (SUD) treatment development. This program is now part of the Division of Therapeutics and Medical Consequences (DTMC), which supports research focused on identification and evaluation of new medications, behavioral interventions, digital therapeutics, and neuromodulatory devices to treat all SUDs, except alcohol. Within an experimental medicine framework, there is a strong focus on treatments with potential for broad impact through FDA approval and widespread dissemination into clinical practice. The overarching goal of this forum is to provide an overview of DTMC's current treatment development research portfolio through six presentations: Medications for 1) Tobacco Use Disorder, 2) Cannabis Use Disorder, 3) Opioid Use Disorder, and 4) Stimulant Use Disorders, 5) behavioral interventions/digital therapeutics for all SUDs, and 6) device-based treatments for all SUDs. Information will be presented in a treatment development 'pipeline' format, showing each candidate medication/intervention being studied and its current Phase/Stage of development (e.g., preclinical, Phase/Stage I, Phase/Stage II). These presentations will provide audience members with up-to-date information on DTMC's treatment development portfolio in a format that will allow them to identify potential gaps and areas ripe for timely additional research in their respective areas of focus/expertise. The broad array of treatment development areas covered may benefit both new and established preclinical and clinical Investigators interested or involved in the development of pharmacological, behavioral/digital, or device-based treatments for SUDs.

Behavioral Interventions and Digital Therapeutics Pipelines
Speaker: **Will Aklin*, NIH/NIDA***

ABSTRACTS

Stimulant Use Disorder Medication Pipeline
Speaker: **Katrina Foster*, NIH/NIDA/DTMC***

Current Pipeline of Device-Based Treatments for SUDs
Speaker: **Julia Donnelly*, National Institute of Drug Abuse/NIH/DHHS***

Medications for Tobacco Use Disorder and Cannabis Use Disorder
Speaker: **Evan Herrmann*, NIDA***

NIDA's Portfolio of Medications Development for Opioid Use Disorder and Overdose
Speaker: **Ivan Montoya*, DHHS/National Institute on Drug Abuse***

Discussant: **Jane Acri*, National Institute of Drug Abuse, National Institutes of Health***

WEDNESDAY, JUNE 19, 2024

8:00 A.M. - 9:30 A.M.

ROLAND IN MEMORIAM
Square Dorchester, 2nd Floor

Chair: **Jack Henningfield*, Pinney Associates, Inc.***

8:00 A.M. - 9:30 A.M.

INNOVATIONS IN DIGITAL INTERVENTIONS FOR SUBSTANCE USE
Av. Van Horne, 2nd Floor

Chair: **Inbal Nahum-Shani*, University of Michigan***
Co-Chair: **Lisa Marsch*, Geisel School of Medicine at Dartmouth***

The rapid growth, affordability and acceptability of digital technologies can revolutionize behavioral interventions for substance use. Modern technologies such as electronic health records (EHRs), telehealth, and mobile devices can facilitate greater access, scalability, and impact. Powerful mobile and sensing technologies can be harnessed to deliver just-in-time adaptive interventions (JITAIs)—interventions that use dynamically changing information about the individual's internal state (e.g., craving, stress), and context (e.g., physical location) to recommend whether and how to deliver interventions in real time, in the individual's natural environment, while minimizing participant effort, burden and habituation. Innovations in artificial intelligence (AI) offer opportunities to further personalize intervention delivery by continually interacting with each participant and learning how to best adapt the intervention to their changing needs as they experience the intervention in real time. This symposium highlights four NIH/NIDA-funded pilot projects, each using digital technologies to build cutting-edge interventions for substance use. The first project focuses on developing a digital intervention to address co-occurring disorders—substance use and depression; the second focuses on designing a digital opioid safety educational intervention that meets patient needs while addressing implementation barriers experienced by pharmacist; the third project

concerns the development of a dyadic JITAI for improving parent-child relationships and reducing substance use; and the fourth project employs AI algorithms to increase mobile health engagement and reduce substance use in real-time. Opportunities and challenges for leveraging advances in digital technologies to prevent and treat substance use will be discussed.

Development of a Digital Intervention for Positive Valence System Dysfunction in Co-Occurring Depression and Cannabis Use
Speaker: **Amanda Collins*, Dartmouth College***

Development and Initial Testing of a Pilot Pharmacy-Based Digital Opioid Safety Intervention
Speaker: **Deepika Rao*, Dartmouth College***

Parents and Teens Together (PATT): Developing a Dyadic Digital Intervention to Prevent SUDs
Speaker: **Amy Hughes Lansing*, University of Vermont***

Development of a Personalized Just-In-Time Adaptive Intervention for Emerging Adults With Regular Cannabis Use
Speaker: **Lara Coughlin*, University of Michigan***

8:00 A.M. - 9:30 A.M.

ADVANCES IN THE UNDERSTANDING OF PTSD-SUBSTANCE USE DISORDER COMORBIDITY ACHIEVED THROUGH LAB-BASED RESEARCH USING THE TRAUMA CUE REACTIVITY PARADIGM
Av. Viger, 2nd Floor

Chair: **Sherry Stewart*, Dalhousie University***
Co-Chair: **Sarah DeGrace*, Dalhousie University***

PTSD and substance use disorder (SUD) are highly comorbid. PTSD-SUD is associated with poorer treatment response, greater impairment, and higher relapse rates than either disorder alone. One potential mechanism underlying this comorbidity is trauma cue-elicited craving, arising through conditioning and commonly studied using the trauma cue reactivity paradigm (CRP). This symposium consists of four papers using the trauma CRP to investigate mechanisms underlying PTSD-SUD comorbidity. Chair Sherry Stewart (Dalhousie, Canada) will present an online study with N=202 trauma-exposed cannabis users examining expressive writing CRP (trauma vs. neutral) x PTSD group (PTSD probable vs. no PTSD) effects on affect, cannabis craving, and accessibility of cannabis information in memory. Co-chair Sarah DeGrace (Dalhousie) will present a systematic review and meta-analysis of the presence, magnitude, and moderators of trauma cue-elicited substance craving across the extant literature with substance-using samples with trauma histories and/or PTSD. Delisa Brown (Medical University of South Carolina [MUSC], USA) will present results from an fMRI study that examined reactivity to trauma, alcohol, and neutral CRPs, and associations with treatment outcomes in a randomized clinical trial among patients with PTSD-SUD. Pablo Romero-Sanchiz (Sussex, UK) will present qualitative analyses of 10 interviews with regular cannabis users with trauma histories after they underwent a trauma CRP, regarding their perceptions of their experience as participants and the ethics of this experimental tool for studying mechanisms underlying PTSD-SUD. Finally, Kathleen Brady (MUSC) will moderate an integrative discussion that

highlights common themes and implications of the findings for improving interventions for those with comorbid PTSD-SUD.

Effects of PTSD and Expressive Writing about a Trauma on Affect, Cannabis Craving, and Cannabis Memory Accessibility in Cannabis Users with Trauma Histories
Speaker: **Sherry Stewart***, Dalhousie University*

A Systematic Review and Meta-Analysis of the Literature on Trauma Cue-Elicited Craving in Substance Users With Trauma Histories or PTSD
Speaker: **Sarah DeGrace***, Dalhousie University*

A Neuroimaging Study of Trauma and Alcohol Cue Reactivity and Associations With Treatment Outcomes
Speaker: **Delisa Brown***, Medical University of South Carolina*

A Qualitative Interview Study on Participants' Lived Experiences and Perceived Ethics of the Trauma Cue Reactivity Paradigm
Speaker: **Mikaela Ethier-Gagnon***, Dalhousie University, Department of Psychiatry*

Moderator: **Kathleen Brady***, Medical University of South Carolina*

8:00 A.M. - 9:30 A.M.

COMPUTATIONAL NEUROSCIENCE AND CANNABIS: PRECLINICAL, BEHAVIORAL AND CLINICAL INSIGHTS
Av. Duluth, 2nd Floor

Chair: **Sarah Yip***, Yale University*
Co-Chair: **Iris Balodis***, McMaster University*

Cannabis is one of the most widely used drugs worldwide. This symposium brings together computational addiction neuroscientists conducting research spanning preclinical, computational behavioral and clinical neuroscience domains—to advance understanding of cannabis neurobiology.
First, Dr. Khokhar assessed the effects of adolescent exposure to vaporized cannabis consisting of varying chemovars (high THC, high CBD, balanced THC/CBD). These studies show long-term, sex-dependent behavioral and network-based functional and structural connectivity alterations in adulthood after adolescent exposure.
Next, Dr. Balodis will present computational behavioral and neural data demonstrating alterations in valuation processes among individuals with heavy cannabis use. Additional results examining cannabinoid metabolites from urine extracts using reversed-phase liquid chromatography-mass spectrometry show how THC metabolites are linked to unique motivational indices of choice behavior.
Dr. Lichenstein will present work identifying a neural network predictive of problem-level cannabis use in a non-clinical college student sample (N=191), as well as data demonstrating that connectivity within this same problem cannabis use network is associated with clinical characteristics in an independent clinical sample of individuals entering treatment for cannabis use disorder.

Finally, Dr. Filbey will present data exploring the same problem cannabis network in a separate sample of individuals with heavy cannabis use (N~300) to determine whether this network also extends to predict individual differences in task-evoked transient craving states and whether this differs as a function of biological sex.
By attending the symposium, audience members will be exposed to novel findings from unpublished datasets and also learn about advanced computational methods for studying cannabis use behaviors.

Cannabis Vaping and the Adolescent Brain: Long Term Effects on Behaviour and Neural Connectivity.
Speaker: **Jibran Khokhar*, Western University***

A Neuroeconomic Approach to Valuation Processes in Individuals with Heavy Cannabis Use
Speaker: **Iris Balodis*, McMaster University***

Identification and External Validation of a Neural Network of Problem Cannabis Use
Speaker: **Sarah Lichenstein*, Yale University School of Medicine***

Problem Cannabis Use Network as a Predictor of Transient Craving for Cannabis
Speaker: **Francesca Filbey*, University of Texas at Dallas***

8:00 A.M. - 9:30 A.M.

NIDA RESEARCH CENTER OF EXCELLENCE GRANTS: HOW THESE COLLABORATIVE CENTERS CONTRIBUTE TO THE UNDERSTANDING AND TREATMENT OF SUBSTANCE USE DISORDERS
Place du Canada, 2nd Floor

Chair: **Mary Torregrossa*, University of Pittsburgh***
Co-Chair: **Colleen McClung*, University of Pittsburgh***

This symposium will provide an update from multiple NIDA P50 Centers and describe how these collaborative projects are providing state of the art mechanistic and clinical studies through integrative team science. Dr. Chesler will describe the use of mouse populations with large genetic diversity in the CSNA, and their discoveries of relationships among biobehavioral addiction risk and underlying genetic and genomic aspects of addiction, and how they have established the heritability and genetic correlation among multiple addiction-related phenotypes. Dr. Cowan will provide an overview of findings from COCA that reveal cell type- and circuit-specific opioid-induced neuroadaptations underlying opioid-cue reactivity and drug seeking, including neural ensembles linked to opioid taking and seeking, epigenetic and genomic influences on drug-cue reactivity, astrocyte and tetrapartite synapse influences on opioid seeking, and non-invasive neuromodulation strategies to curb drug-cue reactivity and craving. Dr. McClung will describe results from both human and rodent studies in CARRS which identify the molecular, cellular and circuit-related mechanisms by which pressures in adolescence brought on by developmental changes in sleep and circadian rhythms paired with early school start times fundamentally change the brain leading to vulnerability for substance use disorders (SUD), and interventions aimed at better aligning the circadian clock in teens with delayed rhythms to reduce risk. Dr. Heifets will describe results from their center at Stanford which focuses on identifying the causal circuit-level actions of multiple clinically-significant

drugs in modulating key SUD-relevant behaviors spanning reward processing, dissociation, and social and spatial cognition using both human and mouse models.

Center for Systems Neurogenetics of Addiction
Speaker: **Elissa Chesler*, The Jackson Laboratory***

Charleston Opioid Center on Addiction (COCA)
Speaker: **Christopher Cowan*, MUSC***

Center for Adolescent Reward, Rhythms and Sleep
Speaker: **Colleen McClung*, University of Pittsburgh***

Neural Circuit Dynamics of Drug Action: Revealing, Uncoupling, and Restoring Altered Brain States
Speaker: **Matthew Pomrenze*, Stanford Medical School***

8:00 A.M. - 9:30 A.M.

CONDITIONED DRUG CRAVING AND RELAPSE: NEW INSIGHTS FROM RATS AND HUMANS
Rue Sainte Catherine-Saint Paul, 2nd Floor

Chair: **Anna Samaha*, University of Montreal***
Co-Chair: **Mandy Le Cocq*, Universite de Montreal***

Drug-associated cues and environments trigger drug craving and relapse. We will describe translationally relevant rat models of cue- and context-induced relapse and neuroimaging data in humans linking corticolimbic activity to drug cue reactivity.
Rita Fuchs will highlight the role of contextual cocaine memories in environment-induced relapse in rats, and the contributions of dorsal raphe corticotropin-releasing factor-expressing neurons innervating the basolateral amygdala to both cocaine memory strength and context-induced reinstatement. Her findings suggest that this monosynaptic neural circuit maintains contextual cocaine memories.
Yavin Shaham will describe new rat models of cue-induced relapse after voluntary abstinence, achieved by introducing adverse consequences to drug taking (punishment) or seeking (electric barrier), or by providing choice between the self-administered drug versus food or social rewards. He will also present associated neurobiological findings.
Rita Goldstein will show that in people with a heroin use disorder heroin-associated cues (relative to non-drug cues) and heroin craving are linked to hyperactivations in corticostriatal regions, as amenable to reductions with treatment/abstinence. Taken together with previous studies in cocaine addiction, these results support a model where addiction is driven by a disproportionally enhanced salience of drug-associated cues.
Marco Leyton will describe brain activation responses to alcohol and non-alcohol cues in young adults. Those with high externalizing behavioral traits predictive of harmful drug use exhibit significant cingulate cortex responses to alcohol (vs. water) cues and a failure to differentiate brain responses to alcohol vs. juice cues. Prior to an addiction, poor differentiations of reward-related cues may disrupt optimal choices, increasing addiction risk.

Novel Mechanisms of Context-Induced Cocaine Relapse

Speaker: **Rita Fuchs*, Washington State University***

Animal Model of Cue-Induced Relapse After Voluntary Abstinence: Behavior and Circuits
Speaker: **Yavin Shaham*, National Institute of Drug Abuse, National Institutes of Health***

Cue-Induced Corticostriatal Activations and Craving in Human Addiction: Naturalistic Measures and Treatment Effects
Speaker: **Rita Goldstein*, Icahn School of Medicine at Mount Sinai***

Brain Responses to Alcohol Cues in Youth at Risk for Substance Use Disorders: A Functional Magnetic Resonance Imaging Study
Speaker: **Marco Leyton*, McGill University***

9:45 A.M. - 11:15 A.M.

SENTINEL NETWORKS FOR EARLY SURVEILLANCE AND WARNING OF SUBSTANCE USE TRENDS IN NORTH AMERICA
Place du Canada, 2nd Floor

Chair: **Linda Cottler*, University of Florida***
Co-Chair: **Erin Parker*, National Institute on Drug Abuse, National Institutes of Health***

Harms caused by the unregulated drug supply in North America remain devastatingly high. These harms are driven by concurrent use of multiple substances such as opioids, stimulants, and benzodiazepines, and a rapidly changing and unpredictable inflow of adulterants such as xylazine, nitazenes, and fentanyl analogues. Substance use trends and drug supply contents shift over time and vary across regions. For this reason, the systematic collection, interpretation, and dissemination of timely information on emerging substance use trends is essential for developing interventions to prevent and reduce harms.

1. **This symposium highlights sentinel surveillance and early warning networks in the US, Canada and Mexico and will showcase unique strategies for collecting, interpreting, and communicating information and outcomes. Highlighted networks include:**
2. **The National Drug Early Warning System (NDEWS), funded to the University of Florida by NIDA, including data from 911 Dispatches, Wastewater Epidemiology; and Rapid Street Reporting;**
3. **The Canadian Community Epidemiology Network on Drug Use (CCENDU), coordinated by the Canadian Centre on Substance Use and Addiction (CCSA);**
4. **The Northwest Community Early Warning System (NCEWS), developed by harm reduction organizations in Baja California, Mexico.**

Presentations will explain project and network features, methodologies, and recent key findings with implications for policy and practice. Presentations will also showcase recent collaborative work between CCENDU, NDEWS and NCEWS on the importance of international sharing of findings and methods. The moderated discussion will highlight similarities and differences between approaches and context, and the added benefits of drawing from each other's experiences.

The Canadian Community Epidemiology Network on Drug Use (CCENDU)
Speaker: **Doris Payer*, Canadian Centre on Substance Use and Addiction***

ABSTRACTS

Surveillance of Drug Use in Baja California, Mexico
Speaker: **Jaime Arredondo Sanchez Lira*, University of Victoria***

911 Dispatch and Community-Level Surveillance
Speaker: **Andrew McCabe*, University of Florida***

Using a Wastewater-Based Epidemiology Framework to Track Community Health and Support Public Health Initiatives
Speaker: **Tara Sabo-Attwood*, University of Florida***

9:45 A.M. - 11:15 A.M.
USING DATA ANALYTICS TO GUIDE COMMUNITY RESPONSES TO THE OPIOID CRISIS
Av. Viger, 2nd Floor

Chair: **John Mantsch*, Medical College of Wisconsin***
Co-Chair: **Rachel Wightman*, Rhode Island Hospital/Alpert Medical School of Brown University***

As the opioid epidemic continues to escalate, so does the need for more effective strategies for guiding community responses. Health agencies, service providers and community organizations provide a wealth of data related to opioid misuse and overdoses. However, our ability to leverage these data to save lives requires the development of innovative data analytical approaches and the establishment of community partnerships through which outcomes can be made actionable. This symposium pulls together teams from Massachusetts (Tufts), North Carolina (University of North Carolina; UNC), Rhode Island (Brown), and Wisconsin (Medical College of Wisconsin/University Wisconsin Milwaukee; MCW/UWM) that are using big data and advanced analytical approaches in partnership with community agencies/organizations to guide responses to the opioid crisis. The team at Brown has developed a drug supply surveillance program that combines ethnographic and toxicological methods to track the local drug supply and rapidly disseminate findings statewide. The team at UNC has created a nationwide mail-in drug checking program that enables rapid testing of drug samples linked to medical harms. The team at MCW/UWM is applying precision epidemiology using advanced geospatial analysis of overdose, resource, and socioeconomic data and data-guided community engagement to identify neighborhood-level characteristics that influence overdoses and recovery. The team at Tufts is utilizing emergency medical services data and other predictors of opioid-related incidents and spatiotemporal predictive models to create a syndromic surveillance system and optimize communication strategies to promote effective dissemination. The utility of these approaches for optimizing community responses and the associated challenges and opportunities will be discussed.

testRI: A community-drive drug supply surveillance system in Rhode Island
Speaker: **Alexandra Collins*, Brown University***

Drug Checking and Harm Reduction
Speaker: **Nabarun Dasgupta*, University of North Carolina***

Precision Epidemiology and the Opioid Crisis: Using Next-Generation Geospatial Analyses to Guide Community-Level Responses
Speaker: **John Mantsch*, Medical College of Wisconsin***

ABSTRACTS

Syndromic Surveillance to Prevent Overdose in Lowell, MA: Data to Action and Evaluation
Speaker: **Shikhar Shrestha*, Tufts University School of Medicine***

Moderator: **Ken Shatzkes*, Foundation for Opioid Response Efforts***

9:45 A.M. - 11:15 A.M.

LET'S BE BLUNT: NEUROCOGNITIVE IMPACTS OF CANNABINOIDS ARE COMPLICATED
Square Dorchester, 2nd Floor

Chair: **Krista Lisdahl*, University of Wisconsin-Milwaukee***
Co-Chair: **Staci Gruber*, McLean Hospital, Harvard Medical School***

Cannabis remains the second most popular substance and innovative product types continue to flood the market. Years of research have demonstrated that the neurocognitive impact of cannabinoids are complicated; thus far, human findings depend on underlying biology and pre-use endocannabinoid signaling, developmental stage during exposure, acute vs. chronic use, patterns of use, content and potency of cannabinoids, and whether someone is using cannabis recreationally or medically. Here, we highlight a series of studies that further contextualize the neurocognitive impact of endocannabinoids and cannabinoids. The first presentation will highlight novel findings linking ex vivo eCB circulating levels, cognition, and downstream substance use initiation during early adolescence in a large national sample. The next speaker will highlight findings showing that cannabinoid content (THC vs. CBD) is linked with memory, inhibition and attention- even in very light early adolescent recreational users. Next, we will focus in on unique acute impact of THC on neurobehavioral measures of reward and inhibitory control processing in young adults with varying levels of recreational cannabis use history. In the final presentation, we will highlight important distinctions in neurocognitive effects between recreational and medical cannabis users, providing insights into why existence of comorbid conditions, motives for use, product choice, and patterns of cannabis use each play a unique role in the impact of cannabis use on cognition across different stages of life. A distinguished moderator will facilitate discussion about clinical and public health implications and future research directions.

All About Context: The Role of Circulating Endocannabinoid Levels in Neurocognition and Substance Use Risk During Early Adolescence
Speaker: **Elizabeth Stinson*, University of Wisconsin-Milwaukee***

Investigating Hair THC vs. CBD and Neurocognition in Youth Enrolled in ABCD Study
Speaker: **Natasha Wade*, University of California, San Diego***

The Acute Effects of Delta-9-THC on Reward Processing and Inhibitory Control Differ Depending on Cannabis Use History Among Young Adults
Speaker: **Natania Crane*, University of Illinois at Chicago***

Cognitive Complexities: Clarifying Recreational vs. Medical Cannabis Use
Speaker: **Staci Gruber*, McLean Hospital, Harvard Medical School***

Moderator: **Francesca Filbey*, University of Texas at Dallas***

ABSTRACTS

9:45 A.M. - 11:15 A.M.

HARNESSING THE OREXIN SYSTEM ACROSS THE TRANSLATIONAL SCIENCE SPECTRUM TO ADVANCE TREATMENTS FOR ADDICTION
Av. Duluth, 2nd Floor

Chair: **Caitlin Martin***, Virginia Commonwealth University*
Co-Chair: **F. Gerard Moeller***, Virginia Commonwealth University*

Emerging preclinical and clinical research highlight how the orexin (hypocretin) system could inform substance use disorder (SUD) medication development. The orexin system regulates homeostasis, impacting sleep, motivation and the stress response, placing it at the center of neurofunctional domains implicated in SUD. However, how the orexin system contributes to SUD treatments is still being elucidated in animal and human studies. Ultimately, uncovering these processes could illuminate multiple therapeutic targets. This CPDD symposium brings together experts in the orexin system and SUD across the translational science spectrum. Presenters will showcase novel pre-clinical and clinical findings at this intersection. After an overview by chair Dr. Martin, Dr. Richardson will present on how orexin-1 receptor antagonism using SB-334867 can influence sensitivity to cocaine seeking in rodents with differential preferences for high fat and sugar diets, as well as how these factors may affect gut microbial communities. Next, Dr. James will present pre-clinical evidence supporting the repurposing of the dual orexin receptor antagonist, suvorexant, for treating cocaine use disorder. Transitioning into human data, Dr. Huhn will present on the effects of suvorexant on diurnal cortisol and self-reported stress during opioid withdrawal among people with opioid use disorder. Dr. Martin will report findings from the first clinical trial of lemborexant, another dual orexin receptor antagonist, among patients on buprenorphine. Lastly, Dr. Nair (NIDA) will moderate the discussion. After symposium participation, attendees will be able to identify potential mechanisms of how the orexin system impacts SUD treatments to inform translational research and, ultimately, clinical care advancements.

The Effect of Orexin Receptor Antagonism on Motivated Behaviors and the Gut Microbiome
Speaker: **Kimberlei Richardson***, Howard University College of Medicine*

Optimizing Time-Of-Day Dosing of Suvorexant for the Management of Cocaine Use Disorder: Evidence From Preclinical Models
Speaker: **Morgan James***, Dept of Psychiatry, Robert Wood Johnson Medical School, Rutgers University*

Dual Orexin Receptor Antagonist Effects on Sleep and Stress Hormones During Opioid Withdrawal
Speaker: **Andrew Huhn***, Johns Hopkins University School of Medicine*

Phase 1b/2a Drug-Drug Interaction Study of Lemborexant as an Adjunctive Treatment to Buprenorphine-Naloxone for Opioid Use Disorder
Speaker: **Caitlin Martin***, Virginia Commonwealth University*

ABSTRACTS

9:45 A.M. - 11:15 A.M.

SEX DIFFERENCES UNDERLYING THE EFFECTS OF PAIN ON OPIOID USE
Rue Sainte Catherine-Saint Paul, 2nd Floor

Chair: **Jessica Higginbotham*, Washington University in St. Louis***
Co-Chair: **Sandra Comer*, Columbia University and NYSPI***

Clinical evidence suggests that the effects of pain on opioid misuse liability are gender/sex specific. Although women are more sensitive to pain, men are more likely to escalate opioid use, misuse prescriptions, and meet diagnostic criteria for opioid use disorder. Despite this, our understanding of sex differences underlying the effects of pain on opioid use remains limited.
Dr. Catherine Cahill (UCLA) will show data indicating that chronic neuropathic pain increased intravenous self-administration (IVSA) of remifentanil during the acquisition phase that was driven by male mice rather than females. When mice transitioned to a harder work effort, all chronic pain animals self-administered fewer reinforcers compared to sham animals during IVSA using fixed-ratio versus progressive-ratio schedules.
Dr. Jose Moron-Concepcion (WashU) will discuss how sex differences in fentanyl self-administration, motivation, and reinstatement emerge under conditions of persistent inflammatory pain. He will highlight mechanisms related to dopamine signaling and ovarian hormones that promote and protect against pain-facilitated fentanyl use in females.
Dr. Wendy Lynch will present data on sex differences in the development of addiction-like features (an enhanced motivation for the drug, physical dependence, vulnerability to relapse) following extended-access fentanyl self-administration and discuss the potential role of hyperkatefiea, or emotional pain/negative affect, in driving these sex differences.
Dr. Sandra Comer will present clinical laboratory data on sex differences and hormonal influences on response to pain and opioid administration. She will also describe potential strategies that have been proposed for treating pain with opioids in combination with other medications (e.g., glial inhibitors, cannabinoids, N-methyl-D-aspartate antagonists).

Impact of Chronic Neuropathic Pain on Opioid Self-Administration in Mice
Speaker: **Catherine Cahill*, University of California Los Angeles***

Sex-Specific Effects of Inflammatory Pain on Fentanyl Self-Administration and Modulation by Ovarian Hormones
Speaker: **Jessica Higginbotham*, Washington University in St. Louis***

Sex Differences in the Development of Addiction-Like Features in a rat Model With Fentanyl
Speaker: **Wendy Lynch*, University of Virginia***

Sex Differences and Hormonal Influences in Responses to Pain and Opioid Administration: Clinical Findings
Speaker: **Sandra Comer*, Columbia University and NYSPI***

ABSTRACTS

9:45 A.M. - 11:15 A.M.

EPIDEMIOLOGY AND PUBLIC HEALTH RESEARCH METHODS
Av. Van Horne, 2nd Floor

Chair: **Maria Parker*, Indiana University – Bloomington***
Co-Chair: **Howard Chilcoat*, Indivior, Inc.***

This proposal is for a continuation of the annual CPDD Epidemiology and Public Health Research Methods evening workshop series that began approximately 20 years ago. This year's workshop will focus on applying machine learning approaches to research questions conducted by epidemiologic and clinical investigators in the field of substance use and related disorders. Machine learning methods are an increasingly important tool for researchers. In this workshop, presentations will span a variety of topics including: 1) Grace Kong, Yale University - "Using Computer Vision Models to Predict E-cigarette Warning Labels on Social Media." For this project, computer visual detection models identify e-cig warning labels on YouTube and Instagram, 2) Georgiy Bobashev, RTI - "Drug use trends in social media (reddit). Exciting results, but what is the ground truth?" He will present about ground truth and the analysis of Reddit data, 3) Maria Parker, Indiana University - "Digital Epidemiology of Prescription Drug References Among Twitter Users." She will present on harnessing multiple natural language processing analyses to explore street and brand name drug-related tweets, 4) Michael Gilbert, Booz Allen Hamilton – "Process and Performance of Machine-Assisted Social Media Research." This project involves using Reddit to understand patients' experiences tapering off Sublocade, and 5) Meredith Meacham, University of California, San Francisco – "Unsupervised machine learning to identify cannabis reduction strategies in an online community." She uses topic modeling to understand cannabis moderation subreddits. All five presenters will discuss pertinent socially and clinically relevant public health implications about substance use on social media.

Using Computer Vision Models to Predict E-Cigarette Warning Label on Social Media
Speaker: **Marzieh Babaeianjelodar*, Yale University School of Medicine***

Drug Use Trends in Social Media (Reddit): Exciting Results, but What is the Ground Truth?
Speaker: **Georgiy Bobashev*, RTI International***

Digital Epidemiology of Prescription Drug Conversations Among Twitter Users
Speaker: **Howard Chilcoat*, Indivior, Inc.***

Process and Performance in Machine Assisted Social Media Research
Speaker: **Michael Gilbert*, Booz Allen Hamilton***

Unsupervised Machine Learning to Identify Cannabis Reduction Strategies in an Online Community
Speaker: **Meredith Meacham*, University of California San Francisco***

ABSTRACTS

11:30 A.M. - 12:30 P.M.

DRUG CHECKING: WHAT RESEARCHERS NEED TO KNOW
Place du Canada, 2nd Floor

Chair: **Chelsea Shover*, David Geffen School of Medicine at UCLA***

Drug checking has a decades-long history as a form of harm reduction practiced by people who use drugs. Techniques accessible to lay people, such as reagent kits or test strips, have been an important way for individuals to become more informed about the contents of substances they plan to consume. More recently, some health care and public health agencies have begun to embrace drug checking as a method to better understand the illicit drug supply at a population level and support harm reduction efforts. This forum, focused on drug checking in the United States, will present a practical tour of key facets of drug checking: technologies, legal considerations, policies, implementation models, information dissemination, and potential for community partnership to expand the possibilities of how drug checking might improve the health of people who use drugs. The panel's technology overview will cover the range of options currently available – from immunoassay test strips to portable spectrometers to laboratory-based mass spectroscopy – along with the strengths and limitations of each. The legal analysis portion will discuss how state- and federal laws and policies influence aspects of drug checking programs, such as participant protection, ability to advertise services, and even what methods can be offered. Finally, two speakers will showcase different approaches to implementing a drug checking program: Washington's statewide harm reduction agency-delivered, University-supported public health model, and a research study conducted at syringe services programs in Los Angeles.

Drug Checking Testing Approaches and Laboratory Partnerships
Speaker: **Edward Sisco*, National Institute of Standards and Technology***

Sunday, June 16, 2024 – Poster Session 1

S1. Associations of Sexual Orientation Discordance and Sexual Identity Fluidity with Alcohol and Other Drug Use Disorders in a National US Sample
Rebecca Evans-Polce*[1], Kara Dickinson[1], Curtiss Engstrom[1], Luisa Kcomt[2], Philip Veliz[3], Carol Boyd[3], Sean Esteban McCabe[3]
[1]*University of Michigan,* [2]*Wayne State University,* [3]*Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing*

S2. Effects of Recent Smoking and Daily Hassles on Mood and Craving During a Cigarette Quit Attempt
Merideth Addicott*[1], Santiago Saldana[1], Edward Ip[1], Alison Oliveto[2], Stacey Daughters[3], Jean Beckham[4]
[1]*Wake Forest University, School of Medicine,* [2]*University of Arkansas for Medical Sciences,* [3]*University of North Carolina, Chapel Hill,* [4]*Duke University*

S3. Differences in E-Cigarette Use Behaviors by High School Grade Level
Vanessa Ponte*[1], Danielle Davis[1], Krysten Bold[1], Grace Kong[1], Meghan Morean[1], Deepa Camenga[2], Wei Li[1], Akshika Sharma[1], Juhan Lee[1], Suchitra Krishnan-Sarin[1]
[1]*Yale University School of Medicine,* [2]*Developmental Neurocognitive Driving Simulation Research Center, Yale University School of Medicine*

S4. Lifetime and 30-Day Drug Use Associated with Higher by FTND Scores
Rachel Antenucci*[1], Karen Cropsey[1]
[1]*The University of Alabama at Birmingham*

S5. Relations Between Motivation to Quit Cigarette Smoking and Treatment Outcomes Among US Veterans With PTSD
Edith Harris*[1], Tilman Schulte[2], Matthew Yalch[3], Brian Borsari[4], Joanna Delacruz[4], Ellen Herbst[5]
[1]*PGSP-Stanford PsyD Consortium, NYU Langone Rusk Institute of Rehabilitation Medicine,* [2]*Palo Alto University,* [3]*Palo Alto University; San Francisco VA Medical Center,* [4]*San Francisco VA Medical Center,* [5]*San Francisco VA Medical Center; University of California, San Francisco*

S6. Persistent Behavioral Effects of Repeated Adolescent Exposure to Heroin and Delta-9-Tetrahydrocannabinol (THC) Vapor
Arnold Gutierrez*[1], Nora Alammari[2], Michael Taffe[1]
[1]*University of California, San Diego,* [2]*California State University, Bakersfield*

S7. Clinical and Demographic Correlates of Childhood Trauma During Methadone Treatment for Opioid Use Disorder
Enoch Ofori*[1], Jocelyn Ra[1], Julia Meyerovich[1], Brian Pittman[2], Joao De Aquino[1]
[1]*Yale University School of Medicine VA CT Healthcare System,* [2]*Yale University School of Medicine*

S8. Buprenorphine Treatment After an Emergency Room Visit for Non-Fatal Opioid Overdose
Sabrina Gaiazov*[1], Angela DeVeaugh-Geiss[1], Lia Pizzicato[2], Swapna Munnangi[2], William Mullen[1], Mitch DeKoven[2]
[1]*Indivior,* [2]*IQVIA*

S9. Describing Patterns of Drug Use and Service Delivery at Supervised Consumption Sites in Canada
Colin Steensma*[1], Isac Lima[1], Ledia Gamil[1], Michelle Ross[1]
[1]*Health Canada*

S10. Pharmacodynamic, Safety and Pharmacokinetic Effects of Co-Administration of the Selective Orexin-1 Receptor Antagonist INDV-2000 and Buprenorphine in Treatment Seeking Individuals with Opioid Use Disorder
Robert Dobbins*[1], Andrew S Huhn[2], Rajinder Shiwach[3], Malcolm A Young[1]
[1]*Indivior Inc.,* [2]*Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA,* [3]*InSite Clinical Research, DeSoto, TX, USA*

S11. Preferred Pharmaceutical-Grade Opioids to Reduce the Use of Unregulated Opioids: A Cross-Sectional Analysis Among People Who Use Unregulated Opioids in Vancouver, Canada
Kelsey Speed*[1], JinCheol Choi[2], Guy Felicella[2], M-J Milloy[3], Thomas Kerr[4], Kanna Hayashi[5]
[1]*University of British Columbia,* [2]*BC Centre on Substance Use,* [3]*BCCSU, University of British Columbia,* [4]*British Columbia Centre on Substance Use,* [5]*British Columbia Centre on Substance Use and Simon Fraser University*

S12. Implementing Contingency Management in a Federally Qualified Health Center (FQHC): Qualitative User-Centered Design of a Low Magnitude Reward Program Compatible with Buprenorphine Treatment
Samantha Ellis*[1], Jax Witzig[2], Diego Basaldu[2], Brittany Rudd[2], Nicole Gastala[2], Alexandra R. Tabachnick[3], Sungha Kang[4], Tondalaya Henry[2], Nathan Stackhouse[2], Margaret Wardle[2]
[1]*University of Illinois at Chicago,* [2]*University of Illinois Chicago,* [3]*Northwestern University,* [4]*Loyola University of Chicago*

S13. Characterization of Reddit Posts on Nitazenes
Jeanmarie Perrone[1], Jennifer Love[2], JaMor Hairston[3], Sahithi Lakamana[3], Abeed Sarker[3]
[1]*Perelman School of Medicine University of Pennsylvania,* [2]*Department of Emergency Medicine, Mount Sinai School of Medicine,* [3]*Department of Biomedical Informatics, School of Medicine, Emory University*

S14. Client preferences for the design and delivery of injectable opioid agonist treatment services: Results From a best-worst scaling task
Sophia Dobischok*[1], Rebecca Metcalfe[2], Nick Bansback[3], Scott MacDonald[4], David Byres[5], Julie LaJeunesse[4], Scott Harrison[4], Bryce Koch[6], Blue Topping[7], Terry Brock[8], Julie Foreman[9], Martin Schechter[10], Eugenia Oviedo-Joekes[3]
[1]*McGill University,* [2]*Core Clinical Sciences,* [3]*School of Population and Public Health, University of British Columbia,* [4]*Providence Health Care,* [5]*Provincial Health Services Authority,* [6]*Dr. Peter Centre,* [7]*Downtown Community Health Centre,* [8]*Lookout Housing and Health Society,* [9]*Hope to Health Research and Innovation Centre,* [10]*University of British Columbia*

S15. Barriers and Facilitators to Injectable Opioid Agonist Treatment Engagement: A Qualitative Study of Patient Experiences in Vancouver, Canada
Samara Mayer*[1], Nadia Fairbairn[2], Al Fowler[3], Ryan McNeil[4]
[1]*BC Centre on Substance Use, University of Victoria - Canadian Institute of Substance Use Research and Institute of Lifelong Aging and Health,* [2]*BC Centre on Substance Use, University of British Columbia,* [3]*BC Centre on Substance Use,* [4]*BC Centre on Substance Use, Yale University School of Medicine*

S16. Psychedelic Use by Practitioners and Therapists: Implications for the Emerging Psychedelic Workforce
Adrianne Wilson-Poe*[1], Kim Hoffman[2], Kellie Pertl[3], Jason Luoma[4], Alissa Bazinet[5], Christopher Stauffer[6], Dennis McCarty[7], P. Todd Korthuis[2]
[1]*Legacy Research Institute,* [2]*Oregon Health and Science University,* [3]*Oregon Health and Sciences University,* [4]*Portland Psychotherapy Clinic, Research, and Training Center,* [5]*Sequoia Center,* [6]*Portland VA Medical Center; Oregon Health and Science University,* [7]*Oregon Health and Science University School of Public Health*

S17. "What Does Recovery Mean to You?" A Mixed-Methods Approach to Uncover Self-Reported Recovery Meanings Among People Seeking Substance Use Disorder (SUD) Treatment In Chile
Ignacio Borquez*[1], Mariel Mateo[2], Noa Krawczyk[3], David Frank[4], Eduardo Valenzuela[5], Sofía Dupré[5], Álvaro Castillo-Carniglia[6]
[1]*NYU School of Medicine,* [2]*Griffith Criminology Institute, Griffith University, Australia,* [3]*Department of Population Health, NYU School of Medicine,* [4]*New York University,* [5]*Center for Studies on Justice and Society (CJS), Pontificia Universidad Católica de Chile,* [6]*Society and Health Research Center, Facultad de Ciencias Sociales y Artes, Universidad Mayor, Chile*

S18. Methodology for Single- vs Polydrug Classification of Poisoning Deaths
Svetla Slavova*[1], Douglas Oyler[1], Sarah Hargrove[1], Holly Hedegaard[1], Bruce A. Goldberger[1], Peter Akpunonu[1], Krassimir Slavov[1], Nabarun Dasgupta[2], Patricia Freeman[1]
[1]*University of Kentucky,* [2]*University of North Carolina*

S19. Co-Occurring Substance Use is a Marker for Greater Internalizing Symptoms Among Adolescents Meeting Screening Criteria for Depression or Anxiety
Geneva Jonathan*[1], Anne Eden Evins[1], Caroline Gray[1], Alec Bodolay[1], Kevin Potter[1], Randi Schuster[1]
[1]*Harvard Medical School/Massachusetts General Hospital*

S20. Examining the Role of Emergency Housing in Safer Supply Prescription Access in British Columbia Amidst Overlapping COVID-19 and Overdose Public Health Emergencies: A Qualitative Study
Sylvia Parusel[1], Taylor Fleming[2], Samara Mayer[3], Manal Mansoor[4], Andrew Ivsins[1], Jade Boyd[1], Ryan McNeil*[5]
[1]*British Columbia Centre on Substance Use,* [2]*The University of British Columbia,* [3]*BC Centre on Substance Use, University of Victoria - Canadian Institute of Substance Use Research and Institute of Lifelong Aging and Health,* [4]*University of British Columbia Faculty of Medicine,* [5]*Yale University School of Medicine*

S21. Behavioral Economic Interactions Between Cannabis and Delta-8
Maribel Rodriguez Perez*[1], Shahar Almog[1], Meredith Berry[1]
[1]*University of Florida*

S22. Predictors of Participation in Prenatal Substance Use Assessment and Intervention Among Pregnant Individuals Who Use Cannabis
Cynthia Campbell*[1], Gwen Lapham[2], Felicia Chi[1], Kelly Young-Wolff[1], Deborah Ansley[3], Carley Castellanos[3], Monique Does[1]
[1]*Kaiser Permanente Northern California,* [2]*Kaiser Permanente Washington Health Research Institute,* [3]*Regional Offices, Kaiser Permanente Northern California, Oakland CA*

S23. Sociodemographic Differences in Cannabis Use Patterns Among a Cohort of Cannabis Consumers: Preliminary Results from the Herbal Heart Study
Ranya Marrakchi El Fellah*[1], Bria-Necole Diggs[1], Amrit Baral[1], David Fakunle[2], Sarah Messiah[3], Raul Gonzalez[4], Claudia Martinez[1], Denise Vidot[5]
[1]*Miller School of Medicine, University of Miami,* [2]*Morgan State University,* [3]*University of Texas Health Science Center,* [4]*Florida International University,* [5]*University of Miami School of Nursing and Health Studies*

S24. Alcohol Use and Racial Discrimination in Later Generations of Latine Immigrants
Pamela Segura*[1], Monica Machada[1], Lillian Polanco-Roman[1]
[1]*The New School*

S25. GLP-1 Agonist Use In Patients Entering Alcohol Use Disorder Treatment
LaTrice Montgomery*[1], John Mendelson[1], Kevin Hallgren[2], Felicia Tuchman[3], Esperance Schaefer[4]
[1]*Ria Health,* [2]*University of Washington,* [3]*The University of New Mexico,* [4]*Harvard University*

S26. Realist Evaluation of the Viability and Transferability of the IACA program, an Alcohol Harm Reduction intervention: A Mixed-Method
Sarah Moriceau*[1], Fuschia Serre[1], Nolwenn Stevens[1], Sarah Perrin[1], Amandine Fillol[1], Linda Cambon[1], Marc Auriacombe[1], Judith Martin-Fernandez[1]
[1]*Universite de Bordeaux*

S27. Adaptations to Contingency Management for Alcohol Use Do Not Increase Efficacy in Individuals who Engage in Pre-Treatment Drinking Consistent with Non-Response
Michael McDonell*[1], Mohammad Keshtkar[2], Katherine Palmer[2], Diana Tyutyunnyk[2], Julianne Jett[2], Sara Parent[2], Rachael Beck[2], Naomi Chaytor[3], Sean Murphy[4], Solmaz Amiri[5], Douglas Weeks[2], Sterling McPherson[3], Richard Ries[6], John Roll[3]
[1]*Washington State University, Program of Excellence in Addictions Research,* [2]*PRISM Collaborative, Department of Community and Behavioral Health, Elson S Floyd College of Medicine, Washington State University,* [3]*Department of Community and Behavioral Health, Elson S Floyd College of Medicine, Washington State University,* [4]*Weill Cornell Medical College,* [5]*IREACH, Elson S Floyd College of Medicine, Washington State University,* [6]*University of Washington*

S28. ABCD Study Youth Perceived Threat, Inhibitory Control, and Alcohol Sipping
Julia Harris*[1], Chase Shankula[1], Krista Lisdahl[1]
[1]*University of Wisconsin-Milwaukee*

S29. Adolescent Gender Diversity and Substance Use Exposure: A Mediating Role of Peer Victimization
Annabel Diestel*[1], Sarahjane Dube[1], Sarah Rodrigues[2], Zoe Hulce[1], N. Arielle Cohn[3], Leigh-Anne Cioffredi[1], Dawn Bounds[2], Hugh Garavan[1], Alexandra Potter[1]
[1]*University of Vermont,* [2]*University of California, Irvine,* [3]*Vermont State University*

S30. Assessing Xylazine Involvement in Non-Fatal Drug Overdoses Using EMS Data for 2023
Andrew McCabe*[1], Linda Cottler[1]
[1]*University of Florida*

S31. Engaging the Great Circle: A Qualitative Study of the Confederated Tribes of Grand Ronde's Mobile Medication Unit
Kim Hoffman*[1], Chantell Smith-Graves[2], Kelly Rowe[3], Jennifer Worth[2], Kellie Pertl[1], James Laidler[2], P. Todd Korthuis[1], Dennis McCarty[1]
[1]*Oregon Health and Science University,* [2]*Great Circle Recovery,* [3]*Grande Ronde Health and Wellness*

S32. Mixed Methods Investigation of Xylazine Use Among People Who Inject Drugs (PWID) in New York City
Courtney McKnight*[1], Chenziheng (Allen) Weng[1], Marley Reynoso[1], Sarah Kimball[1], Mehrdad Khezri[1], Don Des Jarlais[1]
[1]*New York University School of Global Public Health*

S33. Intentional Drug Overdose Deaths and Mood Disorders in Brazil - A 20-Year Overview
Daniela Chiloff*[1], Vitor Tardelli[2], Silvia Martins[3], Thiago Fidalgo[4]
[1]*Federal University of Sao Paulo/Univ. of Sao Paulo Medical School,* [2]*Universidade Federal de Sao Paulo/Centre for Addiction and Mental Health - University of Toronto,* [3]*Columbia University,* [4]*Universidade Federal de Sao Paulo*

S34. Cannabis Use and Cannabis Use Disorder by Psychiatric Disorders: 2001-2002 and 2012-2013
Julia Bujno*[1], Caroline Wisell[1], Malki Stohl[1], Deborah Hasin[2]
[1]*New York State Psychiatric Institute,* [2]*Columbia University*

S35. Aerobic Exercise and Cannabis Use: Findings from the National Longitudinal Study of Adolescent to Adult Health, 1995-2018
Whitney Cordoba-Grueso*[1], Luis Mestre[2], Maria Parker[3]
[1]*Indiana University,* [2]*Yale School of Medicine,* [3]*Indiana University - Bloomington*

S36. Cannabis Use in Young Adults: The Role of Neighborhood Cohesion
Lanamarie Huynh[1], Kenneth Leonard[2], Gregory Homish[3], Jessica Kulak*[1]
[1]*University at Buffalo,* [2]*Clinical and Research Institute on Addictions, University at Buffalo,* [3]*State University of New York at Buffalo*

S37. Why Do Medical Cannabis Patients Use Illicit Medicinal Cannabis in the State of Utah?
Carter Reeves*[1], Clinton Hardy[2], Taylor Kelley[1], Michael Incze[1], Kristi Carlston[3], Adam Gordon[4], Gerald Cochran[1]
[1]*University of Utah,* [2]*University of Utah School of Medicine, Epidemeiology,* [3]*University of Utah School of Medicine,* [4]*University of Utah SoM and VASLCHCS*

S38. Cannabis Use Practices and Behaviors Associated with Cannabis Use Disorder Among Youth in Southern California
Claire Walsh*[1], Jessica Barrington-Trimis[1], Dae Hee Han[1], Alyssa Harlow[1]
[1]*University of Southern California*

S39. Association Between Cannabis Use Frequency and Total Body Water Among Young Black Adults
Larry Keen*[1]
[1]*Virginia State University*

S40. Prenatal Cannabis Exposure: Reasons, Messaging, and Sources of Information
Rebecca Denson*[1], Natania Crane[2], Mayra Guerrero[1], Robin Mermelstein[1]
[1]*University of Illinois at Chicago,* [2]*University of Illinois at Chicago Department of Psychiatry*

S41. Pathways to Prenatal Cannabis Use Among Younger Bisexual People
Natacha De Genna*[1], Lidush Goldschmidt[2], Nicole Boss[3], Robert Coulter[1], Maya Ragavan[1], Gale Richardson[1]
[1]*University of Pittsburgh,* [2]*University of Pittsburgh Medical Center,* [3]*Virginia Commonwealth University*

S42. Piloting an Online Cannabis Dispensary Paradigm for Cannabis Regulatory Science Research
Jacob Borodovsky*[1], Sourish Bairaboina[2], Cara Struble[1], Sarah Preum[2], Alan Budney[1]
[1]*Dartmouth Geisel School of Medicine,* [2]*Dartmouth College*

S43. Factors Associated with Different Cannabis Supply Methods in France: Results From the 2017 Escapad and Health Barometer Surveys
Filiz Eren[1], Solène Wallez[1], Stanislas Spilka[2], Emmanuel Lahaie[3], Selma Faten Rezag-Bara[1], Gauthier Bayle[1], Bertrand Redonnet[1], Viet Nguyen Thanh[3], Jean-Sébastien Cadwallader[4], Murielle Mary-Krause[1], Solène Wallez*[5]
[1]*Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Equipe de Recherche en Epidémiologie Sociale, ERES, F75012, Paris, France,* [2]*French Monitoring Centre for Drugs and Drug Addiction (OFDT), Paris, France,* [3]*French Public Health Agency (Santé Publique France), Paris, France,* [4]*Department of General Practice, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Equipe de Recherche en Epidémiologie Sociale, ERES, F75012, Paris, France,* [5]*INSERM*

S44. The Prevalence of Cannabis Use Disorders in People who Use Medicinal cannabis: A Systematic Review and Meta-Analysis
Danielle Dawson*[1], Daniel Stjepanovic[1], Valentina Lorenzetti[2], Christy Cheung[1], Wayne Hall[1], Janni Leung[1]
[1]*The University of Queensland,* [2]*Australian Catholic University*

S45. Direct and Mediating Effects of Text-Message Delivered Cannabis Use Disorder Treatment with Young Adults: A Large Randomized Clinical Trial
Michael Mason*[1], Douglas Coatsworth[1], Nathaniel Riggs[2], Michael Russell[3], Jeremy Mennis[4], Nikola Zaharakis[5], Aaron Brown[6]
[1]*University of Tennessee,* [2]*Colorado State University,* [3]*Penn State,* [4]*Temple University,* [5]*University of Tennessee Knoxville,* [6]*University of Kentucky*

S46. Differences in Memory Performance Between Cannabis Use Primary Methods in Young Adult HBCU Undergraduates
Emma Quarles*[1], Larry Keen[1]
[1]*Virginia State University*

S47. The Positive Association Between Cannabis Use Disorder Status and Basal Metabolic Rate Among Young Adult African Americans
Alexis Morris*[1], Larry Keen[1]
[1]*Virginia State University*

S48. An Investigation of Differing Effects of CBD for Menstrual-Related Symptoms Between Females Who Are and Are Not On Birth Control
Morgan Ferretti*[1], Noah Gustin[2], Caroline Sokol[2], Marcel Bonn-Miller[3], Jessica Irons[2]
[1]*Univesity of Arkansas,* [2]*James Madison University,* [3]*Charlotte's Web*

S49. Cannabis Use (CU) and Cannabis Use Disorder (CUD) Among Lesbian, Gay, and Bisexual Primary Care Patients in Los Angeles
Naira Setrakian[1], Marjan Javanbakht*[2], Whitney Akabike[3], Lillian Gelberg[4]
[1]*David Geffen School of Medicine at UCLA,* [2]*University of California, Los Angeles, Fielding School of Public Health,* [3]*UCLA Department of Family Medicine,* [4]*University of California Los Angeles, Department of Family Medicine*

S50. State Cannabis Legalization and Opioid Use Disorder in the US Veterans Health Administration, 2005 to 2019
Zachary Mannes*[1], Daniel Alschuler[2], Carol Malte[3], Dana Sacco[4], Mark Olfson[5], Andrew Saxon[6], Melanie Wall[5], Deborah Hasin[4]
[1]*College of Physicians and Surgeons, Columbia University,* [2]*NYSPI,* [3]*Center of Excellence in Substance Abuse Treatment and Education, Veterans Affairs Puget Sound Health Care System,* [4]*Columbia University,* [5]*Columbia University and NYSPI,* [6]*Veterans Affairs Puget Sound Healthcare System*

S51. Quality of Life of Individuals with a Substance Use Disorder in Different Treatment Settings: A Scoping Review
Anna Milliken*[1], Kimberly Collamore[1], Stacy Ryan-Pettes[1]
[1]*Baylor University*

S52. Puff, Pain, and Pillow Talk: Unraveling the Impact of Cannabis Use and Chronic Pain on Sleep Architecture
Tracy Brown*[1], Francesca Filbey[1]
[1]*University of Texas at Dallas*

S53. The Pharmacokinetics and Pharmacodynamics of Acute Oral Administration of a Hemp Derived Product with a 1:1 CBD/CBDA Ratio
Harrison Elder*[1], Austin Zamarripa[1], Robert Davis[2], Beth Dresser[2], Joe Wakshlag[2], Christian Kjaer[2], Ryan Vandrey[1], Tory Spindle[1]
[1]*Johns Hopkins University School of Medicine,* [2]*Cultivate Biologics*

S54. Examining US Medical Cannabis State Registry Data Quality
Rachel Sinclair*[1], Douglas Roehler[2], Felicia Gordon[3], Tristin Smith[3], Brooke Hoots[2], Kevin Boehnke[3]
[1]*Cannabis Strategy Unit, Centers for Disease Control and Prevention, Atlanta, GA, USA and Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA,* [2]*Cannabis Strategy Unit, Centers for Disease Control and Prevention, Atlanta, GA, USA,* [3]*Anesthesiology Department, University of Michigan Medical School, Ann Arbor, MI, USA*

S55. Analysis of Medical Claims Made on Popular E-Commerce Cannabis Platforms: Data Mining and Content Analysis of Leafly and Weedmaps
Matthew Nali[1], Zhuoran Li[1], Jiawei Li[1], Meng Zhen Larsen[1], Doug Roehler[2], Brooke Hoots[2], Tim Mackey[1]
[1]*S-3 Research, LLC,* [2]*U.S. Centers for Disease Control and Prevention*

S56. Age Differences in Patterns of Cannabis Use Among Adults Who Consume Cannabis Frequently
Ofir Livne*[1], Jacob Borodovsky[2], Alan Budney[3], Cara Struble[3], Efrat Aharonovich[4], Mohammad Habib[5], Claire Walsh[6], Dvora Shmulewitz[7], Deborah Hasin[1]
[1]*Columbia University,* [2]*Dartmouth Geisel School of Medicine,* [3]*Geisel School of Medicine at Dartmouth,* [4]*Columbia University and New York State Psychiatric Institute,* [5]*Dartmouth College,* [6]*University of Southern California,* [7]*Israel Center on Addiction*

S57. Implementation Barriers and Facilitator to Screening, Brief Intervention, and Referral to Treatment (SBIRT) for Risky Drug Use in FGHC Primary Care Clinics in the COVID-19 Era: the Quit-Mobile Study
Dallas Swendeman*[1], Melvin Rico[2], Whitney Akabike[3], Leticia Cazares[2], Geoffrey Curran[4], Lillian Gelberg[2]
[1]*University of California Los Angeles,* [2]*University of California Los Angeles, Department of Family Medicine,* [3]*UCLA Department of Family Medicine,* [4]*University of Arkansas for Medical Sciences*

S58. A Survey of Chronic Pain Patients Regarding Drug Use and Opinions on Brain Stimulation as Treatment
Tabassum Sami*[1], Natasha Desilva[2], Diana Martinez[3]
[1]*CUNY School of Medicine,* [2]*Department of Psychiatry, Columbia University,* [3]*Department of Psychiatry, Columbia University, and New York State Psychiatric Institute*

S59. Can Transcranial Low-Intensity Focused Ultrasound Stimulation (tFUS) Map White Matter Connections of Subcortical Networks?
Charles Palmer*[1], Daniel A.N. Barbosa[1], Kevin Caulfield[1], Lisa McTeague[1], Mark S. George[2]
[1]*Medical University of South Carolina,* [2]*Medical University of South Carolina, Ralph H. Johnson VA Medical Center*

S60. Patterns in Health Services Utilization Among Tobacco Users: A Narrative Review
Darren Lov*[1], Lillian Gelberg[2], Marjan Javanbakht[3], Whitney Akabike[4]
[1]*UCLA Fielding School of Public Health,* [2]*University of California Los Angeles, Department of Family Medicine,* [3]*University of California Los Angeles, Fielding School of Public Health,* [4]*UCLA Department of Family Medicine*

S61. Association Between Difficulties in Emotion Regulation and Smoking Cessation in LGBTQ+ Couples
Anna Miner[1], Lucy Schuler[1], Raina Pang[1], Matt Kirkpatrick*[1]
[1]*University of Southern California*

S62. Changes in Co-Use of Cannabis Among Adults Seeking Cigarette Smoking Cessation Treatment
Sabrina Voci[1], Scott Veldhuizen[1], Osnat Melamed[1], Peter Selby[1], Laurie Zawertailo*[1]
[1]*Centre for Addiction and Mental Health*

S63. Informing the Development of Interventions for E-Cigarette Use and Smoking Risk in Young Adults
Denise Tran*[1], Jordan Davis[2], Colin Ring[3], Keegan Buch[1], Eric Pedersen[1]
[1]*Keck School of Medicine University of Southern California,* [2]*RAND Corporation,* [3]*Loma Linda University*

S64. Mental Health and Tobacco Use Initiation Among a Nationally Representative Sample of Black Adolescents During the COVID-19 Pandemic
Wynta Alexander*[1], Adriana Espinosa[2], Lesia M. Ruglass[3], Fiona N. Conway[4], Christine Sheffer[5]
[1]*The Graduate Center, City University of New York,* [2]*The Colin Powell School at The City College of New York,* [3]*The City College of New York, CUNY,* [4]*Steve Hicks School of Social Work at The University of Texas at Austin,* [5]*Roswell Park Comprehensive Cancer Center*

S65. Universal Substance Use Care for Adolescents with Chronic Illnesses: Perspectives From Pediatric Health Professionals, Caregivers, and Teen Patients
Faith Summersett Williams*[1], Sara Becker[2], Geri Donenberg[3], Robert Garofalo[4], Niranjan Karnik[5], Lisa Kuhns[4]
[1]*Feinberg School of Medicine, Northwestern University, Chicago,* [2]*Brown University School of Public Health,* [3]*University o f Illinois at Chicago,* [4]*Lurie Children's Hospital of Chicago,* [5]*University of Illinois Chicago*

S66. Association Between State Cannabis Laws and Opioid Outcomes: A Systematic Review
David Fink*[1], Sarah Gutkind[2], Lauren Gorfinkel[3], Diana Bachowski[4], Zachery Mannes[2], Andrew Saxon[4], Deborah Hasin[2]
[1]*New York State Psychiatric Institute,* [2]*Columbia University,* [3]*University of British Columbia,* [4]*Veterans Affairs Puget Sound Healthcare System*

S67. Associations Between Interoceptive Control of Avoidance and Patterns of Morphine Self-Administration
Shihui Huang*[1], Sydney Cerveny[1], Ethan Steere[1], Anushka Valsan[1], Garrett Denney[1], Morgan Scott[1], Honeyeh Younesie[1], Sasha Abielmona[1], Sophie Robinson[1], Anthony Riley[1]
[1]*The American University*

S68. Comparison of the Antinociceptive and Hypothermic Effects of Mitragynine, the Primary Constituent in Kratom (Mitragyna Speciosa), in Rats and Mice
Samuel Obeng*[1], Takato Hiranita[2], Sushobhan Mukhopadhyay[3], Avi Patel[3], Christopher McCurdy[3], Lance McMahon[1]
[1]*Texas Tech University Health Sciences Center,* [2]*UT Health San Antonio,* [3]*University of Florida*

S69. Opioid Substitution Therapy Programs and the National Campaign to Eliminate Hepatitis C Virus in Taiwan: Current Status and Perspectives in a 2022 National Survey Among Medical Institutions
Wei J. Chen*[1], Yu-Chu Ella Chung[2], Ching-Ing Tseng[2], Sheng-Chang Wang[1], Chieh-Liang Huang[3], Lian-Yu Chen[4], Raoh-Fang Pwu[5]
[1]*National Health Research Institutes,* [2]*Center for Neuropsychiatric Research, National Health Research Institutes, Taiwan,* [3]*China Medical University Hospital,* [4]*Ministry of Health and Welfare, Taiwan,* [5]*Fu-Jen Catholic University*

S70. How Emergency Departments are Responding to the Opioid Crisis: Results from a Statewide Survey in Kentucky
Samantha Harris*[1], Olivia Sugarman[1], Lauren Byrne[1], Vivian Flanagan[1], Sabrina Gattine[1], Isha Desai[1], Omeid Heidari[2], Jason Gibbons[1], Sara Whaley[1], David Lucas[3], Tracy Pugh[3], Allison McBride[3], Brendan Saloner[1]
[1]*Johns Hopkins Bloomberg School of Public Health,* [2]*University of Washington,* [3]*Vital Strategies*

S71. Health-Related Quality of Life Profiles of Individuals with a History of Opioid Use Disorder by Intensity of Criminal-Legal System Involvement
Ali Jalali*[1], Callista Clairemont[1], Kate Hart[2], Danielle Ryan[1], Kathryn McCollister[3], Dennis Watson[2], Christine Grella[4], Michael Dennis[2], Sean Murphy[1]
[1]*Weill Cornell Medical College,* [2]*Chestnut Health Systems,* [3]*University of Miami Miller School of Medicine,* [4]*Chestnut Health Services*

S72. Desires to Breastfeed and Impacts on Duration Among Birthing People With and Without Opioid Use Disorder
Stephanie Mallahan*[1], Andrea Gonzolez[2], Esperanza Valencia[2], Linnea Linde-Krieger[1], Lela Rankin[3], Stacey Tecot[4], Alicia Allen[1]
[1]*University of Arizona, College of Medicine,* [2]*University of Arizona,* [3]*Arizona State University, School of Social Work,* [4]*University of Arizona, School of Anthropology*

S73. Nonprescribed Buprenorphine Use in 2022: Describing Reasons and Associated Factors in a Nationally Representative Survey
Jarratt Pytell*[1], Yaxu Zhuang[2], Karilynn Rockhill[3], Richard Dart[3], Ingrid Binswanger[4]
[1]*University of Colorado Denver School of Medicine,* [2]*University of Colorado Anschutz Medical Campus,* [3]*Rocky Mountain Poison and Drug Center,* [4]*Kaiser Permanente Colorado/Colorado Permanente Medical Group*

S74. School Aged Youth with Intersectional Sexual and Gender Diverse Identities Have Adverse Substance Use and Mental Health Outcomes
Gladys Pachas*[1], Anne Eden Evins[2], Alex Keuroghlian[1], Caroline Gray[1], Alec Bodolay[1], Rosie Du[1], Kevin Potter[1], Randi Schuster[1]
[1]*Massachusetts General Hospital, Harvard Medical School,* [2]*Massachusetts General Hospital-Psychiatry*

S75. Demographic and Mental Health Characteristics Among PWH in Clinical Care Across the US: Differences by Non-Fatal Overdose Status (2019-2023)
Heidi Crane*[1], Bridget Whitney[2], Kenneth Mayer[3], Mari Kitahata[2], Michael Saag[4], Lydia Drumright[2], Joseph Delaney[1]
[1]*University of Washington at Harborview Medical Center,* [2]*University of Washington,* [3]*Harvard Medical School,* [4]*University of Alabama at Birmingham*

S76. Fentanyl Preference and Criminal Legal Involvement: Associations and Differential Outcomes by Incidence of Arrest
Anjalee Sharma*[1], Courtney Nordeck[1], Kristi Dusek[1], Shannon Mitchell[1], Mishka Terplan[1], Robert Schwartz[1], Kim Wireman[2], Jan Gryczynski[1]
[1]*Friends Research Institute,* [2]*Powell Recovery Center*

S77. Qualitative Exploration of Opioid Overdose Response Steps Among Women Who Use Drugs on the Rural Eastern Shore of Maryland
Laura Kroart*[1], Katherine Clegg Smith[2], Julie Evans[2], Jill Owczarzak[2], Becky Genberg[2], Danielle German[2]
[1]*Towson University,* [2]*Johns Hopkins Bloomberg School of Public Health*

S78. The Effect of Insular Orexin Signaling in Mediating the Reinforcing Interoceptive Properties of Hydrocodone
Ashmita Mukherjee*[1], Hay Young Kwok[1], Dreem Ninnasopha[1], Kajol Sontate[1], Sarah Honeycutt[1], Greg Loney[1]
[1]*University at Buffalo*

S79. Sleep, Pain Catastrophizing, and Pain Severity in Persons with Opioid Use Disorder
Allison Wilkerson*[1], Abagail Ault[1], Elizabeth Santa Ana[2], Wendy Muzzy[1], Jenna McCauley[1], Jeffrey Borckardt[1]
[1]*Medical University of South Carolina,* [2]*Medical University of South Carolina and Charleston VAMC*

S80. HIV Pre- and Post-Exposure Prophylaxis Prescribing for Hospitalized People who Inject Drugs Cared for by an Addiction Consult Service
Paul Christine*[1], Hallie Rozansky[2], Morgan Younkin[3], Jason Fox[2], Zoe Weinstein[2], Sebastian Suarez[4], Jessica Stewart[5], Natalija Farrell[5], Jessica Taylor[2]
[1]*University of Colorado School of Medicine,* [2]*Boston University Chobanian and Avedisian School of Medicine,* [3]*Boston Healthcare for the Homeless Program,* [4]*University of Miami Miller School of Medicine,* [5]*Boston Medical Center*

S81. A Qualitative Study of Early Experiences and Outcomes of a Fentanyl Powder Safer Supply Program in Vancouver, Canada
Andrew Ivsins*[1], Christy Sutherland[2], Thomas Kerr[2], Mary Clare Kennedy[3]
[1]*University of British Columbia Faculty of Medicine,* [2]*British Columbia Centre on Substance Use,* [3]*The University of British Columbia*

S82. The Development of Effective and Safe Analgesics and Potential Combination Therapy Approaches: Guidances, Gaps, and Going Forward
Caitlyn Durgin*[1], Ryan Lanier[1], August Buchhalter[2], Jack Henningfield[3], Judy Ashworth[3]
[1]*Pinney Associates,* [2]*PinneyAssociates, Inc.,* [3]*Pinney Associates, Inc.*

S83. Secondary Analysis of Trials of Prolonged Exposure Therapy Among Adults with Co-Occurring Posttraumatic Stress Disorder and Opioid Use Disorder by Gender
Kelly Peck*[1], Sarah Heil[1], Colin Mahoney[2], Rebecca Cole[1], Jillian Giannini[1]
[1]*University of Vermont,* [2]*University of Colorado Colorado Springs*

S84. Comparison of Intravenous vs Subcutaneous Administration of the Monoclonal Antibody, CSX-1004 That Blocks Fentanyl's Effects in Squirrel Monkeys
Rajeev Desai*[1], Brissa Black[1], Emily Burke[1], Paul Bremer[2]
[1]*McLean Hospital/Harvard Medical School,* [2]*Cessation Therapeutics*

S85. Preconception Health Knowledge Among Individuals Receiving Medication Treatment for Opioid Use Disorder
Roxanne Harfmann*[1], Heidi Melbostad[1], Olivia Tarmey[1], Loren Kock[1], Sarah Heil[1]
[1]*University of Vermont*

S86. Predictors of Naloxone Protection Among a Sample of People who Use Illicit Opioids in New York City
Alexander Bennett*[1], Yuyu Chen[2], Adrian Harris[2], Saba Rouhani[2], David Frank[1], Melody Goodman[2], Luther Elliott[1]
[1]*New York University,* [2]*New York University School of Global Public Health*

S87. Overdose Mortality in a Cohort of People Who Use Drugs from the Wisconsin Node of the Rural Opioid Initiative
Rachel Gicquelais*[1], Sara Doyle[2], Caitlin Conway[1], Mikaela Becker[3], Marguerite Burns[1], David Seal[4], Ryan Westergaard[1]
[1]*University of Wisconsin - Madison,* [2]*University of Texas Health - San Antonio,* [3]*Vivent Health,* [4]*Tulane University SPHTM*

S88. Exploring Individual Factors Associated with Risk Levels for Opioid Misuse and Opioid Use Disorder Among Adolescents and Young Adults in the Emergency Department
Autumn Rae Florimbio*[1], Maureen Walton[2], Eve Losman[3], Meredith Philyaw-Kotov[1], Erin Bonar[2]
[1]*University of Michigan, Addiction Center,* [2]*University of Michigan, Addiction Center; Injury Prevention Center, University of Michigan,* [3]*University of Michigan, Department of Emergency Medicine*

S89. The System Isn't Broken; How Do We Fix It? The Need for Workplace Education About Harm Reduction
Nithya Narayanan*[1], Miryam Baied[2], Debbie Humphries[1], Katie Wang[1], Phillip Marotta[2], Robert Heimer[1]
[1]*Yale University,* [2]*Washington University in St. Louis*

S90. Within-Subject Evaluation of Technology-Assisted Buprenorphine Treatment
Sydney Batchelder*[1], Kelly Peck[1], Gary Badger[1], Olivia Tarmey[1], Stacey Sigmon[1]
[1]*University of Vermont*

S91. Resident Perspectives on How Recovery Residences Promote Medications for Opioid Use Disorder Initiation and Support the Medication-Assisted Recovery Pathway
Kathryn Gallardo*[1], J. Michael Wilkerson[1], I. Niles Zoschke[1], Hannah L. N. Stewart[1], Elizabeth A. Henry[2], Sheryl A. McCurdy[1]
[1]*The University of Texas Health Science Center at Houston,* [2]*Recovery People*

S92. Leveraging Photovoice to Gain Perspectives from People with Lived Substance Use Experience on Drivers of the Opioid Epidemic, What can Help, and Using the Medium to Share Insights With Law-Makers
Peter Balvanz*[1], Divya Gumudavelly[1], Nikki Lewis[1], Alyssa Curran[2], Craig McClay[1], Line Gonel[1], Aumani Harris[1], Merielle Saucier[1]
[1]*Boston Medical Center,* [2]*Western Mass Training Consortium*

S93. Qualitative Findings of Adaptive Recovery Management Checkups (RMC-Adaptive) to Improve Retention across the Oud Service Cascade
Jodie Dewey*[1], Christine Grella[2]
[1]*Chestnut Health System's Lighthouse Institute,* [2]*Chestnut Health Services*

S94. Pain Predicts Abstinence During Treatment of Opioid Use Disorder for Individuals Reporting Moderate to Severe Pain
Allison Tegge*[1], Marco Ferreira[2], Peter Garafola[3], Michael Farrell[4], John Marsden[5], Kenneth Lee[6], Anne Le Moigne[7], Frank Gray[8], Warren Bickel[1]
[1]*Fralin Biomedical Research Institute at VTC,* [2]*Virginia Tech,* [3]*Virgina Tech,* [4]*National Drug and Alcohol Research Centre,* [5]*Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London,* [6]*University of Western Ontario Faculty of Medicine,* [7]*Indivior,* [8]*Indivior, Inc.*

S95. Project BETTER: A Randomized Feasibility Trial of a Technology-Delivered Intervention Among Pregnant People Receiving Medication for Opioid Use Disorder
Anna Parlier-Ahmad*[1], Lillia Thumma[1], Sarah Martin[1], Michelle Eglovitch[1], Kameron Simmons[1], Tiffany Kimbrough[1], Dace Svikis[1], Caitlin Martin[1]
[1]*Virginia Commonwealth University*

S96. A Qualitative Analysis of Individual, Relationship, and Community Factors Influencing Non-Initiation of Medications for Opioid Use Disorder During Incarceration
Haily Traxler*[1], Carrie Oser[2]
[1]*University of Kentucky, College of Medicine,* [2]*University of Kentucky*

S97. Interprofessional Perspectives on Caring for Hospitalized Patients with Opioid Use Disorder
Margaret Lowenstein*[1], M Holliday-Davis[1], Lilah Lesniak[1], David Mandell[1], Judy Shea[1]
[1]*Perelman School of Medicine University of Pennsylvania*

S98. "I Always Got to Have Somebody in the Room With Me. I Don't Like Doing That Shit by Myself, and I Got to Go First." How People Who Inject Drugs Engage Harm Reduction Strategies to Stay Safe in the Face of an Increasingly Volatile Drug Market
Abigail Winiker*[1], Karin Tobin[1], Alizay Jalisi[1]
[1]*Johns Hopkins Bloomberg School of Public Health*

S99. Ethical Considerations for Using Biometric Enrollment Technology with Persons who Injection Drugs in Ciudad Juárez, Mexico
Lidia Rodriguez Garcia*[1], Susana Villa Lobos Alavez, BA[2], Miguel Ángel Jácome Santos, MA[2], Julia Lechuga, PhD, MA[3], Jorge Salazar, MD[1], Maria Elena Ramos Rodriguez, MSW[2], John A. Sauceda, PhD, MSc[1], Alexis M. Roth, PhD,MPH[4], Natasha T. Ludwig-Barron, PhD, MPH[5]
[1]*University of California - San Francisco,* [2]*Programa Compañeros,* [3]*Hunter College City University of New York,* [4]*Drexel Dornsife School of Public Health,* [5]*University of California- San Francisco*

S100. Time to Onset of Opioid Use Disorder for People Using Fentanyl versus Heroin: Results from a Cross Sectional Study in Seattle, WA
Samyukta Singh*[1], Caleb Banta-Green[1], Adam Palayew[1]
[1]*University of Washington*

S101. Persistence of the Modifications in the Delivery of Opioid Agonist Therapy During the Pandemic
Negar Shavandi*[1], Julia Saragosa[2], Francesca Di Paola[2], Bruna Brands[3], Maria Zhang[2], Beth Sproule[2]
[1]*University of Toronto,* [2]*Centre for Addiction and Mental Health,* [3]*Health Canada*

S102. Factors Associated with Self-Directed Discharge Among Hospitalized Individuals with a Substance Use Disorder
Raymond Julius Elefante*[1], Lianping Ti[2], Jingxin Lei[2], Jeffrey Morgan[3], Nadia Fairbairn[4], Seonaid Nolan[4]
[1]*University of British Columbia Faculty of Medicine,* [2]*British Columbia Centre on Substance Use,* [3]*BC Centre on Substance Use,* [4]*University of British Columbia*

S103. Journey Mapping Drug Market Disruptions Among Law Enforcement, Public Health, Harm Reduction, and People Who Use Drugs
Erin Comartin[1], Bethany Hedden-Clayton[1], Grant Victor[2], Jennifer Carroll[3], Jes Cochran[4], Ashley Shukait[5], Pam Lynch[6], Brandon del Pozo[7], Sarah Dixon[3], Larry West[1], Bradley Ray[8], Bethany Hedden-Clayton*[1]
[1]*Wayne State University,* [2]*Rutgers University,* [3]*North Carolina State University,* [4]*The Never Alone Project,* [5]*Ashley Shukait Consulting,* [6]*Harm Reduction Michigan,* [7]*Brown University,* [8]*Research Triangle International*

S104. Addressing Opioid Stigma in Pharmacies – Strategies for Pharmacy Professionals
Braiden Cutmore*[1], Andrew Johnston[1], Jordana Rovet[1], Sean Patenaude[1], Sarah Bhatti[2], Beth Sproule[1]
[1]*Centre for Addiction and Mental Health,* [2]*Public Health Agency of Canada*

S105. Identifying and Addressing Process Improvement Goals to Improve Cascade Outcomes Among People with Opioid Use Disorders: Findings from a Criminal Legal/Treatment Provider Local Change Team Study
Lauren Perron[1], Gerald Stahler*[1], Steven Belenko[1], Jennifer Wood[1]
[1]*Temple University*

S106. Preoperative Medication-Assisted Treatment (MAT) for Opioid Use Disorder (OUD) and Outcomes Following Surgery
Alicia Li*[1], Yongmei Huang[2], Jason D. Wright[2]
[1]*College of Physicians and Surgeons, Columbia University,* [2]*Columbia University*

S107. Oxycodone Relapse Induces Sex-Dependent Impairments in Sustained Attention and Pyramidal Neurons of the Medial Prefrontal Cortex
Kyler Nelson*[1], Hailong Li[2], Charles Mactutus[2], Rosemarie Booze[2], Kristen McLaurin[3]
[1]*University of Kentucky, College of Pharmacy,* [2]*University of South Carolina,* [3]*University of Kentucky*

S108. Implications of Hybrid Work Environments on Clinical Teams who Provide Primary Care-Based Opioid Use Disorder Treatment
Steffani Bailey*[1], Tamar Wyte-Lake[1], Shannon Williams[1], Jennifer Lucas[1], Deborah Cohen[1]
[1]*Oregon Health and Science University*

S109. Provision of Recovery Support Services in Opioid Use Disorder (OUD) Treatment Settings: A Secondary Data Analysis of the National Survey of Substance Abuse Treatment Services (N-SSATS) Data
Diadora Finley-Abboud*[1], Judeline Joseph[1], Alivia Williamson[1], Allison Futter[1], Bettina Hoeppner[1]
[1]*Massachusetts General Hospital*

S110. Patterns of Polysubstance Use Among Adults Who Use Opioids: Results from the NDEWS Rapid Street Reporting Study, 2021-2023
Anna Wang*[1], Nae Won[1], Joseph Palamar[2], Linda Cottler[1]
[1]*University of Florida,* [2]*New York University Grossman School of Medicine*

S111. Older Adults in Opioid Use Disorder Treatment: A Systematic Review of Health Outcomes
Tara Chowdhury*[1], Sphoorti Pandit-Kerr[1], Jake Fossum[1], Jennifer Wisdom[2]
[1]*CODA, Inc.,* [2]*The City University of New York*

S112. Primary Care Buprenorphine Provision in the US South and Midwest: Prescribing Changes Post-Data Waiver Elimination
Bailey Osweiler*[1], Miryam Baied[1], Nithya Narayanan[2], Zach Lynch[2], Kaileigh Backes[1], Katie Wang[2], Debbie Humphries[2], Robert Heimer[2], Phillip Marotta[1]
[1]*Washington University in St. Louis,* [2]*Yale University*

S113. Respect for Authority and Opioid Misuse in Justice-Involved Adolescents
Dahlia Williams*[1], James-Angelo Suarez[1], Kimberly Johnson[1], Micah Johnson[1]
[1]*University of South Florida*

S114. Patient Perspectives on an Open Access Model for Methadone Treatment
Lynn Madden*[1], Kim Hoffman[2], Scott Farnum[1], Erica Cannata[1], Kathryn Eggert[1], Kimberly DiMeola[1], Gretchen Hermes[3], Ermonda Markaj[1], Declan Barry[3]
[1]*APT Foundation,* [2]*Oregon Health Sciences University,* [3]*APT Foundation and Yale School of Medicine*

S115. Impact of HCV Status on Healthcare Utilization for Opioid Related Harms Among Patients Receiving Opioid Agonist Therapy
Paige Guyatt*[1], Glenda Babe[2], Tea Rosic[3], Myanca Rodrigues[3], Paxton Bach[4], Richard Perez[2], Claire de Oliveira[5], Jeffrey Samet[6], Victoria Weaver[7], Joanna Dionne[3], Aijaz Ahmed[8], Donghee Kim[8], Lehana Thabane[9], Zainab Samaan[9], Brittany Dennis[10]
[1]*McMaster University School of Medicine,* [2]*ICES McMaster, McMaster University, Hamilton, Ontario, Canada,* [3]*Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton ON Canada,* [4]*University of British Columbia,* [5]*Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada,* [6]*Boston University School of Medicine,* [7]*University of British Columbiua,* [8]*Department of Gastroenterology and Hepatology, Stanford University, Palo Alto, California,* [9]*McMaster University,* [10]*The University of British Columbia*

S116. Trends and Factors Associated with Opioid and Benzodiazepine Co-Prescription Among Individuals with a History of Opioid Use Disorder in the United States
Huiru Dong*[1], Erin Stringfellow[1], Mohammad Jalali[1]
[1]*Harvard Medical School*

S117. Gendered Landscapes: Understanding Gendered Nuances in Drug Use Settings and Behavior
Ananya Bhaktaram*[1], Carl Latkin[2]
[1]*Johns Hopkins Bloomberg School of Public Health,* [2]*Johns Hopkins School of Public Health*

S118. Clinical Risk Management when Delivering Medications for Opioid Use Disorder through Telehealth: A Systematic Review Framed by Process Mapping.
Joseph Tay Wee Teck*[1], Alexander Baldacchino[1]
[1]*University of St. Andrews School of Medicine*

S119. Factors Associated with Cognitive Flexibility in Opioid-Use Disorder: A Pilot Study
Paul Regier*[1], Thais Costa Macedo de Arruda[2], Laura Sinko[2], Anna Rose Childress[1], Anne Teitelman[3]
[1]*University of Pennsylvania,* [2]*Temple University,* [3]*Thomas Jefferson University*

S120. Potential Substance Use Disorder Epidemics Related to Prescription-Drugs in the United States: Development, Validation and Application of a Risk Assessment Approach
Makaya Funk[1], Thomas Patton[1], Cho-Hee Shrader[2], Daniela Abramovitz[1], Alexandra Almeida[1], Ravi Goyal[1], Benjamin Han[1], Britt Skaathun[1], Steffanie Strathdee[1], Davey Smith[1], Annick Borquez[1], Annick Borquez*[3]
[1]*University of California - San Diego,* [2]*Columbia University,* [3]*University of California San Diego*

S121. Emerging Hot Spot Analyses for Rapid Actionable Data for Opioid Response in Kentucky (RADOR-KY)
Daniel Harris*[1], Jeffery Talbert[2], Svetla Slavova[1]
[1]*University of Kentucky,* [2]*University of Kentucky, College of Medicine*

S122. Impact of the Sudden Closure of Mexico's Only Methadone Manufacturing Plant on the Mental, Financial and Social Health of Patients with Opioid Use Disorder (OUD) in Tijuana, Mexico
Jesse Goldshear*[1], Alicia Harvey-Vera[2], Maria Elena Medina-Mora[3], Gudelia Rangel[4], Steffanie Strathdee[2], Annick Borquez[2]
[1]*University of California San Diego, Department of Medicine,* [2]*University of California San Diego,* [3]*National Institute of Psychiatry Ramon de la Fuente,* [4]*Comisión de Salud Fronteriza México-Estados Unidos*

S123. Associations among Drug Acquisition and Use Behaviors, Demographics, Psychosocial Risk Factors, and Opioid-Involved Overdoses: A Sem Analysis
James Swartz*[1], Peipei Zhao[2], Dennis Watson[3], Ross Jacobucci[4], Mary Ellen Mackesy-Amity[2], Dana Franceschini[2], A. David Jimenez[2]
[1]*University of Illinois at Chicago,* [2]*University of Illinois At Chicago,* [3]*Chestnut Health Systems,* [4]*University of Notre Dame*

S124. The Cascade of Care for Individuals with Opioid Use Disorder in Los Angeles County
Katherine Watkins*[1], Christina Crowley[2], Lia Pak[1], Mariah M. Kalmin[1], Hrishikesh K. Belani[3], Kyle Ragins[3], Brian Hurley[4], Beth Ann Griffin[1]
[1]*RAND Corporation,* [2]*Frederick S. Pardee RAND Graduate School, RAND Corporation,* [3]*L.A. County Health Services,* [4]*County of Los Angeles, Department of Public Health*

S125. The Intersection of Discrimination, Substance Use, and Mental Health Help-Seeking in the African American Community
Amudha Balaraman*[1], Alexandria Bauer[2]
[1]*The New School,* [2]*Rutgers University*

S126. Assessing the Use of Research Evidence in State-Level Substance Use Policy
Leanna Kalinowski*[1], Jessica Pugel[2], Elizabeth Long[2], D. Max Crowley[2], J. Taylor Scott[2]
[1]*University at Buffalo,* [2]*Pennsylvania State University*

S127. Mechanical Restraint Use in Patients not Receiving Antipsychotics: An Ad-Hoc Analysis Regarding Potential Drugs of Abuse
George Book*[1], Meghan Thomas[1], Justin Marsden[1], Jingwen Zhang[1], Benjamin Kalivas[1]
[1]*Medical University of South Carolina*

S128. Impulsivity as a Mediator of Trauma History and Self-Harm Among Polysubstance Users
Karina Thiessen*[1], Laura Schmid[1], Stefanie Todesco[1], Chris Schütz[1]
[1]*University of British Columbia*

S129. Polysubstance Use Patterns for New Methadone Patients with Co-Occurring Opioid and Cocaine Use: An Exploratory Analysis
Shannon Mitchell*[1], Jesse Fletcher[2], Jan Gryczynski[1], Maxine Stitzer[1]
[1]*Friends Research Institute,* [2]*Friends Research Institute, Inc.*

S130. Cigarette Smoking and Electronic Nicotine Product Use Among People with Stimulant Use Disorder – Estimates From the 2021 National Survey on Drug Use and Health.
Loren Kock*[1], Tyler Erath[1], Sarah Heil[1]
[1]*University of Vermont*

S131. Eutylone Pre-Exposure Has No Impact on the Aversive Effects of Cocaine and MDMA: Implications of Its Hybrid Neurochemical Mechanisms of Action
Nina Ardabili*[1], Anthony Riley[2]
[1]*American University in Washington, DC,* [2]*The American University*

S132. Mapping the Shadow: Internet Drug Trade Dynamics through the Lens of Public Health
Sergey Soshnikov*[1], Bulat Idrisov[2]
[1]*Central Michigan University,* [2]*University of Washington School of Public Health, Department of Health Systems and Population Health*

S133. Responding to Xylazine Adulteration: Qualitative Insights from People Who Use Drugs and Syringe Services Program Staff
William Eger*[1], Erika Crable[1], Angela Bazzi[1], Corbin McElrath[2], Maia Hauschild[2], Cyrus Owens[2], David Forrest[2], Tyler Bartholomew[2], Hansel Tookes[2]
[1]*University of California - San Diego,* [2]*University of Miami Miller School of Medicine*

S134. Episodic Thinking through Art Creation to Reduce Delay Discounting: A Proof-Of-Concept Evaluation of Two Art Projects in a Residential SUD Treatment Center
Jennifer Hudson*[1], Sergej Grunevski[2], John Sebelius[1], Richard Yi[1]
[1]*University of Kansas,* [2]*Department of Psychiatry, UBHC, and Brain Health Institute, Rutgers University – New Brunswick*

S135. Identification and Characterization of Unrecognized Compounds including Novel Psychoactive Substances and Fentanyl Analogs in Individuals Undergoing Substance Use Disorder Treatment: A Comprehensive Analysis
Brian Dawson*[1], Katie Olson[1], Dave Newcombe[1]
[1]*Ideal Option*

S136. High Concordance Between Urine Toxicology Results and Self-Reported Fentanyl Use Among People Who Use Methamphetamine
Mia Kirk*[1], May McCarthy[2], Andres Reyes[2], Benjamin Chase[2], Jess Anderson[2], Robert Harding[3], Phillip Fiuty[4], Kimberly Page[2], Karla Wagner[5]
[1]*University of Nevada, Reno School of Public Health,* [2]*University of New Mexico Health Sciences Center,* [3]*University of Nevada Reno, School of Community Health Sciences,* [4]*New Mexico Department of Health,* [5]*University of Nevada School of Public Health*

S137. SBIR: RAE cHealth: Assessing the Usability and Acceptability of Digital Health Intervention to Support Peer Recovery-Based SUD Treatment
Stephanie Carreiro*[1], Reynalde Eugene[1], Melissa Taylor[1], Joshua Stapp[2], Nicole Gilbertson[2], Megan Reinhardt[2], Premananda Indic[3]
[1]*University of Massachusetts Medical School,* [2]*RAE Health,* [3]*The University of Texas at Tyler*

S138. Engagement With Overdose Prevention Spaces/Services Among a Community-Based Cohort of Women Sex Workers Who Use Drugs in Metro Vancouver (2017-2022)
Sarah Moreheart*[1], Wiebke Bartels[1], Kanna Hayashi[2], Shira Goldenberg[3]
[1]*Centre for Gender and Sexual Health Equity,* [2]*British Columbia Centre on Substance Use and Simon Fraser University,* [3]*San Diego State University*

S139. Racialized Differences in the Prevalence of Drug Use Disorder Among Transgender Veterans
Abigail Melton*[1], Olivia V. Fletcher[2], Jessie Garcia-Guttierez[3], Amy J. Kennedy[4], Claire Simon[5], Jessica Chen[3], Geetanjali Chander[5], Emily Williams[3]
[1]*University of Washington School of Medicine,* [2]*Veterans Affairs Puget Sound Health Care System,* [3]*University of Washington School of Public Health, Department of Health Systems and Population Health,* [4]*Veterans Affairs Puget Sound Health Care System, 1660 S Columbia Way, Seattle WA, 98102,* [5]*University of Washington*

S140. App-Based Contingency Management for Polysubstance Use: An Exploratory Analysis of App Engagement and Spending Patterns
Maxine Stitzer*[1], Jesse Fletcher[2], Jan Gryczynski[1], Shannon Mitchell[1]
[1]*Friends Research Institute,* [2]*Friends Research Institute, Inc.*

S141. "It's Like the Worst, Most Dangerous High Ever": A Content Analysis of Reddit User's Experience with Xylazine
Omeid Heidari*[1], Olivia Sugarman[2], Abigail Winiker[2], Vivian Flanagan[2], Sabrina Gattine[2], Brendan Saloner[2]
[1]*University of Washington,* [2]*Johns Hopkins Bloomberg School of Public Health*

S142. ENA-001, an Agnostic Respiratory Stimulant, Reverses Xylazine-Fentanyl Induced Respiratory Depression in Rats
Thomas Miller[1], Robert Raffa[1], George Dungan[2], Robert Colucci[3], Jeanette Mathews[1], Errol Gould*[4], Joseph Pergolizzi[1]
[1]*Enalare Therapeutics,* [2]*Dungan Research Associates, LLC,* [3]*Colucci and Associates, LLC,* [4]*Enalare Therapeutics Inc.*

S143. Increasingly Problematic Drug Use and but Very Low HIV Transmission Among Persons who Inject Drugs in New York City: 2021- 2023
Don Des Jarlais*[1], Chenziheng (Allen) Weng[2], Jonathan Feelemyer[1], Marley Reynoso[1], Courtney McKnight[2]
[1]*New York University School of Global Public Health,* [2]*New York University College of Global Public Health*

S144. "If You Go in With a Plan and a Goal, It Can Be Therapeutic": A Qualitative Exploration of Psychedelic Use Among Emerging Adult Cannabis Users in Los Angeles
Bridgid Conn*[1], Meagan Suen[2], Kaia L. Sheean[1], Janna Ataiants[3], Ekaterina Fedorova[3], Stephen E. Lankenau[3], Carolyn F. Wong[1]
[1]*Children's Hospital Los Angeles and University of Southern California,* [2]*Children's Hospital Los Angeles,* [3]*Drexel University Dornsife School of Public Health*

S145. Network Analysis of Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) Items for Alcohol, Tobacco, Cannabis, Sedatives, Prescription Stimulants, and Prescription Opioids.
Dvora Shmulewitz[1], Maor Levitin[1], Roi Eliashar*[1], Shaul Lev-Ran[1]
[1]*Israel Center on Addiction*

S146. Updates to a Pilot Surveillance System to Detect Changes in the Illicit Drug Supply to Guide Timely Harm Reduction Responses
Erin Russell*[1], Edward Sisco[2], Maggie Rybek[3]
[1]*Health Management Associates,* [2]*National Institute of Standards and Technology,* [3]*Maryland Department of Health*

S147. Liver Disease Among People Who Inject drugs: A Prospective Longitudinal Cohort Study Linked to Administrative Hospital Data
Samantha Colledge-Frisby*[1], Michael Curtis[1], Jessica Howell[2], Ericka Flores[3], Paul Dietze[2]
[1]*National Drug Research Institute, Curtin University,* [2]*Burnet Institute,* [3]*St Vincent's Hospital Melbourne*

S148. LC-QTOF/MS Analysis of Plasma Samples Confirms Widespread Multi-Class Polydrug Use in Philadelphia, Pennsylvania
Livio Azzoni*[1], Alia Sovereign[2], Rachel Holbert[3], Emily Hiserodt[4], Matthew Fair[1], Ross Ellison[2], Cecile Denis[5], Amy Jessop[3], Karam Mounzer[4], David Metzger[6], Roy Gerona[7], Luis Montaner[1]
[1]*The Wistar Institute,* [2]*University of CA, San Francisco,* [3]*Prevention Point, Philadelphia,* [4]*Philadelphia FIGHT,* [5]*University of Pennsylvania,* [6]*University of Pennsylvania, Department of Psychiatry,* [7]*San Francisco Veterans Affairs Health Care System*

S149. Oregon's Emerging Psilocybin Services Workforce: An Environmental Scan
Kellie Pertl*[1], Kim Hoffman[1], Adrianne Wilson-Poe[2], Jason Luoma[3], Alissa Bazinet[4], Sarann Bielavitz[1], Dennis McCarty[5], Christopher Stauffer[6], Cameron Wolf[7], P. Todd Korthuis[1]
[1]*Oregon Health and Sciences University,* [2]*Legacy Research Institute,* [3]*Portland Psychotherapy Clinic, Research, and Training Center,* [4]*Sequoia Center,* [5]*Oregon Health and Sciences University School of Public Health,* [6]*Portland VA Medical Center; Oregon Health and Science University,* [7]*Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Prevention*

S150. Sex-Stratified Prevalence of Classic Psychedelics Among Individuals with a History of Cancer in the United States: An Analysis of the National Survey on Drug Use and Health, 2015-2019
Amrit Baral*[1], Yue Pan[1], Alberto Caban-Martinez[1], Paulo Pinheiro[1], WayWay Hlaing[1], Denise Vidot[2]
[1]*Miller School of Medicine, University of Miami,* [2]*School of Nursing and Health Studies, Miller School of Medicine, University of Miami*

S151. Patients' Explanatory Models of Substance Use in Spanish-Speaking Latin American Immigrants at a Community Mental Health Clinic in Connecticut
Javier Ponce Terashima*[1], Adriana Golden[2], Kim Hoffman[3], Michelle Silva[1]
[1]*Yale University School of Medicine,* [2]*Yale University,* [3]*Oregon Health and Science University*

S152. Racial and Ethnic Disparities in Telehealth and Emergency Department Use Among Women with Substance Use Disorder During the COVID-19 Pandemic
Sugy Choi*[1], Leah L. Habersham[2], Brooke S. West[3]
[1]*New York University Grossman School of Medicine,* [2]*Icahn School of Medicine At Mount Sinai,* [3]*Columbia University*

S153. Rapport With Patient Navigator and Health Service Utilization After Hospital Discharge Among Patients with Substance Use Disorders: A Secondary Analysis from the NavSTAR Trial
Courtney Nordeck*[1], Christopher Welsh[2], Shannon Mitchell[1], Robert Schwartz[1], Jan Gryczynski[1]
[1]*Friends Research Institute,* [2]*University of Maryland School of Medicine*

S154. Polygenic Scores for Psychiatric Traits are Associated with Substance Use Phenotypes in a Deeply Phenotyped Sample
Emily Hartwell*[1], Zeal Jinwala[2], Joel Gelernter[3], Henry Kranzler[4], Rachel Kember[5]
[1]*University of Pennsylvania/Philadelphia VAMC,* [2]*University of Pennsylvania,* [3]*Yale University,* [4]*Department of Psychiatry, University of Pennsylvania,* [5]*University of Pennsylvania, Corporal Michael J. Crescenz VAMC*

S155. Exploring Urban Community Stakeholder Perspectives of Drug Decriminalization Reforms in the Baltimore Context
Natalie Flath*[1], Jordan J. White[2], Lawrence Grandpre[3], Corey Shdaimah[4]
[1]*Johns Hopkins Bloomberg School of Public Health,* [2]*Morgan State University,* [3]*Leaders of a Beautiful Struggle,* [4]*University of Maryland School of Social Work*

S156. Adaptations to a Perinatal Psychiatry Access Program to Address the Needs of South Carolina
Alana Dopp*[1], Courtney King[2], Marie Hayes[1], Lizmarie Maldonado[3], Constance Guille[1]
[1]*Medical University of South Carolina,* [2]*Medical University of South Carolina Dept of Psychiatry and Behavioral Sciences,* [3]*College of Health Professions, Department of Leadership and Management, Medical University of South Carolina*

S157. Relationships Between Craving, Quality of Life, Health, and Cocaine Abstinence, With the Treatment Effectiveness Assessment in a Sample of People in Cocaine Dependence Treatment
Crystal Smith*[1], Sterling McPherson[2], Nicole Rodin[3], Mahedi Hassan[1], Andrew Saxon[4]
[1]*Washington State University,* [2]*Washington State University Elson S. Floyd College of Medicine,* [3]*Washington State University, College of Pharmacy and Pharmaceutical Sciences,* [4]*Veterans Affairs Puget Sound Healthcare System*

S158. Repetitive Transcranial Magnetic Stimulation for Stimulant Use Disorders (STIMULUS): Methodology for a Multi-Site, Double-Blind, Randomized Controlled Trial
Zahraa Atoui*[1], Donald Egan[2], Karen Hartwell[3], Susan Sonne[1], Manish Jha[2], Brenda Brunner-Jackson[1], Angela Casey-Willingham[2], Russell Toll[4], Jenna McCauley[1], Madhukar Trivedi[2], Kathleen Brady[1]
[1]*Medical University of South Carolina,* [2]*University of Texas Southwestern Medical Center,* [3]*Medical University of South Carolina; Ralph H. Johnson VAMC,* [4]*University of Texas Southwestern Medical Center,*

S159. Training the Addiction Workforce to Deliver Contingency Management Interventions with Fidelity: Results of a Coaching-To-Criterion Process
Bryan Hartzler*[1], Mitch Doig[1], Kelsey Smith Payne[2], John McIlveen[2]
[1]*University of Washington,* [2]*Oregon Health Authority*

S160. The Compulsion Zone Theory of Cocaine Self-Administration Behavior: A Blueprint for Medications Development
Andrew Norman*[1]
[1]*University of Cincinnati, College of Medicine*

S161. Denial of Prescription Pain Medication Among People Who Use Drugs in Vancouver, Canada
Evelyne Piret*[1], M-J Milloy[1], Pauline Voon[2], JinCheol Choi[2], Kora DeBeck[3], Kanna Hayashi[3], Thomas Kerr[1]
[1]*The University of British Columbia,* [2]*BC Centre on Substance Use,* [3]*Simon Fraser University*

S162. Enhancing Propranolol-Induced Inhibition of Cocaine-Related Reward Memory Reconsolidation: Impact on Cocaine Craving and Use
Michael Saladin*[1], Kevin Gray[1], Aimee McRae-Clark[1], Kathleen Brady[1], Viswanathan Ramakrishnan[2], Nathaniel Baker[1]
[1]*Medical University of South Carolina,* [2]*Department of Public Health Sciences, Medical University of South Carolina*

S163. Imprisonment Among People Who Use Methamphetamine in Victoria, Australia: A Prospective Cohort Study
Michael Curtis*[1], Brendan Quinn[2], Jack Stone[3], Lisa Maher[4], Paul Agius[2], Mark Stoove[2], Bernadette Ward[5], Rebecca Jenkinson[2], Matthew Hickman[3], Peter Higgs[2], Paul Dietze[2]
[1]*National Drug Research Institute, Curtin University,* [2]*Burnet Institute,* [3]*Bristol University,* [4]*Kirby Institute for Infection and Immunity, Faculty of Medicine, UNSW Sydney, Australia,* [5]*School of Rural Health, Monash University*

S164. Sociodemographic Characteristics and Past Month Fentanyl Use Among Acute Stimulant Poisoning Decedents and by Fentanyl Involvement
Yi-Shin Chang*[1], Vanessa McMahan[2], Marley Antolin Muñiz[2], Sarah Brennan[2], Xochitl Luna Marti[2], James Knoll[3], Luke Rodda[4], Phillip Coffin[2]
[1]*Center on Substance Use and Health, San Francisco, Department of Public Health, San Francisco,* [2]*Center on Substance Use and Health, San Francisco Department of Public Health, San Francisco, CA,* [3]*SUNY Upstate Medical University, Syracuse, New York,* [4]*Office of the Chief Medical Examiner, San Francisco, CA*

S165. Nalmefene Selectively Decreases Cocaine Self-Administration under Limited Conditions in Male Rhesus Monkeys
Drew Townsend*[1], Jane Acri[2], Rajeev Desai[3], Jack Bergman[4], Carol Paronis[5]
[1]*NIDA DTMC,* [2]*National Institute of Drug Abuse, National Institutes of Health,* [3]*McLean Hospital/Harvard Medical School,* [4]*McLean Hospital / Harvard Med School,* [5]*McLean Hospital, Harvard Medical School*

S166. Naltrexone for the Treatment of Amphetamine-type Stimulant Use Disorder: A Systematic Review and Meta-analysis of Randomized Placebo-controlled Trials
Gabriel Bastien[1], Christina McAnulty[1], Heidar Sharafi*[2], Laurent Elkrief[3], Daniela Ziegler[3], Didier Jutras-Aswad[1]
[1]*Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada,* [2]*Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM),* [3]*Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada*

S167. Association Between Fentanyl Overdose History and Harm Reduction Behaviors in People Who Use Cocaine
Benedicta Anighoro*[1], Cecilia Nunez[2], Margaret Wardle[2]
[1]*University of Illinois at Chicago,* [2]*University of Illinois Chicago*

S168. Cocaine Craving and Use Outcomes in a Randomized Study to Test the Safety and Effectiveness of Buprenorphine and Naltrexone for the Treatment of Cocaine Dependence
Sterling McPherson*[1], Crystal Smith[1], Nicole Rodin[2], Mahedi Hasan[1], Andrew Saxon[3]
[1]*Washington State University Elson S. Floyd College of Medicine,* [2]*Washington State University College of Pharmacy and Pharmaceutical Sciences,* [3]*Veterans Affairs Puget Sound Health Care System*

S169. Naltrexone Blocks the Sleep-Disrupting Effects of Methamphetamine in Male Rhesus Monkeys
Patrick Davis*[1], James Rowlett[1], Lais Berro[1]
[1]*University of Mississippi Medical Center*

S170. Interest in Treatment, Reducing, and Stopping Stimulant and Opioid Use Among Syringe Service Program Participants in Vermont
Tyler Erath*[1], Rosalie LaCroix[2], Erin O'Keefe[2], Stephen Higgins[1], Richard Rawson[1]
[1]*University of Vermont,* [2]*Howard Center Safe Recovery*

S171. Population Aging and Apparent Decline in Initiation of Injecting Drug Use in Australia
Olivia Price*[1], Dan Lewer[2], Amy Peacock[1], Lisa Maher[3], Farzaneh Zolala[3], Louisa Degenhardt[4], Sarah Larney[5], Seraina Agramunt[6], Paul Dietze[7], Samantha Colledge-Frisby[6], Nick Scott[7], Joanna Wilson[7], Rachel Sutherland[1]
[1]*National Drug and Alcohol Research Centre, UNSW Sydney,* [2]*UCL Collaborative Centre for Inclusion Health,* [3]*Kirby Institute for Infection and Immunity, Faculty of Medicine, UNSW Sydney, Australia,* [4]*National Drug and Alcohol Research Centre,* [5]*Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) and Department of Family Medicine and Emergency Medicine, Université de Montréal,* [6]*National Drug Research Institute, Curtin University,* [7]*Burnet Institute*

S172. Development and Validation of a Hepatitis C Risky Injection Behaviours Index in a Cohort of People who Inject Drugs Located in Montréal, Canada
Gabriel Bastien*[1], Nanor Minoyan[1], Geng Zang[1], Julie Bruneau[1], Didier Jutras-Aswad[1]
[1]*Centre hospitalier de l'Université de Montréal Research Centre*

S173. Treatment Retention Trends in Outpatient MOUD Therapy in an RCT Using ReSET-O: A Mobile App Intervention Providing Cognitive Behavioral Therapy for Opioid Use Disorder Patients.
Sarah Kawasaki*[1], Rachel Zimmerman[2], Nicole Aydinoglo[3], Erik Lehman[2], Lan Kong[2], Edward Nunes[4]
[1]*Penn State Health,* [2]*Penn State College of Medicine,* [3]*NYS Psychiatric Institute,* [4]*Columbia University and New York State Psychiatric Institute*

S174. Examining the Interaction of Involuntary Celibacy and Sex/Gender on Mental Health in a Substance Using Population
William J. Kowalczyk*[1], Kirsten Smith[2], Jeffrey Rogers[3], Jeremiah Bertz[4], David Epstein[5]
[1]*Hartwick College,* [2]*Johns Hopkins University,* [3]*SDSU/UCSD Joint Program in Clinical Psychology,* [4]*National Institute on Drug Abuse, Intramural Research Program,* [5]*NIDA Intramural Research Program*

Monday, June 17, 2024 – Poster Session 2

M1. The Association Linking Adverse Childhood Experiences with Alcohol Expectancies in Young Adulthood: A Longitudinal Study in Taiwan
Ai-Lin Chen*[1], Yi-Tien Hsu[2], An-Jou Chen[2], Chuan-Yu Chen[2]
[1]*Institute of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan,* [2]*National Yang Ming Chiao Tung University*

M2. Male Sex and Hazardous Alcohol Use Following Military Sexual Assault Increase Suicide Risk Among Us Service Members and Veterans
Rebecca Blais*[1], Bingyu Xu[1], Hallie Tannahill[2], Patrick Dulin[3]
[1]*Arizona State University,* [2]*United State Air Force,* [3]*University of Alaska*

M3. Examining the Relationship Between Bullying Involvement and Alcohol Use Among Canadian Youth
Emilia Krzeminska[1], Colin Steensma*[1]
[1]*Health Canada*

M4. Effects of the Social Cold Pressor Task on Stress Reactivity and Alcohol Craving and Demand
Jin Yoon*[1], Scott Lane[2], Joy Schmitz[1], Carolina Haass-Koffler[3], Vincent Dang[1], Lanelle Ochiam[1], Jessica Vincent[1], Robert Suchting[4], Constanza de Dios[4]
[1]*University of Texas Health Science Center,* [2]*University of Texas Health Science Center, McGovern Medical School,* [3]*Brown University,* [4]*The University of Texas Health Science Center At Houston*

M5. Predicting Alcohol Use in Undergraduates: Interactions Between Social Anxiety and Impulsivity
Jillian Hardee*[1], Elizabeth Duval[1]
[1]*University of Michigan*

M6. Sign- And Goal-Tracking in Humans: Associations with Drug and Alcohol Use
Lora Cope*[1], Ha Rim Jung[1], Ryan Klaus[1], Mary Soules[1], Jonathan Morrow[1]
[1]*University of Michigan*

M7. 7-Year Impacts of a Selective Personality-Targeted Alcohol Use Prevention Program on Alcohol and Mental Health Outcomes
Nicola Newton[1], Lexine Stapinski[2], Maree Teesson[2], Natalie Castellanos Ryan[3], Patricia Conrod[4], Samantha Lynch*[5]
[1]*University of Sydney,* [2]*The Matilda Centre for Research in Mental Health and Substance Use at the University of Sydney,* [3]*Universitï¿½ de Montrï¿½al,* [4]*CHU Ste Justine, Universite de Montreal,* [5]*University of Montreal*

M8. The Onset, Progression, and Continuation of Hazardous Drinking Among Women with HIV Enrolled in a Clinical Trial to Reduce Drinking: A Qualitative Assessment of Lifetime Drinking History
Christina Parisi*[1], Abigail Gracy[1], Sashaun Ranger[1], Rebecca Fisk-Hoffman[1], Nanyangwe Siuluta[1], Isaac Payton[1], Robert Cook[1], Shantrel Canidate[1]
[1]*University of Florida*

M9. Leveraging Causal Discovery Analysis to Trace Causal Brain-Behavior Pathways in Substance Use Disorders
Eric Rawls*[1], Marvin Yan[2], Andrea Maxwell[3], Jazmin Camchong[4], Michael Kotlyar[5], Malick Abid[6], Bonnie Klimes-Duggan[2], Kathryn Cullen[7], David Bond[8], Erich Kummerfeld[6]
[1]*University of Minnesota Medical School,* [2]*University of Minnesota Department of Psychology,* [3]*University of Minnesota Department of Psychiatry and Behavioral Sciences, University of Minnesota Medical Scientist Training Program, University of Minnesota Graduate Program in Neuroscience,* [4]*`University of Minnesota Department of Psychiatry and Behavioral Sciences,* [5]*University of Minnesota Department of Experimental and Clinical Pharmacology,* [6]*University of Minnesota Institute for Health Informatics,* [7]*University of Minnesota Department of Psychiatry and Behavioral Sciences,* [8]*Johns Hopkins University Department of Psychiatry and Behavioral Sciences*

M10. A Passive Addiction Recruitment Strategy Among HIV Patients in Alabama: An Opportunity for Equitable Research Participation
Kelly Gagnon[1], Morgan Mulrain[2], Harriette Reed-Pickens[2], Ellen Eaton*[2]
[1]*The University of Alabama at Birmingham,* [2]*Division of Infectious Diseases, The University of Alabama at Birmingham*

M11. Substance Use Differs by Gender and Adverse Childhood Experiences Among People Living With HIV
Lacey Caywood*[1], Marianna Wetherill[2], Casey Bakhsh[3], Spencer Hall[2], Mary Williams[2], Micah Hartwell[4], Sheri Weiser[5]
[1]*University of Oklahoma Health Sciences Center,* [2]*University of Oklahoma Health Sciences Center,* [3]*Tulsa CARES,* [4]*Oklahoma State University Center for Health Sciences,* [5]*University of California San Francisco*

M12. Contingency Management with Stepped Care for Unhealthy Alcohol Use Among Individuals With HIV: Initial Findings From a Multisite Randomized Controlled Trial

E. Jennifer Edelman*[1], James Dziura[2], Yanhong Deng[2], Dominick DePhilippis[3], Sheldon Brown[4], Tekeda Ferguson[5], Vincent Marconi[6], Matthew Bidwell Goetz[7], Maria Rodriguez-Barradas[8], Michael Simberkoff[9], Patricia Molina[10], Amy Weintrob[11], Stephen Maisto[12], Manuel Paris, Jr.[13], Amy Justice[14], Kendall Bryant[15], David Fiellin[16]

[1]*Yale School of Medicine,* [2]*Yale University School of Public Health,* [3]*Veterans Affairs Office of Mental Health and Suicide Prevention, US Department of Veterans Affairs, Washington, D.C. and Department of Psychiatry, Perelman School of Medicine and University of Pennsylvania, Philadelphia, PA,* [4]*James J. Peters Veterans Affairs Medical Center and Icahn School of Medicine at Mount Sinai, New York, NY,* [5]*Department of Epidemiology, Louisiana State University School of Public Health, New Orleans, LA and Comprehensive Alcohol-HIV/AIDS Research Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana,* [6]*Atlanta VAMC, Emory University School of Medicine, and Rollins School of Public Health, Atlanta, GA,* [7]*VA Greater Los Angeles Healthcare System, David Geffen School of Medicine, UCLA, Los Angeles, CA,* [8]*Michael E DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX,* [9]*VA NY Harbor Healthcare System and New York University Grossman School of Medicine, New York, NY,* [10]*Department of Physiology, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA,* [11]*Washington D.C. Veterans Affairs Medical Center and George Washington University, Washington, D.C.,* [12]*Department of Psychology, Syracuse University, Syracuse, NY,* [13]*Department of Psychiatry, Yale School of Medicine, New Haven, CT,* [14]*Department of Internal Medicine, Yale School of Medicine, New Haven, CT and VA Connecticut Healthcare System, Veterans Aging Cohort Study, West Haven, CT,* [15]*National Institute on Alcohol Abuse and Alcoholism HIV/AIDS Program, Bethesda, MD,* [16]*Program in Addiction Medicine, Yale School of Medicine, New Haven, CT; Department of Internal Medicine, Yale School of Medicine, New Haven, CT; Yale Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT; and Department of Emergency Medicine, Yale School of Medicine, New Haven, CT*

M13. Improving SUD Service Follow-Up Rates After ED Visits for Alcohol and Substance Use Disorder in Los Angeles County Managed Care Plan (MCP) Members

Tina Kim*[1]

[1]*Los Angeles County, Dept. of Public Health, Substance Abuse Prevention and Control Bureau*

M14. Spatial Analysis of Substance Misuse Problems Among Justice-Involved Adolescents with Experiences of Childhood Trauma in Hillsborough County, Florida

Skye Bristol*[1], Micah Johnson[2]

[1]*University of Florida,* [2]*University of South Florida*

M15. Sex Differences in the Association Between Problematic Substance Use and Suicidal Ideation in Youths

Manish Jha*[1], Abu Minhajuddin[1], Madhukar Trivedi[2]

[1]*The University of Texas Southwestern Medical Center,* [2]*University of Texas Southwestern Medical Center*

M16. Nationwide Trends in Sedative, Hypnotic, or Anxiolytic Use Disorder Diagnoses in Adolescent and Young Adult Medicaid Enrollees, 2001-2019

Greta Bushnell*[1], Kristen Lloyd[1], Mark Olfson[2], Tobias Gerhard[1], Katherine Keyes[3], Magdalena Cerda[4], Deborah Hasin[5]

[1]*Rutgers University,* [2]*Columbia University and NYSPI,* [3]*Columbia University Mailman School of Public Health,* [4]*Department of Population Health, NYU School of Medicine,* [5]*Columbia University*

M17. Z-Drug Use and Benzodiazepine Use and Misuse Among Lgb Populations: The Role of Psychological Distress

Vitor Tardelli*[1], Thiago Fidalgo[2], Silvia Martins[3]

[1]*Universidade Federal de Sao Paulo/Centre for Addiction and Mental Health - University of Toronto,* [2]*Universidade Federal de Sao Paulo,* [3]*Columbia University*

M18. Cannabis Use Disorder by Consumption Route Among a Cohort of Emerging Adult Cannabis Consumers: Preliminary Results from the Herbal Heart Study
Denise Vidot*[1], Bria-Necole Diggs[2], Ranya Marrakchi El Fellah[2], Amrit Baral[2], Sarah Messiah[3], Claudia Martinez[2], Barry Hurwitz[2], Raul Gonzalez[4]
[1]*University of Miami School of Medicine,* [2]*University of Miami Miller School of Medicine,* [3]*University of Texas Health Science Center,* [4]*Florida International University*

M19. Adult Consequences of Repeated Nicotine and Δ9-Tetrahydrocannabinol (THC) Vapor Inhalation in Adolescent Rats
Arnold Gutierrez[1], Kevin Creehan[1], Yanabel Grant[2], Michael Taffe*[1]
[1]*University of California, San Diego,* [2]*University of California San Diego*

M20. Chronic Oral Dosing of Cannabidiol (CBD) With and Without Low Doses of DELTA-9-TETRAHYDROCANNABINOL (Δ-9-THC)
Dustin Lee*[1], Austin Zamarripa[1], Tory Spindle[1], Ruth Winecker[2], Ron Flegel[3], David Kuntz[4], Edward Cone[5], Ryan Vandrey[1]
[1]*Johns Hopkins University School of Medicine,* [2]*RTI International,* [3]*Substance Abuse and Mental Health Services Administration,* [4]*Clinical Reference Laboratory,* [5]*Johns Hopkins School of Medicine*

M21. Evaluation of the Monoterpenes Alpha-Pinene and Limonene on Sustained Attention in the Rodent Psychomotor Vigilance Task
Elise Weerts*[1], Catherine Moore[1], Ryan Vandrey[1], Bryan Jenkins[1]
[1]*Johns Hopkins University School of Medicine*

M22. Controlled Use of Cannabis Among Young Adults across Changes in Cannabis Policy: A Latent Transition Analysis
Stephen Lankenau*[1], Janna Ataiants[1], Ekaterina Fedorova[1], Bridgid Conn[2], Liyuan Wang[3], Carolyn Wong[2]
[1]*Drexel University Dornsife School of Public Health,* [2]*Children's Hospital Los Angeles and University of Southern California,* [3]*Children's Hospital Los Angeles*

M23. Gender and Telescoping Effects on Mental Health and Behavioral Outcomes Among Cannabis Users
Halle Thomas*[1], David Ledgerwood[1], Leslie Lundahl[2]
[1]*Wayne State University,* [2]*Wayne State University School of Medicine*

M24. Canadian Trends in Cannabis Use: Findings from the Canadian Cannabis Survey
Matthew Dann*[1], Samantha Goodman[1], Fathima Fataar[1], Lynn Sukkarieh[1], Hanan Abramovici[1]
[1]*Health Canada*

M25. Associations Between Chronic, Intermittent, and Acute Financial Strain on Alcohol and Cannabis Use in Men and Women
Sarah Gutkind*[1], Silvia Martins[2], Melanie Wall[3], Deborah Hasin[2]
[1]*Columbia University Mailman School of Public Health,* [2]*Columbia University,* [3]*Columbia University and NYSPI*

M26. Unmasking Fear: Cannabis Reduces Extinction Learning and Neural Activation in Adolescents
Hilary Marusak*[1], Clara Zundel[1], Carmen Carpenter[1], Samantha Ely[1], Leah Gowatch[1], MacKenna Shampine[1], Amanpreet Bhogal[1], Emilie-Clare O'Mara[1], Jovan Jande[1], Sneha Bhargava[1], Shravya Chanomolu[2], Matthew LaCasse[1], Leslie Lundahl[1]
[1]*Wayne State University School of Medicine,* [2]*Michigan State University College of Osteopathic Medicine*

M27. Comparing the Effectiveness of Cannabis to Treat Sleep Impairments Between Those With and Without Sleep Disorders
Allison Herens*[1], Erin Kelly[2], Emily Hajjar[3], Gregory Garber[4], Brooke Worster[4]
[1]*Sidney Kimmel Cancer Center, Thomas Jefferson University,* [2]*Jefferson Medical College of Thomas Jefferson University,* [3]*Jefferson College of Pharmacy,* [4]*Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University*

M28. Mesocorticolimbic Activation is Associated with Abstinence From Cannabis in a Pilot Trial of Varenicline for Cannabis Use Disorder
Erin Martin*[1], Spencer Upton[2], Briar Nowling[1], Brett Froeliger[2], Lindsay Squeglia[1], Kevin Gray[1], Aimee McRae-Clark[1]
[1]*Medical University of South Carolina,* [2]*University of Missouri*

M29. Emotional Reactivity is a Transdiagnostic Risk Factor for Substance Use Initiation in Middle and High School Students
Meghan Costello*[1], Alec Bodolay[1], Caroline Gray[1], Rosie Du[1], Kevin Potter[1], Randi Schuster[1]
[1]*Harvard Medical School/Massachusetts General Hospital*

M30. Me, Myself, and High: Momentary Precipitants and Daily Consequences of Solitary Cannabis Use
Amelia Wedel*[1], Aesoon Park[2]
[1]*Medical University of South Carolina Dept of Psychiatry and Behavioral Sciences,* [2]*Syracuse University*

M31. Cannabis Use and its Association with Treatment Engagement and Other Substance Use: Results From a 90-Day Daily Diary Study
Charles Warnock*[1], E. Jennifer Edelman[2], Trace Kershaw[1], Jessica Muilenberg[3]
[1]*Yale School of Public Health,* [2]*Yale University School of Medicine,* [3]*University of Georgia*

M32. Modes of Cannabis Consumption: Results from a California Statewide Survey
Shuwen Li[1], Jijiang Wang[2], Shu-Hong Zhu[2], Jessica Sun*[2]
[1]*University of California, San Diego,* [2]*University of California - San Diego*

M33. Examination of Motives for Cannabis Use and Mental Health Symptoms on Cannabis Use Trajectories Among Adolescents
Sarah Lehman*[1], Erin Thompson[1], Ashley Adams[1], Christine Kaiver[1], Samuel Hawes[1], Raul Gonzalez[1]
[1]*Florida International University*

M34. Effects of Sustained Cannabis Abstinence on Depressive Symptoms in People with Cannabis Use Disorder
Lyne Baaj*[1], Gabriella Malamud[1], Rachel Rabin[1]
[1]*McGill University*

M35. Overlap of Cannabis Use with Depression and Anxiety Disorders in a Primary Care Setting in Los Angeles, CA
Julia Koerber*[1], Naira Setrakian[2], Un Young Chung[3], Whitney Akabike[4], Lillian Gelberg[5], Marjan Javanbakht[6]
[1]*University of California, Los Angeles,* [2]*David Geffen School of Medicine at UCLA,* [3]*University of California Los Angeles,* [4]*UCLA Department of Family Medicine,* [5]*University of California Los Angeles, Department of Family Medicine,* [6]*University of California Los Angeles, Fielding School of Public Health*

M36. The Effects of Cannabis and Tobacco Co-Administration on Subjective Cannabis Effects in Daily Life
Maggie Bedillion*[1], Emily Ansell[1]
[1]*Penn State University*

M37. Real-Time Predictors of Cannabis Use Among Young Adults: An Ecological Momentary Assessment Study
Timothy Regan*[1], Janardan Devkota[1], Julia McQuoid[2], Kekoa Lopez-Paguyo[3], Nhung Nguyen[3], Meredith Meacham[4], Pamela Ling[5], Johannes Thrul[1]
[1]*Johns Hopkins Bloomberg School of Public Health,* [2]*University of Oklahoma Health Sciences Center,* [3]*Center for Tobacco Control Research and Education, University of California, San Francisco,* [4]*Department of Psychiatry and Behavioral Sciences, University of California, San Francisco,* [5]*Department of Medicine, University of California San Francisco*

M38. Binding Affinity and Functional Activity of 24 Emerging Cannabinoids at the CB1 Receptor and Safety-Related Targets
Neil Varshneya*[1], Cassandra Taylor[1], William Schutzer[2], Laura Kozell[2], Jennifer Schmachtenberg[2], Amy Eshleman[2], Chad Reissig[1], Dominic Chiapperino[1], Aaron Janowsky[2], Atheir Abbas[2]
[1]*United States Food and Drug Administration,* [2]*Veterans Affairs Portland Health Care System*

M39. Young Adult Perceptions on Cannabis Use and Driving While Impaired: The Next Generation
Ty Lee Shields[1], Kenneth Leonard[1], Adriana Raass[1], Gregory Homish[1], Jessica Kulak*[1]
[1]*University at Buffalo*

M40. Individual and Interactive Effects of Oral Cannabis ("Edibles") and Alcohol in Healthy Adults
Carlos Zamarripa*[1], Spencer Lin[2], Madyson Slutzky[2], Denis Antoine[2], Elise Weerts[2], Ryan Vandrey[2], Tory Spindle[2]
[1]*Johns Hopkins University School of Medicine,* [2]*Johns Hopkins University School of Medicine, Department of Psychiatry*

M41. "I Don't Need My Kid to Be High": Prioritizing Harm Reduction and Responsible Cannabis Use During Pregnancy
Erin Gould*[1], Siddhi Ganesh[1], Rachel Ceasar[1]
[1]*Keck School of Medicine University of Southern California*

M42. How Has Cannabis Legalization Impacted Public Health in Canada?
George Mammen*[1], Hanan Abramovici[2]
[1]*Health Canada, Controlled Substances and Cananbis Branch,* [2]*Controlled Substances and Cannabis Branch, Health Canada*

M43. Gender Differences in Cannabis Use and Cannabis Use Disorder Among US Veterans, 2005-2019
Caroline Wisell*[1], Melanie Wall[2], Daniel Alschuler[3], Malka Stohl[4], Deborah Hasin[5]
[1]*Columbia University/New York State Psychiatric Institute,* [2]*Columbia University and NYSPI,* [3]*NYSPI,* [4]*New York State Psychiatric Institute,* [5]*Columbia University*

M44. Tobacco Withdrawal and Cigarette Reinforcement as Mechanisms Underlying the Effects of Reduced Nicotine Content Cigarettes on Adolescent Smoking Behavior
Mariel Bello*[1], Nancy Jao[2], Suzanne Colby[1], Jennifer Tidey[1], Rachel Cassidy[1]
[1]*Brown University School of Public Health,* [2]*Rosalind Franklin University of Medicine and Science*

M45. Do Dual Users Vape When Attempting to Quit Smoking? The Association Between E-Cigarette Use and Concurrent Cigarette Cessation-Related Outcomes in a Prospective Natural History Study
Rhiannon Wiley*[1], William Middleton[1], Shannon O'Connor[1], Fang Fang Chen[1], Stacey Sigmon[1], Elias Klemperer[2]
[1]*University of Vermont,* [2]*University of Vermont College of Medicine*

M46. Is a Traditional Smoking Cessation Program Effective for Vaping Cessation?
Yixuan Chen*[1], Scott Veldhuizen[1], Peter Selby[1], Laurie Zawertailo[1]
[1]*Centre for Addiction and Mental Health*

M47. Developing a Superior, Once-A-Day Oral Smoking Cessation Product Using Real-Time Biosensors
Peter Lee*[1], J. Nicholas Betley[2], Eduardo Martinez[1], Rachael Villari[2], Marc Azar[3]
[1]*SpaceRx LLC.,* [2]*University of Pennsylvania,* [3]*Behavioral Pharma, Inc.*

M48. Experiential Smoking Urges and Nicotine Withdrawal Reduction Among People Under Community Corrections Supervision Enrolled in In Vivo NRT Counseling
William Wagner*[1], Karen Cropsey[1]
[1]*University of Alabama at Birmingham*

M49. Implementing a Clinical Pharmacist-Delivered Tobacco Use Disorder Treatment Involving Medications and Contingency Management for HIV Clinics: A Micro-Costing Analysis
Danielle Ryan*[1], E. Jennifer Edelman[2], Jessica E. Yager[3], June Weiss[2], Keith M. Sigel[4], David Ledgerwood[5], Steven L. Bernstein[6], Sean Murphy[7]
[1]*Weill Cornell Medical Center,* [2]*Yale University School of Medicine,* [3]*State University of New York Downstate Health Sciences University, Brooklyn, NY, United States of Americ,* [4]*Icahn School of Medicine at Mount Sinai,* [5]*Wayne State University,* [6]*Geisel School of Medicine at Dartmouth,* [7]*Weill Cornell Medical College*

M50. The Effects of Smoking Status on Patients in Cardiac Rehabilitation: Results From a National Registry
Diann Gaalema*[1], Blair Yant[2], Bashar Al Hemyari[1], Yu Zhang[3], Katherine Menson[2]
[1]*University of Texas Medical Branch,* [2]*University of Vermont,* [3]*University of Alabama at Birmingham*

M51. The Influence of Flavor on Perception of Nicotine in E-Cigarettes
Danielle Davis*[1], Eugenia Buta[2], Ralitza Gueorguieva[1], Barry Green[2], Suchitra Krishnan-Sarin[1]
[1]*Yale University School of Medicine,* [2]*Yale University*

M52. Interactions Between Using E-Cigarettes and Setting an Abstinence Plan on Cigarette Smoking in LGBTQ+ Individuals
Lucy Schuler*[1], Shirlene Wang[2], Matt Kirkpatrick[1], Raina Pang[1]
[1]*Keck School of Medicine University of Southern California,* [2]*Feinberg School of Medicine Northwestern University*

M53. Use of Electronic Nicotine Delivery Systems Among Primary Care Patients in a Large Urban Health System: Polytobacco Product Use and Cannabis Co-Use
Marjan Javanbakht*[1], Whitney Akabike[2], Sarah Schoetz[3], Lawrence Dardick[2], Lillian Gelberg[2]
[1]*University of California, Los Angeles, Fielding School of Public Health,* [2]*University of California Los Angeles, Department of Family Medicine,* [3]*University of California Los Angeles, Fielding School of Public Health*

M54. Brain PET 18-FDG Hypometabolism and Neurocognitive Deficit in Chronic Inhalants Users
Miguel Angel Mendoza-Meléndez*[1], Nora Kerik-Rotenberg[2], Carlos Aguilar-Palomeque[2], A.B.E. Mendoza-Beltran[3], Ivan Diaz-Meneses[2], A.E. Mendoza-López[3], Iris Valerio-Robles[3], T. Corona-Vazquez[2], Victor Calderón-Salinas[4]
[1]*Metropolitan Autonomous University (UAM-I) / UNAM / Cinvestav / INNN,* [2]*Inst. Nacional De Neurologia Y Neurocirugia,* [3]*National Autonomous University of Mexico,* [4]*Cinvestav*

M55. A Crisis Within a Crisis: Accelerating Racial Disparities in the US Overdose Epidemic
Kumi Smith*[1], Colin Planalp[1], Sarah Bennis[1], Antony Stately[2], Jack Martin[3], Pearl Evans[4], Ivan Nelson[5]
[1]*University of Minnesota,* [2]*Native American Community Clinic,* [3]*Southside Harm Reduction Services,* [4]*Minnesota Department of Health,* [5]*African American Survivor Services*

M56. Prevalence and Correlates of Non-Prescribed Methadone Use Among Adults who Have Injected drugs---Baltimore, Maryland, 2023
Kenneth Feder*[1], Becky Genberg[1]
[1]*Johns Hopkins Bloomberg School of Public Health*

M57. "Blues," "Skittles," and Powder Fentanyl: Understanding The Rapidly Changing Illicitly Manufactured Fentanyl Market in Phoenix, Arizona
Kaylin Sweeney*[1], Madeline Hooten[1], Patricia Timmons[1], Elisabeth Williams[1], Raminta Daniulaityte[1], Haley Coles[2]
[1]*Arizona State University,* [2]*Sonoran Prevention Works*

M58. The Role of Perceived, Enacted, and Internalized Stigma on the Uptake of Medications for Opioid Use Disorder (MOUD) Among Women in the Criminal Legal System
Oluwaseyi Quadri*[1], Emma Skogseth[1], Kristina Brant[2], Eric Harrison[1], Abenaa Jones[1]
[1]*Pennsylvania State University,* [2]*Department of Agricultural Economics, Sociology and Education, Pennsylvania State University*

M59. "Oh Man, You're Just Going to Die:" Police Officer's Perceptions of Fentanyl Pre and Post an Occupational Risk Reduction Training
Janie Simmons*[1], Sonali Rajan[2], Luther Elliott[3]
[1]*www.GetNaloxoneNow.org,* [2]*Columbia University,* [3]*New York University*

M60. Medication Experiences in the Treatment for Opioid Use Disorder: Insights from Reddit
Annick Borquez*[1], Mike Conway[2], David Grelotti[1], Amarnath Gupta[1], Steffanie Strathdee[1], Alexandra Almeida[3]
[1]*University of California San Diego,* [2]*University of Melbourne,* [3]*University of California San Diego and Fiocruz*

M61. Program Descriptions of the "Multi-Sector and Multi-Level Community-Driven Approaches to Remove Structural Racism and Overdose Deaths in Black Indianapolis Communities" (MACRO-B) Project

Dong Chul Seo*[1], Shin H. Lee[1]
[1]*Indiana University School of Public Health Bloomington*

M62. Opioid Prescribing Trajectories Among Medicaid Patients with Long-Term Opioid Use

Sarah Friedman*[1], Paul Snyder[2], Denis Patterson[3], Sarah Hartzell[4], Elaine Albertson[5], Michelle Keller[6]
[1]*University of Nevada Reno, School of Public Health,* [2]*University of Nevada Reno School of Medicine,* [3]*Nevada Advanced Pain Specialists,* [4]*University of Nevada Reno,* [5]*Cedar Sinai Health Care System,* [6]*Leonard Davis School of Gerontology, University of Southern California*

M63. Primary Care Patients with Opioid Use Disorder Symptoms: Engagement in Treatment With Medication

Claire Simon*[1], Theresa Matson[2], Malia Oliver[2], Kevin Hallgren[1], Roger Weiss[3], Katharine Bradley[2]
[1]*University of Washington,* [2]*Kaiser Permanente Washington Health Research Institute,* [3]*McLean Hospital*

M64. Comparative Effectiveness of Telemedicine Versus In-Person Buprenorphine Prescribing for Rural and Urban Patients

Thomas Reese*[1], Nana Addo Padi-Adjirackor[2], Kevin Griffith[2], Bryan Steitz[1], Stephen Patrick[2], Ashley Leech[2], Andrew Wiese[2], Adam Wright[1], Jessica Ancker[2]
[1]*Vanderbilt University School of Medicine,* [2]*Vanderbilt University Health Policy*

M65. A Pilot, Placebo controlled, Dose-Finding, Pharmacodynamic and Pharmacokinetic Study of Orally Administered Botanical Kratom in Non-Dependent, Recreational Polydrug Users with Opioid Experience Under Fed Conditions.

Chad Reissig*[1], Beatrice Setnik[2], Denise Milovan[3], Christopher McCurdy[4], Abhisheak Sharma[4], Greg Hawkins[5], Katherine Bonson[5], Galati Steve[5], Dominic Chiapperino[5]
[1]*FDA Center for Drug Evaluation and Research,* [2]*Altasciences,* [3]*Altasciences Inc,* [4]*University of Florida,* [5]*US Food and Drug Administration*

M66. Pharmacological Characterization of Substituted Nitazenes at Opioid Receptors

Laura Kozell*[1], Amy Eshleman[2], Katherine Wolfrum[3], Tracy Swanson[2], Shelley Bloom[3], Sheila Benware[3], Jennifer Schmachtenberg[3], William Schutzer[4], Aaron Janowsky[4], Atheir Abbas[4]
[1]*Oregon Health and Sciences University,* [2]*Oregon Health and Science University,* [3]*VA Portland Health Care System,* [4]*VA Portland Health Care System / Oregon Health and Science University*

M67. Predicting Fentanyl-Related EMS Incidents Using the Hawkes Process

Daniel Van Zant*[1], Belle Krubitski[2], Andrew McCabe[1], Elan Barenholtz[2], Linda Cottler[1]
[1]*University of Florida,* [2]*Florida Atlantic University*

M68. Validation of a Noninvasive Method for Monitoring the Effect of Synthetic Opioids on Vocal Cord Activity Using Piezoelectric Sensors

Alyssa Rivera*[1], William Schutzer[2], Aaron Janowsky[2], Atheir Abbas[2], Phillip Torralva[2]
[1]*Portland VA Medical Center,* [2]*VA Portland Health Care System / Oregon Health and Science University*

M69. Differential Effect of Implementing Office Based Addiction Treatment in Primary Care on OUD Treatment Across Sex and Race or Ethnicity in the PROUD Trial

Katharine Bradley*[1], Noorie Hyun[2], Abisola Idu[2], Paige Wartko[2], David Liu[3], Abigail Matthews[4], Jennifer McCormack[5], Aimee Campbell[6], Jeffrey Samet[7], Amy Lee[2], Onchee Yu[2], Cynthia Campbell[8], Viviana Horigian[9], Joseph Glass[10], Jordan Braciszewski[11], Julia Arnsten[12], Jennifer Bobb[1]
[1]*Kaiser Permanente Washington Health Research Institute,* [2]*Kaiser Permanente Health Research Institute,* [3]*National Institute on Drug Abuse, National Institutes of Health,* [4]*The Emmes Company,* [5]*The Emmes Company, LLC,* [6]*Columbia University Irving Medical Center and the New York State Psychiatric Institute,* [7]*Boston University School of Medicine,* [8]*Kaiser Permanente Northern California,* [9]*Miller School of Medicine, University of Miami,* [10]*Kasier Permanente Washington Health Research Institute,* [11]*Henry Ford Health System,* [12]*Montefiore Medical Center*

M70. Training the next Generation of Addiction Medicine Physician-Scientists: Four-Year Outcomes of the University of Washington Medical Student Addiction Research Training Program (MedStAR).
Kevin Hallgren*[1], Emily Williams[1], Elenore Bhatraju[1], Helen Jack[1], Joseph Merrill[1], Sara Glick[1], Susan Graham[1], Jared Klein[1], Sebastian Tong[1], Laura-Mae Baldwin[1], Sarah Leyde[1], Geetanjali Chander[1], Judith Tsui[1]
[1]*University of Washington*

M71. Medication Health Centers to Promote Opioid Safety: A Pragmatic Cluster Randomized Trial
Ingrid Binswanger*[1], Shane Mueller[2], Komal Narwaney[2], James Lagrotteria[2], Lane Fairbairn[2], Jason Glanz[2]
[1]*Kaiser Permanente Colorado/Colorado Permanente Medical Group,* [2]*Kaiser Permanente Colorado*

M72. Elimination of Vta to Insular Projections Results in Desensitization to the Adverse Properties of Hydrocodone and Promotes Learning about the Reinforcing Properties.
Kajol Sontate*[1], Dreem Ninnasopha[1], Hay Young Kwok[1], Cerissa Shorter[1], Ashmita Mukherjee[1], Sarah Honeycutt[1], Gregory Loney[2]
[1]*The University At Buffalo - SUNY,* [2]*State University of New York At Buffalo*

M73. Social Renewal of Fentanyl Seeking is Attenuated with Naltrexone
Bree Humburg*[1], Meagan Blanchard[1], Michael Bardo[1]
[1]*University of Kentucky*

M74. Microcosting the Optimization of Prep Implementation Among Sexual and Gender Minority Individuals with a Substance Use Disorder (SUD)
Sean Murphy*[1], Danielle Ryan[1], Raymond Mata[2], Prudence Mendiola[2], Sam Phillips[2], Michael Li[3], Ali Jalali[1], Philip Jeng[1], David Benkeser[4], Cathy Reback[2]
[1]*Weill Cornell Medical College,* [2]*Friends Research Institute,* [3]*University of California Los Angeles,* [4]*Emory*

M75. "I Feel like People Would Look at Me like I'm Dirty or like I'm a Thief:" a Qualitative Exploration of Internal Experiences that Influence Recovery Among Adults at Risk of Opioid-Related Overdose
Hannah Szlyk*[1], Nina Kaiser[2], Jordan Michener[2], Zhuoran Zhang[2], Emily Maranets[2], Lucy Meigs[2], Elecia Worley[2], Erin Kasson[3], Patricia Cavazos[4]
[1]*Washington University School of Medicine,* [2]*Washington University School of Medicine, Department of Psychiatry,* [3]*Washington University School of Medicine Department of Psychiatry,* [4]*Washington University St. Louis*

M76. Prescription Pain Medication Misuse With and Without Heroin Use Among Adolescents: Healthcare Access, Family Support, Academic Functioning, Violence, and Other Risky Behaviors
Laya Jalilian-Khave*[1], Elina Stefanovics[2], Zu Wei Zhai[3], Marc Potenza[4]
[1]*Yale University School of Medicine,* [2]*Yale University School of Medicine, Department of Psychiatry, U.S. Department of Veterans Affairs New England Mental Illness Research and Education Clinical Center (MIRECC), VA Connecticut Healthcare System (116A-4),* [3]*Middlebury College, Middlebury, Program in Neuroscience,* [4]*Yale University School of Medicine, Department of Psychiatry, Yale University School of Medicine, Child Study Center, Yale University Department of Neuroscience, Connecticut Mental Health Center, Connecticut Council On Problem Gambling, Yale University Wu Tsai Institute*

M77. Why Do Patients Decline Buprenorphine in the Emergency Department? Direct Feedback from ED Patients Who Have Accepted and Declined Buprenorphine for Opioid Use Disorder
Angela Moreland*[1], Lindsey Jennings[1], Louise Haynes[1], Kathleen Brady[1], Susan Sonne[1], Suzanne Lane[1], Carrie Papa[1], Kelly Barth[1]
[1]*Medical University of South Carolina*

M78. Human Laboratory Demonstration of Clinically-Meaningful Differences in Sensitivity to Opioids- A Possible Behavioral Risk Phenotype
Robert LeComte*[1], Greer McKendrick[1], Andrew Huhn[1], Patrick Finan[2], Cecilia Bergeria[1], Denis Antoine[1], Kelly Dunn[1]
[1]*Johns Hopkins University School of Medicine,* [2]*University of Virginia*

M79. Communities that Heal Intervention, Data 2000 Waivered Providers and Buprenorphine Prescribing: A Randomized Clinical Trial

Thomas Stopka*[1], Denise Babineau[2], Erin Gibson[3], Charles Knott[2], Debbie Cheng[4], Jennifer Villani[5], Derek Blevins[6], Michelle Lofwall[7], Michael Lyons[8], Laura Fanucchi[7], Raymond Balise[9], Emmanuel Oga[10], Bridget Freisthler[11], T. John Winhusen[12], Nabila El-Bassel[6], Jeffrey Samet[13], Sharon Walsh[14]
[1]*Tufts University School of Medicine,* [2]*Research Triangle Institute,* [3]*Boston Medical Center,* [4]*Boston University,* [5]*NIH/NIDA,* [6]*Columbia University,* [7]*University of Kentucky, College of Medicine,* [8]*University of Cincinnati College of Medicine,* [9]*University of Miami,* [10]*RTI International,* [11]*The Ohio State University,* [12]*University Of Cincinnati Department of Psychiatry and Behavioral Neuroscience,* [13]*Boston University School of Medicine,* [14]*University of Kentucky*

M80. Temporal Trends in NGO-based Supportive Services and HIV Rates Among PWID in Malaysia Between 2012 and 2022

Vicknasingam B Kasinather[1], Syahirah Jhan Abdul Halil Khan[2], Mohamad Yusoff Fasri Abdullah[2], Nadrah Yusoff[2], Jasmin Jalil[2], Richard Schottenfeld[3], Marek Chawarski*[4]
[1]*Centre for Drug Research, Universiti Sains Malaysia,* [2]*Malaysian AIDS Council,* [3]*Howard University College of Medicine,* [4]*Yale School of Medicine*

M81. Accessibility Barriers to Medications for Opioid Use Disorder Treatment: A Qualitative Study of Perspectives from Women With Opioid Use Disorder and Health and Criminal Justice Professionals

Emma Skogseth*[1], Kristina Brant[2], Carl Latkin[3], Abenaa Jones[1]
[1]*Pennsylvania State University,* [2]*Department of Agricultural Economics, Society, and Education, Pennsylvania State University,* [3]*Johns Hopkins School of Public Health*

M82. The Relationship of Alcohol-Related Condition Diagnosis with Opioid Prescription Dose Trajectories and All-Cause Mortality in a Cohort of Patients Receiving Long-Term Opioid Therapy

Jason Glanz*[1], Jarratt Pytell[2], Komal Narwaney[1], Anh Nguyen[1], Ingrid Binswanger[3]
[1]*Kaiser Permanente Colorado,* [2]*University of Colorado Denver School of Medicine; Department of General Internal Medicine,* [3]*Kaiser Permanente Colorado/Colorado Permanente Medical Group*

M83. A Comparison of Neuropsychological Functioning Between Patients with Opioid Use Disorders on Extended-Release Naltrexone and Buprenorphine

Felipe Castillo*[1], Aimee Campbell[1], Tse-Hwei Choo[2], Martina Pavlicova[3], John Rotrosen[4], Jeffrey A Selzer[5], Edward V Nunes[1]
[1]*Columbia University and New York State Psychiatric Institute,* [2]*Columbia University Mailman School of Public Health,* [3]*Columbia University,* [4]*Department of Psychiatry, NYU Langone School of Medicine, New York, NY, United States,* [5]*Northwell Health*

M84. Assessment of the Behavioral Pharmacology of the Low-pKa Fentanyl Analogs, FF3 and NFEPP

Shelley Edwards[1], Bruce Blough[2], Kristian Cowart[3], Grace Howell[3], Aaron Araujo[4], Jacob Haskell[3], Sally Huskinson[3], James Rowlett[3], Marcus Brackeen[2], Kevin Freeman*[3]
[1]*University of Mississippi Medical Center, Dept. of Psychiatry and Human Behavior,* [2]*RTI International,* [3]*University of Mississippi Medical Center,* [4]*AAA6743@umc.edu*

M85. Opioid use and Mental Health Among Individuals With and Without Chronic Pain

Abigail Helm*[1], Paige Shaffer[1], Eleni Kachadoorian[1], Gerardo Gonzalez[2], Smelson David[1]
[1]*University of Massachusetts Chan Medical School,* [2]*Mclean Hospital - Harvard Medical School*

M86. Effectiveness of Hospital Addiction Consult Services for Increasing Post-Discharge Medication for Opioid Use Disorder (MOUD) Treatment Initiation and engagement: Findings from a Pragmatic Trial in 6 New York City Public Hospitals

Jennifer McNeely*[1], Scarlett Wang[2], Yasna Rostam Abadi[2], Charles Barron[3], John Billings[2], Thaddeus Tarpey[2], Jasmine Fernando[2], Noa Appleton[2], Adetayo Fawole[2], Roopa Kalyanaraman Marcello[3], Carla King[2]
[1]*New York University School of Medicine,* [2]*New York University Grossman School of Medicine,* [3]*NYC Health + Hospitals*

M87. Maryland Opioid Overdose Deaths from 2018 to 2021: Occupational Pattern and Its Sociodemographic Variations

Masoumeh Amin-Esmaeili*[1], Ryoko Susukida[1], Himani Byregowda[1], Clifford S. Mitchell[2], Georgette Lavetsky[2], Grace Douglass[2], Renee Johnson[1]

[1]*Johns Hopkins Bloomberg School of Public Health,* [2]*Environmental Health Bureau, Maryland Department of Health, Baltimore, Maryland, USA*

M88. Serious Injection-Related Infections in Hospitalized Adults with Opioid Use Disorder Enrolled in an Ongoing Randomized Clinical Trial

Laura Fanucchi*[1], Alice Thornton[1], Paul Nuzzo[2], Connor VanMeter[2], Evelyn Villacorta[1], Ryan Mynatt[2], Sharon Walsh[2], Loui Chang[1], Wyatt Kunzelman[1], Michelle Lofwall[1]

[1]*University of Kentucky, College of Medicine,* [2]*University of Kentucky*

M89. Peer-Facilitated Telemedicine Hepatitis C Treatment for People Who Use Drugs (PWUD): Patient Perspectives

Kim Hoffman*[1], Gillian Leichtling[2], Sarah Shin[2], Hunter Spencer[3], Tonhi Gailey[3], Andrew Seaman[3], P. Todd Korthuis[3]

[1]*Oregon Health and Science University,* [2]*Comagine Health,* [3]*Oregon Health and Science University*

M90. Access to and Preferences for Reproductive Health Services Amongst Women Who Use Drugs from Rural Communities in the United States

Ximena Levander*[1], Alicia Johnson[2], Miriam Elman[2], Sarann Bielavitz[2], Madison Enderle[3], Gillian Leichtling[4], Sara Magnusson[5], Renee McDowell[3], P. Todd Korthuis[2]

[1]*Oregon Health and Science University,* [2]*Oregon Health and Science University,* [3]*The Ohio State University,* [4]*Comagine Health,* [5]*Public Health Seattle and King County, Washington*

M91. "We're Real Harm Reduction...not Performative Harm Reduction": Exploring How Organizational Values Shape the Delivery of Health Services Within Syringe Services Programs

Rose Laurano*[1], Elana Forman[2], Angela R. Bazzi[3], William H. Eger[4], Jessica Smith[5], Shelby Huffaker[6], Christopher F. Akiba[5], Sheila V. Patel[5], Barrot H. Lambdin[5], Alexis M. Roth[2]

[1]*Drexel University,* [2]*Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA,* [3]*Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, CA, USA,* [4]*School of Medicine, University of California San Diego, La Jolla, CA, USA,* [5]*RTI International, Research Triangle Park, North Carolina, USA,* [6]*Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, California, USA*

M92. High Pain Embodiment in Chronic Pain Patients Increases the Risk for Aberrant Opioid-Related Behavior

Karishma Shah*[1], Margaret Legarreta[1], Erin McGlade[1], Perry Renshaw[1], Deborah Yurgelun-Todd[1]

[1]*University of Utah*

M93. Building a Sensor to Detect and Respond to Opioid Overdose: Experiences on a Wearable Prototype from People Who Inject Drugs

Alexis Roth*[1], Rose Laurano[1], Ally D'Angelo[1], Anush Lingamoorthy[2], Matthew Salzman, MD, MPH[3], Olumuyiwa Oni[4], Jacob Brenner, MD, PhD[5], Benjamin Cocchiaro, MD, MPH[6], Stephen Lankenau, PhD[1], Cameron Baston, MD, MSCE[5]

[1]*Drexel University Dornsife School of Public Health,* [2]*Drexel University,* [3]*Cooper Medical School of Rowan University,* [4]*AltruMed LLC,* [5]*Perelman School of Medicine at University of Pennsylvania,* [6]*Drexel University College of Medicine*

M94. Washington State's Hub and Spoke Model: Effects of Network Characteristics and Outpatient Care on Client Outcomes

Sharon Reif*[1], Maureen Stewart[2], Shay Daily[2], Mary Brolin[3], Margaret Lee[4], Lee Panas[4], Grant Ritter[4], Morgan Shields[5], Shayna Mazel[2]

[1]*Brandeis University, Heller School for Social Policy and Management, Institute for Behavioral Health,* [2]*Brandeis University,* [3]*Brandeis University, Heller School for Social Policy and Management,* [4]*Institute for Behavioral Health, Brandeis University,* [5]*Brown School, Washington University*

M95. Assessing the Psycho-Social Counseling Components in Digital Interventions Used for Opioid Use Disorder (OUD) Treatment
Madison Scialanca*[1], Shannon Mitchell[1], Karen Alexander[1]
[1]*Friends Research Institute*

M96. Adolescent Disparities and Trends in Utilization of Medication for Opioid Use Disorder in Substance Use Treatment Facilities in the United States, 2017-2021
Jesse Boggis*[1], Thadryan Sweeney[1], Lisa Marsch[1], Wesley Marrero[2], Erika Moen[1]
[1]*Geisel School of Medicine at Dartmouth,* [2]*Thayer School of Engineering at Dartmouth*

M97. Buprenorphine Treatment Outcomes Among Racially/Ethnically Diverse Adults at California Emergency Departments Participating in the California Bridge Patient Outcomes Research Evaluation Study
Sabrina Smiley*[1], Allison Rosen[2], Elizabeth Samuels[3], Allison Ober[4], Steve Shoptaw[2], Andrew A Herring[5]
[1]*San Diego State University,* [2]*University of California Los Angeles,* [3]*David Geffen School of Medicine at UCLA,* [4]*RAND Corporation,* [5]*Alameda Health System--Highland Hospital*

M98. Is Abstinence from Illicit Substances Related to PTSD Treatment Outcomes in Those With Co-Occurring PTSD and Opioid Use Disorder?
Jillian Giannini*[1], Rebecca Cole[1], Peter Lontine[1], Kelly Peck[1]
[1]*University of Vermont*

M99. Multicomponent Psychosocial Intervention to Augment Standard Medication Management for Co-Occurring Opioid Use and Mental Health Disorder
Gerardo Gonzalez*[1], Smelson David[2], Wenjun Li[3], Todd Olmstead[4], Paige Shaffer[2], Harter Jennifer[2], Abigail Helm[2], Caputo Kendra[2], Kachadoorian Eleni[2]
[1]*Mclean Hospital - Harvard Medical School,* [2]*University of Massachusetts Chan Medical School,* [3]*University of Massachusetts Lowell,* [4]*University of Texas at Austin*

M100. Impacts of an Innovative Injectable Diacetylmorphine Treatment Program Complemented with Fentanyl Patches on Overdose Vulnerability: A Qualitative Study in Vancouver, Canada
Ryan McNeil*[1], Andrew Ivsins[2], Cara Ng[3], Koharu Loulou Chayama[3], Samara Mayer[4]
[1]*Yale University School of Medicine,* [2]*University of British Columbia,* [3]*British Columbia Centre on Substance Use,* [4]*British Columbia Centre on Substance Use, University of Victoria, Canadian Institute of Substance Use Research and Institute of Lifelong Aging and Health*

M101. Overdose as a Complex Contagion: Modeling the Community Spread of Overdose Events Following Law Enforcement Efforts to Disrupt the Drug Market
Jamie Humphrey*[1], Clyde Schwab[1], Nick Richardson[1], Barrot Lambdin[1], Alex Kral[1], Brad Ray[2]
[1]*RTI International,* [2]*Wayne State University*

M102. The Use of Single-Chain Variable Fragments (scFv) to Reverse Cardiopulmonary and Antinociceptive Effects of Fentanyl in Male Mice
Robert Seaman*[1], Bryan Hannon[1], Dustin Hicks[2], Carly Baehr[2], Marco Pravetoni[1]
[1]*University of Washington,* [2]*University of Minnesota*

M103. Daily Fluctuations in Motivation and Perceived Environmental Access of Nondrug Reward Among People in Opioid Use Disorder Recovery: Person- And Day-Level Associations with Experiencing Nondrug Reward
Samuel Stull*[1], Stephanie Lanza[1]
[1]*The Pennsylvania State University*

M104. Evaluation of a Smartphone Application to Reduce Overdose Risk: Results from a Pilot Clinical Trial With People Who Inject Drugs
Caitlin Conway*[1], Mikaela Becker[2], Sarah Uhm[3], Katy Mijal[1], Ryan Westergaard[1], Rachel Gicquelais[1]
[1]*University of Wisconsin - Madison,* [2]*Vivent Health,* [3]*University of Nebraska Medical Center*

M105. Comparison of G-Protein Biased Mu Agonists to Partial and Full Mu Agonists in Measures of Thermal Antinociception, Respiratory Depression, and Drug Self-Administration in Male and Female Sprague-Dawley Rats
Loc Pham*[1], Tanya Pareek[1], Tooba Shabir[1], Jackson Gilmore[1], Rose Le[1], Alexandra Ladner[1], Aaron Araunjo[1], Bruce Blough[2], Kevin Freeman[1]
[1]*University of Mississippi Medical Center,* [2]*RTI International*

M106. Measuring Endocannabinoid Metabolism in Opioid Treated Chronic Pain Patients With and Without Opioid Use Disorder: A Pet Study with Fatty Acid Amide Hydrolase Radioligand [C-11]CURB
Claire Shyu*[1], Kevin Butler[2], Rachel Tyndale[3], Andrew Smith[4], Vitor Tardelli[5], Stefan Kloiber[1], Isabelle Boileau[4], Bernard Le Foll[3]
[1]*Centre for Addiction and Mental Health, University of Toronto,* [2]*Centre for Addiction and Mental Health, School of Psychology, College of Health and Science, University of Lincoln, UK,* [3]*University of Toronto,* [4]*Centre for Addiction and Mental Health,* [5]*Universidade Federal de Sao Paulo/Centre for Addiction and Mental Health - University of Toronto*

M107. Brain CYPD2 Inhibitor Pretreatment Blunts Oral Oxycodone Induced Conditioned Place Preference in Rats
Agbonlahor Okhuarobo*[1], Doug Funk[2], AD Le[3], Paul Fletcher[4], Sharon Miksys[2], Rachel Tyndale[5]
[1]*University of Toronto,* [2]*Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada,* [3]*Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada,* [4]*Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada, Department of Psychology, University of Toronto, Toronto, Ontario, Canada, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada,* [5]*Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada*

M108. Xylazine Co-Occurrence with Illicit Fentanyl is a Growing Threat in the Deep South: A Retrospective Study of Decedent Data
William Bradford*[1], Mary Figgatt[1], Karen Scott[1], Stacy Marshall[1], Ellen Eaton[1], Daniel Dye[1]
[1]*The University of Alabama at Birmingham*

M109. Co-Located Buprenorphine Services in Primary Care Associated with Reduction in Non-Fatal Overdose in Kentucky
Victoria Green*[1], Sachini Bandara[1], Olivia Sugarman[1], Omeid Heidari[2]
[1]*Johns Hopkins Bloomberg School of Public Health,* [2]*University of Washington*

M110. Ventilatory Depressant Effects of Opioid Mixtures and Reversal of Opioid-Induced Ventilatory Depression
Shawn Flynn*[1], Charles France[1]
[1]*University of Texas Health Science Center at San Antonio*

M111. Forecasting Opioid Overdose Incidents for Rapid Actionable Data for Opioid Response in Kentucky (RADOR-KY)
Aaron Mullen*[1], Peter Rock[1], Daniel Harris[1], Svetla Slavova[1], Jeffery Talbert[2], Cody Bumgardner[1]
[1]*University of Kentucky,* [2]*University of Kentucky, College of Medicine*

M112. Hepatitis C Care Delivery Practices Among Primary Care Providers Who Do and Do Not Prescribe Buprenorphine
Amelia Mohabir*[1], Jocelyn James, MD[2], Claire Simon, MD[3], Allison Cole, MD, MS[3], Judith Tsui, MD, MPH[2]
[1]*University of Washington School of Medicine,* [2]*Department of Medicine, Division of General Internal Medicine, University of Washington,* [3]*Department of Family Medicine, University of Washington*

M113. New Rat Study Suggests a Biologic Basis for Higher Fentanyl Mortality in Men Than Women
Robert Raffa[1], Joseph Pergolizzi[2], Jeannette Mathews[2], Michael Schatman[3], Jeanette Mathews*[4]
[1]*Temple University, University Arizona Neumentum, Enalare, Advantx,* [2]*Enalare Therapeutics,* [3]*NYU Grossman School of Medicine,* [4]*Enalare Therapeutics, Inc.*

M114. In Vivo Imaging Evidence of a Neuroinflammatory Phenotype Among Patients with Opioid Use Disorder
Eric Woodcock*[1], Mark Greenwald[1], Michael Petriello[1], Leslie Lundahl[1], Andrew King[1], Otto Muzik[1]
[1]*Wayne State University*

M115. Experiences of and Recommendations for LGBTQ+-Affirming Substance Use Services: An Exploratory Qualitative Descriptive Study With LGBTQ+ People who Use Opioids and Other Drugs
Margaret Paschen-Wolff*[1], Emily Allen Paine[2], Avery DeSousa[2], Tonda L. Hughes[3], Aimee N.C. Campbell[2]
[1]*Columbia University, New York State Psychiatric Institute,* [2]*Columbia University and New York State Psychiatric Institute,* [3]*Columbia University School of Nursing*

M116. Trends in the Availability of Comprehensive Services Within Outpatient Substance Use Treatment Facilities From 2018-2022
Zoe Lindenfeld*[1], Jonathan Cantor[2], Ji Chang[1]
[1]*New York University,* [2]*RAND Corporation*

M117. How Can States Improve Opioid Use Disorder Medication Use? Evidence From Medicaid's 1115 Substance Use Disorder Waivers
Kyle Hart*[1]
[1]*Oregon Health and Science University*

M118. Counselor Terminological Preferences for Common Treatment Experiences Among Patients Receiving Methadone Treatment
Kathryn Eggert*[1], Kelly Walker[2], Mark Beitel[3], Katherine Cammack[4], Raiza Rossi[5], Marina Gaeta Gazzola[6], Connie Hsaio[7], Teresa Roehrich[1], Lynn Madden[8], Declan Barry[6]
[1]*APT Foundation, Inc.,* [2]*APT Foundation, Inc,* [3]*Yale University, APT Foundation,* [4]*The University of the South,* [5]*Yale University,* [6]*Yale University School of Medicine,* [7]*Yale Department of Psychiatry,* [8]*APT Foundation*

M119. Effects of Opioid Withdrawal on Psychobiology in People Living With HIV
Igor Grant[1], Evgeny Krupitsky[2], Marina Vetrova[3], Anya Umlauf[1], Robert K. Heaton[1], Richard L. Hauger[1], Olga Toussova[3], Donald Franklin[1], Scott L. Letendre[1], George Woody*[4], Elena Blokhina[3], Dmitry Lioznov[3], Edwin Zvartau[3]
[1]*University of California San Diego,* [2]*V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology,* [3]*First Pavlov State Medical University,* [4]*Perelman School of Medicine at the University of Pennsylvania*

M120. A 5-HT2A Inverse Agonist Reduces Precipitated Morphine Withdrawal Syndrome and its Aversiveness
Ping-Hsun Tsai[1], Erica Morales[1], Savannah Nino[1], Isabella Deleon[1], Kessiya Philip[1], Gopika Saji[1], Ruby Gonzalez[1], Yvonne Reed[1], Georgina Moreno[1], Chris Ward[1], David Malin*[2]
[1]*University of Houston-Clear Lake,* [2]*University of Houston, Clear Lake*

M121. A Novel Approach to Managing Neonatal Opioid Withdrawal Syndrome (NOWS): Insights from Rural South Carolina
Rachel Mayo*[1], Jennifer Hudson[2], Lori Dickes[1], Windsor Sherrill[1], Leah Holcomb[1], Bonnie Treado[1], Katie Howle[2], Karrie Jowers[2]
[1]*Clemson University,* [2]*Prisma Health*

M122. Pragmatic Considerations for the Application of Physical Withdrawal Assessments in Patient Studies
Denise Milovan*[1], Thomas Sciascia[2], Megan Shram[3], Cynthia Arons[4], Thomas J. Hudzik[5], Michael Klein[6], Joseph Grieco[7], Beatrice Setnik[8]
[1]*Altasciences Inc.,* [2]*Trevi Therapeutics,* [3]*Altreos Research Partners,* [4]*Pfizer,* [5]*ALAC Group,* [6]*Consultant,* [7]*Tris Pharma,* [8]*Altasciences Inc*

M123. Development of the Subject-Rated Comprehensive Drug Withdrawal Scale (CDWS) to Evaluate the Physical Dependence Potential of Investigational Drugs
Beatrice Setnik*[1], Denise Milovan[1]
[1]*Altasciences*

M124. Conducting Community-Based Research on Substance Use in Rural Canada: Ethical and Methodological Considerations for Future Research
Geoff Bardwell*[1], Kate Hodgson[2], Manal Mansoor[3], Kathryn Colby[2], Amreetha Jayathilake[1]
[1]*University of Waterloo,* [2]*qathet Community Action Team,* [3]*University of British Columbia Faculty of Medicine*

M125. Guanfacine Improves Stroop Performance That in Turn Moderates Drug Treatment Effect on Cumulative Abstinence in Women with Polysubstance Use Disorder
Nia Fogelman[1], Colleen McGowan[1], Stephanie Wemm[1], Marshall Tate[1], Gretchen Hermes[1], Rajita Sinha[1], Stephanie Wemm*[1]
[1]*Yale University School of Medicine*

M126. Alcohol-Focused Treatment with Mindfulness-Oriented Recovery Enhancement Shows Additional Beneficial Effects on Craving for Other Drugs
Laura Gurrieri*[1], Margaret Wardle[1], Eric Garland[2]
[1]*University of Illinois at Chicago,* [2]*University of Utah*

M127. Age Differences in Driving Under the Influence of Cannabis and Alcohol in the US, 2021
Erin Annunziato*[1], Priscila Gonçalves[1], Sarah Gutkind[1], Pia Mauro[1]
[1]*Columbia University*

M128. Polysubstance Use Within Social Networks Among Black Sexually Minoritized Men and Transgender Women in Chicago, Illinois
Megan Marziali*[1], Cho-Hee Shrader[2], Justin Knox[2], Silvia Martins[2], Dana Bezuidenhout[2], Yen-Tyng Chen[3], Dustin Duncan[2], John Schneider[4]
[1]*Columbia University Medical Center,* [2]*Columbia University,* [3]*Rutgers University,* [4]*University of Chicago*

M129. Lifetime Psilocybin Use and Opioid Use Disorder in Pregnant and Non-Pregnant Women of Reproductive Age
Amanda Elmore*[1], Marina Bolser[1], Mirine Richey[1]
[1]*University of South Florida*

M130. Oral Oxycodone Self Administration in Rats with a History of Responding under a Multiple Schedule for Ethanol and Food or Oxycodone and Food
Sarah Melton*[1], William Smith[1], Peter Winsauer[1]
[1]*LSU Health Sciences Center*

M131. PTSD Diagnosis Increases the Mediating Effect of Distress Tolerance on Pain Interference and Opioid Misuse
Marjorie Heule*[1], Nicole Kouri[1], Leslie Lundahl[2], Mark Greenwald[3]
[1]*Wayne State University,* [2]*Wayne State University School of Medicine,* [3]*Wayne State University, Dept of Psychiatry and Behavioral Neurosciences*

M132. Risk Factors Influencing Crime Association Among Veterans with SUD
Camara Wooten[1], Mathew Gregoski[2], Amanda Ornstein[3], Kayla Lamb[3], Elizabeth Santa Ana*[4]
[1]*University of North Carolina School of Medicine,* [2]*Medical University of South Carolina,* [3]*Ralph H. Johnson VA Medical Center,* [4]*Medical University of South Carolina and Charleston VAMC*

M133. Substance Use Diagnoses Increase Risk of 30-Day Unplanned Readmission in a Large Urban Health System
Allison Rosen*[1], Steve Shoptaw[2], Sae Takada[3], Michelle Bholat[4]
[1]*UCLA,* [2]*University of California Los Angeles,* [3]*UCLA Department of Internal Medicine,* [4]*UCLA Department of Family Medicine*

M134. How Do Helping Behaviors Change over the First Six Months for Sober Living House Residents?
Elizabeth Mahoney*[1], Meenakshi Subbaraman[2], Amy Mericle[3], Sarah Zemore[3], Doug Polcin[2]
[1]*Public Health Institute,* [2]*Behavioral Health and Recovery Studies, Public Health Institute,* [3]*Alcohol Research Group*

M135. Establishing the Preliminary Feasibility of a Mobile Phone-Based Intervention for People Who Inject Drugs
Ian Aronson*[1], Mary-Andrée Ardouin-Guerrier[2], Juan Esteban Baus[2], L. Synn Stern[3], Alex S. Bennett[4]
[1]*NDRI-USA,* [2]*NYU School of Global Public Health,* [3]*OnPoint NYC/New York Harm Reduction Educators,* [4]*New York University College of Global Public Health*

M136. Substance Use Disorders Among Human Trafficking Victims: Insights from a National Survey of Emergency Department Visits
Nathaniel Dell*[1], Theresa Anasti[2], Kathleen Preble[3], Hetal Patel[4]
[1]*Washington University School of Medicine,* [2]*Washington University Brown School of Social Work,* [3]*University of Missouri College of Health Sciences,* [4]*Washington University*

M137. Financing Substance Use Prevention in the United States in Healthcare, Education, Community, and Criminal-Legal Settings
Kathryn McCollister*[1], Don Ekanayake[1], Erminia Fardone[1]
[1]*University of Miami Miller School of Medicine*

M138. Associations Across Condom Delay Discounting and Alcohol and Drug Use
Irene Pericot-Valverde*[1], Jin Yoon[2], Constanza de Dios[3], Sarah Voss[1], Catherine Chopade[1], Caroline Allen[1], Haley Neal[1], Roisin Cahill[1], Yuuki Garcia[1], Erik Ortiz[4], Vincent Dang[3], Lanelle Ochiam[3]
[1]*Clemson University,* [2]*University of Texas Health Science Center,* [3]*The University of Texas Health Science Center At Houston,* [4]*Prisma Health*

M139. Impulsivity Facets Associated with Co-Use and Consequences of Alcohol and Cannabis via Perceived Norms
Melissa Rothstein*[1], Amy Stamates[1]
[1]*University of Rhode Island*

M140. Afrocentric Cultural Norms and Substance Use Behaviors Among Black American Emerging Adults
Husain Lateef*[1], Patricia Cavazos[2]
[1]*Washington University in St. Louis,* [2]*Washington University St. Louis*

M141. U. S. Non-Medical Synthetic Drugs Situation, Policy, Controls and Regulations to Reduce Supply
Liqun Wong*[1]
[1]*Department of Justice*

M142. Trends of Polysubstance Use Combinations for the Most Used Substances Among Lesbian, Gay, and Bisexual US Adults
Luis Mestre*[1], Maria Parker[2], Juhan Lee[3], Marney White[4], Krysten Bold[3]
[1]*Yale University, School of Medicine,* [2]*Indiana University - Bloomington,* [3]*Yale University School of Medicine,* [4]*Yale University School of Public Health*

M143. Low Hepatitis C Virus (HCV) Re-Infection Rates Among Current and Former People who Use Drugs Enrolled in an HCV Treatment Trial in Rural Appalachia
Jennifer Havens*[1], Takako Schaninger[1], Michelle Lofwall[1], April Young[2], Sharon Walsh[3]
[1]*University of Kentucky, College of Medicine,* [2]*University of Kentucky, College of Public Health,* [3]*University of Kentucky*

M144. CM at Scale: More Money Works Better
Cristal Cardoso Sao Mateus*[1], Rosemarie Davidson[1], Jade Astin[1], Anthony DeFulio[1]
[1]*Western Michigan University*

M145. Associations Between Recreational Cannabis Legislation and Driving Under the Influence of Alcohol and Other Substances in the US
Priscila Gonçalves*[1], Emilie Bruzelius[2], Natalie Levy[2], Sarah Gutkind[3], Anne Boustead[4], Ardesheer Talati[5], Deborah Hasin[3], Pia Mauro[3], Diana Silver[6], James Macinko[7], Silvia Martins[3]
[1]*New York State Psychiatric Institute / Columbia University,* [2]*Columbia University Mailman School of Public Health,* [3]*Columbia University,* [4]*University of Arizona School of Government and Policy,* [5]*Columbia University and NYSPI,* [6]*New York University,* [7]*University of California, Los Angeles*

M146. Interacting With the Future Self in Virtual Reality Increases Delayed Reward Preference in Early Recovering SUD: Randomized Controlled Trial Testing
Brandon Oberlin*[1], Megayn Lewandowski[1], Mario Dzemidzic[1], Andrew Nelson[2]
[1]*Indiana University School of Medicine,* [2]*Relate XR, LLC*

M147. The Impact of Mental Health Treatment and Medication on Drug Treatment Program Participation in Justice-Involved Adolescents
Nebiyou Daniel*[1], Samay Shah[1], James-Angelo Suarez[1], Kimberly Johnson[1], Micah Johnson[1]
[1]*University of South Florida*

M148. Unraveling HIV Risk and Prevention Among Female Sex Workers in Uganda: Insights from Focus Group Discussions
Jude Ssenyonjo*[1], Michael Copenhaver[1], Colleen Mistler[1], Tanya Adler[1]
[1]*University of Connecticut*

M149. "Their Lives are so Messed up and Using Drugs Probably Gives Them Some Kind of High Status with Friends": White Peoples' Race-Based Stigma Toward People who Use, Sell, and are Addicted to Drugs
Esthelle Ewusi Boisvert*[1], Matt Kirkpatrick[1]
[1]*University of Southern California*

M150. New Psychoactive Substance and Polysubstance Use Patterns Among Adults in 19 US Cities: A Latent Class Analysis
Nicole Fitzgerald*[1], Joseph Palamar[2], Linda Cottler[1]
[1]*University of Florida,* [2]*New York University Grossman School of Medicine*

M151. Is Research Me-Search?: Patterns of Substance Use Among Drug Use Researchers Using a Cross-Sectional Latent Class Analysis of the NDRLE Study
Cho-Hee Shrader[1], Danielle Ompad[2], Ingrid Walker[3], Kyle Snyder[2], Raymond Moody*[4]
[1]*Arizona State University,* [2]*New York University School of Global Public Health,* [3]*University of Washington, Tacoma,* [4]*University of Connecticut*

M152. Feasibility and Efficacy of a Continuing Care Program Following Residential Substance Use Treatment
Jennifer Manuel*[1]
[1]*University of Connecticut School of Social Work*

M153. Closing the Gap: MIT's Program on Entrepreneurship and Innovation for Substance Use Disorder (SUD)
Andres Felipe Salazar Gomez*[1], Katerina Bagiati[1], Hanna Adeyema[1], Carolina Haass-Koffler[2], Cynthia Breazeal[1]
[1]*Massachusetts Institute of Technology (MIT),* [2]*Brown University*

M155. Prefrontal Cortex Projections to the Nucleus Accumbens Mediate Cocaine Seeking Induced by Conditioned and Discriminative Stimuli in Rats
Hajer Algallal*[1], Shaghayegh Najafipashaki[2], Isabel Laplante[2], Anne-Noël Samaha[2]
[1]*Universite de Montreal Faculty of Medicine,* [2]*Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal*

M156. Longitudinal Associations Between Frequency and Recency of Nonmedical Prescription Stimulant Use in Adolescence and Cocaine Use in Young Adulthood: Implications for Screening
Emily Pasman*[1], Philip Veliz[1], Megan Patrick[1], Ty Schepis[2], Vita McCabe[1], Timothy Wilens[3], Sean Esteban McCabe[1]
[1]*University of Michigan,* [2]*Texas State University,* [3]*Massachusetts General Hospital*

M157. Pilot Study of a Brief Online Fentanyl Educational Intervention for People who Use Cocaine
Cecilia Nunez*[1], Benedicta Anighoro[1], Jin Yoon[2], Margaret Wardle[1]
[1]*University of Illinois Chicago,* [2]*University of Texas Health Science Center*

M158. 'Drug Cutting' Perspectives and Implications on Reducing Harms of Fentanyl Adulterated Stimulants: A Qualitative Study of People who Distribute Drugs
Patrick Kelly*[1], Stephanie Vento[1], Madeline Noh[1], Traci Green[2], Josiah Rich[3], Jaclyn Hughto[1]
[1]*Brown University School of Public Health,* [2]*Heller School for Social Policy and Management, Brandeis University,* [3]*The Miriam Hospital*

M159. Parkin Impacts Energy Metabolism and Stress Responses in Methamphetamine Use Disorder
Akhil Sharma[1], Anna Moszczynska*[1]
[1]*Wayne State University*

M160. A Comparative Study of Behavioral Effects of Novel Designer Drugs in Male Rodents
Ritu Shetty*[1], Rebecca Hill[1], Jared McDonald[1], Megana Sundar[1], Michael Gatch[1]
[1]*University of North Texas Health Science Center*

M161. Cracks in the Ice: Are Australians Changing Their Attitudes About Crystal Methamphetamine?
Steph Kershaw*[1], Amelia Russell[2], Louise Birrell[2], Anna Grager[2], Nicola Newton[2], Lexine Stapinski[2], Katrina Champion[2], Maree Teesson[2], Cath Chapman[2]
[1]*The Matilda Centre for Research in Mental Health and Substance Use at the University of Sydney,* [2]*The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney*

M162. All or Nothing? Associations Between Binary Patterns in Cocaine Use and Potential Psychological Mechanisms of Use
Rachel Sun*[1], Samantha Ellis[2], Constanza deDios[3], Scott Lane[3], Joy Schmitz[3], Margaret Wardle[2]
[1]*University of Illinois Urbana-Champaign,* [2]*University of Illinois Chicago,* [3]*University of Texas Health Science Center*

M163. Reproductive Outcomes, Prenatal Healthcare Utilization, and Predictors Among the Justice-Involved Young Women Who Used Drugs: A Population-Based Data Linkage Study in Taiwan
Tan-Wen Hsieh*[1], Rosetta Siew[2], Wenmay Rei[2], Sheng-Chang Wang[1], Chuan-Yu Chen[2]
[1]*National Health Research Institutes,* [2]*National Yang Ming Chiao Tung University*

M164. The Effects of Acupuncture Stimulation at Shenmen (HT7) on Brain Stimulation Reward in Rats
Seong Shoon Yoon*[1]
[1]*Daegu Haany University*

M165. A Discrimination Procedure to Compare Reward Seeking Triggered by Discriminative and Conditioned Stimuli in Rats
Shaghayegh Najafipashaki*[1], Mandy Le Cocq[2], Domiziana Casale[1], Anna Samaha[1]
[1]*University of Montreal,* [2]*Universite de Montreal*

M166. Determination of Yohimbine's Reinforcing Actions in Male and Female Rats
Briana Renda[1], Brooke Ginson[1], Francesco Leri*[1]
[1]*University of Guelph*

M167. Association Between Psychiatric Comorbidity and Retention in Substance Use Disorder Treatment: Results from Multi-Site Randomized Controlled Trials of Pharmacological and Behavioral Interventions
Himani Byregowda*[1], Masoumeh Amin-Esmaeili[1], Ryoko Susukida[1], Kwanghyun Kim[1], Ramin Mojtabai[1], Rosa Crum[1]
[1]*Johns Hopkins Bloomberg School of Public Health*

M168. Engaging African American Faith-Based Leaders in a Substance Use Learning Collaborative (LC)
Holly Hagle*[1], Dawn Tyus[2], An-Lin Cheng[3], Kaleea Lewis[4], Sara Trompeter[3], Blackeney Quandra[5], Akshat Gandhi[4], Dipti Subramaniam[6], Ashley Helle[4], Laurie Krom[3], Gavin Bart[7]
[1]*UMKC,* [2]*Morehouse School of Medicine,* [3]*University of Missouri, Kansas City,* [4]*University of Missouri, Columbia,* [5]*NIH/NIDA,* [6]*Saint Louis University School of Medicine,* [7]*bartx005@umn.edu*

M169. Facilitators and Barriers to Implementing HIV Testing and Pre-Exposure Prophylaxis in Substance Use Treatment Programs
Maria Herrera*[1], Anjali Mahajan[2], Stephen Bonett[2], Shoshana Aronowitz[2], Jose Bauermeister[2], Daniel Teixeira da Silva[3]
[1]*Children's Hospital of Philadelphia,* [2]*University of Pennsylvania School of Nursing,* [3]*University of Pennsylvania National Clinician Scholars Program*

M170. A Tailored SUD Treatment Program for Female Offender Reentry: Successful Outcomes with a High-Risk Population
Hana Ghiathi[1], Katherine Hatcher[1], Michael Vitacco[1], Aaron Johnson*[1]
[1]*Augusta University*

M171. The Impact of the Number of Positive Adult Relationships on Treatment Participation Among Justice-Involved Adolescents with Substance Use Disorder
Nurimar Ortega Santiago*[1], Elian Ruiz-Arevalo[1], Anthony Carmona[1], Dylanis Lopez Ruiz[1], Elzbieta Wiedbusch[1], James-Angelo Suarez[1], Kimberly Johnson[1], Micah Johnson[1]
[1]*University of South Florida*

M172. Exploring the Association Between PTSD Indicators and Substance Use Disorder Among Sexually Abused Justice-Involved Adolescents
Jordan Barringer*[1], Elian Ruiz-Arevalo[1], James-Angelo Suarez[1], Kimberly Johnson[1], Micah Johnson[1]
[1]*University of South Florida*

M173. State Legislators Knowledge and Awareness of Substance Use Prevention Research
Elizabeth Long*[1], Patrick O'Neill[1], Brittany Gay[1], D. Max Crowley[1], J. Taylor Scott[1]
[1]*Pennsylvania State University*

M174. Issues Faced in the Management of Youths Using Substances: A Qualitative Approach
Amirul Danial Azmi*[1], Suzaily Wahab[1]
[1]*Universiti Kebangsaan Malaysia Medical Centre*

M175. Self-Reported past 12-Month Fentanyl Use: Results from an Anonymous Multi-City Intercept Survey
Nae Won*[1], Andrew McCabe[1], Anna Wang[1], Joseph Palamar[2], Linda Cottler[1]
[1]*University of Florida,* [2]*New York University Grossman School of Medicine*

M176. Assessing Health Research Participation by Patterns of Polysubstance Use Among Community-Based Populations in Northern Florida
Christian Conger*[1], Linda Cottler[1]
[1]*University of Florida*

Tuesday, June 18, 2024 – Poster Session 3

T1. Open Board

T2. Providing Information and Advice in Brief Motivational Interventions: A Quantitative Process Analysis
Jacques Gaume*[1], Cristiana Fortini[1], Stephanie Blanc Perler[1], Molly Magill[2], Jim McCambridge[3], Nicolas Bertholet[1], Jean-Bernard Daeppen[1]
[1]*Lausanne University Hospital,* [2]*Brown University,* [3]*University of York*

T3. Alcohol and Tobacco Use Among Adolescent Asian Americans and Pacific Islanders: Analysis of Ethnic Subgroup and Gender Differences
Ting Luo*[1], Yue-Lin Zhuang[2], Shu-Hong Zhu[2]
[1]*University of California, San Diego,* [2]*University of California - San Diego*

T4. Evaluating Non-Abstinence ENDPOINTS: The Viability of Drinking Risk Levels as Outcomes in Treatments for Comorbid Posttraumatic Stress Disorder and Substance Use Disorders
Jordan Gette*[1], Antonio Morgan-Lopez[2], Denise Hien[3], Teresa Lopez-Castro[4]
[1]*Rutgers University,* [2]*RTI International,* [3]*Rutgers Center of Alcohol and Substance Use Studies, Graduate School of Applied and Professional Psychology,* [4]*The City University of New York*

T5. Coverage and Management of Alcohol Use Disorder Treatment Services and Medications in Medicaid Managed Care Plans
Sage Feltus*[1], Christina Andrews[2], Dominic Hodgkin[1], Constance Horgan[1], Cindy Thomas[4], Maureen Stewart[4]
[1]*Brandeis University Heller School for Social Policy and Management,* [2]*University of South Carolina,* [3]*Brandeis University*

T6. Clinical Utility of Self-Reported Unhealthy Alcohol Use With Serum PEth in Young Volunteers
Paola Zuluaga[1], Marvin Bueno[1], Daniel Fuster[1], Carmen García[2], Julia Casado[1], Andrea Caicedo[3], Anna Hernández-Rubio[1], Robert Muga[1], Daniel Fuster*[4]
[1]*Internal Medicine Service. Hospital Universitari Germans Trias i Pujol,* [2]*Biochemistry Department. Hospital Universitari Germans Trias i Pujo,* [3]*Pharmacology Department. Hospital Universitari Germans Trias i Pujol,* [4]*Hospital Universitari Germans Trias i Pujol*

T7. Discriminative Stimulus Effects of Ethanol, Alprazolam and Pentobarbital in Rats
Tamara Morris*[1], Ashley Henderson[1], Annamarie Hirschberger[1], Peter Winsauer[1]
[1]*LSU Health Sciences Center*

T8. Prevalence of Substance Use Among Adolescents in Hotspot Areas in Malaysia, its Risk Factors and Association with Risky Sexual Attitude
Suzaily Wahab*[1], Muhammad Afiq Zulkifly[1], Nor Ba'yah Abdul Kadir[2]
[1]*Universiti Kebangsaan Malaysia Medical Centre,* [2]*Faculty of Social Sciences and Humanities, Universiti Kebangsaan Malaysia*

T9. Perception of the Association Between the Menstrual Cycle and Substance Use in Young Adult Women
Emily A. Levine*[1], Emma W. Trapani[1], Allen J. Bailey[1], Dawn E. Sugarman[2], Laura A. Payne[2], Shelly F. Greenfield[2], R. Kathryn McHugh[2]
[1]*McLean Hospital,* [2]*McLean Hospital, Harvard Medical School*

T10. Sexual Risk Behaviors and Drug Use Correlates with HIV and STI Testing Among Black Youth
Nimisha Srikanth*[1], Sitara Weerakoon[2], Christina Aivadyan[1], Bryce Takenaka[1], Raquel Rose[1], Jaleah Rutledge[1], Ijeoma Opara[1]
[1]*Yale School of Public Health,* [2]*Yale University School of Medicine*

T11. Impact of ADHD Symptomatology and Sex on Adolescent Substance Use Initiation
ReJoyce Green*[1], Samantha Margherio[2], Alexis Garcia[1], Kevin Gray[1], Lindsay Squeglia[1]
[1]*Medical University of South Carolina,* [2]*Virginia Tech*

T12. Prenatal Exposure to Xylazine Using Umbilical Cord Tissue in an At-Risk Population
Guida Brown*[1], Joseph Jones[2]
[1]*Guided by Guida,* [2]*United States Drug Testing Laboratories*

T13. Impact of a System-Wide Clinician Educational Program on Benzodiazepine and Non-Benzodiazepine Sedative-Hypnotic Prescribing in an Integrated Health System
Rulin Hechter*[1], Adovich Rivera[2], AnMarie Nguyen[2], William Lieu[3], Britta Amundsen[2], Deborah Ling Grant[2], Patricia Gray[4], Steven Steinberg[5]
[1]*Kaiser Permanente Southern California,* [2]*Department of Research and Evaluation, Kaiser Permanente Southern California,* [3]*Department of Drug Use Management, Kaiser Permanente,* [4]*Pharmacy Administration, Kaiser Permanente,* [5]*Department of Family Medicine, Southern California Permanente Medical Group*

T14. Cannabis Use Patterns and Demographics in Adolescent Emergency Department Patients with Cyclic Vomiting Associated With Chronic Cannabis Use
Joshua Bloom[1], Francesca Beaudoin[2], Timmy Lin[3], Caroline Wunsch[4], Ashley Gaipo[3], Carolyn Ortega[3], Rachel Wightman[1], Rachel Wightman*[5]
[1]*Alpert Medical School, Brown University,* [2]*Brown University School of Public Health,* [3]*Brown Emergency Medicine,* [4]*Lifespan Department of Psychiatry and Behavioral Health Services,* [5]*Rhode Island Hospital/Alpert Medical School of Brown University*

T15. The Intersection of Cannabis Use and ADHD: Patterns, Correlates, and Clinical Implications
Jennie Ryan*[1], Allison Herens[1], Mitchell Fruchtman[2], Philip Veliz[3], Brooke Worster[4]
[1]*Thomas Jefferson University,* [2]*Sidney Kimmel Sidney Kimmel Medical School, Thomas Jefferson University,* [3]*Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing,* [4]*Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University*

T16. A Structural Equation Model Analysis on Attention Deficit Hyperactivity Disorder, Childhood Trauma, and Substance Misuse Among Female Adolescents in the Juvenile Justice System
Elzbieta Wiedbusch*[1], James-Angelo Suarez[1], Micah Johnson[1]
[1]*University of South Florida*

T17. Prenatal Cannabis and Tobacco Use and Alcohol/Drug Problems in First Degree Relatives
Dace Svikis*[1], Anna Wiese[1], Nancy Jallo[1], Lisa Brown[1]
[1]*Virginia Commonwealth University*

T18. Cannabis Abstinence Associated with Improved Inhibitory Control in Adolescents
Randi Schuster[1], Matteo Torquati*[2], Kevin Potter[3], Jodi Gilman[3], Anne Eden Evins[3]
[1]*Harvard Medical School, Massachusetts General Hospital,* [2]*Massachusetts General Hospital, Psychiatry Research,* [3]*Massachusetts General Hospital-Psychiatry*

T19. Projected Cannabis Demand Predicts Future Cannabis Use
Rebecca Kurnellas*[1], Cassie Sutton[2], Hailey Taylor[2], Aaron Smith[3], Ricarda Foxx[4], Ali Yurasek[4], Richard Yi[2]
[1]*University of Kansas,* [2]*The University of Kansas,* [3]*University of Kentucky,* [4]*University of Florida*

T20. The Association Between State Cannabis Policies and Cannabis Use Among Adults and Youth, United States, 2002-2019
Seema Pessar[1], Rosalie Pacula*[1], Marlene Lira[2], Rosanna Smart[3], Timothy Naimi[4]
[1]*University of Southern California,* [2]*Boston University,* [3]*RAND Corporation,* [4]*University of Victoria*

T21. Perceptions of Cannabis and its Associations with Mental Health Amongst Budtenders in Southern Ontario
Darby Lowe*[1], Cindy Wang[1], Tony George[2]
[1]*Centre for Addiction and Mental Health,* [2]*University of Toronto*

T22. The Associations Between Cannabis Use and HIV Related Outcomes Among Black Sexual Minority Men: A Systematic Review
Christopher Magana[1], Justin Knox*[2], Dustin Duncan[3], Allison Wilson[4], John Schneider[4]
[1]*Columbia University and New York State Psychiatric Institute,* [2]*Columbia University,* [3]*Department of Epidemiology, Mailman School of Public Health, Columbia University,* [4]*University of Chicago*

T23. Developing a Culturally Grounded Social-Ecological Model of Cannabis Norms and Use Among Black Adolescents: A Qualitative Study
Kanila Brown*[1], Devin Banks[2], Rachel Winograd[1]
[1]*University of Missouri- St. Louis,* [2]*Washington University School of Medicine*

T24. Pharmacology of Newer Synthetic Cannabinoids at the CB1 Receptor
Laura Kozell[1], Amy Eshleman[1], Tracy Swanson[1], Shelley Bloom[2], John Reed[2], Katherine Wolfrum[2], Jennifer Schmachtenberg[2], William Schutzer[2], Aaron Janowsky[2], Atheir Abbas*[2]
[1]*Oregon Health and Science University,* [2]*VA Portland Health Care System*

T25. Availability of Cannabinoid Products in Online Vape Shops
Nora Satybaldiyeva*[1], Raquel Harati[1], Tomas Mejorado[1], Nick Morales[2], Shannon Ellis[1], John Ayers[1], Eric Leas[1]
[1]*UC San Diego,* [2]*CSU San Marcos*

T26. Cannabis and Alcohol Use Trajectories: A Qualitative Analysis of Contributing Factors and Interconnections
Ekaterina Fedorova*[1], Janna Ataiants[1], Bridgid Conn[2], Carolyn Wong[2], Stephen Lankenau[1]
[1]*Drexel University Dornsife School of Public Health,* [2]*Children's Hospital Los Angeles and University of Southern California*

T27. Characterization of E-Commerce Cannabis-Derived Product Marketing Targeting Students, Veterans, and Active Military
Matthew Nali*[1], Zhuoran Li[1], Meng Zhen Larsen[2], Douglas Roehler[3], Timothy Mackey[4]
[1]*S-3 Research, LLC,* [2]*University of California, San Diego,* [3]*Centers for Disease Control and Prevention,* [4]*University of California - San Diego*

T28. Development of ARTM-194 as a Novel Therapeutic for Cannabis Use Disorder
Rangan Maitra*[1]
[1]*Artiam Bio Inc.*

T29. Co-Use of Alcohol and Cannabis and HIV Status Neutral Care Engagement Among Young Black Sexually Minoritized and Gender Expansive Groups: An Event-Level Analysis of the Neighborhoods and Networks (N2) Cohort Study in Chicago
Yen-Tyng Chen*[1], Ellen Almirol[2], Justin Knox[3], Jade Pagkas-Bather[4], Dustin Duncan[5], John Schneider[4]
[1]*Rutgers University,* [2]*The Chicago Center for HIV Elimination, University of Chicago, Chicago, IL,* [3]*Columbia University,* [4]*University of Chicago,* [5]*Columbia University Mailman School of Public Health*

T30. Lifetime Trauma as a Risk Mechanism for Hazardous Cannabis Use in LGBTQIA+ Young Adults
Leah Cingranelli*[1], Krutika Rathod[1], Patricia A. Goodhines[1]
[1]*University of Maine*

T31. Psychiatric Diagnoses and Cannabis Use in Pregnancy Increases the Risk of Adverse Maternal Outcomes
Kristin Prewitt*[1], Bharti Garg[1], Eleasa Sokolski[1], Aaron Caughey[1], Jamie Lo[1]
[1]*Oregon Health and Sciences University*

T32. Emerging Adults' Reasons for Cannabis Use and Reductions in Use: Leveraging Qualitative Methods to Develop Novel Prevention Intervention Strategies
Kathryn Gex*[1], Shannon Phillips[1], Kevin Gray[1], Rachel Tomko[1]
[1]*Medical University of South Carolina*

T33. Characterizing Online Questions and Answers about Cannabis Use and Pregnancy: Data Mining and Content Analysis on the Social Media Platform Quora
Qing Xu*[1], Christine Wenzel[1], Jiawei Li[1], Zhuoran Li[1], Beverly Wolpert[2], Catharine Trice[2], Cassandra L. Taylor[2], Timothy Mackey[1]
[1]*S-3 Research LLC,* [2]*Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS)*

T34. Prevalence and Correlates of Cannabis Use Among Youth Ages 14–17 From the United States (US) in 2021: The Role of Family Structure
Peter Driezen*[1], Danielle Smith[2], Connor Martin[2], David Hammond[3], Karin Kasza[2]
[1]*University of Waterloo,* [2]*Roswell Park Comprehensive Cancer Center,* [3]*Universtiy of Waterloo*

T35. THC Modifies Microglial Phenotype and Induces Synaptic Pruning in Frontal Cortex of Adolescent Mice

Iness Charfi*[1], Derek Robertson[2], Florian Wünnemann[3], Antônia Sâmia Fernandes do Nascimento[2], Severine Leclerc[2], Gregor Andelfinger[3], Graziella Di Cristo[4], Graciela Piñeyro[5]
[1]*CHU Ste-Justine Research Center, Université de Montréal,* [2]*CHU Ste-Justine Research Centre, 3175 Côte-Ste-Catherine, Montréal, QC, H3T 1C5, Canada,* [3]*CHU Ste-Justine Research Centre, 3175 Côte-Ste-Catherine, Montréal, QC, H3T 1C5, Canada; Department of Pediatrics, Université de Montréal, Montreal, QC H3T 1J4, Canada,* [4]*CHU Ste-Justine Research Centre, 3175 Côte-Ste-Catherine, Montréal, QC, H3T 1C5, Canada; Departments of Neuroscience, Université de Montréal, Montreal, QC H3T 1J4, Canada,* [5]*CHU Ste-Justine Research Centre, 3175 Côte-Ste-Catherine, Montréal, QC, H3T 1C5, Canada; Department of Pharmacology, Université de Montréal, Montreal, QC H3T 1J4, Canada*

T36. To Stop or Not to Stop Cannabis Use in Pregnancy: Characteristics Associated with Late 3rd Trimester Use

Nancy Jallo*[1], Lisa Brown[1], Anna Weiss[1], Carl Wolf[1], Robert Balster[1], Dace Svikis[1]
[1]*Virginia Commonwealth University*

T37. Mental Health Clinicians' Practices for Improving Engagement and Outcomes for Pregnant Patients who Use Cannabis

Maha Mian*[1], Monique Does[2], Andrea Altschuler[3], Andrea Green[2], Deborah Ansley[4], Carley Castellanos[4], Derek Satre[5], Kelly Young-Wolff[3]
[1]*University of California, San Francisco,* [2]*Kaiser Permanente Northern California, Division of Research, Oakland, CA,* [3]*Kaiser Permanente Northern California,* [4]*Regional Offices, Kaiser Permanente Northern California, Oakland CA,* [5]*Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA*

T38. Ask the Experts: Community Engagement Studios to Inform Research on Cannabis Use in Cancer Symptom Management

Brittney Greene*[1], Grace McKenzie[1], Keenan Gibbons[1], Salimah Meghani[2], Brooke Worster[3], Rebecca Ashare[1]
[1]*State University of New York at Buffalo,* [2]*Abramson Cancer Center at the University of Pennsylvania and the University of Pennsylvania School of Nursing,* [3]*Sidney Kimmel Cancer Center, Thomas Jefferson University*

T39. Investigating the Relationship Between Cannabis Expectancies and Anxiety, Depression, and Pain Responses After Acute Flower and Edible Cannabis Use

Margy Chen*[1], Emily Kramer[1], Laurel Gibson[1], L. Cinnamon Bidwell[1], Kent Hutchison[2], Angela Bryan[1]
[1]*The University of Colorado Boulder,* [2]*University of Colorado School of Medicine*

T40. Genetic Factors Associated with Alcohol and Cannabis Use Disorders in a High-Risk American Indian Population

Qian Peng*[1], Cindy Ehlers[1]
[1]*The Scripps Research Institute*

T41. Assessing the Relationship Between Body Mass Index and Substance Craving Among Patients with Substance Use Disorder

Sophia Gonzalez*[1], Tulay Koru-Sengul[1], Renae Schmidt[1], Dikla Shmueli-Blumberg[2], Sara St. George[1], Rui Duan[1], Daniel Feaster[1], Viviana Horigian[1]
[1]*University of Miami Miller School of Medicine,* [2]*Emmes Corporation*

T42. Assessing Tobacco Product Abuse Liability in the Context of the Appropriate for the Protection of Public Health (APPH) Regulatory Standard

Andrea Vansickel*[1]
[1]*Altria Client Services LLC*

T43. Differences in Cognition and Smoking Abstinence Rates Among People With and Without HIV

Sera Levy*[1], Robert Schnoll[2], David Metzger[2], Frank Leone[2], Rebecca Ashare[1]
[1]*State University of New York At Buffalo,* [2]*Department of Psychiatry, University of Pennsylvania*

T44. Smoking Abstinence Disrupts Acquisition but Does Not Impair Probabilistic Reversal Learning in Humans
Sarah Tonkin*[1], Ashton Baltazar[1], Taylor Love[1], Laili Boozary[1], Adam Leventhal[2], Kyle Simmons[3], Joseph McClernon[4], Jason Oliver[1]
[1]*University of OklahomaHealth Sciences Center,* [2]*Keck School of Medicine, University of Southern California,* [3]*Oklahoma State University,* [4]*Duke University*

T45. "Icy" Flavor Components in E-cigarette Images: Influence on Liking and Intention to Use Among Youth Who are Susceptible to E-cigarette Use
Wei Li*[1], Danielle Davis[1], Eugenia Buta[2], Barry Green[2], Kathleen Garrison[1], Suchitra Krishnan-Sarin[1]
[1]*Yale University School of Medicine,* [2]*Yale University*

T46. The Association Between Sleep Health and Multiple Tobacco Product Use Among Low-Income Smokers
Jamie Gajos*[1], S. Justin Thomas[1], Karen Gamble[1], Karen Cropsey[1]
[1]*The University of Alabama at Birmingham*

T47. Trauma and Smoking Dependence Motives Among Individuals Involved in the Criminal Legal System
Dominique Black*[1], Karen Cropsey[1], Andres Azuero[1], Matthew Carpenter[2], Peter Hendricks[1], Adrienne Lahti[1]
[1]*The University of Alabama at Birmingham,* [2]*Medical University of South Carolina*

T48. Examining Engagement in Contingency Management for Smoking Cessation Among Homeless-Experienced Veterans: The Role of Dual Diagnosis
Alexandra Venegas*[1], Taylor Harris[1]
[1]*West Los Angeles VA Medical Center*

T49. Effects of Nicotine Flux and Form on Speed and Total Amount of Arterial Blood Nicotine Delivery During Acute E-Cigarette Vaping
Stephen Baldassarri*[1], Emma McKinney[1], Stylianos Mysirlidis[1], Mehak Sharma[1], Reagan Blohowiak[1], Phillip Joseph[1], Tore Eid[1], Haleh Nadim[1], Elyana Hanna[2], Nareg Karaoghlanian[2], Ayomipo Adeniji[3], Alan Shihadeh[2], Thomas Eissenberg[4], Suchitra Krishnan-Sarin[1], Stephanie O'Malley[1], Ahmad El-Hellani[3], Soha Talih[2]
[1]*Yale University,* [2]*American University of Beirut,* [3]*The Ohio State University,* [4]*Virginia Commonwealth University*

T50. Perceived Discrimination Acutely and Vicariously Affects Daily Perceived Support and Stress Between Same-Sex Couples During a Tobacco Quit Attempt
Jimi Huh*[1], Lucy Schuler[2], Ryan Lee[1], Raina Pang[1], Matt Kirkpatrick[1]
[1]*University of Southern California,* [2]*Keck School of Medicine University of Southern California*

T51. The Role of Chronic Pain in Smoking and Smoking Cessation: A Secondary Analysis of Program Data
Laurie Zawertailo*[1], Sabrina Voci[1], Scott Veldhuizen[1], Peter Selby[1]
[1]*Centre for Addiction and Mental Health*

T52. Paramedic Initiation of Buprenorphine for Opioid Use Disorder on a Statewide Basis: Program Initiation and Early Results
Robert Rosenbaum*[1], Kate Brookins[2], Mollee Dworkin[3], Sydney Kappers[4], Michelle Jones[4], Joanna Champney[2]
[1]*Delaware Division of Public Health,* [2]*Delaware Division of Substance Abuse and Mental Health,* [3]*Delaware Division of Public Health, EMSPS,* [4]*Delaware Division of Public Health, Office of EMS*

T53. Targeting the Endocannabinoid System for the Treatment of Multidimensional Opioid Withdrawal in Rats
Catherine Moore*[1], Bryan Jenkins[1], Christopher Cunningham[2], Elise Weerts[1]
[1]*Johns Hopkins University School of Medicine,* [2]*Concordia University Wisconsin*

T54. Dental Disease Prevalence Among Individuals Who Use Transmucosal Buprenorphine
Douglas Oyler*[1], Robert Payne[1], Craig Miller[1], Marcia Rojas-Ramirez[1]
[1]*University of Kentucky*

T55. Experiences of People Who Use Opioids and Other Content Experts in Philadelphia on Xylazine: Wounds, Withdrawal, and Sedation
Megan Reed*[1], Tracy Esteves Camacho[1], Mary Jo Larson[2]
[1]*Thomas Jefferson University,* [2]*Brandeis University, Heller School for Social Policy and Management*

T56. Gender Differences in Opioid Overdose Outcomes, Concerns about Carrying Naloxone, and OEND Program Preferences
Bailey Pridgen*[1], William Wagner[1], Michelle Sisson[1], Karen Cropsey[1]
[1]*The University of Alabama at Birmingham*

T57. Integrating MOUD in Non-Medical Community Organizations: Better Together MOUD (BT-MOUD)
Denise Scott*[1], Richard Schottenfeld[1], Ernest Clover[2], Kendrick Curry[3], Shayna Waites[1], Gloria Cain[1], Maya Patton[1], Malik Pattrick[1], Dephanie Jordan[1], Kayla Bulluck[1], Marek Chawarski[4]
[1]*Howard University College of Medicine,* [2]*District of Columbia Dream Center,* [3]*Pennsylvania Ave. Baptist Church,* [4]*Yale School of Medicine*

T58. The Proud Trial Over 3 Years: Impact of Massachusetts Model of Nurse Care Management for Office-Based Addiction Treatment on OUD Treatment in Primary Care
Gwen Lapham*[1], Noorie Hyun[2], Jennifer Bobb[1], Paige Wartko[2], Abigail Matthews[3], Onchee Yu[2], Jennifer McCormack[4], Amy Lee[2], David Liu[5], Jeffrey Samet[6], Katharine Bradley[1]
[1]*Kaiser Permanente Washington Health Research Institute,* [2]*Kaiser Permanente Health Research Institute,* [3]*The Emmes Company,* [4]*The Emmes Company, LLC,* [5]*National Institute on Drug Abuse, National Institutes of Health,* [6]*Boston University School of Medicine*

T59. Contingency Management Reduces Individual Differences in Treatment Outcomes Due to Delay Discounting
Shelby Goodwin*[1], Nicolas Samson[1], Harris Khan[1], Indu Madhuranthakam[1], Seth Gray[1], Alisha Suman[1], Arriana Swiderski[1], Matthew Salzman[2], Bethany Raiff[1]
[1]*Rowan University,* [2]*Addiction Medicine, Cooper University Health Care*

T60. Barriers and Facilitators to Mobile-Based Services Offered by Syringe Services Programs in New York State
Cristina Chin, LMSW, MPH*[1], Winston Luhur, MPH[1], Grace Corry[1], Czarina Behrends, PhD, MPH[1]
[1]*Weill Cornell Medical College*

T61. Long-Duration Antagonist to Treat Opioid Overdose
Larry Zana*[1], Saadyah Averick PhD[2], Darren Wolfe PhD[1], Sophia Battaglia[1], James Oxley PhD[3], Robin Sloan MS[1]
[1]*Consegna Pharma Inc.,* [2]*AHN,* [3]*Southwest Research Institute*

T62. Correlates of Naloxone Ownership Among Older Adults in Opioid Treatment Programs
Wayne Kepner*[1], Benjamin Han[2], Angela Bazzi[3]
[1]*SDSU/UCSD Joint Program,* [2]*University of California - San Diego,* [3]*University of California, San Diego*

T63. Perspectives of Providers and Staff in Harm Reduction Implementation in Outpatient Addiction Clinics
Raagini Jawa*[1], Margaret Shang[2], Gary McMurtrie[1], Megan Hamm[1], José Luiggi-Hernández[1], Jane Liebschutz[1]
[1]*University of Pittsburgh,* [2]*University of Pittsburgh Medical Center*

T64. Antinociceptive and Discriminative Stimulus Effects of Seven Novel Fentanyl Analogs
Michael Gatch*[1], Jeanne Priddy[1], Rebecca Hill[1], Ritu Shetty[1]
[1]*University of North Texas Health Science Center*

T65. Concordance of Suspected, Self-Reported Co-Occurrence of Fentanyl with Other Drugs of Use and Urine Drug Testing Among People who use Drugs in Rhode Island
Leah Shaw*[1], Katie Biello[1], Jane Buxton[2], Jacqueline Goldman[1], Scott Hadland[3], Susan Sherman[4], Alexandria Macmadu[1], Brandon Marshall[1]
[1]*Brown University School of Public Health,* [2]*University of British Columbia,* [3]*Harvard Medical School,* [4]*Department of Health, Behavior and Society, Bloomberg School of Public Health*

T66. Psychometric Performance of a Tool to Measure Internalized Drug Use and Medications for Opioid Use Disorder Stigma Among People Who Use Drugs in Dar Es Salaam, Tanzania
Stacy M. Endres-Dighe*[1], Linda B. Mlunde[2], Emmanuel Oga[3], Jessie K. Mbwambo[4], Zawadi Shomari[2], Judith Mkufya[2], Elizabeth Nguma[2], Lucy C. Teemba[2], Khalida Saalim[3], Laura Nyblade[3]
[1]*The Ohio State University,* [2]*Muhimbili University of Health and Allied Sciences, School of Public Health and Social Sciences,* [3]*RTI International,* [4]*Muhimbili National Hospital, Department of Psychiatry and Mental Health*

T67. Risk of COVID-19 Hospitalization and Death in Patients on Chronic Opioid Therapy and With Opioid Use Disorder
Morgan Ford*[1], Anh Nguyen[1], Ingrid Binswanger[2], Komal Narwaney[1], Jason Lyons[1], Deborah Rinehart[3], David McClure[4], Jason Glanz[1]
[1]*Kaiser Permanente Colorado,* [2]*Kaiser Permanente Colorado/Colorado Permanente Medical Group,* [3]*Denver Health and Hospital Authority,* [4]*Marshfield Clinic Research Institute*

T68. Communities at the Crossroads: Exploring Cultural Variations in Opioid Mortality Across the United States
Kelsey Isman*[1], Salvatore Giorgi[1], Brenda Curtis[1]
[1]*NIH/NIDA-IRP*

T69. Building Connection: Overdose Survivors' and Professional Service Providers' Recommendations for Improving Immediate Post-Overdose Care
Angela Bazzi*[1], Simeon Kimmel[2], Alykhan Nurani[2], Jeff Desmarais[3], Shannon O'Malley[4], Alexander Walley[2], Andres Hoyos-Cespedes[3], Jaylen Clarke[4], Sunday Taylor[4], Dan Dooley[4], Ranjani Paradise[3]
[1]*University of California, San Diego,* [2]*Boston Medical Center,* [3]*Institute for Community Health,* [4]*Boston Public Health Commission*

T70. A Longitudinal National Study of Continuity of Substance Use Disorder Symptom Severity and Medical Use of Prescribed Controlled Medications During Middle Adulthood
Philip Veliz*[1], Megan E. Patrick[2], Joshua Truchan[1], Rebecca J. Evans-Polce[1], Emily Pasman[1], Ty S. Schepis[3], Timothy E. Wilens[4], Vita V. McCabe[1], Sean Esteban McCabe[1]
[1]*Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing,* [2]*University of Michigan,* [3]*Texas State University,* [4]*Massachusetts General Hospital*

T71. Reductions in Injection Equipment Sharing in Peer-Facilitated Hepatitis C Treatment
Hunter Spencer*[1], Ryan Cook[1], Kim Hoffman[1], Soomin Shin[1], Gillian Leichtling[2], Ann Thomas[3], Judith Leahy[3], Tonhi Gailey[1], Devin Gregoire[1], Andrew Seaman[4], P. Todd Korthuis[1]
[1]*Oregon Health and Science University,* [2]*Comagine Health,* [3]*Oregon Health Authority,* [4]*Oregon Health and Science University, Central City Concern*

T72. "You Can't Incarcerate Yourself out of the Drug Problem in America:" The Burden of Additional Criminalization of Fentanyl
Samantha Nall[1], Cole Jurecka[1], Betsy Craft[2], Joshua Barocas[3], Katherine LeMasters[3], Paul Christine*[3]
[1]*University of Colorado Anschutz Medical Campus,* [2]*University of Colorado Health Sciences Center,* [3]*University of Colorado School of Medicine*

T73. Trajectories of Medical Use of Prescription Opioids and Longitudinal Associations with Substance Use Disorder Symptoms in Adulthood (Ages 35-60)
Sean Esteban McCabe*[1], Megan E. Patrick[2], Ty S. Schepis[3], Emily Pasman[1], Timothy E. Wilens[4], Rebecca J. Evans-Polce[1], Vita V. McCabe[1], Anna Wang[1], Philip T. Veliz[1]
[1]*Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing,* [2]*University of Michigan,* [3]*Texas State University,* [4]*Massachusetts General Hospital*

T74. Receiving Medications for Opioid Use Disorder in Maryland Correctional Facilities and at a Community-Based Low-Threshold Buprenorphine Program Post-Release: Patient and Staff Perspectives
Ashley Truong*[1], Victoria Green[1], Sachini Bandara[1], Deborah Agus[2], Omeid Heidari[3]
[1]*Johns Hopkins Bloomberg School of Public Health,* [2]*Behavioral Health Leadership Institute,* [3]*University of Washington*

T75. Is Once Daily Enough? Assessing the Impact of Timing of Methadone Dose on Pain Sensitivity via Quantitative Sensory Testing in Persons with Opioid Use Disorder
Jocelyn Ra[1], Julia Meyerovich[1], Brian Pittman[1], Joao De Aquino[1], Joao De Aquino*[2]
[1]*Yale University School of Medicine VA CT Healthcare System,* [2]*Yale University School of Medicine*

T76. Pilot Implementation of a Drug Overdose Reporting Tool Among Texas Harm Reduction Organizations
Jake Samora*[1], Katie McCormick[1], Justin Benzer[1], Suzannah Creech[1], Kasey Claborn[1]
[1]*The University of Texas at Austin*

T77. Perspectives and Experiences with Sleep and Recovery Among Women Receiving Buprenorphine for Opioid Use Disorder
Michelle Eglovitch*[1], Anna Beth Parlier-Ahmad[1], Alison Patev[1], Brenna Cook[1], Chengxian Shi[1], Stephanie Violante[1], Joseph Dzierzewski[2], Morgan James[3], Caitlin Martin[1]
[1]*Virginia Commonwealth University,* [2]*National Sleep Foundation,* [3]*Rutgers Robert Wood Johnson Medical School*

T78. Prevalence of Fentanyl Among Middle and Older Adults with Nonfatal Opioid Overdose
Alyssa Falise*[1], Kim Aldy[2], Jeffrey Brent[3], Paul Wax[2], Rachel Culbreth[2], Alex Krotulski[4], Shao Li[2], Sharan Campleman[2], Barry Logan[4], Stephanie Abston[2], Adrienne Hughes[5], Rob Hendrickson[5], Alexandra Amaducci[6], Bryan Judge[7], Joseph Carpenter[8], Michael Levine[9], Diane Calello[10], Christopher Meaden[10], Jennie Buchanan[11], Joshua Shulman[12], Evan Schwarz[13], Alex Manini[14]
[1]*American College of Medical Toxicology,* [2]*American College of Medical Toxicology, Phoenix, AZ,* [3]*University of Colorado School of Medicine,* [4]*Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation, Willow Grove, PA,* [5]*Oregon Health and Science University, Portland, OR,* [6]*Lehigh Valley Health Network/USF Morsani College of Medicine, Allentown, PA,* [7]*Corewell Health, Michigan State University, Grand Rapids, MI,* [8]*Emory University School of Medicine, Atlanta, GA,* [9]*University of California-Los Angeles, Los Angeles, CA,* [10]*Rutgers New Jersey Medical School, Newark, NJ,* [11]*Denver Health Medical Center, Denver, CO,* [12]*University of Pittsburgh School of Medicine, Pittsburgh, PA,* [13]*University of California- Los Angeles, Los Angeles, CA,* [14]*Icahn School of Medicine at Mount Sinai, New York, NY*

T79. Harm Reduction and Substance Use Disorder Treatment Program Relations: Perspectives of Syringe Services Program Operators in Michigan
Molly Reid*[1], Samantha Harris[2], Sabrina Gattine[2], Suzanne Grieb[2], Fernanda Aranda[2], Catherine Tomko[2], Mary Aguirre[3], Eric Hulsey[4], Sara Whaley[2], Brendan Saloner[2], Sean Allen[1]
[1]*Johns Hopkins University,* [2]*Johns Hopkins Bloomberg School of Public Health,* [3]*Michigan Department of Health and Human Services,* [4]*Vital Strategies*

T80. Healing Measurement Center Study Protocol to Enhance Opioid Use Disorder Recovery Through Measurement Based Care
Renee Cloutier*[1], Arnie Aldridge[2], Kelli Scott[3]
[1]*University of Pittsburgh,* [2]*RTI International,* [3]*Brown University Center for Alcohol and Addiction Studies*

T81. Overdose Detection Technologies for People Who Use Alone
Ju Nyeong Park*[1], Erin Thompson[2], Joseph Rosen[3], Jessica Tardif[2], Ryan Koch[2], Christina Vasquez[1], Haley McKee[4], Michelle McKenzie[4], Traci Green[5], Susan Ramsey[1]
[1]*Brown University,* [2]*Harm Reduction Innovation Lab, Rhode Island Hospital,* [3]*Johns Hopkins University,* [4]*COBRE on Opioids and Overdose,* [5]*Brandeis University*

T82. Provider Perspectives on Child Protective Services Reporting for Perinatal Patients with Opioid Use Disorder
Samantha Girasulo*[1], Kimberly A. Yonkers[2], Joy Kaufman[3], Ariadna Forray[3]
[1]*Yale School of MedicineDept of Psychiatry,* [2]*University of Massachusetts Chan Medical School,* [3]*Yale School of Medicine*

T83. The Dark Side of Resilience: An Exploratory Investigation of Dark Triad Traits Among Individuals with Opioid Use Disorder
Suky Martinez*[1], Jermaine Jones[2]
[1]*Johns Hopkins University School of Medicine,* [2]*Columbia University Irving Medical Center*

T84. Health and Economic Outcomes of Offering Buprenorphine in Shelters in Massachusetts: Results of a Simulation Model
Emily Stewart[1], Avik Chatterjee*[1], Sabrina A. Assoumou[2], Stavroula A. Chrysanthopoulou[3], Rebecca Arden Harris[4], Ryan O'Dea[1], Bruce Schackman[5], Laura White[6], Benjamin P. Linas, MD MPH[2]
[1]*Boston Medical Center,* [2]*Boston University School of Medicine,* [3]*Brown University,* [4]*University of Pennsylvania Perelman School of Medicine,* [5]*Weill Cornell Medical College,* [6]*Boston University School of Public Health*

T85. Gender Differences in Illicit Drug Access, Use and Use Disorder: Analysis of National Survey on Drug Use and Health Data
Robyn Ellis*[1], Allen Bailey[1], Chloe Jordan[1], Hannah Shapiro[2], Shelly Greenfield[1], R. Kathryn McHugh[1]
[1]*McLean Hospital, Harvard Medical School,* [2]*McLean Hospital*

T86. Development and Validation of Machine-Learning Algorithms Predicting Retention, Overdoses, and All-Cause Mortality Among US Military Veterans Treated with Buprenorphine for Opioid Use Disorder
Corey Hayes*[1], Nahiyan Noor[1], Rebecca Raciborski[2], Bradley Martin[1], Adam Gordon[3], Katherine Hoggatt[4], Teresa Hudson[1], Michael Cucciare[1]
[1]*University of Arkansas for Medical Sciences,* [2]*Central Arkansas Veterans Healthcare System,* [3]*University of Utah SoM and VASLCHCS,* [4]*San Francisco VA Medical Center*

T87. Depression Scores Modulate the Relationship Between Stress-Reactivity and Opioid Demand
abitha Moses*[1], Mark Greenwald[2]
[1]*Wayne State University School of Medicine,* [2]*Wayne State University, Dept of Psychiatry and Behavioral Neurosciences*

T88. Approach to Opioid Use Disorder with a State Overdose System of Care
Kate Brookins*[1], Robert Rosenbaum[2], Joanna Champney[1], Paul Westlake[2]
[1]*Delaware Division of Substance Abuse and Mental Health,* [2]*Delaware Division of Public Health EMS and Preparedness Section*

T89. Development and Validation of a Shorter Version of the PROMIS Quality of Life and Patient Preference Rating (PROPr) With People Coming out of County Jails with Opioid Use Disorders
Michael Dennis*[1], Richard Lennox[1], Kate Hart[1], Sierra Castedo de Martell[2]
[1]*Chestnut Health Systems,* [2]*Chestnut Health Systems/ JEAP Initiative*

T90. Characteristics of Primary Care Patients with Risky Opioid Use: Baseline Data From the "Subthreshold Opioid Use Disorder Prevention" (STOP) Trial of a Collaborative Care Intervention, Conducted in the NIDA Clinical Trials Network
Yasna Rostam Abadi[1], Jennifer McNeely[1], Geetha Subramaniam[2], Rebecca Stone[1], Noa Appleton[1], Travis Lovejoy[3], Lillian Gelberg[4], Donna Beers[5], Catherine Abrams[6], Leslie Revoredo[7], Jennifer McCormack[7], Margaret Kline[7], Song Zhang[7], Tobie Kim[7], Ashley Case[7], Jane Liebschutz[8], Jennifer McNeely*[9]
[1]*NYU Grossman School of Medicine,* [2]*National Institute on Drug Abuse,* [3]*Oregon Health and Science University,* [4]*David Geffen School of Medicine at UCLA,* [5]*Boston Medical Center,* [6]*Emory University,* [7]*The Emmes Company, LLC,* [8]*University of Pittsburgh,* [9]*New York University School of Medicine*

T91. Rapid Methadone Induction for People Who Use Fentanyl: A Case Series from an Opioid Treatment Program
Scott Steiger*[1], Caravella McCuistian[2], Leslie Suen[3], Brad Shapiro[2], D. Andrew Tompkins[2], Alexander Bazazi[2]
[1]*Division of General Internal Medicine at Zuckerberg San Francisco General Hospital, University of California, San Francisco,* [2]*Division of Substance Abuse and Addiction Medicine at Zuckerberg San Francisco General Hospital, Department of Psychiatry and Behavioral Sciences, University of California San Francisco,* [3]*Division of General Internal Medicine at Zuckerberg San Francisco General Hospital, Department of Medicine, University of California San Francisco*

T92. Comparative Effectiveness of Buprenorphine/Naloxone Versus Methadone for Treatment of Opioid Use Disorder: Emulating Target Trials with Population-Level Data
Bohdan Nosyk*[1], Jeong Eun Min[2], Fahmida Homayra[2], Megan Kurz[2], Brenda Carolina Guerra-Alejos[2], Ruyu Yan[1], Micah Piske[2]
[1]*Simon Fraser University,* [2]*Centre for Advancing Health Outcomes*

T93. Employment and Changes in Substance Use Stigma from Incarceration to Community Reentry Among Justice-Involved Women
Matt Webster*[1], Martha Tillson[1], Mary Levi[1], Jaxin Annett[1], Megan Dickson[1], Michele Staton[2]
[1]*University of Kentucky,* [2]*University of Kentucky, College of Medicine*

T94. Peer Recovery Support Services for Individuals Receiving Medication-Assisted Treatment for Opioid Use Disorder: Benefits and Barriers
Farren Larson[1], Neal Masri*[1], Jim May[1], Dawn Farrell-Moore[1]
[1]*Richmond Behavioral Health Authority*

T95. Association Between Opioid Consumption Frequency and Substance Use-Associated Problems During Opioid Agonist Treatment in Individuals with Prescription-Type Opioid Use Disorder: Exploratory Results from the OPTIMA Study
Anne Bouthillier*[1], Gabriel Bastien[1], Christina McAnulty[1], Hamzah Bakouni[1], M. Eugenia Socias[2], Bernard Le Foll[3], Didier Jutras-Aswad[1]
[1]*Université de Montréal,* [2]*University of British Columbia,* [3]*University of Toronto*

T96. Rural and Urban Patients' Telehealth Use and Preferences for the Treatment of Opioid Use Disorder
Tyrone Borders*[1], Nick Zaller[2]
[1]*University of Kentucky,* [2]*University of Arkansas for Medical Sciences*

T97. Implementation Intervention Development with Alaska Native and American Indian Community Partners to Culturally Center Delivery of Opioid Treatment
Aimee Campbell*[1], Margaret Paschen-Wolff[2], Angel Vasquez[3], Hanna Hebden[3], Kelley Jansen[4], Favian Kennedy[5], Jill Kessler[6], Abigail Matthews[7], Sandra Radin[8], Carmen Rosa[9], Jennifer Shaw[10], Antony Stately[11], Catherine Arnatt[4], Katherine Schneider[4], Kamilla Venner[3]
[1]*New York State Psychiatric Institute Division on Substance Use Disorders,* [2]*Columbia University and New York State Psychiatric Institute,* [3]*University of New Mexico,* [4]*Southcentral Foundation,* [5]*Anpetu Luta Otipi, Oglala Sioux Tribe,* [6]*Missouri Breaks Research Institute,* [7]*The Emmes Company,* [8]*University of Washington,* [9]*National Institute of Drug Abuse, National Institutes of Health,* [10]*University of Alaska Fairbanks,* [11]*Native American Community Clinic*

T98. Time to Discontinuation of Opioid Agonist Treatments in Ontario, Canada: A Population-Based Retrospective Cohort Study
Robert Andrew Kleinman*[1], Paul Kurdyak[2]
[1]*University of Toronto,* [2]*Institute for Mental Health Policy Research, Centre for Addiction and Mental Health*

T99. Seeking Treatment while Unhoused: A Qualitative Study Investigating the Experiences of People Experiencing Homelessness Enrolled in Outpatient Methadone Treatment
Emma Thompson*[1], Marina Gaeta Gazzola[2], Kim Hoffman[3], Gul Saeed[4], Colin Baylen[2], Lynn Madden[5], Kathryn Eggert[5], Mark Beitel[6], Declan Barry[7]
[1]*New Jersey Medical School,* [2]*Department of Emergency Medicine, NYU Langone Health/New York Health and Hospitals Bellevue Hospital Center,* [3]*Oregon Health and Science University,* [4]*Department of Internal Medicine, Roger Williams Medical Center,* [5]*APT Foundation Inc.,* [6]*Yale University, APT Foundation Inc.,* [7]*Yale University School of Medicine*

T100. Effects of a Naloxone "Surges" in Ohio on Opioid Overdose Deaths
Bridget Freisthler*[1], John Myers[2], Abigail Shoben[1], Soledad Fernandez[2]
[1]*The Ohio State University,* [2]*The Ohio State University Wexner Medical Center*

T101. Cost of a Group Technology-Based HIV and Sexually Transmitted Infection Prevention Intervention for Black Justice-Involved Women Who Use Drugs
Laura Starbird[1], Dawn Goddard-Eckrich[2], Louisa Gilbert[2], Tim Hunt[2], Halle Bangura[3], Bruce Schackman*[4], Nabila El-Bassel[2]
[1]*University of Pennsylvania School of Nursing,* [2]*Columbia University,* [3]*Princeton University,* [4]*Weill Cornell Medical College*

T102. Chronic Pain Acceptance Predicts Opioid Misuse and Readiness to Taper Among Patients Taking Opioids for Chronic Pain
Taylor Crouch*[1], Emily Donovan[2], Wally Smith[1], Dace Svikis[2]
[1]*Virginia Commonwealth University, School of Medicine,* [2]*Virginia Commonwealth University*

T103. Concordance Between Self-Reported and Objectively Assessed Substance Use Amongst Patients Receiving Methadone or Buprenorphine for Opioid Use Disorder
Hunter Smith[1], Christopher Evonko[1], Margot Ledford[1], Wendy Washington[1], David Reeser[2], David MacQueen*[1]
[1]*University of North Carolina Wilmington,* [2]*OpiAID, Inc.*

T104. Medication Receipt and Opioid Overdose Among US Medicaid Enrollees Newly Diagnosed with Opioid Use Disorder From 2016-2019
Peter Treitler[1], Richard Hermida[2], Hillary Samples[3], SH Crystal*[4]
[1]*Boston University,* [2]*Rutgers University,* [3]*Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research,* [4]*Rutgers*

T105. Comparative Effectiveness of Urine Drug Testing Schedules Alongside Opioid Agonist Treatment
Megan Kurz[1], Brenda Carolina Guerra-Alejos*[1], Jeong Eun Min[1], Bohdan Nosyk[2]
[1]*Centre for Advancing Health Outcomes,* [2]*Simon Fraser University*

T106. Egocentric Social Network Correlates of Substance Use Stigma Among Incarcerated Women with Opioid Use Disorder
Martha Tillson*[1], Carrie Oser[1], Jaxin Annett[1], Megan Dickson[1], Matt Webster[1], Michele Staton[2]
[1]*University of Kentucky,* [2]*University of Kentucky, College of Medicine*

T107. Beyond Rest: Unraveling the Nexus of Sleep Deficiency, Environment, Control, and their Influence on Opioid Use Disorder Treatment Outcomes
Johanna Elumn*[1], Inessa Cohen[2], Luzan JadKarim[2], Lisa Puglisi[2], Hsiuju Lin[3], David Fiellin[2], Klar Yaggi[2], Emily Wang[2]
[1]*Yale School of Medicine,* [2]*Yale University School of Medicine,* [3]*University of Connecticut School of Social Work and CT Dept of Mental Health and Addiction Services*

T108. A Qualitative Investigation of Veterans' Perceived Barriers to Medication Treatment for Opioid Use Disorder
Noah Wolkowicz*[1], Christie Musket[1], Mehmet Sofuoglu[1], Erin Reilly[2], Robert MacLean[1], Galina Portnoy[1]
[1]*VA Connecticut Healthcare, Yale Medical School,* [2]*VA Bedford Healthcare System, University of Massachusetts Chan School of Medicine*

T109. Analysis of Carfentanil Detection and Associated Polysubstance Use from a National Database of Clinical Urine Drug Testing Results
Barrett Bolin*[1], Penn Whitley[1], Eric Dawson[1], Kelly Olson[1], Steven Passik[1], Angela Huskey[1]
[1]*Millennium Health, LLC*

T110. Factors Associated with Carrying Naloxone Among People who Inject Drugs in New York City: A Mixed-Methods Analysis
Sarah Kimball*[1], Chenziheng (Allen) Weng[1], Marley Reynoso[1], Courtney McKnight[1], Don Des Jarlais[1]
[1]*New York University School of Global Public Health*

T111. Changes in the Use of Non-Prescribed Hydromorphone and Unregulated Opioids Among People Who Use Drugs in Vancouver, Canada, 2018-2022
Kanna Hayashi*[1], M-J Milloy[2], JinCheol Choi[3], Rupinder Brar[4], Dean Wilson[3], Kora DeBeck[5], Thomas Kerr[2]
[1]*British Columbia Centre on Substance Use and Simon Fraser University,* [2]*British Columbia Centre on Substance Use and University of British Columbia,* [3]*British Columbia Centre on Substance Use,* [4]*Vancouver Coastal Health Authority,* [5]*British Columbia Centre on Substance Use and Simon Fraser University*

T112. Age and Sex Differences in Medication Sources for Misuse in Us Adolescents and Young Adults
Ty Schepis*[1], Jason Ford[2], Philip Veliz[3], Brady West[4], Sean Esteban McCabe[3]
[1]*Texas State University,* [2]*University of Central Florida,* [3]*Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing,* [4]*University of Michigan*

T113. Using Signaling Profiles to Score the Relative Risk of Respiratory Depression of Street Opioids
Paul Dallaire*[1], Giacomo Trottier[2], Derek Robertson[3], Frederic Langlois[4], Mikin Patel[4], Graciela Pineyro[5]
[1]*Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine,* [2]*Department of Pharmacology and Physiology, Université de Montréal,* [3]*CHU Ste-Justine Research Centre, 3175 Côte-Ste-Catherine, Montréal, QC, H3T 1C5, Canada,* [4]*Health Canada,* [5]*University of Montreal*

T114. Effects of Gabapentinoids on the Discriminative Stimulus Effects of Fentanyl and Cocaine in Male Rats
Takato Hiranita*[1], Shawn Flynn[1], Amanda Grisham[1], Abram Mijares[1], Erin Murphy[1], Charles France[1]
[1]*UT Health San Antonio*

T115. Longitudinal Association Between Discrimination and Prescription Opioid Misuse Among Individuals with Chronic Pain: Exploring Pain, Anxiety, and Depressive Symptoms as Mediators
Patricia Timmons*[1], Rachel Aaron[2], Lakeya McGill[3], Stephen Wegener[2], Claudia Campbell[4], Chung Jung Mun[5]
[1]*Arizona State University,* [2]*Department of Physical Medicine and Rehabilitation, Johns Hopkins School of Medicine,* [3]*Division of General Internal Medicine at the University of Pittsburgh School of Medicine,* [4]*Johns Hopkins University School of Medicine,* [5]*Johns Hopkins Bayview Medical Center*

T116. The Intersection of Gender and Fatal Opioid Overdoses: A Systematic Review and Meta-Analysis
Louisa Picco*[1], Lucas Neumaier[1], Nazgol Karimi[1], Wai Chung Tse[1], Tina Lam[1], Suzanne Nielsen[1]
[1]*Monash University*

T117. Syringe Exchange-Based Telemedicine Linkage to Opioid Use Disorder Treatment: Results from a Mixed Method Randomized Trial of the STAMINA Intervention
Dennis Watson*[1], Dana Franceschini[2], James Swartz[2], Jodie Dewey[1], Mary Ellen Mackesy-Amiti[2], Lisa Taylor[1], Monte Staton[2], Peipei Zhao[2], Sarah Messmer[2], Antonio Jimenez[2], Nicole Gastala[2]
[1]*Chestnut Health Systems,* [2]*University of Illinois at Chicago*

T118. Prevalence of Fentanyl Co-Ingestion among Patients with Opioid and Non-Opioid Drug Overdoses who Visit the Emergency Department
Dana Sacco*[1], Marc Probst[1], Silvia Martins[2], Sandra Comer[3], Zachary Mannes[4], Bernard Chang[1]
[1]*Columbia University Irving Medical Center,* [2]*Columbia University,* [3]*Columbia University and NYSPI,* [4]*College of Physicians and Surgeons, Columbia University*

T119. Disagreement on Problematic Substance Use in Parent-Child Dyads with Early Psychosis
Max Cook[1], Patrick Kelly[1], Julie McCarthy*[2]
[1]*McLean Hospital,* [2]*McLean Hospital, Harvard Medical School*

T120. "When She's there, I No Longer Worry about Her Being arrested" – Family Perspectives on Compulsory Drug Rehabilitation in Vietnam and Implications for Community-Based Approaches
Trang Nguyen*[1], Hoe Han[1], Anh Nguyen[1], Thanh Thuy Dinh[2], Gavin Bart[3], Giang Le[1]
[1]*Hanoi Medical University,* [2]*Centre for Training and Research on Substance Abuse - HIV, Hanoi Medical University,* [3]*University of Minnesota*

T121. Methadone Maintenance Treatment Adherence and Opioids Use Among Patients Engaging Methamphetamine Use in Vietnam
Diep Bich Nguyen[1], Trang Nguyen*[1], Huy Do[1], Truc Thanh Thai[2], Van Hoang[1], Michael Li[3], Li Li[3], Giang Le[1]
[1]*Hanoi Medical University,* [2]*Hochiminh City University of Medicine and Pharmacology,* [3]*University of California Los Angeles*

T122. Developing e-Covery: A Geographic Ecological Momentary Intervention to Support Recovery Among Individuals Reporting Co-Occurring Alcohol and Opioid Use
Adam Viera*[1], E. Jennifer Edelman[2], Jessica Muilenberg[3], Carolyn Lauckner[4], Trace Kershaw[5]
[1]*Collaborative Center to Advance Health Services,* [2]*Yale University School of Medicine,* [3]*University of Georgia,* [4]*University of Kentucky College of Medicine,* [5]*Yale School of Public Health*

T123. Identifying and Addressing Trauma to Promote Racial Equity in Substance Use Disorder Treatment Outcomes
Natrina Johnson*[1], Daneiris Heredia-Perez[1], Phillip Reason[2], Corinne A. Beaugard[3], Avik Chatterjee[4], Sheila E. Chapman[4], Kaku So-Armah[4], Christina S. Lee[5], Amy M. Yule[4], Miriam Komaromy[1]
[1]*Grayken Center for Addiction at Boston Medical Center,* [2]*Boston Public Health Commission,* [3]*Boston Medical Center Department of Psychiatry,* [4]*Boston University Chobanian and Avedisian School of Medicine,* [5]*Boston University School of Social Work*

T124. Changes in Risk-Taking Among People Who Received Cognitive Behavioral Therapy Versus an Other Treatment for Substance Use
Jennifer Loya*[1], Theresa Babuscio[1], Charla Nich[1], Brian Kiluk[1]
[1]*Yale University School of Medicine*

T125. Risky Polysubstance Use Among People Who Use Opioids in a Community-Based Study
Jennifer Lorvick*[1], Madeleine George[1], Jordana Hemberg[1], Joy Piontak[1], Megan Comfort[1]
[1]*RTI International*

T126. Alcohol and Stimulant Use Among Patients with Opioid Use and Mental Health Disorders Receiving Treatment Through Primary Care
Mariah Kalmin*[1], Christina Crowley[2], Colleen McCullough[1], Kirsten Becker[1], Beth Ann Griffin[1], Katherine Watkins[1]
[1]*RAND Corporation,* [2]*Frederick S. Pardee RAND Graduate School, RAND Corporation*

T127. Nicotine-Induced Facilitation of Punishment Resistant Fentanyl Consumption: The Role of Striatal Mechanisms
Sarah Honeycutt*[1], Ashmita Mukherjee[1], Elizabeth Gilles-Thomas[1], Gregory Loney[2]
[1]*University at Buffalo,* [2]*State University of New York At Buffalo*

T128. Barriers and Facilitators to the Implementation of an Opioid and Alcohol Co-Use Medication Management Intervention
Grace Broussard*[1], Kenneth Hohmeier[2], Field Craig[3], Adam Gordon[1], Kristi Carlston[1], Alina Cernasev[2], Gerald Cochran[1]
[1]*University of Utah,* [2]*University of Tennessee,* [3]*University of Texas, El Paso*

T129. Exploration of Remote Harm Reduction Service Delivery Strategies in Rural Settings
Erin Augustine*[1], John Bresett[1], Dylan Angle[1], Lawrence J Ouellet[2], Brandon Corpus[1], Alicia Dawdani[1], Tenny Miller[3], Juliet Pineros[3], Mai Pho[1]
[1]*The University of Chicago,* [2]*Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois Chicago, Chicago, IL,* [3]*University of Illinois Chicago*

T130. Decoding Multisystem Intervention Barriers to Women's Residential SUD Treatment: A Multisite Qualitative Study
Dean Rivera*[1], Benjamin Henwood[2], Steven Sussman[3], Suzanne Wenzel[2], Anindita Dasgupta[1], Aimee Campbell[4], Elwin Wu[1], Hortensia Amaro[5]
[1]*Columbia University School of Social Work,* [2]*Suzanne Dworak-Peck School of Social Work, University of Southern California,* [3]*Keck School of Medicine, University of Southern California,* [4]*Columbia University Irving Medical Center Department of Psychiatry and New York State Psychiatric Institute,* [5]*Herbert Wertheim College of Medicine and Robert Stempel College of Public Health and Social Work, Florida International University*

T131. Associations Between Medical Cannabis, Cigarette, and Alcohol Use Among Patients with Chronic Pain: A Daily Diary Study
Johannes Thrul*[1], Bryant Stone[2], Janardan Devkota[1], Kelly Dunn[3], Vadim Zipunnikov[4], Ryan Vandrey[3], Patrick Finan[5]
[1]*Johns Hopkins Bloomberg School of Public Health,* [2]*Johns Hokpins University,* [3]*Johns Hopkins University School of Medicine,* [4]*Johns Hopkins University,* [5]*University of Virginia*

T132. Understanding the Interplay: Substance Use, Health Literacy, Self-Efficacy and HIV Worry in Sexual Risk Behaviors
Kaixuan An[1], Adrianne Gilmore-Thomas[1], Logan Cummings[1], Naomi Brown[1], Lanelle Ochiam[1], Tyler Rose[1], Angela Heads*[1]
[1]*The University of Texas Health Science Center at Houston*

T133. Exploring Technology Access and Comfort (Computers vs. Smartphones) in Residential Substance Use Treatment
Jennifer Le*[1], Nadra E. Lisha[2], Caravella McCuistian[3]
[1]*University of California, San Francisco,* [2]*School of Medicine, University of California, San Francisco,* [3]*Department of Psychiatry and Behavioral Sciences, University of California, San Francisco*

T134. Association Between Cannabis Use and Nicotine Use Persistence Among Adolescents
Dae Hee Han*[1], Alyssa Harlow[1], Dayoung Bae[1], Junhan Cho[1], Sandrah Eckel[1], Rob McConnell[1], Jessica Barrington-Trimis[1], Janet Audrain-McGovern[2], Adam Leventhal[1]
[1]*University of Southern California,* [2]*University of Pennsylvania*

T135. Characterizing Substance Use Disorder on Reddit Through Network Analysis and Transitions of Use Between Opioids, Cannabis, and Other Drugs
Meng Zhen Larsen*[1], Matthew Nali[2], Zhuoran Li[3], Joshua Yang[4], Timothy Mackey[2]
[1]*University of California, San Diego,* [2]*University of California - San Diego,* [3]*S-3 Research, LLC,* [4]*California State University - Fullerton*

T136. Declines in Drug Use Among Participants of Two Different Drug Treatment Courts: Comparison of a Traditional Model to an Opioid Court Model
D. Lynn Homish[1], Rachel Hoopsick[2], Malaiikha McCormick-Cisse[1], Gregory Homish[1], Linda Kahn[1], Malaiikha McCormick-Cisse*[3]
[1]*State University of New York at Buffalo,* [2]*University of Illinois Urbana-Champaign,* [3]*University at Buffalo*

T137. Functional Impairment in Daily Living During Long-Term Remission from Substance Use Disorders
Bridget Hayes*[1]
[1]*Cornell University*

T138. "Do They Really Want the Help?" Barriers and Facilitators to Substance Use Treatment for Young Adults Experiencing Homelessness
Graham DiGuiseppi*[1], Benjamin Henwood[2], Colin Ring[3], Nina Christie[4], Shaddy Saba[2], Laura Petry[2], Joan Tucker[1], Jordan Davis[1], Eric Rice[2]
[1]*RAND Corporation,* [2]*University of Southern California,* [3]*Loma Linda University,* [4]*University of New Mexico*

T139. “Who the Hell Wants Everybody to Die?”: The Vital Role of Drug Use Networks in Reducing Substance Use-Related Harms
Bethany Hedden-Clayton*[1], Jes Cochran[2], Alex Kral[3], Jennifer Carroll[4], Grant Victor[5], Erin Comartin[1], Bradley Ray[3]
[1]*Wayne State University,* [2]*The Never Alone Project,* [3]*RTI International,* [4]*North Carolina State University,* [5]*Rutgers*

T140. Perceived Impact of COVID-19 on Substance Use Among People Who Use Opioids (PWUO) in the Southeastern United States
Skye Holm*[1], Tanja Laschober[2], Susan Tross[3], Mary Hatch[4]
[1]*University of Washington School of Medicine,* [2]*University of Washington, Addictions, Drug and Alcohol Institute,* [3]*Columbia University Irving Medical Center/NYS Psychiatric Institute,* [4]*University of Washington Addictions, Drug and Alcohol Institute, Department of Psychiatry and Behavioral Sciences, Seattle, WA*

T141. Predictors of Non-Fatal Overdose in the Month Following Discharge from Residential Treatment
Jennifer Ellis*[1], Jill Rabinowitz[2], Martin Hochheimer[1], Orrin Ware[3], Justin Strickland[1], Andrew Huhn[1]
[1]*Johns Hopkins University School of Medicine,* [2]*Rutgers Brain Health Institute,* [3]*University of North Carolina at Chapel Hill*

T142. The Relationship Between Alcohol Use, Mental Health Conditions, and Sexual Experiences with Partner Practicing Injected Drugs Among GBMSM: An Analysis from NESARC-III Survey
Awirut Oon-arom*[1], Bernard Le Foll[2]
[1]*Chiang Mai University,* [2]*University of Toronto*

T143. Personality Comparison by Drug Use Disorder and Sex in a Sample of Individuals with Comorbid Drug and Alcohol Use Disorder
Nicole Boss*[1], Wyatt Brown[1], Anna Beth Parlier-Ahmad[1], Kathryn Polak[1], Alexis Edwards[1], Kenneth Kendler[1], Dace Svikis[1]
[1]*Virginia Commonwealth University*

T144. Exploring the Effects of Posttraumatic Stress and Substance Use Disorders on Health-Related Quality of Life
Carolyn Bazan*[1], Alexandria Bauer[1]
[1]*Rutgers University*

T145. State-Level Substance Use Policies as Drivers of Health Disparities Among Pregnant People Who Use Drugs in the United States: Exploring Potential Pathways and Mechanisms
Morgan Philbin*[1], Megan Marziali[2], Emilie Bruzelius[2], Pia Mauro[2], Kristen Underhill[3], Ariana Emami[2], Evan Eschilman[2], Silvia Martins[2]
[1]*University of California San Francisco,* [2]*Columbia University,* [3]*Cornell University*

T146. Developing a Comprehensive Inventory to Define Harm Reduction Housing
Sofia Zaragoza*[1], Joseph Silcox[1], Sabrina Rapisarda[1], Patricia Case[2], Clara To[3], Charlie Summers[1], Sarah Kolawaski[3], Avik Chatterjee[3], Traci Green[1]
[1]*Heller School for Social Policy and Management, Brandeis University,* [2]*Northeastern University,* [3]*Boston Medical Center*

T147. Racial and Ethnic Disparities in Telehealth and Emergency Department Use Among Women with Substance Use Disorder During the COVID-19 Pandemic
Sugy Choi*[1], Leah L. Habersham[2], Brooke S. West[3]
[1]*New York University Grossman School of Medicine,* [2]*Icahn School of Medicine At Mount Sinai,* [3]*Columbia University*

T148. The Role of Military Identity in Non-Medical Prescription and Illicit Drug Use Among Reserve and National Guard Soldiers
Bonnie Vest*[1], D. Lynn Homish[1], Gregory Homish[1]
[1]*State University of New York at Buffalo*

T149. Expert Advisory Panel Recommendations for Implementing Contingency Management into Rural Recovery Housing
David Ledgerwood*[1], Milena Stott[2], Stacey Quesada[3], Marci Sontag[3], Rachael Beck[4], Michael McDonell[4], David Johnson[2], Dominick DePhilippis[5], Sherrie Donnelly[6], Bryan Hartzler[7], Tammera Nauts[8], Matthew Novak[9], James Peck[10], Carla Rash[11]
[1]*Wayne State University,* [2]*The Fletcher Group, Inc.,* [3]*Center for Public Health Innovation at CI International,* [4]*Washington State University, Program of Excellence in Addictions Research,* [5]*Veterans Affairs Office of Mental Health and Suicide Prevention, US Department of Veterans Affairs, Washington, D.C. and Department of Psychiatry, Perelman School of Medicine and University of Pennsylvania, Philadelphia, PA,* [6]*Mid-State Health Network,* [7]*University of Washington,* [8]*Montana Primary Care Association,* [9]*University of Maryland, Baltimore County,* [10]*University of California, Los Angeles,* [11]*UConn School of Medicine*

T150. Examining Inadequate Response to Substance Use Disorder Treatment: A Scoping Review
Erminia Fardone*[1], Don Ekanayake[2], Kathryn McCollister[2], James McKay[3]
[1]*Miller School of Medicine, University of Miami,* [2]*University of Miami Miller School of Medicine,* [3]*University of Pennsylvania*

T151. The National Institute on Drug Abuse (NIDA) Addiction Treatment Discovery Program: Preclinical Evaluation of Potential Pharmacotherapies for Substance Use Disorders (SUDs)
Carol Hubner[1], David White*[1]
[1]*National Institute of Drug Abuse, National Institutes of Health*

T152. Addressing E-Cigarette Use in Adolescents: Initiatives to Support Vaping Cessation Services at the Hospital for Sick Children and Across Canada
Madelynn Hannah*[1], Trisha Tulloch[2], Marc P Fadel[3], Beth Sproule[4]
[1]*Hospital for Sick Children,* [2]*Division of Adolescent Medicine, Hospital for Sick Children, Toronto, ON, Canada; Nicotine Dependence Clinic, Centre for Addiction and Mental Health, Toronto, ON, Canada; Division of Adolescent Medicine, Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada,* [3]*Department of Psychiatry, Hospital for Sick Children, Toronto, ON, Canada; Division of Child and Youth Mental Health, Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada,* [4]*Centre for Addiction and Mental Health*

T153. Sex Differences in Lifetime Non-Medical Prescription Opioid and Cannabis Use Among Older Adults in the All of Us Research Program
Vijaya Seegulam*[1], Kaitlyn Swacil[1], Liva LaMontagne[1], Catherine Striley[1], Linda Cottler[1]
[1]*University of Florida*

T154. Exploring the Use of Psychedelic Drugs for Personal Growth and Mental Health Improvement: Early Qualitative Lessons from Focus Groups
Jennifer Jewell*[1], Anastasia Cornell[1], Madison Calloway[1], Caleb James[1], Kim Hoffman[2], Adie Rae[3], P. Todd Korthuis[2], Andrew Monte[1]
[1]*Rocky Mountain Poison and Drug Safety,* [2]*Oregon Health and Science University,* [3]*Legacy Research Institute*

T155. Misuse Potential of Medicinal Ketamine in Real-World Clinical Contexts, Part 2: Patients with a History of Substance Use Disorders
Meredith Berry*[1], Shahar Almog[1]
[1]*University of Florida*

T156. Misuse Potential of Medicinal Ketamine in Real-World Clinical Contexts, Part 1: Patients with At-Home Prescribed Ketamine
Shahar Almog*[1], Alexia Obrochta[1], Albert Garcia-Romeu[2], Meredith Berry[1]
[1]*University of Florida,* [2]*Johns Hopkins University School of Medicine*

T157. Methamphetamine Use Practices, Motivations, and Perceived Benefits and Risks: Exploring Gender Differences
Madeline Hooten*[1], Sydney Silverstein[2], Raminta Daniulaityte[1]
[1]*Arizona State University,* [2]*Boonshoft School of Medicine Wright State University*

T158. Training and Technical Assistance for Peer-Delivered Contingency Management
Christi Hildebran[1], Erin Stack[1], Linda Peng[2], Bryan Hartzler[3], Alexis Cooke[1], Ryan Cook[2], Gillian Leichtling[1], Judith Leahy[4], Kelsey Smith Payne[4], Lynn Kunkel[2], Kim Hoffman[2], P. Todd Korthuis*[2]
[1]*Comagine Health,* [2]*Oregon Health and Science University,* [3]*University of Washington,* [4]*Oregon Health Authority*

T159. Exploring Cost-Effectiveness of treatment Interventions for pregnant individuals With Methamphetamine Use Disorder (MUD): A Decision Modeling Approach
Rana Jawish*[1], Abdelrahman Younis[1], Casey Tak[1], Adam Gordon[1], Marcela Smid[1]
[1]*University of Utah*

T160. Associations Between Route of Drug Consumption and HIV and HCV Diagnosis Among People Who Inject Drugs in Seattle, Washington
Thomas Fitzpatrick*[1], Judith Tsui[2], Courtney Moreno[3], Sara Glick[4]
[1]*University of Washington,* [2]*Department of Medicine, Division of General Internal Medicine, University of Washington,* [3]*Public Health - Seattle and King County,* [4]*University of Washington School of Medicine*

T161. Craving and its Dynamics as Predictors of Stimulants Use: An Ecological Momentary Assessment Study
Fuschia Serre*[1], Laura Lambert[1], Cassandre Romao[1], Axel Allache[1], Emmanuelle Baillet[1], Léa Donnadieu[1], Charlotte Kervran[1], Virginie Beltran[2], Jean Pierre Daulouede[2], Marc Auriacombe[1]
[1]*Universite de Bordeaux,* [2]*Bizia*

T162. Longitudinal Relationships Between Us Adolescents' Medical Use of Non-Stimulant or Stimulant Therapy for ADHD and the Risk of Future Illicit Stimulant Use and Substance-Related Driving Accidents
Vita V. McCabe*[1], Philip T. Veliz[2], Emily Pasman[1], Ty S. Schepis[3], Timothy E. Wilens[4], Megan E. Patrick[1], Sean Esteban McCabe[2]
[1]*University of Michigan,* [2]*Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing,* [3]*Texas State University,* [4]*Massachusetts General Hospital*

T163. Trajectories of Craving in the Course of Pharmacotherapy Trials for Methamphetamine Use Disorder
Ramin Mojtabai*[1], Ryoko Susukida[2], Mehdi Farokhnia[3], Trang Nguyen[2], Kelly Dunn[4], Masoumeh Aminesmaeili[2]
[1]*Tulane University,* [2]*Johns Hopkins Bloomberg School of Public Health,* [3]*Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, MD, USA,* [4]*Johns Hopkins University School of Medicine*

T164. Probiotics Alter the Gut Microbiota and Affective Responses to Cessation From Methamphetamine Exposure in a Sex-Selective Manner in Rats
Therese Kosten*[1], Kristi Hoffman[2], Shadab Forouzan[1]
[1]*University of Houston,* [2]*Baylor College of Medicine*

T165. Resistance of Cocaine Reinforcement to Fixed Vs. Variable Regularity of Punishment in Male and Female Rhesus Monkeys
William Doyle*[1], Kevin Freeman[1], Josh Woods[1], Sally Huskinson[1]
[1]*University of Mississippi Medical Center*

T166. The Late Positive Potential Predicts Cocaine Use Disorder Treatment Response
Douglas Calvillo*[1], Heather Webber[2], Jin Yoon[2], Constanza de Dios[2], Robert Suchting[2], Jessica Vincent[2], Vincent Dang[2], Lanelle Ochaim[2], Francesco Versace[3], Charles Green[2], Scott Lane[2], Joy Schmitz[2]
[1]*UTHealth Center for Neurobehavioral Research on Addiction,* [2]*The University of Texas Health Science Center At Houston,* [3]*MD Anderson Cancer Center*

T167. A Methamphetamine Treatment Mobile App for Sexual Minority Men: Participant Characteristics Associated with App Utilization
Cathy Reback*[1], Chunqing Lin[2], Raymond Mata[1], Michael Li[3]
[1]*Friends Research Institute,* [2]*Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles,* [3]*University of California Los Angeles*

T168. The Peers Expanding Engagement in Stimulant Harm Reduction with Contingency Management Study
Alexis Cooke*[1], Erin Stack[1], Linda Peng[2], Ryan Cook[2], Bryan Hartzler[3], Gillian Leichtling[1], Christi Hildebran[1], Judith Leahy[4], Kelsey Smith Payne[4], Lynn Kunkel[2], Kim Hoffman[2], P. Todd Korthuis[2]
[1]*Comagine Health,* [2]*Oregon Health and Science University,* [3]*University of Washington,* [4]*Oregon Health Authority*

T169. Evaluation of the Abuse Potential of the Cholesterol-24-Hydroxylase Inhibitor, Soticlestat, in Drug-Discrimination and Self-Administration Tests
David Heal*[1], Sharon Rowton[2], Sharon Smith[1], Jane Gosden[1], Kristin Horn[3], Gvido Cebers[3], James Blank[3]
[1]*DevelRx Ltd,* [2]*Labcorp Early Development Laboratories Ltd,* [3]*Takeda Development Center Americas, Inc.*

T170. Human Abuse Potential Study of the Novel Antiepileptic Drug Soticlestat in Recreational Drug Users
Kerri Schoedel*[1], Elizabeth Hanson[2], Mahnaz Asgharnejad[2], Sam Hsiao[2], Debra Kelsh[3], Venkatesha Murthy[2]
[1]*Altreos Research Partners, Inc.,* [2]*Takeda Development Center Americas, Inc.,* [3]*Altasciences*

T171. Assessment of Withdrawal-Induced Physical Dependence in Rats After Administration of the Potent Cholesterol-24-Hydroxylase Inhibitor, Soticlestat
Sharon Rowton*[1], David Heal[2], Sharon Smith[2], Jane Gosden[2], Kristin Horn[3], Gvido Cebers[3], James Blank[3]
[1]*Labcorp Early Development Laboratories Ltd,* [2]*DevelRx Ltd,* [3]*Takeda Development Center Americas, Inc.*

T172. Novel Psychoactive Substance Use: Exploring Experiences of Pregnant and Postpartum Individuals with Substance Use Disorders
Marcela Smid*[1], Jasmin Charles[2], Joseph Worden[3]
[1]*Univeristy of Utah Health,* [2]*University of Utah Health,* [3]*University of Utah School of Medicine*

T173. A Pilot Trial of Symptom-Triggered Alcohol Withdrawal Management Delivered Over Telemedicine
Matthew Sloan[1], Ke Bin Xiao[1], Victor Tang[1], Emiy Simpkin[1], Anthony Ngoy[1], Nikki Bozinoff[1], Victor Tang*[2]
[1]*Centre for Addiction and Mental Health,* [2]*University of Toronto*

T174. Cannabis is Not a Substitute for Other Drugs Among Sober Living House Residents
Meenakshi Subbaraman*[1], Elizabeth Mahoney[1], Amy Mericle[2], Sarah Zemore[2], Doug Polcin[1]
[1]*Behavioral Health and Recovery Studies, Public Health Institute,* [2]*Alcohol Research Group*

T175. Complex Working Memory is Differentially Related to Return to Use Among Patients with Co-Occurring Alcohol and Stimulant Use Disorder Verses Alcohol Use Disorder Alone
Renée Dembo[1], Christy Wong[2], Angela Mueller[3], Steven Batki[1], David Pennington*[2]
[1]*UCSF and San Francisco VA Medical Center,* [2]*San Francisco Veterans Affairs Health Care System,* [3]*UCSF*

Wednesday, June 19, 2024 – Poster Session 4

W1. Benefits of Helping in Three Contexts for Maintaining Recovery Among Sober Living House Residents
Sarah Zemore*[1], Elizabeth Mahoney[2], Amy Mericle[3], Meenakshii Subbaraman[4], Doug Polcin[2]
[1]*Alcohol Research Group of the Public Health Institute,* [2]*Behavioral Health and Recovery Studies, Public Health Institute,* [3]*Alcohol Research Group,* [4]*Public Health Institute*

W2. Effects of Development, Sex, and Alcohol Use on Mesolimbic Resting-State Functional Connectivity
Angelica Morales*[1], Scott Jones[2], Dakota Kliamovich[1], Birgitta Carlson[1], Brooke Simpson[1], Daniel Lopez[1], Bonnie Nagel[1]
[1]*Oregon Health and Science University*

W3. Trend of Alcohol and Tobacco Consumption Among Women in Asian Countries in the Recent Decade
Jasmin Choi*[1], Ziming Xuan[2]
[1]*New York University School of Public Health,* [2]*Boston University School of Public Health*

W4. Unhealthy Alcohol Use is Associated with Past Experiences of Intimate Partner Sexual Violence and Current Immune Activation Among Kenyan Women Engaged in Sex Work
Daniel Tolstrup*[1], Sarah Roberts[2], Ruth Deya[3], George Wanje[4], Juma Shafi[5], Vrasha Chohan[3], Jocelyn James[3], Cheryl Day[6], Geetanjali Chander[3], R. Scott McClelland[7], Susan Graham[7]
[1]*University of Washington School of Medicine,* [2]*Research Triangle Institute International,* [3]*Department of Medicine, University of Washington,* [4]*Department of Global Health, University of Washington,* [5]*Institute of Tropical and Infectious Diseases, University of Nairobi,* [6]*Department of Microbiology and Immunology, School of Medicine, Emory University,* [7]*Departments of Medicine, Global Health, and Epidemiology, University of Washington*

W5. Anger Mediates the Relationship Between Changes in Alcohol Consumption and Violence: A Longitudinal Examination Among Iraq/Afghanistan-Era Veterans
Krista Miloslavich*[1], Pallavi Aurora[2], Jean Beckham[3], Eric Elbogen[3], Margaret Wardle[1], Kirsten Dillon[3]
[1]*University of Illinois Chicago,* [2]*VA Mid-Atlantic Mental Illness Research, Education and Clinical Center,* [3]*Duke University School of Medicine*

W6. Using Ecological Momentary Assessment to Test the Food and Alcohol Disturbance Model in Adults with Binge-Spectrum Eating Disorders
Megan Wilkinson*[1], Alessandra Cerruto[1], Adrienne Juarascio[1]
[1]*Drexel University*

W7. An Open-Source Device for Measuring Drinking Microstructure in Socially Housed Rats
Jude Frie*[1], Jibran Khokhar[2]
[1]*University of Western Ontario,* [2]*Western University*

W8. Association of Alcohol Use with Sex, Trauma and Abuse in a Prospective Cohort of Gay and Bisexual Men in Kenya – Anza Mapema, Kisumu, Kenya
Nathaniel Lohman*[1], Susan Graham[2], Fredrick Otieno[3]
[1]*University of Washington School of Medicine,* [2]*University of Washington, Department of Global Health,* [3]*Nyanza Reproductive Health Society*

W9. Assessment of the Publication Trends of the Harm Reduction Studies over 40 Years
Naonori Yasuma*[1], Ayumi Takano[2]
[1]*Ageonomori clinic,* [2]*Department of Drug Dependence Research, National Institute of Mental Health, National Center of Neurology and Psychiatry*

W10. Functional Brain Connectivity Predictors of Prospective Substance Use Initiation in Adolescence
Omid Kardan*[1], Meghan Martz[1], Mike Angstadt[1], Katie McCurry[1], Jillian Hardee[1], Lora Cope[1], Alexander Weigard[1], Luke Hyde[1], Chandra Sripada[1], Mary Heitzeg[1]
[1]*University of Michigan*

W11. Detection of Benzodiazepines in British Columbia's Unregulated Drug Supply Using Point-Of-Care Drug Checking Technologies: A Validation Study
Hannah Crepeault*[1], Samuel Tobias[2], Evan Wood[2], Stephanie Dubland[3], Aaron Shapiro[4], Lianping Ti[2]
[1]*The University of British Columbia,* [2]*British Columbia Centre on Substance Use,* [3]*Drug Analysis Service of Canada,* [4]*BC Centre for Disease Control*

W12. Is Unintentional Benzodiazepine Consumption Associated with Frequency of Drug Checking Utilization? A Cross-Sectional Study
Lauren Airth*[1], Trevor Goodyear[2], Brandon Marshall[3], Cameron Grant[4], Mark Lysyshyn[5], Susan Sherman[6], Evan Wood[7], Lianping Ti[7]
[1]*University of British Columbia,* [2]*British Columbia Centre on Substance Use; University of British Columbia,* [3]*Brown University School of Public Health,* [4]*BC Centre on Substance Use,* [5]*Vancouver Coastal Health,* [6]*Department of Health, Behavior and Society, Bloomberg School of Public Health,* [7]*British Columbia Centre on Substance Use*

W13. Evaluating Xylazine Immunoassay Test Strips in Street-Based Samples of Rocks, Powder, Pills, and Tar in Los Angeles, California
Caitlin Molina*[1], Ruby Romero[1], Edward Sisco[2], Joseph Friedman[1], David Goodman-Meza[3], Leslie Nunez[1], Thomas Urich[4], Elham Jalayer[5], Spider Davila[6], Soma Snakeoil[7], Sonya Guerra[7], Jen Elizabeth[7], Chelsea Shover[1]
[1]*UCLA David Geffen School of Medicine,* [2]*National Institute of Standards and Technology,* [3]*University of California Los Angeles,* [4]*University of Southern California,* [5]*Bienestar Human Services,* [6]*Community Health Project LA,* [7]*The Sidewalk Project*

W14. Discrimination and Self-Regulation as Predictors of Cannabis Use Among Latinx College Students
Rick Cruz*[1]
[1]*Arizona State University*

W15. Ethnic Differences in Adverse Childhood Experiences Among a Cohort of Cannabis Consumers and Non-Consumers: Preliminary Results from the Herbal Heart Study
David Fakunle*[1], Amrit Baral[2], Ranya Marrakchi El Fellah[2], Bria-Necole Diggs[2], Sarah Messiah[3], Raul Gonzalez[4], Denise Vidot[5]
[1]*Morgan State University,* [2]*University of Miami Miller School of Medicine,* [3]*University of Texas Health Science Center,* [4]*Florida International University,* [5]*University of Miami School of Nursing and Health Studies*

W16. Blunt Smoking Trends in the United States: Findings from the National Survey on Drug Use and Health, 2004-2021
Brian Fairman*[1]
[1]*University of Arkansas for Medical Sciences*

W17. Disproportionate Trends of Cannabis Use Behaviors Among a Representative Sample United States Adults With and Without Depression or Psychological Distress From 2005 to 2019
Matthew Myers*[1], Kipling Bohnert[2]
[1]*Michigan State University College of Human Medicine,* [2]*University of Michigan and Department of Veterans Affairs*

W18. Association Between Different Types of Adverse Childhood Experiences and Adolescent Substance Use
Sarah Stoddard*[1], Chelsea Moore[2], Bingxin Chen[2], Philip Veliz[3]
[1]*University of Michigan,* [2]*University of Michigan School of Nursing,* [3]*Center for the Study of Drugs, Alcohol, Smoking and Health, University of Michigan School of Nursing*

W19. Prenatal Cannabis: Motivations and Use Patterns
Lisa Blair*[1], Kathy Rademacher[2], Letitia Ducas[2], Aubrey Jones[3], Kristin Ashford[2]
[1]*Wayne State University,* [2]*University of Kentucky, College of Nursing,* [3]*University of Kentucky, College of Social Work*

W20. Histories of Daily Cannabis Use Patterns and Reported Negative Effects: A Content Analysis of Three Cannabis-Centric Communities on Reddit
Savannah Brenneke*[1], Eloise Estrada[2], Epifania Ortiz[2], Louie Martinez[2], Alexandra DeLucia[3], Johannes Thrul[4], Meredith Meacham[5]
[1]*Substance Abuse and Mental Health Services Administration (SAMHSA),* [2]*Johns Hopkins Krieger School of Arts and Sciences,* [3]*Johns Hopkins Center for Language and Speech Processing,* [4]*Johns Hopkins Bloomberg School of Public Health,* [5]*University of California San Francisco*

W21. Leveraging Cannabis-Centric Reddit Communities to Explore Patterns of Cannabis Product, Modes and Frequency of Use Between 2010-2019
Savannah Brenneke[1], Alexandra DeLucia[2], Gwenyth Portillo Wightman[2], Carlos Aguirre[2], Johannes Thrul[1], Meredith Meacham*[3]
[1]*Johns Hopkins Bloomberg School of Public Health,* [2]*Johns Hopkins Center for Language and Speech Processing,* [3]*University of California San Francisco*

W22. Cannabis Use in Rural Versus Urban Young Adults: The Role of Subjective Social Status and Coping Styles
Krutika Rathod*[1], Leah Cingranelli[1], Patricia Goodhines[1]
[1]*University of Maine*

W23. Insight and Treatment: Examining the Dynamic Influence of Perceived Need, Symptom Severity, and Demographics on Treatment for Cannabis Use Disorder
Wenhua Lu*[1], Renee Goodwin[2]
[1]*The City University of New York Medical School,* [2]*The City University of New York and Columbia University*

W24. Emerging Adults' Cannabis Use in Georgia Following Legalization
Ilia Nadareishvili*[1], Sowmya R. Rao[2], David Otiashvili[3], Natalia Gnatienko[1], Jeffrey Samet[1], Karsten Lunze[1], Irma Kirtadze[4]
[1]*Boston University School of Medicine,* [2]*Boston University School of Public Health,* [3]*Addiction Research Center - Alternative Georgia,* [4]*Ilia State University*

W25. Characterizing Hemp-Derived Alternative Cannabis Products Available Online and at National Retail Stores
Ashley Dowd*[1], Harrison Elder[2], Meagan Robichaud[3], Austin Zamarripa[2], Tory Spindle[2], Edward Cone[4], Mahmoud ElSohly[5], Waseem Gul[5], Timothy Murphy[5], Iram Shahzadi[5], Ruth Winecker[6], Ron Flegel[7], Svante Vikingsson[6], Marcel O. Bonn-Miller Bonn-Miller[8], Ryan Vandrey[2]
[1]*Medical University of South Carolina,* [2]*Johns Hopkins University School of Medicine,* [3]*Johns Hopkins University Bloomberg School of Public Health,* [4]*Johns Hopkins School of Medicine,* [5]*ElSohly Laboratories Inc,* [6]*RTI International,* [7]*Substance Abuse and Mental Health Services Administration,* [8]*Charlotte's Web*

W26. Public Perceptions of Risks Associated with Driving After Cannabis Use
Stella Resko*[1], Emily Pasman[2], Gaby Mohr-Avitia[1], Sydney O'Shay[3], Elizabeth Agius[1]
[1]*Wayne State University,* [2]*University of Michigan,* [3]*Utah State University*

W27. Efficacy of Contingency Management Approaches for Cannabis Use Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Marcelo Lima[1], Vitor Tardelli[1], Thiago Fidalgo[1], Thiago Fidalgo*[2]
[1]*UNIFESP,* [2]*Universidade Federal de Sao Paulo*

W28. Correlates of Expenditure on Cannabis by Patients with Cannabis Use Disorder: Secondary Analysis of a Randomised Controlled Trial
Rahul Mathur*[1], Siddharth Sarkar[2], Anil Singh[2], Yatan Pal Singh Balhara[3], Gauri Kaloiya[4]
[1]*MBBS, MD,* [2]*National Drug Dependence Treatment Centre, AIIMS, New Delhi, India,* [3]*National Drug Dependence Treatment Centre, All India Instittue of Medical Sciences, New Delhi,* [4]*National Drug Dependence Treatment Centre*

W29. Modes of Cannabis Administration and Their Associations with Binge Drinking Among 12th Grade Students in the United States: A Cross-Sectional Analysis from 2018-2021
Michelle Goulette*[1], Gregory Homish[2], Alison Haney[2], Jessica Kulak[2]
[1]*State University of New York At Buffalo,* [2]*State University of New York at Buffalo*

W30. Alcohol, Tobacco, and Marijuana Peer Use: Associations with Prenatal Cannabis Use
Anna Wiese*[1], Nancy Jallo[1], Lisa Brown[1], Dace Svikis[1]
[1]*Virginia Commonwealth University*

W31. Cannabis Using Postpartum Mothers: Will They Come? A Feasibility Study
Lisa Brown*[1], Nancy Jallo[1], Anna Wiese[1], Liangsuo Ma[1], Dace Svikis[1]
[1]*Virginia Commonwealth University*

W32. Effects of Extended Cannabis Abstinence in People with Major Depressive Disorder: Preliminary Data on Sex Differences
Maryam Sorkhou[1], Tony George*[2]
[1]*University of Toronto and CAMH,* [2]*University of Toronto*

W33. Real-World Cue Reactivity and Subjective Stress Independently Predict Cannabis Craving in Individuals With CUD
Ryan Conway[1], Morgan Pearlman[1], Rajita Sinha[1], Stephanie Wemm[1], Ryan Conway*[2]
[1]*Yale University School of Medicine, Department of Psychiatry,* [2]*Yale Medical School*

W34. The Emerging Threat of Cannabis Dabbing on Psychosis: A 10-Year Longitudinal Study
Maria Didaskalou*[1], Julien Ouellet[1], Diana Stratulat[1], Roxane Assaf[1], Stéphane Potvin[2], Patricia Conrod[3]
[1]*Université de Montréal,* [2]*Centre de recherche de l'Institut Universitaire en Santé Mentale de Montréal, Université de Montréal,* [3]*CHU Ste Justine, Universite de Montreal*

W35. A Double-Blind, Randomized, Placebo-Controlled Study Examining the Effects of CBN With and Without CBD on Sleep Quality
Ivori Zvorsky*[1], Marcel O. Bonn-Miller[1], Matthew T. Feldner[2], Teah M. Bynion[3], Graham Eglit[4], Megan Brunstetter[1], Maja Kalaba[5], Erica Peters[6], Mike Hennessy[7]
[1]*Charlotte's Web,* [2]*Arkansas Clinic for Stress and Anxiety,* [3]*University of Arkansas,* [4]*University of California San Diego,* [5]*GSK,* [6]*Charlotte's Web Consultant,* [7]*Wana Brands*

W36. Intimate Partner Violence Victimization in Emerging Adulthood: Associations With Frequent Cannabis Use in Emerging and Early Adulthood
Cat Munroe*[1], Christina Tam[1], Joyce Gee[1], Libo Li[1], Deidre Patterson[1], Carrie Pettus[2], Nina Mulia[1]
[1]*Alcohol Research Group, Public Health Institute,* [2]*Wellbeing and Equity Innovations*

W37. Mental Health and Coping Strategies Among Emerging Adult Cannabis Consumers and Non-Consumers Living in South Florida: Preliminary Results of the Herbal Heart Study
Anurag Aka*[1], Amrit Baral[2], Yash Agrawal[1], Bria-Necole Diggs[2], Ranya Marrakchi El Fellah[2], David Fakunle[3], Raul Gonzalez[4], Barry Hurwitz[2], Claudia Martinez[2], Denise Vidot[5]
[1]*University of Miami College of Arts and Sciences,* [2]*University of Miami Miller School of Medicine,* [3]*Morgan State University,* [4]*Florida International University,* [5]*University of Miami School of Nursing and Health Studies*

W38. Developmental Changes and the Impact of Emerging Adulthood Milestones on Cannabis Use and Related Outcomes Among Cannabis-Using Young Adults from Age 18 to 23 in Los Angeles
Carolyn Wong*[1], Omoloa Odejimi[2], Liyuan Wang[3], Bridgid Conn[1], Ekaterina Fedorova[4], Janna Ataiants[4], Stephen Lankenau[4]
[1]*Children's Hospital Los Angeles and University of Southern California,* [2]*University of Nevada Las Vegas,* [3]*Children's Hospital Los Angeles,* [4]*Drexel University Dornsife School of Public Health*

W39. Exploring Unexpected Adverse Effects from an Intervention to Reduce Cigarette Smoking: A Secondary Analysis of a Randomized Factorial Trial
Elias Klemperer*[1], Sulamunn Coleman[2], Jessica Cook[3]
[1]*University of Vermont College of Medicine,* [2]*University of Vermont,* [3]*University of Wisconsin, Center for Tobacco Research and Intervention*

W40. Characteristics of Adolescents Presenting for a Pharmacotherapy Vaping Cessation Trial who Never Smoked Tobacco Regularly
Randi Schuster[1], Cori Cather[1], Gladys Pachas[1], Vanessa Iroegbulem[1], Jason Raymond Dufour[1], Kelly Danica Casottana[1], Jason Zhao[1], Kevin Potter[1], Alec Bodolay[1], Anne Eden Evins*[1]
[1]*Massachusetts General Hospital-Psychiatry*

W41. Rates of Exposure to Exogenous or Endogenous Estradiol and Progesterone: Preliminary Findings with Implications for Substance Use Research
Chrystal Vergara-Lopez*[1], William Rozum[2], Sydney Iacoi[2], Hector Lopez-Vergara[2], Alicia Allen[3]
[1]*Brown University,* [2]*University of Rhode Island,* [3]*University of Arizona*

W42. A Test of Nicotine Product Substitution for Cigarettes and Differences by Vulnerabilities to Smoking Using the Experimental Tobacco Marketplace
Marc Jerome Feinstein*[1], Tyler Erath[2], Eric Thrailkill[2], Michael DeSarno[2], Norman Medina[2], Stephen Higgins[2], Elias Klemperer[3]
[1]*Univ. of Vermont College of Medicine,* [2]*University of Vermont,* [3]*University of Vermont College of Medicine*

W43. A Randomized Controlled Six-Way Crossover Study to Characterize the Nicotine Pharmacokinetics of a Novel Oral Nicotine Pouch Product
Katy Webb*[1], Jeffery Edmiston[1], Gang Sun[1], Jennifer Smith[1], Mohamadi Sarkar[1]
[1]*Altria Client Services LLC*

W44. Cigarette Smoking Trajectories of US Young Adults by Sex from 45 Years of a Nationally Representative Cohort
Moriah Harton*[1], Maria Parker[2]
[1]*Indiana University,* [2]*Indiana University - Bloomington*

W45. Exposure to Bupropion-Sr vs. Placebo is Associated with Reductions in Smoking Among Persons Who are Receiving Methadone and Have No Stated Interest in Smoking Cessation
Orrin Ware*[1], Annie Umbricht[2], Maxine Stitzer[3], Kelly Dunn[2]
[1]*University of North Carolina at Chapel Hill,* [2]*Johns Hopkins University School of Medicine,* [3]*Friends Research Institute*

W46. Randomized Clinical Trial Examining Reduced Nicotine Content Cigarettes Among Pregnant People with Socioeconomic Disadvantage
Sarah Heil*[1], Kristin Ashford[2], Letitia Ducas[2], Janine Barnett[2], Andrea McCubbin[2], Loren Kock[1], Roxanne Harfmann[1], Anne Dougherty[1], Michael DeSarno[1], Stephen Higgins[1]
[1]*University of Vermont,* [2]*University of Kentucky*

W47. Nicotine and Other Substance Use Among Young Women with Type 1 Diabetes
Enzo Plaitano*[1], Catherine Stanger[1]
[1]*Dartmouth College*

W48. Anticipating the Impact of Bail Reform on Connecting People Who Use Drugs to Services Upon Reentry in Illinois: Stakeholder Perspectives from the Reducing Opioid Mortality in Illinois Study
India Hilty*[1], Emily Claypool[2], Emmanuel Amoako[2], Rana Aburuman[2], John Bresett[2], Julia Riordan[2], Maggie Kaufmann[3], Harold Pollack[4], Mai Pho[2], Bouris Alida[2]
[1]*The University of Chicago The Pritzker School of Medicine,* [2]*The University of Chicago,* [3]*University of Illinois at Chicago,* [4]*University of Chicago School of Social Service Administration*

W49. Adapting a Rapid Low-Dose Buprenorphine Initiation Protocol for a Mobile Clinic Setting
Sarah Messmer*[1], Mackenzie Smith[1], Anna Patterson[1], Abigail Elmes[1], Jennie Jarrett[1], Elisabeth Poorman[1], Christine S. Soran[2], Steven Fisher[1], Michelle Geier[3], Leslie Suen[2]
[1]*University of Illinois at Chicago,* [2]*University of California - San Francisco,* [3]*San Francisco Department of Public Health*

W50. More Bang for Your Buck: Contingency Management Outperforms Economic Models
Rosemarie Davidson[1], Haily Traxler*[2], Anthony DeFulio[1]
[1]*Western Michigan University,* [2]*University of Kentucky, College of Medicine*

W51. The Effects of Morphine on Fecal Motility Among Rats Eating a High Fat/High Carbohydrate or Ketogenic Diet
Nina Beltran[1], Vanessa Minervini[2], Katherine Serafine*[1]
[1]*The University of Texas at El Paso,* [2]*Creighton University*

W52. Rural-Urban Overdose Experiences Among Incarcerated Women with Opioid Use Disorder
Megan Dickson*[1], Martha Tillson[1], Matt Webster[1], Carl Leukefeld[1], Shawn Jamison[2], Jaxin Annett[1], Mary Levi[1], Michele Staton[3]
[1]*University of Kentucky,* [2]*Berea College,* [3]*University of Kentucky, College of Medicine*

W53. The Impact of Mental Health on Retention in OAT
Thi Tran*[1], Emma Zahra[1], Rebecca McKetin[1], Brodie Clark[1], Georgia MacPherson[1], Louisa Degenhardt[1]
[1]*National Drug and Alcohol Research Centre, UNSW Sydney*

W54. Patterns of Opioid Use Disorder Among Pregnant and Postpartum Women in the United States From 2015-2020
Silvia Martins*[1], Yongmei Huang[1], Weijia Fan[1], Luis Segura[1], Emilie Bruzelius[1], Megan Marziali[1], Pia Mauro[1], Morgan Philbin[2]
[1]*Columbia University,* [2]*University of California San Francisco*

W55. Assessing the Relationship Between Community Socioeconomic Conditions and Opioid Use Disorder Across an Urban-To-Rural Spectrum
Melissa Poulsen*[1], Cara Nordberg[1], Joseph DeWalle[1], Wade Berrettini[2], Brian Schwartz[3]
[1]*Geisinger,* [2]*University of Pennsylvania,* [3]*Johns Hopkins Bloomberg School of Public Health*

W56. Continuing Barriers to Prescribing Buprenorphine for Opioid Use Disorder: Results from a Recent Statewide Survey of Healthcare Providers
Nora Marino*[1], Adrienne Call[1], Dana Franceschini[2], James Swartz[2]
[1]*NORC at the University of Chicago,* [2]*University of Illinois Chicago*

W57. Patient and Provider Experiences with Opioid Use Disorder Care Delivered via Telehealth: A Systematic Mixed-Studies Review
Shoshana Aronowitz*[1], Naomi Zucker[2], Morgan Thompson[1], Justin Clapp[3], David Mandell[3]
[1]*University of Pennsylvania School of Nursing,* [2]*University of Pennsylvania School of Arts and Sciences,* [3]*University of Pennsylvania Perelman School of Medicine*

W58. Nalfurafine is Aversive at Analgesic Doses - Non-Clinical Evidence to Indicate It is Not an Atypical Kappa Opioid Receptor Agonist
Eloise Kuijer[1], Sarah Bailey[1], Wonnacott Sue[1], Chris Bailey[1], David Heal[2], Sharon Smith*[2]
[1]*Department of Life Sciences, University of Bath, Bath, UK,* [2]*DevelRx Ltd, Biocity, Nottingham, UK*

W59. Understanding Homelessness Experiences and Social Determinants of Health Among People Experiencing Homelessness Enrolled in Methadone Treatment
Marina Gaeta Gazzola*[1], Colin Baylen[2], Gul Saeed[3], Kim Hoffman[4], Emma Thompson[5], Lynn Madden[6], Kathryn Eggert[7], Mark Beitel[8], Declan Barry[9]
[1]*NYU Langone Medical Center,* [2]*Department of Emergency Medicine, NYU Langone Health/New York Health and Hospitals Bellevue Hospital Center,* [3]*APT Foundation, Inc., Yale University School of Medicine,* [4]*Oregon Health and Science University,* [5]*New Jersey Medical School,* [6]*APT Foundation,* [7]*APT Foundation, Inc.,* [8]*Yale University, APT Foundation,* [9]*Yale University School of Medicine*

W60. Implementation of a Locally-Tailored Health Communications Campaign to Reduce Stigma and Opioid Overdose Deaths in Ohio: Evidence From the Healing Communities Study
Jamie Luster*[1], Brooke Crockett[1], Kelli Bursey[2], Jennifer Reynolds[2]
[1]*The Ohio State University,* [2]*Oak Ridge Associated Universities*

W61. The Relationship Between Victimization, Traumatic Stress, and Overdose Experiences Among Incarcerated Women
Michele Staton[1], Martha Tillson[2], Carrie Oser[3], Matt Webster[1], Carl Leukefeld[1], Megan Dickson[1], Mary Levi[2], Laura Fanucchi[1], Megan Dickson*[2]
[1]*University of Kentucky, College of Medicine,* [2]*University of Kentucky,* [3]*University of Kentucky, Department of Sociology*

W62. Capacity-Building via Quality Assurance Monitoring in a Multi-site Study with Alaska Native and American Indian Community Research Partners
Angel Vasquez*[1], Roberta Chavez[1], Margaret Paschen-Wolff[2], Kyle Smith[1], Kelley Jansen[3], Kamilla Venner[1], Aimee Campbell[4]
[1]*University of New Mexico,* [2]*Columbia University and New York State Psychiatric Institute,* [3]*Southcentral Foundation,* [4]*Columbia University Irving Medical Center and New York Psychiatric Institute*

W63. ADX106772, an mGlu2 Receptor Positive Allosteric Modulator, Selectively Attenuates Oxycodone- but not Sweetened Condensed Milk-Seeking Behavior
Jessica Illenberger*[1], Francisco Flores-Ramirez[1], Alessandra Matzeu[1], Robert Lutjens[2], Remi Martin-Fardon[1]
[1]*The Scripps Research Institute,* [2]*Addex Therapeutics*

W64. The Use of the Pittsburgh Sleep Quality Index to Screen for Different Types of Sleep Disturbance in Opioid Treatment Programs
Connie Hsaio*[1], Kimberly DiMeola[2], Kelly Walker[3], Michael Stein[4], Klar Yaggi[1], Declan Barry[5]
[1]*Yale University,* [2]*APT Foundation,* [3]*The University of the South,* [4]*Boston University School of Public Health,* [5]*Yale University School of Medicine*

W65. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder
Jennifer Bello Kottenstette*[1], Kevin Xu[2], Joanne Salas[3], Bronwyn Bedrick[4], Richard Grucza[5]
[1]*Saint Louis University School of Medicine,* [2]*Washington University School of Medicine,* [3]*St. Louis University,* [4]*Johns Hopkins University,* [5]*St Louis University School of Medicine*

W66. Piloting Virtual Shared Medical Appointments Among Individuals with Opioid Use Disorder
M. Justin Coffey[1], Clare Mulford[2], Ashley Lopez[2], Janessa Perrin[2], Thomas Keith Riddle[2], Hanna Sabbagh[2], Cynthia Jimes[2], Marlene Lira*[3]
[1]*Workit Health, Geisinger Commonwealth School of Medicine,* [2]*Workit Health,* [3]*Workit Health, Johns Hopkins Bloomberg School of Public Health*

W67. Bridging the Regulatory gap: Identifying Opportunities to Enhance Buprenorphine Access in West Virginia's Opioid Crisis Response
Judith Feinberg[1], Kwan Bernadine[1], Frederick Altice[2], Stephanie Hutter-Thomas[1], Jacob Workman[1], Lane Robert[1], Lynn Madden*[3]
[1]*West Virginia University School of Medicine,* [2]*Yale University School of Medicine,* [3]*APT Foundation*

W68. Disparate Roles of Medicaid in Financing Buprenorphine Across States
SH Crystal*[1], Peter Treitler[2], Fangzhou Xie[3], Jay Xu[4], Elizabeth Stone[3], Jennifer Miles[3]
[1]*Rutgers,* [2]*Boston University,* [3]*Rutgers University,* [4]*UCLA*

W69. Naloxone Stigma Among People with Substance Use Disorder: Characteristics and Associations With Stigma toward Medication for Opioid Use Disorder (MOUD)
Devin Banks*[1], Xiao Li[1], Brandon Park[2], Rachel Winograd[2], Patricia Cavazos[1]
[1]*Washington University School of Medicine,* [2]*University of Missouri-St. Louis*

W70. A Pilot Study Examining the Feasibility of a Virtual Reality Pain Management Intervention Groups in Methadone Maintenance Treatment
Kimberly DiMeola*[1], Christopher J. Cutter[2], Jeffrey Haynes[1], Kimberly Hieftje[3], Mark Beitel[4], Raiza Rossi[5], Lynn M Madden[6], Declan T Barry[7]
[1]*APT Foundation,* [2]*APT Foundation, Child Study Center, Yale School of Medicine,* [3]*Department of Pediatrics, Yale School of Medicine,* [4]*APT Foundation, Child Study Center, Yale School of Medicine, Department of Internal Medicine, Yale School of Medicine,* [5]*Department of Internal Medicine, Yale School of Medicine,* [6]*APT Foundation, Department of Internal Medicine, Yale School of Medicine,* [7]*APT Foundation, Child Study Center, Yale School of Medicine, Department of Psychiatry, Yale School of Medicine*

W71. Recovery Environment Risk and Opioid Overdose: Findings from the Recovery Initiation and Management After Overdose Study
Christine Grella*[1], Caroline Allen[2], Michael Dennis[2]
[1]*Chestnut Health Services,* [2]*Chestnut Health Systems*

W72. Developing a Digital Intervention to Increase Women's Engagement in Medication Treatment for Opioid Use Disorder: Provider Perspectives
Dawn Sugarman*[1], Emily A. Levine[2], Callie Wang[3], Lisa Marsch[4], Roger Weiss[2], Shelly Greenfield[5]
[1]*McLean Hospital, Harvard Medical School,* [2]*McLean Hospital,* [3]*University of Central Florida,* [4]*Geisel School of Medicine at Dartmouth,* [5]*McLean Hospital - Harvard Medical School*

W73. The Impact of Severe Mental Illness on Treatment Retention and All-Cause Mortality of Individuals in Opioid Agonist Treatment: A Retrospective Data Linkage Study
Nicola Jones*[1], Thomas Santo Jr.[2], Amy Gibson[1], Julia Lappin[1], Nicholas Lintzeris[3], Louisa Degenhardt[1], Sarah Larney[4], Natasa Gisev[1]
[1]*National Drug and Alcohol Research Centre,* [2]*National Drug and Alcohol Research Centre, UNSW Sydney,* [3]*South Eastern Sydney Local Health District,* [4]*Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) and Department of Family Medicine and Emergency Medicine, Université de Montréal*

W74. Lessons Learned from Project JUNO Community, a Patient Navigator and Contingency Management Program Helping Justice-Involved Individuals With Opioid Use Disorder Start and Stay in Treatment
Alexandra Haas*[1], Maria Olivas[2], Caravella McCuistian[3], Tyler Mains[4], Christine S. Soran[1], Lisa Pratt[4], D. Andrew Tompkins[2]
[1]*University of California, San Francisco,* [2]*University of California San Francisco School of Medicine,* [3]*Department of Psychiatry and Behavioral Sciences, School of Medicine, University of California San Francisco,* [4]*San Francisco Department of Public Health*

W75. Behavioral Health Outcomes Associated with MHealth App Usage Among Medicaid Recipients with Substance Misuse
Patricia Cavazos*[1], Hannah Szlyk[2], Nathan Dell[2], Xiao Li[2], Rachel Winograd[3]
[1]*Washington University St. Louis,* [2]*Washington University School of Medicine, Department of Psychiatry,* [3]*University of Missouri- St. Louis*

W76. Hepatitis C Care Continuum Among People Who Inject Drugs in King County, WA
Jenni Ebersberger*[1], Judith Tsui[2], Maria Corcorran[3], Sara Glick[4]
[1]*University of Washington School of Medicine,* [2]*Department of Medicine, Division of General Internal Medicine, University of Washington,* [3]*University of Washington, Department of Medicine, Division of Allergy and Infectious Diseases,* [4]*University of Washington*

W77. The Continued Usefulness of Social Media Recruitment for Surveys of People who Use Opioids
Elizabeth Nesoff*[1], Qingyue Li[2], Wenqian Li[2], Silvia Martins[3]
[1]*University of Pennsylvania Perelman School of Medicine,* [2]*University of Pennsylvania School of Social Policy and Practice,* [3]*Columbia University*

W78. A Tale of Two Men: A Case Study Applying Social Homeostasis Theory in People Who Inject Opioids
Nina Christie*[1], Vanya Vojvodic[2], John Monterosso[2]
[1]*University of New Mexico,* [2]*University of Southern California*

W79. Trauma-Related Help-Seeking Among Women in Substance Use Treatment: Barriers to Care and Recommendations for Improving Service Delivery
Greyson Chapman*[1], Allison Smith[1], Madelyn Brancato[1], Irene Pericot-Valverde[1], Heidi Zinzow[1]
[1]*Clemson University*

W80. Does Increasing Compensation and Number of Visits Lead to Linkage and Engagement Improvements with Outpatient Treatment in Patients Initiating Medication for Opioid Use Disorder (MOUD)? Evaluating HOUDINI LINK 2.0 Vs. 1.0
Maria Olivas[1], Alexandra Haas[1], Caravella McCuistian[1], Paula Lum[1], Emma Weinberger[1], D. Andrew Tompkins*[2]
[1]*University of California, San Francisco,* [2]*University of California San Francisco School of Medicine*

W81. Baseline Demographic and Clinical Profile Differences in Individuals Initiating Medication for Opioid Use Disorder Treatment: Exploring the Role of Alcohol and Tobacco Smoking Co-Addiction
Joanne Bae*[1], Gabriela Léon[1], Cari Coles[1], Andre Miguel[1], Crystal Smith[1], Sterling McPherson[1]
[1]*Washington State University*

W82. Open Board

W83. Increasing Initiation of Medications for Opioid Use Disorder through Recovery Coaches: The Impact of Implementation Setting
Hannah Knudsen*[1], Amanda Fallin-Bennett[1], Laura Fanucchi[2], Michelle Lofwall[2], Margaret McGladrey[1], Carrie Oser[1], Sharon Walsh[1]
[1]*University of Kentucky,* [2]*University of Kentucky, College of Medicine*

W84. Buprenorphine Injection Among Rural Persons who Use Drugs
Kaitlin Zinsli[1], P. Todd Korthuis[2], Thomas Stopka[3], Peter Friedmann[4], William Zule[5], Hannah Cooper[6], April Young[7], Judith Feinberg[8], Mai Pho[9], Wiley Jenkins[10], William Miller[11], Vivian Go[12], David Seal[13], Ryan Westergaard[14], Joseph Delaney[15], Judith Tsui*[1]
[1]*University of Washington,* [2]*Oregon Health and Science University,* [3]*Department of Public Health and Community Medicine, Tufts University,* [4]*University of Massachusetts Medical School-Baystate and Baystate Health,* [5]*RTI International,* [6]*Emory University,* [7]*University of Kentucky, College of Public Health,* [8]*West Virginia University School of Medicine,* [9]*The University of Chicago,* [10]*Department of Population Science and Policy, SIU School of Medicine, Springfield, IL,* [11]*Department of Epidemiology, University of North Carolina,* [12]*University of North Carolina,* [13]*Tulane University SPHTM,* [14]*University of Wisconsin - Madison,* [15]*University of Washington at Harborview Medical Center*

W85. Project Echo for Opioid Use Disorders Advances Best Practices
Karen Hartwell*[1], Lauren Linder[2], Kelly Barth[2], Suzanne Lane[2], Alyssa Rafferty[2], Angela Moreland[2]
[1]*Medical University of South Carolina; Ralph H. Johnson VAMC,* [2]*Medical University of South Carolina*

W86. Treatment Delivery and Prescribing Medications for Opioid Use Disorder Among American Indian and Alaska Native Adults During the Height of the COVID-19 Pandemic
Maia McCluskey[1], Kait Hirchak*[2], Kelsey Bajet[2], Meenakshi Richardson[2], Raquel Shaffer[3], Beverly Keyes[4], Karen Oliver[5], Frankie Kropp[6], Michael McDonell[7], Aimee Campbell[8], Kamilla Venner[9]
[1]*Gonzaga University,* [2]*Washington State University,* [3]*Tribal Health,* [4]*Tribal Wellness Center,* [5]*KEAO Consulting,* [6]*College of Medicine, University of Cincinnati,* [7]*Washington State University, Program of Excellence in Addictions Research,* [8]*Columbia University Irving Medical Center and New York Psychiatric Institute,* [9]*University of New Mexico*

W87. Budget Impact Tool for Integrating Buprenorphine and Outpatient Parenteral Antibiotic Therapy for People who Inject Drugs Hospitalized with Severe Infections
Shashi Kapadia[1], Joseph Pérez*[2], Philip Jeng[3], Laura Fanucchi[4], Michelle Lofwall[4], Sean Murphy[3]
[1]*Weill Cornell Medical College, Division of Infectious Diseases,* [2]*Weill Cornell Medicine,* [3]*Weill Cornell Medicine - Dept of Population Health Sciences,* [4]*University of Kentucky, College of Medicine, College of Medicine, Center on Drug and Alcohol Research*

W88. Longitudinal Trajectories in Recovery Capital and Associations with Substance Use Among Adult Drug Treatment Court Clients
Kyler Knapp*[1], Jessica Kulak[1], D. Lynn Homish[1], Gregory Homish[1], Linda Kahn[1]
[1]*State University of New York at Buffalo*

W89. Exploring the Relationship Between Social and Emotional Learning Skills and Opioid Misuse Among Justice-Involved Adolescents
Anthony Carmona*[1], Kimberly Johnson[1], James-Angelo Suarez[1], Micah Johnson[1]
[1]*University of South Florida*

W90. Neuroanatomical Alterations in Opioid Use Disorder: A Comprehensive Surface-Based Morphometry Analysis
Abhishek Ghosh*[1], Abhishek Verma[2], Simranjit Kaur[3], Chirag Kamal Ahuja[4], Ritu Nehra[5], Paramjeet Singh[4], Manish Modi[6], Debasish Basu[7]
[1]*Postgraduate Institute of Medical Education and Research,* [2]*Postgraduate Institute of Medical Education and Research, Chandigarh, India,* [3]*Department of Computer Science and Engineering, Thapar Institute of Engineering and Technology, Patiala, Punjab, India,* [4]*Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India,* [5]*Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India,* [6]*Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, India,* [7]*Drug Deaddiction and Treatment Center, Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India*

W91. Trauma Histories, Symptoms, and Vicarious Trauma Among Opioid Treatment Program Staff: Implications for Provider Functioning and Treatment Delivery
Linnea Linde-Krieger*[1], Beth Meyerson[1], Allison Huff[1], Gregory Carter[2], Benjamin Brady[3]
[1]*University of Arizona College of Medicine,* [2]*Indiana University School of Nursing,* [3]*Western Michigan University*

W92. Community Violence Predicting Opioid Use Among Justice-Involved Adolescents
Tamira Godfrey-Andrade*[1], Hannah Jacob[1], James-Angelo Suarez[1], Kimberly Johnson[1], Micah Johnson[1]
[1]*University of South Florida*

W93. The Association Between Interoceptive Awareness and Opioid Misuse in Justice-Involved Adolescents: Understanding Mindful Awareness in Body-Oriented Therapy Outcomes
Samay Shah*[1], Dylanis Lopez Ruiz[1], Nebiyou Daniel[1], James-Angelo Suarez[1], Micah Johnson[1]
[1]*University of South Florida*

W94. The Effect of Parental Supervision on Opioid Misuse Among Justice-Involved Adolescents
Michael Fredette*[1], Elian Ruiz-Arevalo[1], Micah Johnson[1], Kimberly Johnson[1], James-Angelo Suarez[1]
[1]*University of South Florida*

W95. Telehealth Equity: Telehealth for Opioid Agonist Treatment Was Accessible and Effective in a Deep South Cohort of People with HIV and Comorbid Opioid Use Disorder
Julie England[1], William Bradford[1], Ellen Eaton[1], William Bradford*[2]
[1]*The University of Alabama At Birmingham,* [2]*The University of Alabama at Birmingham*

W96. Risk Factors for Multiple Skin and Soft Tissue Infections Among People Who Inject Drugs (PWID) in Los Angeles, CA and Denver, CO 2021/22.
Siddhi Ganesh[1], Jesse Goldshear[1], Karen Corsi[2], Patricia Wilkins[2], Eric Kovalsky[2], Kelsey Simpson[3], Cheyenne Page[1], Ricky Bluthenthal*[4]
[1]*Keck School of Medicine University of Southern California,* [2]*Department of Psychiatry, University of Colorado Denver School of Medicine,* [3]*University of California - San Diego,* [4]*University of Southern California, Keck School of Medicine*

W97. Youth Perspectives on Illicit Fentanyl and Pills in Oregon: Knowledge, Gaps, and Trust
Erin Stack[1], Sarah Shin*[1], Gillian Leichtling[1], Judith Leahy[2], P. Todd Korthuis[3]
[1]*Comagine Health,* [2]*Oregon Health Authority,* [3]*Oregon Health and Science University*

W98. Economic Burden of Opioid Use Disorder Among Pregnant and Postpartum People
Leah Habersham*[1], Daniel Kuhr[2], Yasmin Hurd[2], Ellerie Weber[2]
[1]*Icahn School of Medicine at Mount Sinai,* [2]*Icahn School of Medicine at Mount Sinai*

W99. The Association Between Poly-Victimization and Opioid Misuse Among Justice-Involved Adolescents
Elian Ruiz-Arevalo*[1], Michael Fredette[1], James-Angelo Suarez[1], Kimberly Johnson[1], Micah Johnson[1]
[1]*University of South Florida*

W100. The Impact of ADHD and Treatment on Opioid Misuse Among Justice-Involved Adolescents in Florida
Hannah Jacob*[1], Dylanis Lopez Ruiz[1], Elzbieta Wiedbusch[1], James-Angelo Suarez[1], Kimberly Johnson[1], Micah Johnson[1]
[1]*University of South Florida*

W101. The Association of Borderline Personality Disorder Traits Among Justice-Involved Adolescents who Misuse Opioids from Divorced/Separated Homes
Liliana Nicho*[1], Michael Fredette[1], James-Angelo Suarez[1], Micah Johnson[1]
[1]*University of South Florida*

W102. The Effects of Structured Activity Involvement on Opioid Misuse in Justice-Involved Adolescents
Elliot Santaella Aguilar*[1], Darrin Holmes[1], James-Angelo Suarez[1], Kimberly Johnson[1], Micah Johnson[1]
[1]*University of South Florida*

W103. The Association Between Irritability and Opioid Misuse in Justice-Involved Adolescents
Yarian Pagan-Matta*[1], Elliot Santaella Aguilar[1], James-Angelo Suarez[1], Kimberly Johnson[1], Micah Johnson[1]
[1]*University of South Florida*

W104. Recent Trends in the Utilization of Long-Acting Injectable Buprenorphine in Kentucky
Lindsey Hammerslag*[1], Anita Silwal[2], Michelle Lofwall[3], Laura Fanucchi[3], Patricia Freeman[1], Dustin Miracle[4], Feitong Lei[1], Katherine Marks[5], Svetla Slavova[1], Sharon Walsh[1], Jeffery Talbert[3]
[1]*University of Kentucky,* [2]*Substance Use Priority Research Area,* [3]*University of Kentucky, College of Medicine,* [4]*University of Kentucky College of Pharmacy,* [5]*Cabinet for Health and Family Services, Department for Behavioral Health, Developmental and Intellectual Disabilities*

W105. The Frequency and Characteristics of Brokered Illegal Drug Sales and Measuring Local Demand
Georgiy Bobashev*[1], Lee Hoffer[2], Emily Hadley[1], Allison Schlosser[3]
[1]*RTI International,* [2]*Case Western Reserve University,* [3]*University of Nebraska*

W106. Open Board

W107. Healthcare Access through Facilitated Telemedicine for Underserved Populations: A Stepped Wedge Cluster Randomized Controlled Trial of Hepatitis C Virus Treatment among Persons with Opioid Use Disorder
Andrew Talal[1], Marianthi Markatou[2], Anran Liub[2], Ponni Perumalswamic[3], Amreen Dinanic[3], Jonathan Tobin[4], Lawrence Brown*[5]
[1]*Division of Gastroenterology, Hepatology, and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY,* [2]*Department of Biostatistics, University at Buffalo, Buffalo, NY,* [3]*Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY,* [4]*Clinical Directors Network, Inc. (CDN), New York, NY,* [5]*Weill Cornell Medical College*

W108. Health Service Utilization, Substance Use Treatment and Death in Patients with Opioid Use Disorder and Hepatitis C: A Prospective Cohort Study With Administrative Database Linkage
Brittany Dennis*[1], Glenda Babe[2], Tea Rosic[3], Myanca Rodrigues[3], Paxton Bach[4], Richard Perez[2], Claire de Oliveira[5], Jeffrey Samet[6], Victoria Weaver[7], Joanna Dionne[3], Aijaz Ahmed[8], Donghee Kim[8], Lehana Thabane[3], Zainab Samaan[9]
[1]*The University of British Columbia,* [2]*ICES McMaster, McMaster University, Hamilton, Ontario, Canada,* [3]*Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton ON Canada,* [4]*University of British Columbia,* [5]*Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada,* [6]*Boston University School of Medicine,* [7]*University of British Columbia,* [8]*Department of Gastroenterology and Hepatology, Stanford University, Palo Alto, California,* [9]*Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada*

W109. Xylazine Knowledge, Use and Exposure in Rhode Island: Preliminary Findings from a Drug Checking Cohort
Rachel Serafinski*[1], Merci Ujeneza[1], Ju Nyeong Park[2], Michelle McKenzie[3], Traci Green[4]
[1]*Rhode Island Hospital,* [2]*Brown University,* [3]*Lifespan,* [4]*Heller School for Social Policy and Management, Brandeis University*

W110. Barriers and Facilitators of MOUD Implementation in Specialty Treatment Programs in New Jersey: A Qualitative Study
Isha Desai*[1], Katie Burke[1], Jewyl Raikes[1], Justin Xu[1], Yuzhong Li[2], Brendan Saloner[1], Sachini Bandara[1], Kenneth Feder[1], Noa Krawczyk[3]
[1]*Johns Hopkins Bloomberg School of Public Health,* [2]*NYU School of Global Public Health,* [3]*NYU Grossman School of Medicine*

W111. The Effect of Friendship Types on Opioid Misuse Among Justice-Involved Adolescents
Kristina Banoob*[1], James-Angelo Suarez[1], Kimberly Johnson[1], Micah E Johnson[1]
[1]*University of South Florida*

W112. Analyzing Depression Severity and Opioid Misuse in Justice-Involved Adolescents
Joel Kallarackal*[1], James-Angelo Suarez[1], Elzbieta Wiedbusch[1], Kimberly Johnson[1], Micah Johnson[1]
[1]*University of South Florida*

W113. The Impact of Low Family Engagement on Opioid Misuse Among Justice Involved Adolescents
Erika Gonzalez*[1], Kimberly Johnson[1], Micah Johnson[1]
[1]*University of South Florida*

W114. Impact of Varied Levels of Suicidal Ideation on Opioid Misuse in Justice-Involved Adolescents
Aditya Samal*[1], Anthony Carmona[1], Elzbieta Wiedbusch[1], James-Angelo Suarez[1], Kimberly Johnson[1], Micah Johnson[1]
[1]*University of South Florida*

W115. Evaluating Opioid Misuse Among Justice-Involved Adolescents with Mental Health Problems
Darrin Holmes*[1], Elliot Santaella Aguilar[1], James-Angelo Suarez[1], Kimberly Johnson[1], Micah Johnson[1]
[1]*University of South Florida*

W116. Analyzing the Association of School Exclusion Disciplines on Opioid Misuse Among Justice-Involved Adolescents
Dylanis Lopez Ruiz*[1], Hannah Jacob[1], Samay Shah[1], Elzbieta Wiedbusch[1], James-Angelo Suarez[1], Kimberly Johnson[1], Micah Johnson[1]
[1]*University of South Florida*

W117. Understanding Who Uses Drug Checking Services and Why: Participant and Samples Characteristics from a Community-Based Drug Checking Study in Los Angeles, California
Ruby Romero*[1], Caitlin Molina[1], Pamina Gorbach[2], Steven Shoptaw[3], Chelsea Shover[1]
[1]*David Geffen School of Medicine at UCLA,* [2]*University of California Los Angeles, Fielding School of Public Health,* [3]*University of California Los Angeles, Department of Family Medicine*

W118. Engagement in the HIV Prep Care Cascade Among People Who Inject Drugs in Rural Kentucky
Hilary Surratt*[1], Sarah Brown[2], Abby Burton[1], Will Cranford[1], Laura Fanucchi[3], Christie Green[4], Stephanie Mersch[1], Rebecca Rains[5], Philip Westgate[1]
[1]*University of Kentucky,* [2]*Barbourville ARH Hospital,* [3]*University of Kentucky, College of Medicine,* [4]*Cumberland Valley District Health Department,* [5]*Knox County Health Department*

W119. Behavioral and Health Outcome Differences by Heroin or Methamphetamine Preference Among People in Rural Us Communities Who Use Both Substances.
Lyndsey Mixson*[1], Bridget Whitney[2], Stephanie Ruderman[2], Lydia Drumright[2], Mai Pho[3], Wiley Jenkins[4], Ryan Westergaard[5], David Seal[6], Vivian F. Go[7], William Miller[8], William Zule[9], P. Todd Korthuis[10], Peter Friedmann[11], Thomas Stopka[12], Gordon Smith[13], Judith Feinberg[14], Hannah Cooper[15], April Young[16], Dominique Heinke[17], Judith Tsui[18], Heidi Crane[17], Joseph Delaney[17]
[1]*University of Washington/Harborview Medical Center,* [2]*University of Washington,* [3]*The University of Chicago,* [4]*Department of Population Science and Policy, SIU School of Medicine, Springfield, IL,* [5]*University of Wisconsin - Madison,* [6]*Tulane University SPHTM,* [7]*Gillings School of Global Public Health, The University of North Carolina at Chapel Hill,* [8]*Department of Epidemiology, University of North Carolina,* [9]*RTI International,* [10]*Oregon Health and Science University,* [11]*Baystate Health,* [12]*Department of Public Health and Community Medicine, Tufts University,* [13]*West Virginia University,* [14]*West Virginia University School of Medicine,* [15]*Emory University,* [16]*University of Kentucky, College of Public Health,* [17]*University of Washington at Harborview Medical Center,* [18]*Department of Medicine, Division of General Internal Medicine, University of Washington*

W120. Demographic and Clinical Differences Between Individuals Initiating Medication for Opioid Use Disorder with a Positive Versus a Negative Stimulant Urinalysis Result
Cari Coles*[1], Courtney Batts[1], Joanne Bae[1], Gabriela León[1], Crystal Smith[1], Sterling McPherson[1], Andre Miguel[1]
[1]*Washington State University Elson S. Floyd College of Medicine*

W121. Patterns of Polysubstance Use Among People Who Inject Drugs Using the National HIV Behavioral Surveillance System: A Latent Class Analysis
Kechna Cadet*[1], Rashelle Musci[2], Renee Johnson[2], Dita Broz[3], Janet C. Burnett[4], Colin Flynn[5], Danielle German[2], Sabriya Linton[2]
[1]*Columbia University Mailman School of Public Health,* [2]*Johns Hopkins Bloomberg School of Public Health,* [3]*Centers for Disease Control and Prevention,* [4]*National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control,* [5]*Infectious Disease and Environmental Health Administration*

W122. Adaptive Employment Among People Who Use Drugs: Development of an (In)formality Scale of Economic Engagement
Lindsey Richardson*[1], Anita Minh[1], Maren Tergesen[1], Rosemary Hunt[2], Deb McCormack[2], Allison Laing[1], Johanna Li[3]
[1]*The University of British Columbia,* [2]*British Columbia Centre on Substance Use,* [3]*Embers Eastside Works*

W123. Investigating Group Modality Dose Effects of an HIV/STI Intervention for Black Women in Community Supervision in New York City, NY: A Moderation Analysis
Nishita Dsouza*[1], Dawn Goddard-Eckrich[2], Mingway Chang[3], Mary Russo[3], Elwin Wu[4], Nabila El-Bassel[4], Louisa Gilbert[4]
[1]*Columbia School of Social Work,* [2]*Social Intervention Group, Columbia University, School of Social Work,* [3]*Social Intervention Group, Columbia University School of Social Work,* [4]*Columbia University*

W124. Implications for Overdose Response Among People Experiencing Homelessness Who Co-Use Fentanyl and Stimulants in San Francisco and New York: Findings From Phase 1 of a Longitudinal Study
Kelly Knight*[1], Sedona Koenders[1], Dallas Augustine[2], Zena Dhatt[1], Tianna Jacques[1], Grace Taylor[1], Ryan McNeil[3]
[1]*University of California - San Francisco,* [2]*San Jose State University,* [3]*Yale University*

W125. Impact of Comorbid Alcohol Dependence on Neurocognitive Impulsivity, Externalizing and Internalizing Traits in Opiate and Stimulant Users
Elena Psederska*[1], Kiril Bozgunov[1], Dimitar Nedelchev[1], Georgi Vasilev[1], Jasmin Vassileva[2]
[1]*Bulgarian Addictions Institute,* [2]*Virginia Commonwealth University, School of Medicine*

W126. Identifying Higher-Risk Motivations for Polydrug Use Among Sexual and Gender Minority Youth Who Use Alcohol
Raymond Moody*[1], Lisa Eaton[1], Ryan Watson[1]
[1]*University of Connecticut*

W127. A Qualitative Field Study of Barriers to Drug Checking in US Festival Settings
Cianna Piercey*[1], Thomas Schlechter[1], Riley Ahern[1], Devin Henry[1], Joseph Cameron[1], Mikayla Allen-Collins[1], Hollis Karoly[1]
[1]*Colorado State University*

W128. Polysubstance Use is Associated With a 4.8-Fold Greater Prevalence of Non-Fatal Overdose Than Single Substance Use Among PWH in Care 2019-2023
Lydia Drumright*[1], Joseph Delaney[2], Bridget Whitney[1], Kenneth Mayer[3], Dominique Heinke[2], Mindy Dai[1], Rob Fredericksen[1], Stephanie Ruderman[1], Lyndsey Mixson[4], Lara Haidar[5], Richard Moore[6], Sonia Napravnik[7], Mary MaCaul[6], Inga Peter[8], Katerina Christopoulos[9], Edward Cachay[10], Laura Bamford[10], Jeffrey Jacobson[11], Mari Kitahata[1], Michael Saag[12], Geetanjali Chander[13], Crane Heidi[1]
[1]*University of Washington,* [2]*University of Washington at Harborview Medical Center,* [3]*Harvard Medical School,* [4]*University of Washington/Harborview Medical Center,* [5]*University of Manitoba,* [6]*Johns Hopkins University School of Medicine,* [7]*University of North Carolina at Chapel Hill,* [8]*Icahn School of Medicine at Mount Sinai,* [9]*University of California at San Francisco,* [10]*University of California at San Diego,* [11]*Case Western Reserve University,* [12]*University of Alabama at Birmingham,* [13]*University of Washington Seattle, School of Medicine*

W129. Exploring Cannabis Usage Patterns and Outpatient Treatment Persistence Among Individuals with Polydrug Use Disorder
Guilherme Kortas*[1], Dângela Lassi[2], Andre Malbergier[2], João M. Castaldelli-Maia[2]
[1]*nstituto Perdizes, Hospital das Clinicas da FMUSP, São Paulo, SP, Brazil,* [2]*Instituto Perdizes, Hospital das Clinicas da FMUSP, São Paulo, SP, Brazil*

W130. Mental Health Care Barriers for Women Involved in the Criminal Legal System with Substance Use Disorders: A Qualitative Study
Sienna Strong-Jones*[1], Kristina Brant[2], Emma Skogseth[3], Oluwaseyi Quadri[3], Eric Harrison[3], Abenaa Jones[3]
[1]*Pennsylvania State University,* [2]*Department of Agricultural Economics, Sociology, and Education, Pennsylvania State University,* [3]*Department of Human Development and Family Studies, Pennsylvania State University*

W131. Co-Occurring Methamphetamine Use and Depressive Symptoms Among Patients in Methadone Maintenance Treatment in Vietnam
Thuy Dao[1], Trang Nguyen*[1], Diep Bich Nguyen[1], Van Hoang[1], Li Li[2], Michael Li[2], Steve Shoptaw[2], Giang Le[1]
[1]*Hanoi Medical University,* [2]*University of California Los Angeles*

W132. Perceived and Detected Contents of Remnant Drug Samples from a Community Drug Checking Cohort Study
Merci Ujeneza*[1], Rachel Serafinski[1], Michelle McKenzie[2], Ju Nyeong Park[3], Traci Green[4]
[1]*Rhode Island Hospital,* [2]*Lifespan,* [3]*Brown University,* [4]*Heller School for Social Policy and Management, Brandeis University*

W133. HIV and Hepatitis C Prevalence Among People Who Use Drugs From 8 Syringe Services Programs in the US
Sara Glick*[1], Jeremy Beckford[2], Anthony Morgan[1], Nicky Cotta[1], Maria Corcorran[1], Don Des Jarlais[3], Talia Pindyck[4], Amy Baugher[4], Janet C. Burnett[4]
[1]*University of Washington School of Medicine,* [2]*University of Washington School of Public Health,* [3]*New York University School of Global Public Health,* [4]*Centers for Disease Control and Prevention*

W134. Adverse Childhood Experiences and Adolescent Substance Use After the COVID-19 Pandemic
Sunny Shin[1], Casey Burton[1], Casey Corso*[1]
[1]*Virginia Commonwealth University*

W135. Open Board

W136. Do People with Substance Misuse (SM) Use Distinct Pain Treatment Modalities?
Marc Rosen*[1], Kathryn Gilstad-Hayden[2], John Sellinger[2], Christina Lazar[1], Steve Martino[2], Sarah Meshberg-Cohen[1]
[1]*Yale University/VA Connecticut Healthcare System,* [2]*Yale University Department of Psychiatry*

W137. Comparison of Contingency Management Protocols for Reducing Illicit Drug Use Among a Community-Based Sample of Women Engaging in Polysubstance Use
Kathleen Ward*[1], Adam Carrico[2], Daniel Vader[1], Silvana Mazzella[3], Reneé Moore[1], Alexis Roth[1]
[1]*Drexel University Dornsife School of Public Health,* [2]*Florida International University Robert Stempel College of Public Health and Social Work,* [3]*Prevention Point Philadelphia*

W138. Effects of Self- or Experimenter-Administered Cocaine on Ethanol Drinking in Adult Male Rhesus Monkeys
Joshua Prete*[1], Miracle Collier[2], Phillip Epperly[2], Paul Czoty[2]
[1]*Wake Forest University Graduate School,* [2]*Wake Forest University School of Medicine*

W139. Guanfacine Reduces Drug Craving, Stress and Increases the Number of Abstinence Days in Women with Polysubstance Use Disorder (PSUD): A Pilot 2-Site Clinical Study
Stephanie Wemm*[1], Nia Fogelman[1], Liam Sullivan[1], Erin Vacey[2], Suraj Bera[2], Gretchen Hermes[1], James Swain[2], Helen Fox[3], Rajita Sinha[1]
[1]*Yale University School of Medicine,* [2]*Stony Brook Univeristy School of Medicine,* [3]*Stony Brook University*

W140. Nutritional Status of People Living with HIV Who Use Substances: Implications for Food is Medicine to Promote Whole Person Wellbeing
Marianna Wetherill*[1], Casey Bakhsh[2], Lacey Caywood[1], Spencer Hall[1], Mary Williams[1], Micah Hartwell[3], Sheri Weiser[4]
[1]*University of Oklahoma Health Sciences Center,* [2]*Tulsa CARES,* [3]*Oklahoma State University Center for Health Sciences,* [4]*University of California San Francisco*

W141. Development of a Novel Oral Therapeutic with a First-In-Class Mechanism Targeting Substance Addiction and Reduction in Risk of Relapse
Nurulain Zaveri*[1], Dennis Yasuda[1], Willma Polgar[1], Michael Meyer[1], Giordano De Guglielmo[2], Imad Damaj[3]
[1]*Astraea Therapeutics,* [2]*The Scripps Research Institute,* [3]*Virginia Commonwealth University*

W142. Age of Cannabis Use Initiation, Anxiety, and Depression in Emerging Adulthood in an Ethnically Diverse Cohort: Preliminary Results from the Herbal Heart Study
Bria-Necole Diggs*[1], Amrit Baral[1], Ranya Marrakchi El Fellah[1], Sarah Messiah[2], Claudia Martinez[1], Barry Hurwitz[1], Raul Gonzalez[3], Denise Vidot[4]
[1]*University of Miami Miller School of Medicine,* [2]*University of Texas Health Science Center,* [3]*Florida International University,* [4]*University of Miami School of Nursing and Health Studies*

W143. Access to and Satisfaction with Telemedicine Addiction Care During the COVID-19 Pandemic
David Reading*[1], Paxton Bach[2], JinCheol Choi[3], Kora DeBeck[1], Thomas Kerr[1], Kanna Hayashi[4]
[1]*British Columbia Centre on Substance Use,* [2]*University of British Columbia,* [3]*BC Centre on Substance Use,* [4]*British Columbia Centre on Substance Use and Simon Fraser University*

W144. Open Board

W145. Ethical Conflict Experienced by Obstetric Providers Caring for Pregnant and Postpartum Women with Substance Use Disorders: A Mixed Studies Review
Caroline Darlington*[1], Peggy Compton[2]
[1]*University of Pennsylvania,* [2]*University of Pennsylvania, School of Nursing*

W146. Substance Use Monitoring Among People Who Use Drugs Using a Novel Assay to Test Dried Blood Spot Specimens
Kaitlin Zinsli*[1], Janet C. Burnett[2], Alex J. Krotulski[3], Melissa Fogarty[4], Devin Kress[4], Barry L. Logan[3], Anthony Morgan[5], Jeremy Beckford[6], Brandon L. Guthrie[6], Judith Tsui[7], Sara Glick[6]
[1]*University of Washington,* [2]*Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control, USA,* [3]*Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation, Willow Grove, PA,* [4]*Center for Forensic Science Research and Education, Fredric Rieders Family Foundation, Horsham, PA, USA,* [5]*Allergy and Infectious Disease, University of Washington, Seattle, WA, USA,* [6]*Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA; Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA,* [7]*Department of Medicine, Division of General Internal Medicine, University of Washington*

W147. International Drug Policy Study Trends with Psychedelic Drugs: A Spotlight on Psilocybin, LSD, and MDMA
Myfanwy Graham*[1], Wayne Hall[2], Rosalie Pacula[3], David Hammond[4]
[1]*Monash University,* [2]*University of Queensland,* [3]*University of Southern California,* [4]*Universtiy of Waterloo*

W148. Source Localized Auditory ERP Sensory and Preattentive Correlates of Psilocybin-Induced Ego-Dissolution Related Effects
Destiny Carbello*[1], Tomáš Páleníček[2]
[1]*Florida International University,* [2]*National Institute of Mental Health, Czech Republic*

W149. Anxiety Scores may Be Associated with Differences in Induction Onto Sublingual Buprenorphine Among Participants With Moderate/Severe Methamphetamine Use Disorder and Opioid Misuse
Steven Nieto*[1], Madhukar Trivedi[2], Udi Ghitza[3], Erik Anderson[4], Tara Chowdhury[5], Julie Croff[6], Timothy Hall[7], Judith Tsui[8], Thomas Carmody[2], Sidarth Wakhlu[2], Manish Jha[9], Steve Shoptaw[10]
[1]*University of California, Los Angeles,* [2]*University of Texas Southwestern Medical Center,* [3]*National Institute on Drug Abuse, National Institutes of Health,* [4]*Alameda Health System - Highland Hospital,* [5]*CODA, Inc.,* [6]*Oklahoma State University Center for Health Sciences,* [7]*University of California, Department of Family Medicine,* [8]*Department of Medicine, Division of General Internal Medicine, University of Washington,* [9]*University of Texas Southwestern Medical Center, Department of Psychiatry,* [10]*University of California Los Angeles*

W150. Approach-Bias Retraining Intervention Effects on Stimulant-Related Memory Associations Among Inpatients with a Primary Stimulant Use Disorder
Stefanie Todesco*[1], Liam Gorsuch[1], Thomas Chao[2], Karina Thiessen[1], Christian Schutz[1]
[1]*University of British Columbia,* [2]*University of British Comumbia*

W151. Repeated Methamphetamine Administration Increased Mitochondrial Density in Substantia Nigra Pars Compacta Dopamine and Locus Coeruleus Norepinephrine Neurons
Aishwarya Bhowmik*[1], Steven Graves[2]
[1]*University of Minnesota Medical School,* [2]*University of Minnesota*

W152. Attrition Rate: The Unsolved Problem of RCTS for Cocaine Use Disorders
Amanda B. Sinatora*[1], Juliana P. M. Santos[1], Kevin Xu[2], Vitor S. Tardelli[1], Thiago M. Fidalgo[1]
[1]*Escola Paulista De Medicina - Universidade Federal De São Paulo,* [2]*Department of Psychiatry – Washington University School of Medicine in St. Louis*

W153. Open Board

W154. Increasing Rates of Stimulant Use Among Patients with Opioid Use Disorder Receiving Substance Use Treatment: Findings From a Prospective Cohort Study
Elise Jackson*[1], Paxton Bach[2], Zainab Samaan[3], Brittany Dennis[4]
[1]*University of British Columbia Faculty of Medicine,* [2]*University of British Columbia,* [3]*McMaster University,* [4]*The University of British Columbia*

W155. The Effects of Extended Versus Short Intermittent-Access Self-Administration Sessions on Cocaine-Seeking Induced by Discriminative and Conditioned Stimuli
Amélie Mainville-Berthiaume*[1], Hajer Algallal[1], Sema Hazem[2], Coralie Godbout[1], Anne-Noël Samaha[1]
[1]*Université de Montréal,* [2]*Concordia University*

W156. Patient and Provider Demand for and Readiness to Adopt Medications for Stimulant Use Disorders in Real-World Settings: Pre-Planning toward Accelerated Implementation
Enya Vroom*[1], Erin Finley[2], Tara Karns-Wright[1], Carma Deem Bolton[1], Jennifer Potter[3]
[1]*The University of Texas Health Science Center at San Antonio,* [2]*UT Health San Antonio,* [3]*University of Texas Health San Antonio*

W157. Rural Community Peer Partnerships for Improving Methamphetamine-Associated Heart Failure Screening and Engagement (PEER-HEART): A Research and Implementation Protocol
Brian Chan*[1], Kim Hoffman[2], Ryan Cook[2], Ximena Levander[2], Paul Gonzales[3], Evan Shalen[2], Kellie Pertl[4], Michelle Beam[2], Cooper Kersey[5], Shanna Smith[6], Tabetha Evernden[6], Megan Cheslock[2], Christopher Longnecker[5], P. Todd Korthuis[2]
[1]*Oregon Health and Science University,* [2]*Oregon Health and Science University,* [3]*Bay Areas First Step,* [4]*Oregon Health and Sciences University,* [5]*University of Washington,* [6]*Bay Area First Step*

W158. Development of a Model to Distinguish Methamphetamine Use from Alcohol Use Based on Sleep and Heart Rate Conditions Assessed by a Wearable Activity Tracker
Ayumi Takano*[1], Koki Ono[2], Futaba Umemura[2], Makito Sato[3], Kayo Okuda[3], Jun Sese[3], Toshihiko Matsumoto[2]
[1]*National Institute of Mental Health, National Center of Neurology and Psychiatry,* [2]*Department of Drug Dependence Research, National Institute of Mental Health, National Center of Neurology and Psychiatry,* [3]*Humanome Lab., Inc.*

W159. Open Board

W160. Application of Causal Forest Model to Examine Treatment Effect Heterogeneity in Substance Use Disorder Psychosocial Treatments
Ryoko Susukida[1], Masoumeh Amin-Esmaeili[1], Elena Badillo-Goicoechea[1], Trang Nguyen[1], Elizabeth Stuart[1], Michael Rosenblum[1], Kelly Dunn[2], Ramin Mojtabai[1], Ramin Mojtabai*[3]
[1]*Johns Hopkins Bloomberg School of Public Health,* [2]*Johns Hopkins University School of Medicine,* [3]*Tulane University*

W161. Comparing Racial and Ethnic Differences on Access to Wellness Services for People in Substance Use Treatment
Jaime Smith*[1], Nadra Lisha[1], Jennifer Le[1], Caravella McCuistian[1]
[1]*University of California, San Francisco*

W162. Strategies to Improve Equitable and Evidence-Based Hospital Care for Pregnant People with a Substance Use Disorder: A Rapid Scoping Review
Carla King*[1], Gregory Laynor[1], Adetayo Fawole[1], Jennifer Jennifer McNeely[1], Matthew Lee[1], Sugy Choi[1]
[1]*NYU Grossman School of Medicine*

W163. Parental Mental Health and Family Conflict on Behavioral Inhibition and Activation Among Youth in the ABCD Study®
Neo Gebru*[1], Wesley Thompson[2], Micah Johnson[3], Alexandra Potter[4], Hugh Garavan[5]
[1]*Brown University,* [2]*University of California, San Diego,* [3]*University of South Florida,* [4]*University of Vermont Department of Psychiatry,* [5]*University of Vermont*

W164. Prospective Prediction of Adult Substance Use Disorder Outcomes in a High Risk Sample of Youth Using Machine Learning and Predictors From Multiple Domains
Alexander Weigard*[1], Katherine McCurry[2], Lora Cope[2], Meghan Martz[2], Robert Zucker[2], Ivo Dinov[2], Mary Heitzeg[2]
[1]*Univerisity of Michgian,* [2]*University of Michigan*

W165. Technology-Based Substance Use Interventions for Young Adults and College students: A Systematic Review and Meta-Analysis
Audrey Hai*[1], Jocelyn Simons[1], Laura Curran[1], Kate Carey[2], Patrick Bordnick[1]
[1]*Tulane University,* [2]*Brown University*

W166. Characterizing Barriers to Substance Use treatment: A Latent Class Analysis Using the NSDUH 2020-2021 Surveys
Karlyn Edwards*[1], Bryant Shuey[1], Lakeya McGill[1], Jessica Merlin[2], Jane Liebschutz[1]
[1]*University of Pittsburgh,* [2]*University of Pittsburgh School of Medicine*

W167. The Impact of Anti-Stigma Education in the Healthcare Field: A Program Design
Madison Walsh*[1], Cara Poland[1]
[1]*Michigan State University*

W168. Assessing the Association Between Increased Student-Adult Connections, Perceptions of School, and Substance Misuse Rates Among Justice-Involved Adolescents
James-Angelo Suarez*[1], Elzbieta Wiedbusch[1], Micah Johnson[1]
[1]*University of South Florida*

W169. Association of Telemedicine Policies Implemented During the COVID-19 Pandemic with Receipt of Substance Use Disorder Treatment
Kayla Tormohlen*[1], Matthew Eisenberg[2], Alex McCourt[2], Jiani Yu[1], Emma McGinty[1]
[1]*Weill Cornell Medicine,* [2]*Johns Hopkins Bloomberg School of Public Health*

W170. Exploring Anabolic-Androgenic Steroids Use Among Cisgender Gay, Bisexual, and Queer Men
Eric Kutscher*[1], Arslaan Arshed[2], Richard Greene[2], Mat Kladney[2]
[1]*Icahn School of Medicine at Mount Sinai,* [2]*NYU Langone Health; Bellevue Hospital Center*

W171. The Syndemics of Anabolic-Androgenic Steroid Misuse Among Young Latino Sexual Minority Men
Alexander Auchus*[1], David Strong[2], David Grelotti[1], Aaron Blashill[3]
[1]*UCSD School of Medicine,* [2]*UCSD Herbert Wertheim School of Public Health and Human Longevity Science,* [3]*Department of Psychology, San Diego State University*

W172. Placebo Effect and its Impact on Human Abuse Potential Studies
Ling Chen*[1]
[1]*US Food and Drug Administration*

W173. Experiences of Discrimination and Alcohol Involvement at the Intersection of Race/Ethnicity and Gender
Hector Lopez-Vergara*[1], William Rozum[1], Sydney Iacoi[1], Jodi Sutherland Charvis[1], Chrystal Vergara-Lopez[2]
[1]*University of Rhode Island,* [2]*Brown University*

W174. Novel Psychoactive Substance Use: A Survey of Pregnant and Postpartum Individuals With Substance Use Disorders
Joseph Worden[1], Jasmin Charles[2], Marcela Smid[3], Jasmin Charles*[4]
[1]*University of Utah,* [2]*University of Utah Health,* [3]*Univeristy of Utah Health,* [4]*University of Utah School of Medicine*

2023-2024 Donors

Sudie Back
Robert Balster
Marcel O. Bonn-Miller
Qiana Brown
Julie Bruneau
Sandra Comer
James Cook
Kelly Dunn
Raymond Julius Elefante
William Fantegrossi
Kevin Freeman
Diann Gaalema
Albert Garcia-Romeu
Cassandra Gipson
Gerardo Gonzalez
Charles Gorodetzky
Lea Greenberg
Patricia Grigson
Margaret Haney
Stephen and Julie Hansen
Greg Harris
Deborah Hasin
Corey Hayes
Angela Heads
Sarah Heil
Jack Henningfield
Denise Hien
Jesse Howard
Amy Janes
Laurel Koepernik
Scott Lane
Ximena Levander
Joshua Lile
Scott Lukas
John Mantsch
Silvia Martins
Deborah Mash
Dennis McCarty
Sterling McPherson
Rick Mees
John Mendelson
Angela Moreland
Linda Porrino
Marc Potenza
Marco Pravetoni
James Rowlett
Gregory Sahlem
Katherine Serafine
Rischard Starr
Maxine Stitzer
William Stoops
Catherine Striley
Yung-Fong Sung-Holtzman
Dace Svikis
Michael Taffe
D. Andrew Tompkins
Judith Tsui
Alexander Walley
Carl Wolf
George Woody

SAVE THE DATE

The College *on* Problems *of* Drug Dependence

The Sheraton New Orleans Hotel

June 14-18, 2025

2025



NEW ORLEANS, **LOUISIANA**

THE COLLEGE ON PROBLEMS OF DRUG DEPENDENCE
EST 1929